<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:cc="http://web.resource.org/cc/"
 xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:admin="http://webns.net/mvcb/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel rdf:about="https://www.mdpi.com/rss/journal/diabetology">
		<title>Diabetology</title>
		<description>Latest open access articles published in Diabetology at https://www.mdpi.com/journal/diabetology</description>
		<link>https://www.mdpi.com/journal/diabetology</link>
		<admin:generatorAgent rdf:resource="https://www.mdpi.com/journal/diabetology"/>
		<admin:errorReportsTo rdf:resource="mailto:support@mdpi.com"/>
		<dc:publisher>MDPI</dc:publisher>
		<dc:language>en</dc:language>
		<dc:rights>Creative Commons Attribution (CC-BY)</dc:rights>
						<prism:copyright>MDPI</prism:copyright>
		<prism:rightsAgent>support@mdpi.com</prism:rightsAgent>
        						<items>
			<rdf:Seq>
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/12/228" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/227" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/226" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/225" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/224" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/223" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/222" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/221" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/220" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/219" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/218" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/217" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/216" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/215" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/214" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/213" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/212" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/211" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/210" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/11/209" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/208" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/207" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/206" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/205" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/204" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/203" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/202" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/201" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/200" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/199" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/198" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/197" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/196" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/195" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/194" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/193" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/192" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/191" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/190" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/189" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/188" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/10/187" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/186" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/185" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/184" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/183" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/182" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/181" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/180" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/179" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/178" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/177" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/176" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/174" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/175" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/173" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/172" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/171" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/170" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/169" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/168" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/167" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/166" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/165" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/164" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/163" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/162" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/9/161" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/160" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/159" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/158" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/157" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/156" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/155" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/154" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/153" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/152" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/151" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/150" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/149" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/148" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/147" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/146" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/145" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/144" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/143" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/8/142" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/141" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/140" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/139" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/138" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/137" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/136" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/135" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/134" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/133" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/132" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/131" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/130" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2673-4540/7/7/129" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="https://creativecommons.org/licenses/by/4.0/" />
	</channel>

        <item rdf:about="https://www.mdpi.com/2673-4540/7/12/228">

	<title>Diabetology, Vol. 7, Pages 228: Agreement Between Indian Diabetes Risk Score and Framingham Risk Score Across the Glycemic Spectrum in a Central Indian Population</title>
	<link>https://www.mdpi.com/2673-4540/7/12/228</link>
	<description>Background: The Indian Diabetes Risk Score (IDRS) and Framingham Risk Score (FRS) are widely used to assess diabetes and cardiovascular risk in Indian populations, but their agreement is unclear. We evaluated the performance of IDRS for type 2 diabetes mellitus (T2DM), the agreement between IDRS and FRS, and the metabolic profile of participants classified discordantly. Methods: In a cross-sectional analysis of 449 adults from Bhopal recruited through community screening for a case-control study, IDRS and FRS were calculated with clinical, biochemical, and medication data. Results: IDRS showed high sensitivity (89.0%) but low specificity (35.8%) for T2DM. Agreement between the two classifications was poor (&amp;amp;kappa; = 0.027, p = 0.129), and 54.6% of participants were classified as IDRS High but FRS Not High. Within this discordant group, participants with T2DM had substantial insulin resistance (HOMA-IR 4.05), atherogenic dyslipidemia, and near-universal abdominal obesity. Among all participants with T2DM, statin use was more frequent in the FRS Not-High group (13.2% vs. 3.4%), so a medication effect on lipids cannot be excluded. Conclusions: IDRS and FRS capture different dimensions of cardiometabolic risk and are not interchangeable in this sample. Many participants, including those with T2DM, had considerable metabolic burden despite not being classified as high-risk by FRS. These cross-sectional findings require longitudinal evaluation.</description>
	<pubDate>2026-11-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 228: Agreement Between Indian Diabetes Risk Score and Framingham Risk Score Across the Glycemic Spectrum in a Central Indian Population</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/12/228">doi: 10.3390/diabetology7120228</a></p>
	<p>Authors:
		Lokendra Rathod
		Sameera Khan
		Sweta Mishra
		Swasti Shubham
		Manoj Kumawat
		Ravindra M. Samarth
		Manoj Kumar
		Tanim Arpit Singh
		Samradhi Singh
		Rajnarayan R. Tiwari
		Archana Tiwari
		Devojit Kumar Sarma
		</p>
	<p>Background: The Indian Diabetes Risk Score (IDRS) and Framingham Risk Score (FRS) are widely used to assess diabetes and cardiovascular risk in Indian populations, but their agreement is unclear. We evaluated the performance of IDRS for type 2 diabetes mellitus (T2DM), the agreement between IDRS and FRS, and the metabolic profile of participants classified discordantly. Methods: In a cross-sectional analysis of 449 adults from Bhopal recruited through community screening for a case-control study, IDRS and FRS were calculated with clinical, biochemical, and medication data. Results: IDRS showed high sensitivity (89.0%) but low specificity (35.8%) for T2DM. Agreement between the two classifications was poor (&amp;amp;kappa; = 0.027, p = 0.129), and 54.6% of participants were classified as IDRS High but FRS Not High. Within this discordant group, participants with T2DM had substantial insulin resistance (HOMA-IR 4.05), atherogenic dyslipidemia, and near-universal abdominal obesity. Among all participants with T2DM, statin use was more frequent in the FRS Not-High group (13.2% vs. 3.4%), so a medication effect on lipids cannot be excluded. Conclusions: IDRS and FRS capture different dimensions of cardiometabolic risk and are not interchangeable in this sample. Many participants, including those with T2DM, had considerable metabolic burden despite not being classified as high-risk by FRS. These cross-sectional findings require longitudinal evaluation.</p>
	]]></content:encoded>

	<dc:title>Agreement Between Indian Diabetes Risk Score and Framingham Risk Score Across the Glycemic Spectrum in a Central Indian Population</dc:title>
			<dc:creator>Lokendra Rathod</dc:creator>
			<dc:creator>Sameera Khan</dc:creator>
			<dc:creator>Sweta Mishra</dc:creator>
			<dc:creator>Swasti Shubham</dc:creator>
			<dc:creator>Manoj Kumawat</dc:creator>
			<dc:creator>Ravindra M. Samarth</dc:creator>
			<dc:creator>Manoj Kumar</dc:creator>
			<dc:creator>Tanim Arpit Singh</dc:creator>
			<dc:creator>Samradhi Singh</dc:creator>
			<dc:creator>Rajnarayan R. Tiwari</dc:creator>
			<dc:creator>Archana Tiwari</dc:creator>
			<dc:creator>Devojit Kumar Sarma</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7120228</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-22</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-22</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>12</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>228</prism:startingPage>
		<prism:doi>10.3390/diabetology7120228</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/12/228</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/227">

	<title>Diabetology, Vol. 7, Pages 227: Zebrafish Models of Diabetes: Comparative Physiology, Experimental Paradigms, and Insights into Metabolic Dysfunction and Recovery</title>
	<link>https://www.mdpi.com/2673-4540/7/11/227</link>
	<description>Diabetes mellitus is a systemic disorder characterized by the transition from early multi-organ compensatory adaptation to progressive metabolic decompensation and irreversible tissue injury. While mammalian models remain foundational, the zebrafish (Danio rerio) has emerged as a powerful vertebrate model for resolving the in vivo choreography of metabolic homeostasis, inter-organ crosstalk, and endogenous tissue regeneration. In this review, we examine the pathophysiology of diabetes through the lens of clinical heterogeneity and multi-organ dysfunction, establishing a comparative framework among humans, rodents, and zebrafish. We evaluate key species-specific differences&amp;amp;mdash;including teleost gene duplications, yolk-dependent larval nutrition, non-thermogenic adipose biology, and distinct hepatic and cardiovascular structural organizations&amp;amp;mdash;that shape phenotypic interpretation. We critically assess experimental paradigms used to disrupt metabolic homeostasis, including dietary overload, ambient glucose immersion, targeted genetic lesions, and chemogenetic &amp;amp;beta;-cell ablation. Importantly, we expand beyond disease induction to emphasize the zebrafish as a unique platform for dissecting multi-organ recovery&amp;amp;mdash;spanning the kinetics of hepatic steatosis resolution, adipose depot remodeling, the restoration of insulin sensitivity, multiple cellular routes of &amp;amp;beta;-cell neogenesis, and persistent epigenetic metabolic memory. To maximize translational validity, models must be defined by rigorously validated cellular and functional endpoints rather than broad diagnostic labels. Integrating live multi-organ imaging, high-throughput phenotypic screening, and omics approaches in zebrafish offers critical mechanistic insights into metabolic resilience, organ plasticity, and tissue recovery, providing valuable complementary avenues for human diabetes research.</description>
	<pubDate>2026-11-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 227: Zebrafish Models of Diabetes: Comparative Physiology, Experimental Paradigms, and Insights into Metabolic Dysfunction and Recovery</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/227">doi: 10.3390/diabetology7110227</a></p>
	<p>Authors:
		Shuhei Kuwabara
		Tomoki Miyata
		Ayako Tonoki
		Takamasa Mizoguchi
		Takashi Miki
		Motoyuki Itoh
		</p>
	<p>Diabetes mellitus is a systemic disorder characterized by the transition from early multi-organ compensatory adaptation to progressive metabolic decompensation and irreversible tissue injury. While mammalian models remain foundational, the zebrafish (Danio rerio) has emerged as a powerful vertebrate model for resolving the in vivo choreography of metabolic homeostasis, inter-organ crosstalk, and endogenous tissue regeneration. In this review, we examine the pathophysiology of diabetes through the lens of clinical heterogeneity and multi-organ dysfunction, establishing a comparative framework among humans, rodents, and zebrafish. We evaluate key species-specific differences&amp;amp;mdash;including teleost gene duplications, yolk-dependent larval nutrition, non-thermogenic adipose biology, and distinct hepatic and cardiovascular structural organizations&amp;amp;mdash;that shape phenotypic interpretation. We critically assess experimental paradigms used to disrupt metabolic homeostasis, including dietary overload, ambient glucose immersion, targeted genetic lesions, and chemogenetic &amp;amp;beta;-cell ablation. Importantly, we expand beyond disease induction to emphasize the zebrafish as a unique platform for dissecting multi-organ recovery&amp;amp;mdash;spanning the kinetics of hepatic steatosis resolution, adipose depot remodeling, the restoration of insulin sensitivity, multiple cellular routes of &amp;amp;beta;-cell neogenesis, and persistent epigenetic metabolic memory. To maximize translational validity, models must be defined by rigorously validated cellular and functional endpoints rather than broad diagnostic labels. Integrating live multi-organ imaging, high-throughput phenotypic screening, and omics approaches in zebrafish offers critical mechanistic insights into metabolic resilience, organ plasticity, and tissue recovery, providing valuable complementary avenues for human diabetes research.</p>
	]]></content:encoded>

	<dc:title>Zebrafish Models of Diabetes: Comparative Physiology, Experimental Paradigms, and Insights into Metabolic Dysfunction and Recovery</dc:title>
			<dc:creator>Shuhei Kuwabara</dc:creator>
			<dc:creator>Tomoki Miyata</dc:creator>
			<dc:creator>Ayako Tonoki</dc:creator>
			<dc:creator>Takamasa Mizoguchi</dc:creator>
			<dc:creator>Takashi Miki</dc:creator>
			<dc:creator>Motoyuki Itoh</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110227</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-20</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-20</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>227</prism:startingPage>
		<prism:doi>10.3390/diabetology7110227</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/227</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/226">

	<title>Diabetology, Vol. 7, Pages 226: Patients with Pancreatic Cancer with a History of Short- and Long-Term Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/11/226</link>
	<description>Background/Objectives: The relationship between pancreatic cancer (PC) and diabetes mellitus (DM) is complex. The aim was to investigate the prevalence of DM in patients with PC diagnosed within two years of the PC diagnosis (NODM) and in patients diagnosed more than two years previously (LSDM), and to determine the clinical profile and prognosis of these patients. Methods: A retrospective case&amp;amp;ndash;control study of patients diagnosed with PC drawn from the Lleida Population-Based Cancer Registry (Spain). Data were collected from the electronic health records. The cases were patients with PC who had a history of diabetes of &amp;amp;le;2 years (NODM) or &amp;amp;gt;2 years (LSDM), and the controls were patients with PC who did not have diabetes. The factors associated with NODM and LSDM were determined using adjusted odds ratios (aOR) via logistic regression models. Results: A total of 574 patients with PC were studied; 40.2% were diabetic (cases) and 59.8% were non-diabetic (controls). Of the cases, 24.7% had NODM and 75.3% had LSDM. The group with NODM was associated with the 65&amp;amp;ndash;74 age group (OR 3.09; 95% CI 1.47&amp;amp;ndash;6.49) and had higher levels of transaminase abnormalities (p &amp;amp;lt; 0.001) and hypertension (OR 13.50; 95% CI 3.33&amp;amp;ndash;54.8). The group with LSDM was associated with being aged 74 years or older (aOR 2.38; 95% CI 1.44&amp;amp;ndash;3.91), being overweight (aOR 1.96; 95% CI 1.15&amp;amp;ndash;3.35) and having coronary heart disease (aOR 2.17; 95% CI 1.29&amp;amp;ndash;3.66). The mean survival time was shorter in the LSDM group (315 days) than in the NODM group (433 days) (p &amp;amp;lt; 0.017). Conclusions: Co-diagnosis of PC and DM is common. DM and its comorbidities exhibit different characteristics depending on the time of diagnosis, prior to the onset of PC. These differences may help to identify patients who could benefit from monitoring strategies.</description>
	<pubDate>2026-11-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 226: Patients with Pancreatic Cancer with a History of Short- and Long-Term Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/226">doi: 10.3390/diabetology7110226</a></p>
	<p>Authors:
		Araceli Fuentes
		Josep Montserrat-Capdevila
		Isaac Torres
		Dídac Florensa
		Leonardo Galván
		Jordi Mateo
		Francesc Solsona
		Pere Godoy
		</p>
	<p>Background/Objectives: The relationship between pancreatic cancer (PC) and diabetes mellitus (DM) is complex. The aim was to investigate the prevalence of DM in patients with PC diagnosed within two years of the PC diagnosis (NODM) and in patients diagnosed more than two years previously (LSDM), and to determine the clinical profile and prognosis of these patients. Methods: A retrospective case&amp;amp;ndash;control study of patients diagnosed with PC drawn from the Lleida Population-Based Cancer Registry (Spain). Data were collected from the electronic health records. The cases were patients with PC who had a history of diabetes of &amp;amp;le;2 years (NODM) or &amp;amp;gt;2 years (LSDM), and the controls were patients with PC who did not have diabetes. The factors associated with NODM and LSDM were determined using adjusted odds ratios (aOR) via logistic regression models. Results: A total of 574 patients with PC were studied; 40.2% were diabetic (cases) and 59.8% were non-diabetic (controls). Of the cases, 24.7% had NODM and 75.3% had LSDM. The group with NODM was associated with the 65&amp;amp;ndash;74 age group (OR 3.09; 95% CI 1.47&amp;amp;ndash;6.49) and had higher levels of transaminase abnormalities (p &amp;amp;lt; 0.001) and hypertension (OR 13.50; 95% CI 3.33&amp;amp;ndash;54.8). The group with LSDM was associated with being aged 74 years or older (aOR 2.38; 95% CI 1.44&amp;amp;ndash;3.91), being overweight (aOR 1.96; 95% CI 1.15&amp;amp;ndash;3.35) and having coronary heart disease (aOR 2.17; 95% CI 1.29&amp;amp;ndash;3.66). The mean survival time was shorter in the LSDM group (315 days) than in the NODM group (433 days) (p &amp;amp;lt; 0.017). Conclusions: Co-diagnosis of PC and DM is common. DM and its comorbidities exhibit different characteristics depending on the time of diagnosis, prior to the onset of PC. These differences may help to identify patients who could benefit from monitoring strategies.</p>
	]]></content:encoded>

	<dc:title>Patients with Pancreatic Cancer with a History of Short- and Long-Term Diabetes</dc:title>
			<dc:creator>Araceli Fuentes</dc:creator>
			<dc:creator>Josep Montserrat-Capdevila</dc:creator>
			<dc:creator>Isaac Torres</dc:creator>
			<dc:creator>Dídac Florensa</dc:creator>
			<dc:creator>Leonardo Galván</dc:creator>
			<dc:creator>Jordi Mateo</dc:creator>
			<dc:creator>Francesc Solsona</dc:creator>
			<dc:creator>Pere Godoy</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110226</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-20</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-20</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>226</prism:startingPage>
		<prism:doi>10.3390/diabetology7110226</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/226</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/225">

	<title>Diabetology, Vol. 7, Pages 225: Diabetic Foot Ulcers: Complications, Healing, and Impact on Quality of Life</title>
	<link>https://www.mdpi.com/2673-4540/7/11/225</link>
	<description>Diabetic foot ulcers (DFUs) are a common and serious complication of diabetes, significantly affecting patients&amp;amp;rsquo; quality of life. This narrative review illustrates the incidence and clinical impact of DFUs, highlighting key associated complications including vascular compromise and associated tissue necrosis, infection, and limb loss. In this review, the diagnostic approaches, imaging modalities, and both surgical and non-surgical treatment strategies for managing and preventing these complications are described. These include revascularization procedures to aid in healing and limb salvage and correcting foot deformities resulting from Charcot&amp;amp;rsquo;s arthropathy. The review also outlines established and novel wound healing techniques with the use of bioengineered tissue substitutes, cell-based therapies and growth factors, among others. Collectively, these strategies emphasize the importance of a multidisciplinary approach to healing DFUs and preventing their reoccurrence.</description>
	<pubDate>2026-11-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 225: Diabetic Foot Ulcers: Complications, Healing, and Impact on Quality of Life</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/225">doi: 10.3390/diabetology7110225</a></p>
	<p>Authors:
		Madeleine M. Gomez
		Raisa G. Alvarez Vargas
		Sharanjeet K. Thind
		</p>
	<p>Diabetic foot ulcers (DFUs) are a common and serious complication of diabetes, significantly affecting patients&amp;amp;rsquo; quality of life. This narrative review illustrates the incidence and clinical impact of DFUs, highlighting key associated complications including vascular compromise and associated tissue necrosis, infection, and limb loss. In this review, the diagnostic approaches, imaging modalities, and both surgical and non-surgical treatment strategies for managing and preventing these complications are described. These include revascularization procedures to aid in healing and limb salvage and correcting foot deformities resulting from Charcot&amp;amp;rsquo;s arthropathy. The review also outlines established and novel wound healing techniques with the use of bioengineered tissue substitutes, cell-based therapies and growth factors, among others. Collectively, these strategies emphasize the importance of a multidisciplinary approach to healing DFUs and preventing their reoccurrence.</p>
	]]></content:encoded>

	<dc:title>Diabetic Foot Ulcers: Complications, Healing, and Impact on Quality of Life</dc:title>
			<dc:creator>Madeleine M. Gomez</dc:creator>
			<dc:creator>Raisa G. Alvarez Vargas</dc:creator>
			<dc:creator>Sharanjeet K. Thind</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110225</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-19</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-19</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>225</prism:startingPage>
		<prism:doi>10.3390/diabetology7110225</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/225</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/224">

	<title>Diabetology, Vol. 7, Pages 224: Global Research Trends on Climate- and Environment-Related Exposures and Diabetes: A Scientometric Analysis</title>
	<link>https://www.mdpi.com/2673-4540/7/11/224</link>
	<description>Aim: This study aimed to characterize the global scientific landscape, collaboration patterns, thematic structure, and temporal evolution of research on climate- and environment-related exposures, diabetes, and pancreatic endocrine and metabolic research between 2020 and 2025. Materials and Methods: A scientometric study was conducted using publications indexed in Scopus. The search was conducted on 12 September 2026 and was restricted to documents published between 2020 and 2025. A total of 1151 records were retrieved, of which 409 met the predefined eligibility criteria and were included in the final analysis. Bibliographic data were analyzed using Bibliometrix in R and VOSviewer. The analysis covered scientific output, citations, authorship, international collaboration, Bradford&amp;amp;rsquo;s Law of Scattering, keyword co-occurrences, thematic evolution and collaboration. The reporting process followed RAMIBS techniques. Results: The complete dataset consisted of 409 documents from 166 sources, showing a 20.8% growth rate and an average of 18.6 citations for each document. The literature has been contributed to by 2258 authors, averaging 8.3 co-authors per document with an international co-authorship rate of 31.3%. Most of the literature types were articles (n = 340), while the rest were reviews (n = 53). The Bradford model indicated seven core journals with a good fit (R2 = 0.9847; p = 0.14). Keyword analysis indicates that the most dominant keyword is air pollution. Thematic evolution showed increasing emphasis on environmental health, mortality, chronic disease, and climate change. Country collaboration was strongest across North America, Europe, and East Asia. Exploratory life-cycle modeling suggested continued growth in scientific production during the study period. Conclusions: Research linking climate change with pancreatic endocrine and metabolic health expanded rapidly and developed a strongly collaborative and interdisciplinary structure. Air pollution, particulate matter, and diabetes-related outcomes remained central, while recent research broadened toward environmental health and disease burden.</description>
	<pubDate>2026-11-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 224: Global Research Trends on Climate- and Environment-Related Exposures and Diabetes: A Scientometric Analysis</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/224">doi: 10.3390/diabetology7110224</a></p>
	<p>Authors:
		Isabel Pinedo-Torres
		Marlon Yovera-Aldana
		Ivan Calderon-Cortez
		Fran Espinoza-Carhuancho
		Juan Alvitez
		Frank Mayta-Tovalino
		</p>
	<p>Aim: This study aimed to characterize the global scientific landscape, collaboration patterns, thematic structure, and temporal evolution of research on climate- and environment-related exposures, diabetes, and pancreatic endocrine and metabolic research between 2020 and 2025. Materials and Methods: A scientometric study was conducted using publications indexed in Scopus. The search was conducted on 12 September 2026 and was restricted to documents published between 2020 and 2025. A total of 1151 records were retrieved, of which 409 met the predefined eligibility criteria and were included in the final analysis. Bibliographic data were analyzed using Bibliometrix in R and VOSviewer. The analysis covered scientific output, citations, authorship, international collaboration, Bradford&amp;amp;rsquo;s Law of Scattering, keyword co-occurrences, thematic evolution and collaboration. The reporting process followed RAMIBS techniques. Results: The complete dataset consisted of 409 documents from 166 sources, showing a 20.8% growth rate and an average of 18.6 citations for each document. The literature has been contributed to by 2258 authors, averaging 8.3 co-authors per document with an international co-authorship rate of 31.3%. Most of the literature types were articles (n = 340), while the rest were reviews (n = 53). The Bradford model indicated seven core journals with a good fit (R2 = 0.9847; p = 0.14). Keyword analysis indicates that the most dominant keyword is air pollution. Thematic evolution showed increasing emphasis on environmental health, mortality, chronic disease, and climate change. Country collaboration was strongest across North America, Europe, and East Asia. Exploratory life-cycle modeling suggested continued growth in scientific production during the study period. Conclusions: Research linking climate change with pancreatic endocrine and metabolic health expanded rapidly and developed a strongly collaborative and interdisciplinary structure. Air pollution, particulate matter, and diabetes-related outcomes remained central, while recent research broadened toward environmental health and disease burden.</p>
	]]></content:encoded>

	<dc:title>Global Research Trends on Climate- and Environment-Related Exposures and Diabetes: A Scientometric Analysis</dc:title>
			<dc:creator>Isabel Pinedo-Torres</dc:creator>
			<dc:creator>Marlon Yovera-Aldana</dc:creator>
			<dc:creator>Ivan Calderon-Cortez</dc:creator>
			<dc:creator>Fran Espinoza-Carhuancho</dc:creator>
			<dc:creator>Juan Alvitez</dc:creator>
			<dc:creator>Frank Mayta-Tovalino</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110224</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-19</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-19</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>224</prism:startingPage>
		<prism:doi>10.3390/diabetology7110224</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/224</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/223">

	<title>Diabetology, Vol. 7, Pages 223: Baseline Prediction of a Two-Year Reduction in a DIAL2-Derived Annual Cardiovascular Risk Estimate in Type 2 Diabetes: The DIAL-STEP Study</title>
	<link>https://www.mdpi.com/2673-4540/7/11/223</link>
	<description>Background: Longitudinal changes in calculated cardiovascular risk estimates vary among individuals with type 2 diabetes. We investigated whether baseline clinical data predict a relative decrease of at least 10% in a DIAL2-derived calibrated one-year risk estimate (P1Y) over approximately two years. Methods: This retrospective single-centre prediction analysis included 324 patients with valid paired scores from 332 retained clinical records. The primary elastic net model excluded treatment-group indicators; random forest was a comparator. We used three repetitions of nested stratified five-fold validation, conditional patient bootstrap intervals, and a separate bootstrap repeating model development. Additional analyses examined simpler predictor sets, continuous changes and age-fixed estimates. Results: The criterion was met by 135/324 patients (41.7%). Mean test-fold area under the receiver operating characteristic curve (AUROC) was 0.783 for elastic net and 0.784 for random forest; average precision was 0.754 and 0.744, and Brier score 0.183 and 0.187. Averaged held-out elastic net predictions had AUROC 0.786 (conditional 95% interval 0.738&amp;amp;ndash;0.834) and calibration slope 0.990. A four-variable benchmark had mean AUROC 0.770, and a DIAL2-component benchmark 0.792. At fixed baseline age, 230/324 (71.0%) met the criterion; the separately tuned model had mean AUROC 0.739. Median individual score change was &amp;amp;minus;0.10 percentage points. Conclusions: Baseline data discriminated subsequent calculated-score trajectories in internal validation. Most predictive information was contained in baseline score constituents, and classification was sensitive to age. The analysis does not establish clinical event reduction, causal drug effects or readiness for clinical use; independent validation and assessment of decision utility are required.</description>
	<pubDate>2026-11-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 223: Baseline Prediction of a Two-Year Reduction in a DIAL2-Derived Annual Cardiovascular Risk Estimate in Type 2 Diabetes: The DIAL-STEP Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/223">doi: 10.3390/diabetology7110223</a></p>
	<p>Authors:
		Provvidenza Villari
		Antonio Maria Labate
		</p>
	<p>Background: Longitudinal changes in calculated cardiovascular risk estimates vary among individuals with type 2 diabetes. We investigated whether baseline clinical data predict a relative decrease of at least 10% in a DIAL2-derived calibrated one-year risk estimate (P1Y) over approximately two years. Methods: This retrospective single-centre prediction analysis included 324 patients with valid paired scores from 332 retained clinical records. The primary elastic net model excluded treatment-group indicators; random forest was a comparator. We used three repetitions of nested stratified five-fold validation, conditional patient bootstrap intervals, and a separate bootstrap repeating model development. Additional analyses examined simpler predictor sets, continuous changes and age-fixed estimates. Results: The criterion was met by 135/324 patients (41.7%). Mean test-fold area under the receiver operating characteristic curve (AUROC) was 0.783 for elastic net and 0.784 for random forest; average precision was 0.754 and 0.744, and Brier score 0.183 and 0.187. Averaged held-out elastic net predictions had AUROC 0.786 (conditional 95% interval 0.738&amp;amp;ndash;0.834) and calibration slope 0.990. A four-variable benchmark had mean AUROC 0.770, and a DIAL2-component benchmark 0.792. At fixed baseline age, 230/324 (71.0%) met the criterion; the separately tuned model had mean AUROC 0.739. Median individual score change was &amp;amp;minus;0.10 percentage points. Conclusions: Baseline data discriminated subsequent calculated-score trajectories in internal validation. Most predictive information was contained in baseline score constituents, and classification was sensitive to age. The analysis does not establish clinical event reduction, causal drug effects or readiness for clinical use; independent validation and assessment of decision utility are required.</p>
	]]></content:encoded>

	<dc:title>Baseline Prediction of a Two-Year Reduction in a DIAL2-Derived Annual Cardiovascular Risk Estimate in Type 2 Diabetes: The DIAL-STEP Study</dc:title>
			<dc:creator>Provvidenza Villari</dc:creator>
			<dc:creator>Antonio Maria Labate</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110223</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-17</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-17</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>223</prism:startingPage>
		<prism:doi>10.3390/diabetology7110223</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/223</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/222">

	<title>Diabetology, Vol. 7, Pages 222: Equivalence of Biosimilar and Innovator Semaglutide in Adults with Type 2 Diabetes: A 52-Week Real-World Target Trial Emulation</title>
	<link>https://www.mdpi.com/2673-4540/7/11/222</link>
	<description>Background/Objectives: Lower-cost biosimilar semaglutide products are increasingly used in settings where the innovator product is unaffordable, yet long-term comparative clinical data from the populations that use them are scarce. We compared the 52-week effectiveness, persistence and safety of biosimilar and innovator semaglutide in adults with type 2 diabetes. Methods: We emulated a target equivalence trial using routinely collected records of 1000 adults (18&amp;amp;ndash;75 years; HbA1c 7.0&amp;amp;ndash;10.0%) who initiated once-weekly biosimilar (n = 500) or innovator (n = 500) semaglutide at two specialist diabetes centres in Islamabad, Pakistan, between December 2024 and July 2025, with follow-up to July 2026. Confounding was addressed by propensity score overlap weighting on 14 baseline covariates. The primary outcome, change in HbA1c from baseline to week 52 among all initiators, was estimated by overlap-weighted analysis of covariance after multiple imputation; equivalence required the 90% confidence interval (CI) to lie within &amp;amp;plusmn;0.30 percentage points. Results: Overlap weighting achieved exact covariate balance, with an effective sample size of 976. HbA1c decreased by 1.42 and 1.39 percentage points with biosimilar and innovator semaglutide, respectively (adjusted difference &amp;amp;minus;0.03; 90% CI &amp;amp;minus;0.12 to 0.07), meeting the equivalence criterion; all eight sensitivity analyses concurred. Body weight decreased by 6.3% and 6.2% (difference &amp;amp;minus;0.13%; 95% CI &amp;amp;minus;0.71 to 0.45), and none of 27 secondary cardiometabolic outcomes differed after false-discovery-rate control. Persistence at 52 weeks was 93.2% and 94.6% (hazard ratio for discontinuation 1.29; 95% CI 0.77&amp;amp;ndash;2.14), and recorded adverse events were comparable. Conclusions: In routine practice, biosimilar semaglutide was equivalent to innovator semaglutide in HbA1c reduction over 52 weeks, with comparable weight, cardiometabolic, persistence and safety outcomes. Prospective multicentre studies including immunogenicity assessment are warranted.</description>
	<pubDate>2026-11-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 222: Equivalence of Biosimilar and Innovator Semaglutide in Adults with Type 2 Diabetes: A 52-Week Real-World Target Trial Emulation</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/222">doi: 10.3390/diabetology7110222</a></p>
	<p>Authors:
		Nauman Niaz
		Muhammad Umar Wahab
		Shanila Akhtar
		Azra Rafiq
		Tooba Malik
		Muhammad Daoud Butt
		</p>
	<p>Background/Objectives: Lower-cost biosimilar semaglutide products are increasingly used in settings where the innovator product is unaffordable, yet long-term comparative clinical data from the populations that use them are scarce. We compared the 52-week effectiveness, persistence and safety of biosimilar and innovator semaglutide in adults with type 2 diabetes. Methods: We emulated a target equivalence trial using routinely collected records of 1000 adults (18&amp;amp;ndash;75 years; HbA1c 7.0&amp;amp;ndash;10.0%) who initiated once-weekly biosimilar (n = 500) or innovator (n = 500) semaglutide at two specialist diabetes centres in Islamabad, Pakistan, between December 2024 and July 2025, with follow-up to July 2026. Confounding was addressed by propensity score overlap weighting on 14 baseline covariates. The primary outcome, change in HbA1c from baseline to week 52 among all initiators, was estimated by overlap-weighted analysis of covariance after multiple imputation; equivalence required the 90% confidence interval (CI) to lie within &amp;amp;plusmn;0.30 percentage points. Results: Overlap weighting achieved exact covariate balance, with an effective sample size of 976. HbA1c decreased by 1.42 and 1.39 percentage points with biosimilar and innovator semaglutide, respectively (adjusted difference &amp;amp;minus;0.03; 90% CI &amp;amp;minus;0.12 to 0.07), meeting the equivalence criterion; all eight sensitivity analyses concurred. Body weight decreased by 6.3% and 6.2% (difference &amp;amp;minus;0.13%; 95% CI &amp;amp;minus;0.71 to 0.45), and none of 27 secondary cardiometabolic outcomes differed after false-discovery-rate control. Persistence at 52 weeks was 93.2% and 94.6% (hazard ratio for discontinuation 1.29; 95% CI 0.77&amp;amp;ndash;2.14), and recorded adverse events were comparable. Conclusions: In routine practice, biosimilar semaglutide was equivalent to innovator semaglutide in HbA1c reduction over 52 weeks, with comparable weight, cardiometabolic, persistence and safety outcomes. Prospective multicentre studies including immunogenicity assessment are warranted.</p>
	]]></content:encoded>

	<dc:title>Equivalence of Biosimilar and Innovator Semaglutide in Adults with Type 2 Diabetes: A 52-Week Real-World Target Trial Emulation</dc:title>
			<dc:creator>Nauman Niaz</dc:creator>
			<dc:creator>Muhammad Umar Wahab</dc:creator>
			<dc:creator>Shanila Akhtar</dc:creator>
			<dc:creator>Azra Rafiq</dc:creator>
			<dc:creator>Tooba Malik</dc:creator>
			<dc:creator>Muhammad Daoud Butt</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110222</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-15</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-15</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>222</prism:startingPage>
		<prism:doi>10.3390/diabetology7110222</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/222</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/221">

	<title>Diabetology, Vol. 7, Pages 221: Sleep Health and Glucose&amp;ndash;Insulin Homeostasis in Adults: A Scoping Review</title>
	<link>https://www.mdpi.com/2673-4540/7/11/221</link>
	<description>Background/Objectives: Type 2 diabetes (T2D) is a growing global health burden, affecting over 450 million people worldwide. Identifying modifiable behavioral risk factors impacting glucose metabolism is essential for T2D prevention. Sleep has emerged as a key, yet underrecognized determinant of cardiometabolic health. This scoping review aimed to synthesize evidence published between 2020 and 2025 evaluating the relationship between sleep and glucose&amp;amp;ndash;insulin homeostasis in adults. Methods: A systematic scoping review was conducted following PRISMA guidelines, using sleep and glucose/insulin-related keywords. Primary studies in English involving men and women (&amp;amp;ge;18 years) reporting objective or subjective sleep measures alongside glucose&amp;amp;ndash;insulin outcomes from PubMed were included. Results: In sum, 42 studies were retained out of 479 identified records. Several, but not all, studies showed that experimentally shortened sleep duration was associated with some impairment of glucose&amp;amp;ndash;insulin homeostasis, including elevated fasting glucose, fasting insulin, glycated hemoglobin, and insulin resistance. Conversely, extending sleep duration among short sleepers was associated with improved glycemic regulation. Studies including subjective assessments of sleep yielded similar associations, with poor sleep quality and short self-reported sleep duration linked to impaired glucose metabolism and higher T2D risk. Sleep disorders further compound dysregulation of glucose&amp;amp;ndash;insulin homeostasis, with dose-dependent effects observed for both obstructive sleep apnea severity and restless leg syndrome. Conclusions: Sleep is a promising target to improve glycemic control, although confirmatory clinical trials are needed. Screening for sleep disorders and promoting healthy sleep habits may be integrated for T2D risk reduction. Future research should assess multiple sleep dimensions in relation to glucose&amp;amp;ndash;insulin regulation to inform clinical practice.</description>
	<pubDate>2026-11-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 221: Sleep Health and Glucose&amp;ndash;Insulin Homeostasis in Adults: A Scoping Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/221">doi: 10.3390/diabetology7110221</a></p>
	<p>Authors:
		Paul Peyrel
		Chrysler Mitchell
		Pascale Mauriège
		Denis R. Joanisse
		Prachi Singh
		</p>
	<p>Background/Objectives: Type 2 diabetes (T2D) is a growing global health burden, affecting over 450 million people worldwide. Identifying modifiable behavioral risk factors impacting glucose metabolism is essential for T2D prevention. Sleep has emerged as a key, yet underrecognized determinant of cardiometabolic health. This scoping review aimed to synthesize evidence published between 2020 and 2025 evaluating the relationship between sleep and glucose&amp;amp;ndash;insulin homeostasis in adults. Methods: A systematic scoping review was conducted following PRISMA guidelines, using sleep and glucose/insulin-related keywords. Primary studies in English involving men and women (&amp;amp;ge;18 years) reporting objective or subjective sleep measures alongside glucose&amp;amp;ndash;insulin outcomes from PubMed were included. Results: In sum, 42 studies were retained out of 479 identified records. Several, but not all, studies showed that experimentally shortened sleep duration was associated with some impairment of glucose&amp;amp;ndash;insulin homeostasis, including elevated fasting glucose, fasting insulin, glycated hemoglobin, and insulin resistance. Conversely, extending sleep duration among short sleepers was associated with improved glycemic regulation. Studies including subjective assessments of sleep yielded similar associations, with poor sleep quality and short self-reported sleep duration linked to impaired glucose metabolism and higher T2D risk. Sleep disorders further compound dysregulation of glucose&amp;amp;ndash;insulin homeostasis, with dose-dependent effects observed for both obstructive sleep apnea severity and restless leg syndrome. Conclusions: Sleep is a promising target to improve glycemic control, although confirmatory clinical trials are needed. Screening for sleep disorders and promoting healthy sleep habits may be integrated for T2D risk reduction. Future research should assess multiple sleep dimensions in relation to glucose&amp;amp;ndash;insulin regulation to inform clinical practice.</p>
	]]></content:encoded>

	<dc:title>Sleep Health and Glucose&amp;amp;ndash;Insulin Homeostasis in Adults: A Scoping Review</dc:title>
			<dc:creator>Paul Peyrel</dc:creator>
			<dc:creator>Chrysler Mitchell</dc:creator>
			<dc:creator>Pascale Mauriège</dc:creator>
			<dc:creator>Denis R. Joanisse</dc:creator>
			<dc:creator>Prachi Singh</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110221</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-12</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-12</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>221</prism:startingPage>
		<prism:doi>10.3390/diabetology7110221</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/221</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/220">

	<title>Diabetology, Vol. 7, Pages 220: Adherence, Persistence and Discontinuation of Incretin Mimetics and Sodium Glucose Transporter 2 Inhibitors: A Narrative Review</title>
	<link>https://www.mdpi.com/2673-4540/7/11/220</link>
	<description>Type 2 diabetes mellitus (T2D) requires long-term pharmacological management, and real-world treatment effectiveness depends critically on adherence, persistence and the appropriate management of discontinuation. This narrative review examines the evidence on these three dimensions of medication-taking behaviour, with a focus on glucagon-like peptide-1 receptor agonists (GLP-1RAs), the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide and sodium-glucose cotransporter-2 inhibitors (SGLT2i), whose cardiorenal and metabolic benefits can only be realized if treatment is initiated and maintained over time. We discuss the heterogeneity of adherence and persistence definitions and measurement methods. Roughly half of patients with T2D achieve commonly used adherence thresholds, and both adherence and persistence decline over time; suboptimal adherence is associated with poorer glycaemic control and higher rates of hospitalization and mortality. Once-weekly GLP-1RA formulations are generally associated with better persistence than daily or oral regimens, whereas SGLT2i adherence is comparable to, or in some cohorts better than, that of GLP-1RAs. Current data do not show that dual agonism improves tolerability or persistence. Discontinuation is frequent, often temporary, sometimes clinically appropriate and, when unplanned, associated with loss of metabolic and cardiorenal benefit. We review strategies to improve adherence and persistence, including education, proactive management of adverse effects, early follow-up, attention to emotional well-being and multicomponent interventions, and argue for a person-centred approach that identifies individual barriers rather than labelling patients as &amp;amp;ldquo;non-adherent&amp;amp;rdquo;.</description>
	<pubDate>2026-11-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 220: Adherence, Persistence and Discontinuation of Incretin Mimetics and Sodium Glucose Transporter 2 Inhibitors: A Narrative Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/220">doi: 10.3390/diabetology7110220</a></p>
	<p>Authors:
		Stefano Ciardullo
		Martina Botta
		Gianluca Perseghin
		</p>
	<p>Type 2 diabetes mellitus (T2D) requires long-term pharmacological management, and real-world treatment effectiveness depends critically on adherence, persistence and the appropriate management of discontinuation. This narrative review examines the evidence on these three dimensions of medication-taking behaviour, with a focus on glucagon-like peptide-1 receptor agonists (GLP-1RAs), the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide and sodium-glucose cotransporter-2 inhibitors (SGLT2i), whose cardiorenal and metabolic benefits can only be realized if treatment is initiated and maintained over time. We discuss the heterogeneity of adherence and persistence definitions and measurement methods. Roughly half of patients with T2D achieve commonly used adherence thresholds, and both adherence and persistence decline over time; suboptimal adherence is associated with poorer glycaemic control and higher rates of hospitalization and mortality. Once-weekly GLP-1RA formulations are generally associated with better persistence than daily or oral regimens, whereas SGLT2i adherence is comparable to, or in some cohorts better than, that of GLP-1RAs. Current data do not show that dual agonism improves tolerability or persistence. Discontinuation is frequent, often temporary, sometimes clinically appropriate and, when unplanned, associated with loss of metabolic and cardiorenal benefit. We review strategies to improve adherence and persistence, including education, proactive management of adverse effects, early follow-up, attention to emotional well-being and multicomponent interventions, and argue for a person-centred approach that identifies individual barriers rather than labelling patients as &amp;amp;ldquo;non-adherent&amp;amp;rdquo;.</p>
	]]></content:encoded>

	<dc:title>Adherence, Persistence and Discontinuation of Incretin Mimetics and Sodium Glucose Transporter 2 Inhibitors: A Narrative Review</dc:title>
			<dc:creator>Stefano Ciardullo</dc:creator>
			<dc:creator>Martina Botta</dc:creator>
			<dc:creator>Gianluca Perseghin</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110220</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-11</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-11</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>220</prism:startingPage>
		<prism:doi>10.3390/diabetology7110220</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/220</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/219">

	<title>Diabetology, Vol. 7, Pages 219: Barriers and Facilitators to Physical Activity Among Children with Type 1 Diabetes: A Qualitative Study of Parents&amp;rsquo; and Healthcare Providers&amp;rsquo; Perspectives in Saudi Arabia</title>
	<link>https://www.mdpi.com/2673-4540/7/11/219</link>
	<description>Background/Objectives: Regular physical activity is an important component of healthy development and diabetes management for children with type 1 diabetes (T1D). However, concerns about hypoglycemia, limited knowledge of T1D-related physical activity and glucose management, inadequate school support, and other contextual factors may restrict participation. This qualitative study explored barriers and facilitators influencing physical activity among children with T1D from the perspectives of parents and healthcare providers in Saudi Arabia. Methods: One-to-one semi-structured interviews were conducted with parents of children with T1D and healthcare providers involved in pediatric diabetes care. Participants were purposively recruited at King Saud Medical City Pediatric Hospital. Interviews were conducted in February 2025 and analyzed using thematic analysis, with the Social Ecological Model guiding the interview domains and interpretation. Twenty-three participants were included: 13 parents and 10 healthcare providers. Results: Six themes were identified: (1) physical activity practices and preferences; (2) barriers to physical activity; (3) strategies for managing blood glucose during activity; (4) parental and professional support systems; (5) need for structured programs; and (6) societal awareness and stigma. Fear of hypoglycemia, limited school preparedness, lack of awareness, and limited routine activity were important barriers, while glucose monitoring, family and professional guidance, and structured support were described as facilitators. Conclusions: The findings support the need for practical education, trained school personnel, structured physical activity opportunities, and coordinated support across families, healthcare services, schools, and communities.</description>
	<pubDate>2026-11-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 219: Barriers and Facilitators to Physical Activity Among Children with Type 1 Diabetes: A Qualitative Study of Parents&amp;rsquo; and Healthcare Providers&amp;rsquo; Perspectives in Saudi Arabia</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/219">doi: 10.3390/diabetology7110219</a></p>
	<p>Authors:
		Huda Al Qarni
		Manal A. Alhumud
		Maram Ali Alwadi
		</p>
	<p>Background/Objectives: Regular physical activity is an important component of healthy development and diabetes management for children with type 1 diabetes (T1D). However, concerns about hypoglycemia, limited knowledge of T1D-related physical activity and glucose management, inadequate school support, and other contextual factors may restrict participation. This qualitative study explored barriers and facilitators influencing physical activity among children with T1D from the perspectives of parents and healthcare providers in Saudi Arabia. Methods: One-to-one semi-structured interviews were conducted with parents of children with T1D and healthcare providers involved in pediatric diabetes care. Participants were purposively recruited at King Saud Medical City Pediatric Hospital. Interviews were conducted in February 2025 and analyzed using thematic analysis, with the Social Ecological Model guiding the interview domains and interpretation. Twenty-three participants were included: 13 parents and 10 healthcare providers. Results: Six themes were identified: (1) physical activity practices and preferences; (2) barriers to physical activity; (3) strategies for managing blood glucose during activity; (4) parental and professional support systems; (5) need for structured programs; and (6) societal awareness and stigma. Fear of hypoglycemia, limited school preparedness, lack of awareness, and limited routine activity were important barriers, while glucose monitoring, family and professional guidance, and structured support were described as facilitators. Conclusions: The findings support the need for practical education, trained school personnel, structured physical activity opportunities, and coordinated support across families, healthcare services, schools, and communities.</p>
	]]></content:encoded>

	<dc:title>Barriers and Facilitators to Physical Activity Among Children with Type 1 Diabetes: A Qualitative Study of Parents&amp;amp;rsquo; and Healthcare Providers&amp;amp;rsquo; Perspectives in Saudi Arabia</dc:title>
			<dc:creator>Huda Al Qarni</dc:creator>
			<dc:creator>Manal A. Alhumud</dc:creator>
			<dc:creator>Maram Ali Alwadi</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110219</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-09</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-09</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>219</prism:startingPage>
		<prism:doi>10.3390/diabetology7110219</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/219</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/218">

	<title>Diabetology, Vol. 7, Pages 218: Association Between the Acceptability of Dietary Weighing and Clinical Characteristics in Patients with Type 2 Diabetes: Exploration of a Potential Screening Indicator of Poor Adherence</title>
	<link>https://www.mdpi.com/2673-4540/7/11/218</link>
	<description>Background/Objectives: Although dietary therapy forms the cornerstone of type 2 diabetes management, strict regimens frequently impose significant cognitive and psychosocial burdens, reducing adherence. This cross-sectional study investigated patient acceptability of individual dietary advice commonly used in nutritional counseling and its clinical associations, aiming to identify a practical screening method for potentially poor adherence. Methods: Among 128 outpatients with type 2 diabetes receiving regular nutritional counseling, patients evaluated their acceptability of 13 standard dietary advice items using a 4-point scale (0 points = Cannot do, 3 points = Can do). We comprehensively analyzed correlations between item-specific acceptability scores and clinical characteristics, including hemoglobin A1c (HbA1c), dietary adherence, and complications. Results: While acceptability for eating vegetables before carbohydrates was extremely high (98%), weighing staple foods and seasonings yielded the highest proportion of 0-point responses (17%, 22 patients). The acceptability score for weighing correlated positively with the nutritional counseling adherence rate (&amp;amp;rho; = 0.25) and negatively with HbA1c (&amp;amp;rho; = &amp;amp;minus;0.19), estimated salt intake (&amp;amp;rho; = &amp;amp;minus;0.28), and diabetic retinopathy (&amp;amp;rho; = &amp;amp;minus;0.28) (all p &amp;amp;lt; 0.05). In multivariate logistic regression, the 0-point response to weighing remained significantly associated with lower nutritional adherence (odds ratio [OR] = 0.36, p = 0.02), higher salt intake (OR = 1.96, p &amp;amp;lt; 0.01), and elevated HbA1c (OR = 1.53, p = 0.04), even after adjusting for covariates. Conclusions: Low acceptability of weighing staple foods and seasonings was associated with poorer dietary adherence and worse glycemic control in patients with type 2 diabetes. Assessing this item may help identify patients who could benefit from individualized nutritional counseling. Further prospective studies are needed to validate its utility as a screening indicator.</description>
	<pubDate>2026-11-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 218: Association Between the Acceptability of Dietary Weighing and Clinical Characteristics in Patients with Type 2 Diabetes: Exploration of a Potential Screening Indicator of Poor Adherence</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/218">doi: 10.3390/diabetology7110218</a></p>
	<p>Authors:
		Sachiko Kawakubo
		Haruka Osada
		Azusa Yamamoto
		Kaori Shimada
		Azusa Ishikawa
		Sayaka Shinozuka
		Marina Yamashita
		Minami Yokouchi
		Naoko Wada
		Hiroyuki Ito
		</p>
	<p>Background/Objectives: Although dietary therapy forms the cornerstone of type 2 diabetes management, strict regimens frequently impose significant cognitive and psychosocial burdens, reducing adherence. This cross-sectional study investigated patient acceptability of individual dietary advice commonly used in nutritional counseling and its clinical associations, aiming to identify a practical screening method for potentially poor adherence. Methods: Among 128 outpatients with type 2 diabetes receiving regular nutritional counseling, patients evaluated their acceptability of 13 standard dietary advice items using a 4-point scale (0 points = Cannot do, 3 points = Can do). We comprehensively analyzed correlations between item-specific acceptability scores and clinical characteristics, including hemoglobin A1c (HbA1c), dietary adherence, and complications. Results: While acceptability for eating vegetables before carbohydrates was extremely high (98%), weighing staple foods and seasonings yielded the highest proportion of 0-point responses (17%, 22 patients). The acceptability score for weighing correlated positively with the nutritional counseling adherence rate (&amp;amp;rho; = 0.25) and negatively with HbA1c (&amp;amp;rho; = &amp;amp;minus;0.19), estimated salt intake (&amp;amp;rho; = &amp;amp;minus;0.28), and diabetic retinopathy (&amp;amp;rho; = &amp;amp;minus;0.28) (all p &amp;amp;lt; 0.05). In multivariate logistic regression, the 0-point response to weighing remained significantly associated with lower nutritional adherence (odds ratio [OR] = 0.36, p = 0.02), higher salt intake (OR = 1.96, p &amp;amp;lt; 0.01), and elevated HbA1c (OR = 1.53, p = 0.04), even after adjusting for covariates. Conclusions: Low acceptability of weighing staple foods and seasonings was associated with poorer dietary adherence and worse glycemic control in patients with type 2 diabetes. Assessing this item may help identify patients who could benefit from individualized nutritional counseling. Further prospective studies are needed to validate its utility as a screening indicator.</p>
	]]></content:encoded>

	<dc:title>Association Between the Acceptability of Dietary Weighing and Clinical Characteristics in Patients with Type 2 Diabetes: Exploration of a Potential Screening Indicator of Poor Adherence</dc:title>
			<dc:creator>Sachiko Kawakubo</dc:creator>
			<dc:creator>Haruka Osada</dc:creator>
			<dc:creator>Azusa Yamamoto</dc:creator>
			<dc:creator>Kaori Shimada</dc:creator>
			<dc:creator>Azusa Ishikawa</dc:creator>
			<dc:creator>Sayaka Shinozuka</dc:creator>
			<dc:creator>Marina Yamashita</dc:creator>
			<dc:creator>Minami Yokouchi</dc:creator>
			<dc:creator>Naoko Wada</dc:creator>
			<dc:creator>Hiroyuki Ito</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110218</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-06</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-06</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>218</prism:startingPage>
		<prism:doi>10.3390/diabetology7110218</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/218</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/217">

	<title>Diabetology, Vol. 7, Pages 217: Extended-Wear Insulin Infusion Sets in People with Type 1 Diabetes: A Scoping Review</title>
	<link>https://www.mdpi.com/2673-4540/7/11/217</link>
	<description>Background/Objectives: Infusion sets are essential for continuous subcutaneous insulin infusion. Conventional sets require replacement every 2&amp;amp;ndash;3 days, while recent research has focused on extending wear time to reduce treatment burden and support automated insulin delivery. We aimed to characterize evidence on extended-wear infusion sets (&amp;amp;gt;3 and &amp;amp;le;7 days) in people with type 1 diabetes (T1D), focusing on survival, safety, insulin delivery, glycemic outcomes, pharmacokinetic/pharmacodynamic parameters, and user experience. Methods: A scoping review was conducted according to PRISMA-ScR. The protocol was registered in the Open Science Framework (OSF; DOI: 10.17605/OSF.IO/TNKJ5). MEDLINE/PubMed, Embase, Scopus, Web of Science Core Collection, and Cochrane CENTRAL were searched for studies published from 1 January 2020 to 4 September 2026. Eligible studies evaluated infusion sets worn for &amp;amp;gt;3 days in people with T1D and reported extended-wear outcomes. Results: Of 229 records identified, 103 unique references were screened and 11 underwent full-text assessment. Ten publications met the inclusion criteria, representing 9 independent sources of evidence. In the largest studies, 7-day set survival ranged from 77.8% to 95%, depending on device and failure criteria. Some studies reported deterioration in glycemic or pharmacodynamic measures with prolonged wear, whereas others showed good tolerability and reduced burden from set changes. Conclusions: Extended-wear infusion sets can remain functional for 4&amp;amp;ndash;7 days in a substantial proportion of people with T1D, although performance may decline with increasing wear time. Evidence is limited by heterogeneity in devices and study designs, small samples, few direct comparisons, and difficulty isolating the infusion set effect from other technological components. Independent comparative studies are needed to establish safety, insulin delivery stability, and clinical benefit.</description>
	<pubDate>2026-11-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 217: Extended-Wear Insulin Infusion Sets in People with Type 1 Diabetes: A Scoping Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/217">doi: 10.3390/diabetology7110217</a></p>
	<p>Authors:
		Gonzalo Díaz Soto
		María de la O Nieto de la Marca
		Sofía Del Amo Simón
		Marta Sánchez Ibáñez
		Pablo Fernández Velasco
		</p>
	<p>Background/Objectives: Infusion sets are essential for continuous subcutaneous insulin infusion. Conventional sets require replacement every 2&amp;amp;ndash;3 days, while recent research has focused on extending wear time to reduce treatment burden and support automated insulin delivery. We aimed to characterize evidence on extended-wear infusion sets (&amp;amp;gt;3 and &amp;amp;le;7 days) in people with type 1 diabetes (T1D), focusing on survival, safety, insulin delivery, glycemic outcomes, pharmacokinetic/pharmacodynamic parameters, and user experience. Methods: A scoping review was conducted according to PRISMA-ScR. The protocol was registered in the Open Science Framework (OSF; DOI: 10.17605/OSF.IO/TNKJ5). MEDLINE/PubMed, Embase, Scopus, Web of Science Core Collection, and Cochrane CENTRAL were searched for studies published from 1 January 2020 to 4 September 2026. Eligible studies evaluated infusion sets worn for &amp;amp;gt;3 days in people with T1D and reported extended-wear outcomes. Results: Of 229 records identified, 103 unique references were screened and 11 underwent full-text assessment. Ten publications met the inclusion criteria, representing 9 independent sources of evidence. In the largest studies, 7-day set survival ranged from 77.8% to 95%, depending on device and failure criteria. Some studies reported deterioration in glycemic or pharmacodynamic measures with prolonged wear, whereas others showed good tolerability and reduced burden from set changes. Conclusions: Extended-wear infusion sets can remain functional for 4&amp;amp;ndash;7 days in a substantial proportion of people with T1D, although performance may decline with increasing wear time. Evidence is limited by heterogeneity in devices and study designs, small samples, few direct comparisons, and difficulty isolating the infusion set effect from other technological components. Independent comparative studies are needed to establish safety, insulin delivery stability, and clinical benefit.</p>
	]]></content:encoded>

	<dc:title>Extended-Wear Insulin Infusion Sets in People with Type 1 Diabetes: A Scoping Review</dc:title>
			<dc:creator>Gonzalo Díaz Soto</dc:creator>
			<dc:creator>María de la O Nieto de la Marca</dc:creator>
			<dc:creator>Sofía Del Amo Simón</dc:creator>
			<dc:creator>Marta Sánchez Ibáñez</dc:creator>
			<dc:creator>Pablo Fernández Velasco</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110217</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-06</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-06</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>217</prism:startingPage>
		<prism:doi>10.3390/diabetology7110217</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/217</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/216">

	<title>Diabetology, Vol. 7, Pages 216: When Mitochondrial Quality Control Is Overwhelmed: A Capacity&amp;ndash;Burden Perspective on Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/11/216</link>
	<description>Mitochondrial quality control (MQC) is essential for maintaining mitochondrial integrity, metabolic flexibility, and cellular homeostasis. Rather than functioning as isolated pathways, molecular repair and proteostasis, mitochondrial dynamics, mitophagy, and mitochondrial biogenesis form an interconnected network that continuously detects, compensates for, removes, and replaces damaged mitochondrial components. In type 2 diabetes (T2D), chronic nutrient excess, metabolic stress, and low-grade inflammation disrupt this network. Increased metabolic flux and electron pressure within the respiratory chain promote excessive reactive oxygen species (ROS) production and oxidative damage to mitochondrial proteins, lipids, and mitochondrial DNA (mtDNA). Persistent stress challenges molecular repair capacity, alters the balance of mitochondrial fusion and fission, impairs mitophagic clearance, and compromises mitochondrial renewal. These abnormalities interact with one another, promoting the accumulation of dysfunctional mitochondria and establishing a self-reinforcing cycle of oxidative stress, inflammation, insulin resistance, and pancreatic &amp;amp;beta;-cell dysfunction. This review examines the molecular mechanisms through which metabolic stress disrupts the MQC network in T2D and considers the tissue-specific consequences of impaired MQC. This further discusses established antidiabetic therapies and emerging mitochondria-targeted interventions that may modulate different components of the MQC network, including oxidative stress, molecular repair, mitochondrial dynamics, mitophagy, and biogenesis. By framing MQC as an integrated and interconnected network rather than a series of strictly sequential or hierarchical defenses, this review provides a framework for understanding how impaired MQC contributes to T2D pathogenesis and for identifying therapeutic strategies aimed at restoring mitochondrial and metabolic homeostasis.</description>
	<pubDate>2026-11-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 216: When Mitochondrial Quality Control Is Overwhelmed: A Capacity&amp;ndash;Burden Perspective on Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/216">doi: 10.3390/diabetology7110216</a></p>
	<p>Authors:
		Yoshimi Homma
		</p>
	<p>Mitochondrial quality control (MQC) is essential for maintaining mitochondrial integrity, metabolic flexibility, and cellular homeostasis. Rather than functioning as isolated pathways, molecular repair and proteostasis, mitochondrial dynamics, mitophagy, and mitochondrial biogenesis form an interconnected network that continuously detects, compensates for, removes, and replaces damaged mitochondrial components. In type 2 diabetes (T2D), chronic nutrient excess, metabolic stress, and low-grade inflammation disrupt this network. Increased metabolic flux and electron pressure within the respiratory chain promote excessive reactive oxygen species (ROS) production and oxidative damage to mitochondrial proteins, lipids, and mitochondrial DNA (mtDNA). Persistent stress challenges molecular repair capacity, alters the balance of mitochondrial fusion and fission, impairs mitophagic clearance, and compromises mitochondrial renewal. These abnormalities interact with one another, promoting the accumulation of dysfunctional mitochondria and establishing a self-reinforcing cycle of oxidative stress, inflammation, insulin resistance, and pancreatic &amp;amp;beta;-cell dysfunction. This review examines the molecular mechanisms through which metabolic stress disrupts the MQC network in T2D and considers the tissue-specific consequences of impaired MQC. This further discusses established antidiabetic therapies and emerging mitochondria-targeted interventions that may modulate different components of the MQC network, including oxidative stress, molecular repair, mitochondrial dynamics, mitophagy, and biogenesis. By framing MQC as an integrated and interconnected network rather than a series of strictly sequential or hierarchical defenses, this review provides a framework for understanding how impaired MQC contributes to T2D pathogenesis and for identifying therapeutic strategies aimed at restoring mitochondrial and metabolic homeostasis.</p>
	]]></content:encoded>

	<dc:title>When Mitochondrial Quality Control Is Overwhelmed: A Capacity&amp;amp;ndash;Burden Perspective on Type 2 Diabetes</dc:title>
			<dc:creator>Yoshimi Homma</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110216</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-05</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-05</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>216</prism:startingPage>
		<prism:doi>10.3390/diabetology7110216</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/216</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/215">

	<title>Diabetology, Vol. 7, Pages 215: Polypharmacy in the Spanish Population with Diabetes: Sociodemographic, Clinical, and Lifestyle Determinants Based on the 2020 and 2023 National Health Surveys</title>
	<link>https://www.mdpi.com/2673-4540/7/11/215</link>
	<description>Background/Objectives. Polypharmacy is increasingly common among people with diabetes, who frequently accumulate comorbidities and guideline-driven drug therapies. This study aimed to estimate the prevalence of polypharmacy among Spanish adults with diabetes and to identify its sociodemographic, clinical, and lifestyle determinants, comparing data from 2020 and 2023. Methods. A cross-sectional study was done. The year 2020 European Health Interview Survey in Spain and the year 2023 Spanish National Health Survey were the databases used. We applied a 1:1 matching by age, sex, and autonomous community of residence. Adults with physician-diagnosed diabetes were compared with matched controls without diabetes. Polypharmacy was defined as the concurrent use of 5 or more of 10 selected non-antidiabetic drug classes. Sex-specific univariable and multivariable logistic regression models were fitted. Results. The prevalence of polypharmacy among participants with diabetes increased from 18.5% in 2020 to 22.1% in 2023 versus 7.7% and 11.2% among matched controls. In 2023, polypharmacy was more frequent among participants with diabetes than among their matched controls in both sexes, affecting 29.3% of women (vs. 16.1% of controls) and 14.8% of men (vs. 6.2% of controls). Poor self-perceived health (OR 4.84, 95% CI 2.94&amp;amp;ndash;7.99, in men; OR 4.13, 95% CI 2.82&amp;amp;ndash;6.06, in women), chronic mental health problems (OR 4.36, 95% CI 3.01&amp;amp;ndash;6.31, in men; OR 4.19, 95% CI 3.22&amp;amp;ndash;5.44, in women), hypertension (OR 2.74, 95% CI 1.81&amp;amp;ndash;4.15 in men; OR 3.52, 95% CI 2.58&amp;amp;ndash;4.80, in women), and, among women, older age (OR 1.03, 95% CI 1.01&amp;amp;ndash;1.04, per year) and alcohol consumption (OR 1.60, 95% CI 1.16&amp;amp;ndash;2.22) were independent determinants of polypharmacy in the group with diabetes. Conclusions. Polypharmacy is highly prevalent among Spanish adults with diabetes&amp;amp;mdash;particularly older women with multimorbidity&amp;amp;mdash;and rose between 2020 and 2023 in parallel with population-wide trends. Integrated chronic care models and systematic deprescribing strategies, rather than single-disease prescribing approaches, are needed.</description>
	<pubDate>2026-11-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 215: Polypharmacy in the Spanish Population with Diabetes: Sociodemographic, Clinical, and Lifestyle Determinants Based on the 2020 and 2023 National Health Surveys</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/215">doi: 10.3390/diabetology7110215</a></p>
	<p>Authors:
		Tomás Chivato-Martín-Falquina
		Elena Miñana-Olmo
		Ana López-de-Andrés
		Rodrigo Jiménez-García
		</p>
	<p>Background/Objectives. Polypharmacy is increasingly common among people with diabetes, who frequently accumulate comorbidities and guideline-driven drug therapies. This study aimed to estimate the prevalence of polypharmacy among Spanish adults with diabetes and to identify its sociodemographic, clinical, and lifestyle determinants, comparing data from 2020 and 2023. Methods. A cross-sectional study was done. The year 2020 European Health Interview Survey in Spain and the year 2023 Spanish National Health Survey were the databases used. We applied a 1:1 matching by age, sex, and autonomous community of residence. Adults with physician-diagnosed diabetes were compared with matched controls without diabetes. Polypharmacy was defined as the concurrent use of 5 or more of 10 selected non-antidiabetic drug classes. Sex-specific univariable and multivariable logistic regression models were fitted. Results. The prevalence of polypharmacy among participants with diabetes increased from 18.5% in 2020 to 22.1% in 2023 versus 7.7% and 11.2% among matched controls. In 2023, polypharmacy was more frequent among participants with diabetes than among their matched controls in both sexes, affecting 29.3% of women (vs. 16.1% of controls) and 14.8% of men (vs. 6.2% of controls). Poor self-perceived health (OR 4.84, 95% CI 2.94&amp;amp;ndash;7.99, in men; OR 4.13, 95% CI 2.82&amp;amp;ndash;6.06, in women), chronic mental health problems (OR 4.36, 95% CI 3.01&amp;amp;ndash;6.31, in men; OR 4.19, 95% CI 3.22&amp;amp;ndash;5.44, in women), hypertension (OR 2.74, 95% CI 1.81&amp;amp;ndash;4.15 in men; OR 3.52, 95% CI 2.58&amp;amp;ndash;4.80, in women), and, among women, older age (OR 1.03, 95% CI 1.01&amp;amp;ndash;1.04, per year) and alcohol consumption (OR 1.60, 95% CI 1.16&amp;amp;ndash;2.22) were independent determinants of polypharmacy in the group with diabetes. Conclusions. Polypharmacy is highly prevalent among Spanish adults with diabetes&amp;amp;mdash;particularly older women with multimorbidity&amp;amp;mdash;and rose between 2020 and 2023 in parallel with population-wide trends. Integrated chronic care models and systematic deprescribing strategies, rather than single-disease prescribing approaches, are needed.</p>
	]]></content:encoded>

	<dc:title>Polypharmacy in the Spanish Population with Diabetes: Sociodemographic, Clinical, and Lifestyle Determinants Based on the 2020 and 2023 National Health Surveys</dc:title>
			<dc:creator>Tomás Chivato-Martín-Falquina</dc:creator>
			<dc:creator>Elena Miñana-Olmo</dc:creator>
			<dc:creator>Ana López-de-Andrés</dc:creator>
			<dc:creator>Rodrigo Jiménez-García</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110215</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-11-02</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-11-02</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>215</prism:startingPage>
		<prism:doi>10.3390/diabetology7110215</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/215</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/214">

	<title>Diabetology, Vol. 7, Pages 214: Association of SGLT2 Inhibitor Use with Leukocyte Telomere Length in Patients with Type 2 Diabetes Mellitus with and Without Chronic Kidney Disease</title>
	<link>https://www.mdpi.com/2673-4540/7/11/214</link>
	<description>Objective: This study aimed to investigate telomere length characteristics in patients with type 2 diabetes mellitus (T2DM) according to the presence of chronic kidney disease (CKD) and the use of sodium&amp;amp;ndash;glucose cotransporter 2 (SGLT2) inhibitors. Materials and Methods: The study included 100 patients with T2DM, who were divided into groups according to the presence of CKD (50 patients in each group). Renal function parameters, urinary albumin-to-creatinine ratio, the presence of cardiovascular disease, and leukocyte telomere length were assessed. Telomere length was measured by monochrome multiplex quantitative polymerase chain reaction, with determination of the T/S ratio and residual telomere length (&amp;amp;Delta;T/S). The association between SGLT2 inhibitor therapy and telomere length parameters was additionally analyzed. Results: After adjustment for age, patients with CKD had significantly lower residual telomere length (&amp;amp;Delta;T/S; p = 0.035), while pathologically short telomeres were observed more frequently (20.8% vs. 2.1%; p = 0.0076). SGLT2 inhibitor use was associated with greater telomere length irrespective of CKD status. In multivariable regression analysis restricted to patients with CKD, SGLT2 inhibitor use was independently associated with greater leukocyte telomere length (B = 0.434; 95% CI: 0.227&amp;amp;ndash;0.642; p &amp;amp;lt; 0.001). Conclusions: Patients with T2DM and CKD demonstrate more pronounced age-adjusted telomere shortening, suggesting accelerated biological aging. SGLT2 inhibitor use is associated with preservation of telomere length irrespective of CKD status, which may indicate a potential effect of this drug class on cellular senescence.</description>
	<pubDate>2026-10-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 214: Association of SGLT2 Inhibitor Use with Leukocyte Telomere Length in Patients with Type 2 Diabetes Mellitus with and Without Chronic Kidney Disease</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/214">doi: 10.3390/diabetology7110214</a></p>
	<p>Authors:
		Yanina Rebrova
		Yanina Saienko
		Kostiantyn Midlovets
		Veronika Korcheva
		Borys Mankovsky
		</p>
	<p>Objective: This study aimed to investigate telomere length characteristics in patients with type 2 diabetes mellitus (T2DM) according to the presence of chronic kidney disease (CKD) and the use of sodium&amp;amp;ndash;glucose cotransporter 2 (SGLT2) inhibitors. Materials and Methods: The study included 100 patients with T2DM, who were divided into groups according to the presence of CKD (50 patients in each group). Renal function parameters, urinary albumin-to-creatinine ratio, the presence of cardiovascular disease, and leukocyte telomere length were assessed. Telomere length was measured by monochrome multiplex quantitative polymerase chain reaction, with determination of the T/S ratio and residual telomere length (&amp;amp;Delta;T/S). The association between SGLT2 inhibitor therapy and telomere length parameters was additionally analyzed. Results: After adjustment for age, patients with CKD had significantly lower residual telomere length (&amp;amp;Delta;T/S; p = 0.035), while pathologically short telomeres were observed more frequently (20.8% vs. 2.1%; p = 0.0076). SGLT2 inhibitor use was associated with greater telomere length irrespective of CKD status. In multivariable regression analysis restricted to patients with CKD, SGLT2 inhibitor use was independently associated with greater leukocyte telomere length (B = 0.434; 95% CI: 0.227&amp;amp;ndash;0.642; p &amp;amp;lt; 0.001). Conclusions: Patients with T2DM and CKD demonstrate more pronounced age-adjusted telomere shortening, suggesting accelerated biological aging. SGLT2 inhibitor use is associated with preservation of telomere length irrespective of CKD status, which may indicate a potential effect of this drug class on cellular senescence.</p>
	]]></content:encoded>

	<dc:title>Association of SGLT2 Inhibitor Use with Leukocyte Telomere Length in Patients with Type 2 Diabetes Mellitus with and Without Chronic Kidney Disease</dc:title>
			<dc:creator>Yanina Rebrova</dc:creator>
			<dc:creator>Yanina Saienko</dc:creator>
			<dc:creator>Kostiantyn Midlovets</dc:creator>
			<dc:creator>Veronika Korcheva</dc:creator>
			<dc:creator>Borys Mankovsky</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110214</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-30</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-30</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>214</prism:startingPage>
		<prism:doi>10.3390/diabetology7110214</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/214</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/213">

	<title>Diabetology, Vol. 7, Pages 213: Assessment of Diabetes-Related Nutritional Knowledge and Adherence to Dietary Recommendations Among Patients with Type 2 Diabetes at Mthatha Hospital Complex, Eastern Cape, South Africa: A Facility-Based Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/11/213</link>
	<description>Objective: To assess diabetes-related nutritional knowledge, dietary adherence, and factors associated with poor dietary adherence among patients with type 2 diabetes mellitus (T2DM) attending the Mthatha Hospital Complex in the Eastern Cape, South Africa. Methods: A facility-based cross-sectional study was conducted between May and December 2025 among 227 patients with T2DM attending Mthatha Regional Hospital and Nelson Mandela Academic Hospital. Participants were selected using systematic sampling. Data were collected using a structured interviewer-administered questionnaire. Nutritional knowledge was assessed using items adapted from the revised General Nutrition Knowledge Questionnaire, while dietary adherence was measured using the nine-item Perceived Dietary Adherence Questionnaire (PDAQ). Binary logistic regression was performed to identify factors associated with poor dietary adherence. Results: The median age of participants was 61 years (IQR: 49&amp;amp;ndash;68), and 53.3% were female. Overall, 48.5% (95% CI: 42.0&amp;amp;ndash;54.9) of participants had poor dietary adherence, while 61.2% (95% CI: 54.8&amp;amp;ndash;67.4) demonstrated high diabetes-related nutritional knowledge. Poor dietary adherence was significantly associated with age &amp;amp;le; 30 years [Adjusted Odds Ratio (AOR) = 6.36, 95% CI: 1.36&amp;amp;ndash;29.74)], low nutritional knowledge (AOR = 4.89, 95% CI: 2.24&amp;amp;ndash;10.65), gathering with friends and family (AOR = 4.75, 95% CI: 1.87&amp;amp;ndash;12.05), eating outside the home (AOR = 2.79, 95% CI: 1.27&amp;amp;ndash;6.13), and uncontrolled HbA1c levels (AOR = 2.55, 95% CI: 1.25&amp;amp;ndash;5.19). Attendance at nutrition education sessions was associated with lower odds of poor dietary adherence (AOR = 0.22, 95% CI: 0.05&amp;amp;ndash;0.97). Conclusions: Significant knowledge-related, social, behavioral, and environmental barriers to optimal dietary adherence persist, highlighting the need for strengthened diabetes nutrition education, patient-centered interventions, and supportive public health strategies that facilitate healthy dietary practices and improved glycaemic control.</description>
	<pubDate>2026-10-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 213: Assessment of Diabetes-Related Nutritional Knowledge and Adherence to Dietary Recommendations Among Patients with Type 2 Diabetes at Mthatha Hospital Complex, Eastern Cape, South Africa: A Facility-Based Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/213">doi: 10.3390/diabetology7110213</a></p>
	<p>Authors:
		Akhona Namhla Tshico
		Sibusiso Cyprain Nomatshila
		Mirabel Kah-Keh Nanjoh
		Nomaxabiso Mildred Mooi
		Teke Ruffin Apalata
		</p>
	<p>Objective: To assess diabetes-related nutritional knowledge, dietary adherence, and factors associated with poor dietary adherence among patients with type 2 diabetes mellitus (T2DM) attending the Mthatha Hospital Complex in the Eastern Cape, South Africa. Methods: A facility-based cross-sectional study was conducted between May and December 2025 among 227 patients with T2DM attending Mthatha Regional Hospital and Nelson Mandela Academic Hospital. Participants were selected using systematic sampling. Data were collected using a structured interviewer-administered questionnaire. Nutritional knowledge was assessed using items adapted from the revised General Nutrition Knowledge Questionnaire, while dietary adherence was measured using the nine-item Perceived Dietary Adherence Questionnaire (PDAQ). Binary logistic regression was performed to identify factors associated with poor dietary adherence. Results: The median age of participants was 61 years (IQR: 49&amp;amp;ndash;68), and 53.3% were female. Overall, 48.5% (95% CI: 42.0&amp;amp;ndash;54.9) of participants had poor dietary adherence, while 61.2% (95% CI: 54.8&amp;amp;ndash;67.4) demonstrated high diabetes-related nutritional knowledge. Poor dietary adherence was significantly associated with age &amp;amp;le; 30 years [Adjusted Odds Ratio (AOR) = 6.36, 95% CI: 1.36&amp;amp;ndash;29.74)], low nutritional knowledge (AOR = 4.89, 95% CI: 2.24&amp;amp;ndash;10.65), gathering with friends and family (AOR = 4.75, 95% CI: 1.87&amp;amp;ndash;12.05), eating outside the home (AOR = 2.79, 95% CI: 1.27&amp;amp;ndash;6.13), and uncontrolled HbA1c levels (AOR = 2.55, 95% CI: 1.25&amp;amp;ndash;5.19). Attendance at nutrition education sessions was associated with lower odds of poor dietary adherence (AOR = 0.22, 95% CI: 0.05&amp;amp;ndash;0.97). Conclusions: Significant knowledge-related, social, behavioral, and environmental barriers to optimal dietary adherence persist, highlighting the need for strengthened diabetes nutrition education, patient-centered interventions, and supportive public health strategies that facilitate healthy dietary practices and improved glycaemic control.</p>
	]]></content:encoded>

	<dc:title>Assessment of Diabetes-Related Nutritional Knowledge and Adherence to Dietary Recommendations Among Patients with Type 2 Diabetes at Mthatha Hospital Complex, Eastern Cape, South Africa: A Facility-Based Cross-Sectional Study</dc:title>
			<dc:creator>Akhona Namhla Tshico</dc:creator>
			<dc:creator>Sibusiso Cyprain Nomatshila</dc:creator>
			<dc:creator>Mirabel Kah-Keh Nanjoh</dc:creator>
			<dc:creator>Nomaxabiso Mildred Mooi</dc:creator>
			<dc:creator>Teke Ruffin Apalata</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110213</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-29</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-29</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>213</prism:startingPage>
		<prism:doi>10.3390/diabetology7110213</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/213</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/212">

	<title>Diabetology, Vol. 7, Pages 212: Sex Differences in Conventional Coagulation and Platelet Parameters Among Adults with Type 2 Diabetes: A Cross-Sectional Study in Mongolia</title>
	<link>https://www.mdpi.com/2673-4540/7/11/212</link>
	<description>Background: Sex-related differences in hemostasis may contribute to variation in cardiovascular risk among individuals with type 2 diabetes mellitus (T2DM); however, evidence regarding conventional coagulation and platelet parameters in this population remains limited. This study investigated sex differences in coagulation and platelet parameters among adults with T2DM in Mongolia. Methods: This cross-sectional study included 250 adults with T2DM. Conventional coagulation parameters, including activated partial thromboplastin time (aPTT), prothrombin time (PT), international normalized ratio (INR), thrombin time (TT), and fibrinogen, as well as platelet count, mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT), were evaluated. Between-sex differences were assessed using appropriate parametric or nonparametric tests. Sequential linear regression models were used to examine associations with sex, with progressive adjustment for age, body mass index, current smoking, alcohol use, HbA1c, diabetes duration, and chronic diabetic complication status. Results: Of 250 participants, 117 were men and 133 were women. Women had shorter PT (10.20 [9.90&amp;amp;ndash;10.53] vs. 10.70 [10.28&amp;amp;ndash;11.10] s; p &amp;amp;lt; 0.001), lower INR (0.96 [0.92&amp;amp;ndash;0.98] vs. 1.00 [0.96&amp;amp;ndash;1.04]; p &amp;amp;lt; 0.001), and shorter aPTT (25.90 [24.80&amp;amp;ndash;27.30] vs. 26.70 [25.18&amp;amp;ndash;27.90] s; p = 0.045), while platelet count (281 [238.5&amp;amp;ndash;329] vs. 243 [205&amp;amp;ndash;278] &amp;amp;times;109/L; p &amp;amp;lt; 0.001) and PCT (0.271 [0.234&amp;amp;ndash;0.320] vs. 0.236 [0.201&amp;amp;ndash;0.283]%; p &amp;amp;lt; 0.001) were higher in women. In the fully adjusted model, female sex remained associated with shorter PT (B = &amp;amp;minus;0.499 s, 95% CI &amp;amp;minus;0.747 to &amp;amp;minus;0.250; p &amp;amp;lt; 0.001) and lower INR (B = &amp;amp;minus;0.051, 95% CI &amp;amp;minus;0.072 to &amp;amp;minus;0.029; p &amp;amp;lt; 0.001), as well as higher platelet count (B = 37.838 &amp;amp;times; 109/L, 95% CI 19.012&amp;amp;ndash;56.663; p &amp;amp;lt; 0.001) and PCT (B = 0.034%, 95% CI 0.005&amp;amp;ndash;0.063; p = 0.024). aPTT was not independently associated with sex after adjustment (B = &amp;amp;minus;0.551 s, 95% CI &amp;amp;minus;1.333 to 0.231; p = 0.166). Conclusions: Among Mongolian adults with T2DM, women had shorter PT and INR and higher platelet count and PCT than men after multivariable adjustment. Although aPTT differed between sexes in the unadjusted comparison, the association was not significant in regression analysis. These findings demonstrate sex-related variation in routinely measured hemostatic parameters in T2DM and support consideration of biological sex when interpreting these laboratory measures.</description>
	<pubDate>2026-10-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 212: Sex Differences in Conventional Coagulation and Platelet Parameters Among Adults with Type 2 Diabetes: A Cross-Sectional Study in Mongolia</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/212">doi: 10.3390/diabetology7110212</a></p>
	<p>Authors:
		Narkhajid Galsanjigmed
		Bulgan Erdenetsogt
		Baigalmaa Erdenebaatar
		Narangerel Bayarsaikhan
		Nayanjin Ochirpurev
		Urangoo Tegshee
		Jansaya Yesyenbol
		Dulguun Tsolmon
		Munkh-Uchral Nordog
		Bayasgalan Purevdorj
		Otgonbat Altangerel
		Oyuntugs Byambasukh
		</p>
	<p>Background: Sex-related differences in hemostasis may contribute to variation in cardiovascular risk among individuals with type 2 diabetes mellitus (T2DM); however, evidence regarding conventional coagulation and platelet parameters in this population remains limited. This study investigated sex differences in coagulation and platelet parameters among adults with T2DM in Mongolia. Methods: This cross-sectional study included 250 adults with T2DM. Conventional coagulation parameters, including activated partial thromboplastin time (aPTT), prothrombin time (PT), international normalized ratio (INR), thrombin time (TT), and fibrinogen, as well as platelet count, mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT), were evaluated. Between-sex differences were assessed using appropriate parametric or nonparametric tests. Sequential linear regression models were used to examine associations with sex, with progressive adjustment for age, body mass index, current smoking, alcohol use, HbA1c, diabetes duration, and chronic diabetic complication status. Results: Of 250 participants, 117 were men and 133 were women. Women had shorter PT (10.20 [9.90&amp;amp;ndash;10.53] vs. 10.70 [10.28&amp;amp;ndash;11.10] s; p &amp;amp;lt; 0.001), lower INR (0.96 [0.92&amp;amp;ndash;0.98] vs. 1.00 [0.96&amp;amp;ndash;1.04]; p &amp;amp;lt; 0.001), and shorter aPTT (25.90 [24.80&amp;amp;ndash;27.30] vs. 26.70 [25.18&amp;amp;ndash;27.90] s; p = 0.045), while platelet count (281 [238.5&amp;amp;ndash;329] vs. 243 [205&amp;amp;ndash;278] &amp;amp;times;109/L; p &amp;amp;lt; 0.001) and PCT (0.271 [0.234&amp;amp;ndash;0.320] vs. 0.236 [0.201&amp;amp;ndash;0.283]%; p &amp;amp;lt; 0.001) were higher in women. In the fully adjusted model, female sex remained associated with shorter PT (B = &amp;amp;minus;0.499 s, 95% CI &amp;amp;minus;0.747 to &amp;amp;minus;0.250; p &amp;amp;lt; 0.001) and lower INR (B = &amp;amp;minus;0.051, 95% CI &amp;amp;minus;0.072 to &amp;amp;minus;0.029; p &amp;amp;lt; 0.001), as well as higher platelet count (B = 37.838 &amp;amp;times; 109/L, 95% CI 19.012&amp;amp;ndash;56.663; p &amp;amp;lt; 0.001) and PCT (B = 0.034%, 95% CI 0.005&amp;amp;ndash;0.063; p = 0.024). aPTT was not independently associated with sex after adjustment (B = &amp;amp;minus;0.551 s, 95% CI &amp;amp;minus;1.333 to 0.231; p = 0.166). Conclusions: Among Mongolian adults with T2DM, women had shorter PT and INR and higher platelet count and PCT than men after multivariable adjustment. Although aPTT differed between sexes in the unadjusted comparison, the association was not significant in regression analysis. These findings demonstrate sex-related variation in routinely measured hemostatic parameters in T2DM and support consideration of biological sex when interpreting these laboratory measures.</p>
	]]></content:encoded>

	<dc:title>Sex Differences in Conventional Coagulation and Platelet Parameters Among Adults with Type 2 Diabetes: A Cross-Sectional Study in Mongolia</dc:title>
			<dc:creator>Narkhajid Galsanjigmed</dc:creator>
			<dc:creator>Bulgan Erdenetsogt</dc:creator>
			<dc:creator>Baigalmaa Erdenebaatar</dc:creator>
			<dc:creator>Narangerel Bayarsaikhan</dc:creator>
			<dc:creator>Nayanjin Ochirpurev</dc:creator>
			<dc:creator>Urangoo Tegshee</dc:creator>
			<dc:creator>Jansaya Yesyenbol</dc:creator>
			<dc:creator>Dulguun Tsolmon</dc:creator>
			<dc:creator>Munkh-Uchral Nordog</dc:creator>
			<dc:creator>Bayasgalan Purevdorj</dc:creator>
			<dc:creator>Otgonbat Altangerel</dc:creator>
			<dc:creator>Oyuntugs Byambasukh</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110212</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-28</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-28</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>212</prism:startingPage>
		<prism:doi>10.3390/diabetology7110212</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/212</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/211">

	<title>Diabetology, Vol. 7, Pages 211: Immune Cell Remodeling and Chronic Inflammation in Obesity: Implications for Insulin Resistance and Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/11/211</link>
	<description>Obesity is accompanied by chronic low-grade inflammation and increases the risk of type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, and other inflammatory disorders. Growing evidence indicates that metabolic cues generated in obesity actively reshape immune-cell differentiation and function and thereby contribute to disease progression. In this narrative review, we synthesize recent advances in obesity-associated nutrient excess remodel macrophages, dendritic cells, innate lymphoid cells, and T-cell subsets, emphasizing the evidence linking these changes to adipose inflammation and insulin resistance. We highlight lipid-dependent regulation of the T helper 17 (Th17)/regulatory T (Treg) cell balance, including acetyl-CoA carboxylase 1 (ACC1)-dependent de novo fatty acid biosynthesis and regulation of retinoid-related orphan receptor gamma t (ROR&amp;amp;gamma;t) by 1-oleoyl-lysophosphatidylethanolamine (LPE [1-18:1]), as a representative mechanism by which cellular metabolism controls lineage-defining transcriptional programs. Finally, we discuss emerging therapeutic approaches, including weight loss and glucagon-like peptide-1 (GLP-1)-based therapies, blockade of inflammatory mediators, reprogramming of immune-cell metabolism, and restoration of inflammation resolution. A better understanding of these metabolic&amp;amp;ndash;immune interactions may facilitate the development of new strategies for obesity-associated inflammatory and metabolic diseases.</description>
	<pubDate>2026-10-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 211: Immune Cell Remodeling and Chronic Inflammation in Obesity: Implications for Insulin Resistance and Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/211">doi: 10.3390/diabetology7110211</a></p>
	<p>Authors:
		Keisuke Yamamoto
		Yusuke Endo
		</p>
	<p>Obesity is accompanied by chronic low-grade inflammation and increases the risk of type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, and other inflammatory disorders. Growing evidence indicates that metabolic cues generated in obesity actively reshape immune-cell differentiation and function and thereby contribute to disease progression. In this narrative review, we synthesize recent advances in obesity-associated nutrient excess remodel macrophages, dendritic cells, innate lymphoid cells, and T-cell subsets, emphasizing the evidence linking these changes to adipose inflammation and insulin resistance. We highlight lipid-dependent regulation of the T helper 17 (Th17)/regulatory T (Treg) cell balance, including acetyl-CoA carboxylase 1 (ACC1)-dependent de novo fatty acid biosynthesis and regulation of retinoid-related orphan receptor gamma t (ROR&amp;amp;gamma;t) by 1-oleoyl-lysophosphatidylethanolamine (LPE [1-18:1]), as a representative mechanism by which cellular metabolism controls lineage-defining transcriptional programs. Finally, we discuss emerging therapeutic approaches, including weight loss and glucagon-like peptide-1 (GLP-1)-based therapies, blockade of inflammatory mediators, reprogramming of immune-cell metabolism, and restoration of inflammation resolution. A better understanding of these metabolic&amp;amp;ndash;immune interactions may facilitate the development of new strategies for obesity-associated inflammatory and metabolic diseases.</p>
	]]></content:encoded>

	<dc:title>Immune Cell Remodeling and Chronic Inflammation in Obesity: Implications for Insulin Resistance and Type 2 Diabetes</dc:title>
			<dc:creator>Keisuke Yamamoto</dc:creator>
			<dc:creator>Yusuke Endo</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110211</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-27</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-27</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>211</prism:startingPage>
		<prism:doi>10.3390/diabetology7110211</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/211</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/210">

	<title>Diabetology, Vol. 7, Pages 210: Paradoxes in Modern Diabetes Care: Time, Context, Complexity, and the Limits of Biomarker-Based Reasoning</title>
	<link>https://www.mdpi.com/2673-4540/7/11/210</link>
	<description>Observations described as paradoxical are common in diabetes: intensive glucose lowering may fail to improve macrovascular outcomes; long-term benefit may persist after HbA1c convergence; SGLT2 inhibitors can cause an early eGFR dip despite kidney protection; ketoacidosis may occur without marked hyperglycaemia; and contrasting GIP receptor strategies can coexist with effective GLP-1-based therapy. We conducted a structured narrative review of PubMed/MEDLINE literature updated to 8 September 2026, prioritising randomised trials, meta-analyses, consensus statements, and human mechanistic evidence. We propose a two-level framework for interpreting these observations. At the biological level, apparent contradictions arise from time, clinical context, and system complexity. At the measurement and inference level, dynamic and heterogeneous biology may be compressed into snapshots, thresholds, aggregate estimates, or simplified representations of biological state. The framework is applied to intensive glycaemic control and metabolic memory, early retinopathy worsening and treatment-induced neuropathy, SGLT2-associated eGFR change and euglycaemic ketoacidosis, multi-receptor pharmacology, HbA1c in advanced kidney disease, the obesity paradox, and statin-associated dysglycaemia. These phenomena do not share a single biological mechanism. Rather, they illustrate how interpretation can become misleading when relevant temporal, contextual, systems-level, or representational information is omitted, or when biomarkers, mechanisms, surrogates, prediction, and patient-relevant outcomes are treated as interchangeable evidential roles.</description>
	<pubDate>2026-10-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 210: Paradoxes in Modern Diabetes Care: Time, Context, Complexity, and the Limits of Biomarker-Based Reasoning</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/210">doi: 10.3390/diabetology7110210</a></p>
	<p>Authors:
		Ferenc Sztanek
		</p>
	<p>Observations described as paradoxical are common in diabetes: intensive glucose lowering may fail to improve macrovascular outcomes; long-term benefit may persist after HbA1c convergence; SGLT2 inhibitors can cause an early eGFR dip despite kidney protection; ketoacidosis may occur without marked hyperglycaemia; and contrasting GIP receptor strategies can coexist with effective GLP-1-based therapy. We conducted a structured narrative review of PubMed/MEDLINE literature updated to 8 September 2026, prioritising randomised trials, meta-analyses, consensus statements, and human mechanistic evidence. We propose a two-level framework for interpreting these observations. At the biological level, apparent contradictions arise from time, clinical context, and system complexity. At the measurement and inference level, dynamic and heterogeneous biology may be compressed into snapshots, thresholds, aggregate estimates, or simplified representations of biological state. The framework is applied to intensive glycaemic control and metabolic memory, early retinopathy worsening and treatment-induced neuropathy, SGLT2-associated eGFR change and euglycaemic ketoacidosis, multi-receptor pharmacology, HbA1c in advanced kidney disease, the obesity paradox, and statin-associated dysglycaemia. These phenomena do not share a single biological mechanism. Rather, they illustrate how interpretation can become misleading when relevant temporal, contextual, systems-level, or representational information is omitted, or when biomarkers, mechanisms, surrogates, prediction, and patient-relevant outcomes are treated as interchangeable evidential roles.</p>
	]]></content:encoded>

	<dc:title>Paradoxes in Modern Diabetes Care: Time, Context, Complexity, and the Limits of Biomarker-Based Reasoning</dc:title>
			<dc:creator>Ferenc Sztanek</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110210</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-27</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-27</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>210</prism:startingPage>
		<prism:doi>10.3390/diabetology7110210</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/210</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/11/209">

	<title>Diabetology, Vol. 7, Pages 209: Distinct Src, STAT3, and MAPK Immunoreactivity in Peripheral Blood-Derived Cell-Block Preparations and Qualitative Protein Patterns in Isolated PBMCs from Patients with Type 1 and Type 2 Diabetes Mellitus</title>
	<link>https://www.mdpi.com/2673-4540/7/11/209</link>
	<description>Background: Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) have distinct pathogenic mechanisms but share inflammatory and immune-related alterations. Src, signal transducer and activator of transcription 3 (STAT3), and mitogen-activated protein kinase (MAPK) signaling pathways play important roles in immune regulation and cellular stress responses. However, patterns of these signaling-related proteins in peripheral blood-derived cellular preparations and isolated Peripheral blood mononuclear cells (PBMCs) from patients with T1DM and T2DM remain incompletely characterized. This study aimed to compare STAT3, Src, Extracellular signal-regulated kinases &amp;amp;frac12; (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) immunoreactivity in peripheral blood-derived cell-block preparations and to descriptively examine total and phosphorylated protein patterns in isolated PBMCs from patients with T1DM and T2DM. Methods: Peripheral blood samples were obtained from 15 patients with T1DM, 15 patients with T2DM, and 15 healthy controls. For Western blot analysis, PBMCs were isolated from heparinized blood using Ficoll&amp;amp;ndash;Paque density-gradient centrifugation. For immunohistochemistry, separate Ethylenediaminetetraacetic acid (EDTA)-anticoagulated peripheral blood samples were processed by direct centrifugation to obtain cellular pellets, which were fixed and paraffin-embedded. STAT3, Src, ERK1/2, and p38 MAPK immunoreactivity was evaluated semi-quantitatively in these peripheral blood-derived cell-block preparations, whereas total and phosphorylated protein patterns were examined qualitatively by Western blot analysis of isolated PBMCs. Results: Immunohistochemical analysis revealed significant differences in STAT3, Src, ERK1/2, and p38 MAPK immunoreactivity among the three groups (all p &amp;amp;lt; 0.001). STAT3 and ERK1/2 immunoreactivity was strongest in T1DM, whereas Src and p38 MAPK immunoreactivity was most prominent in T2DM. Qualitative Western blot analysis showed visually different total and phosphorylated protein band patterns among the displayed representative samples, including more prominent total STAT3 bands in the Control and T1DM samples and greater relative p-STAT3 band intensity in the T2DM samples. However, the groups differed significantly in age (p &amp;amp;lt; 0.001), and detailed clinical covariates were unavailable; therefore, the observed between-cohort differences cannot be attributed specifically to diabetes type. Conclusions: In this exploratory cohort, differences in STAT3, Src, ERK1/2, and p38 MAPK immunoreactivity were observed among the three study groups, together with qualitative Western blot differences among the displayed representative PBMC samples. Because of substantial age imbalance, unavailable clinical covariates, the semi-quantitative nature of immunohistochemical scoring, and the absence of participant-level quantitative Western blot data, these observations cannot be interpreted as diabetes-type-specific signaling differences or evidence of pathway activation. Further studies using age-matched, clinically characterized cohorts, quantitative protein analyses, and cell-subset-specific approaches are required.</description>
	<pubDate>2026-10-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 209: Distinct Src, STAT3, and MAPK Immunoreactivity in Peripheral Blood-Derived Cell-Block Preparations and Qualitative Protein Patterns in Isolated PBMCs from Patients with Type 1 and Type 2 Diabetes Mellitus</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/11/209">doi: 10.3390/diabetology7110209</a></p>
	<p>Authors:
		Günsel Kirman
		Engin Deveci
		Sevgi İrtegün Kandemir
		Zafer Pekkolay
		Gülsüm Pektanç Şengül
		</p>
	<p>Background: Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) have distinct pathogenic mechanisms but share inflammatory and immune-related alterations. Src, signal transducer and activator of transcription 3 (STAT3), and mitogen-activated protein kinase (MAPK) signaling pathways play important roles in immune regulation and cellular stress responses. However, patterns of these signaling-related proteins in peripheral blood-derived cellular preparations and isolated Peripheral blood mononuclear cells (PBMCs) from patients with T1DM and T2DM remain incompletely characterized. This study aimed to compare STAT3, Src, Extracellular signal-regulated kinases &amp;amp;frac12; (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) immunoreactivity in peripheral blood-derived cell-block preparations and to descriptively examine total and phosphorylated protein patterns in isolated PBMCs from patients with T1DM and T2DM. Methods: Peripheral blood samples were obtained from 15 patients with T1DM, 15 patients with T2DM, and 15 healthy controls. For Western blot analysis, PBMCs were isolated from heparinized blood using Ficoll&amp;amp;ndash;Paque density-gradient centrifugation. For immunohistochemistry, separate Ethylenediaminetetraacetic acid (EDTA)-anticoagulated peripheral blood samples were processed by direct centrifugation to obtain cellular pellets, which were fixed and paraffin-embedded. STAT3, Src, ERK1/2, and p38 MAPK immunoreactivity was evaluated semi-quantitatively in these peripheral blood-derived cell-block preparations, whereas total and phosphorylated protein patterns were examined qualitatively by Western blot analysis of isolated PBMCs. Results: Immunohistochemical analysis revealed significant differences in STAT3, Src, ERK1/2, and p38 MAPK immunoreactivity among the three groups (all p &amp;amp;lt; 0.001). STAT3 and ERK1/2 immunoreactivity was strongest in T1DM, whereas Src and p38 MAPK immunoreactivity was most prominent in T2DM. Qualitative Western blot analysis showed visually different total and phosphorylated protein band patterns among the displayed representative samples, including more prominent total STAT3 bands in the Control and T1DM samples and greater relative p-STAT3 band intensity in the T2DM samples. However, the groups differed significantly in age (p &amp;amp;lt; 0.001), and detailed clinical covariates were unavailable; therefore, the observed between-cohort differences cannot be attributed specifically to diabetes type. Conclusions: In this exploratory cohort, differences in STAT3, Src, ERK1/2, and p38 MAPK immunoreactivity were observed among the three study groups, together with qualitative Western blot differences among the displayed representative PBMC samples. Because of substantial age imbalance, unavailable clinical covariates, the semi-quantitative nature of immunohistochemical scoring, and the absence of participant-level quantitative Western blot data, these observations cannot be interpreted as diabetes-type-specific signaling differences or evidence of pathway activation. Further studies using age-matched, clinically characterized cohorts, quantitative protein analyses, and cell-subset-specific approaches are required.</p>
	]]></content:encoded>

	<dc:title>Distinct Src, STAT3, and MAPK Immunoreactivity in Peripheral Blood-Derived Cell-Block Preparations and Qualitative Protein Patterns in Isolated PBMCs from Patients with Type 1 and Type 2 Diabetes Mellitus</dc:title>
			<dc:creator>Günsel Kirman</dc:creator>
			<dc:creator>Engin Deveci</dc:creator>
			<dc:creator>Sevgi İrtegün Kandemir</dc:creator>
			<dc:creator>Zafer Pekkolay</dc:creator>
			<dc:creator>Gülsüm Pektanç Şengül</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7110209</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-24</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-24</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>209</prism:startingPage>
		<prism:doi>10.3390/diabetology7110209</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/11/209</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/208">

	<title>Diabetology, Vol. 7, Pages 208: Beyond Hydration: Natural Mineral Water and Metabolic Health</title>
	<link>https://www.mdpi.com/2673-4540/7/10/208</link>
	<description>Background: Natural mineral water (NMW) is a heterogeneous dietary exposure whose composition varies substantially among sources. Objective: This critical review examines human intervention evidence on NMW in relation to metabolic health across healthy adults and populations with hypercholesterolaemia, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD) while separating direct clinical findings from mechanistic evidence. Methods: Seven principal human intervention studies were identified in the clinical synthesis. Results: Controlled studies did not show a reproducible glucose-lowering effect attributable to mineralwater composition. Selected studies nevertheless reported changes in postprandial insulin dynamics, glycoalbumin, oxidative status, gastrointestinal or microbiota-related variables, and intestinal, inflammatory, and hepatic outcomes. Calcium and magnesium in mineral water are bioavailable, but mineral absorption should not be interpreted as evidence of disease-specific efficacy. The literature is constrained by small samples, chemically dissimilar waters, heterogeneous populations, variable intervention durations, and inconsistent comparator designs. Conclusions: Accordingly, current evidence supports NMW primarily as a source-specific nutritional exposure rather than an established metabolic intervention. Future trials should use analytically characterized intervention and control waters, predefined outcomes, adequate durations, and clearly defined metabolic phenotypes to determine whether particular hydrochemical profiles produce reproducible metabolic effects.</description>
	<pubDate>2026-10-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 208: Beyond Hydration: Natural Mineral Water and Metabolic Health</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/208">doi: 10.3390/diabetology7100208</a></p>
	<p>Authors:
		Eleni Pavlidou
		Eleni Melenikioti
		Aristeidis Fasoulas
		Constantinos Giaginis
		Sousana K. Papadopoulou
		</p>
	<p>Background: Natural mineral water (NMW) is a heterogeneous dietary exposure whose composition varies substantially among sources. Objective: This critical review examines human intervention evidence on NMW in relation to metabolic health across healthy adults and populations with hypercholesterolaemia, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD) while separating direct clinical findings from mechanistic evidence. Methods: Seven principal human intervention studies were identified in the clinical synthesis. Results: Controlled studies did not show a reproducible glucose-lowering effect attributable to mineralwater composition. Selected studies nevertheless reported changes in postprandial insulin dynamics, glycoalbumin, oxidative status, gastrointestinal or microbiota-related variables, and intestinal, inflammatory, and hepatic outcomes. Calcium and magnesium in mineral water are bioavailable, but mineral absorption should not be interpreted as evidence of disease-specific efficacy. The literature is constrained by small samples, chemically dissimilar waters, heterogeneous populations, variable intervention durations, and inconsistent comparator designs. Conclusions: Accordingly, current evidence supports NMW primarily as a source-specific nutritional exposure rather than an established metabolic intervention. Future trials should use analytically characterized intervention and control waters, predefined outcomes, adequate durations, and clearly defined metabolic phenotypes to determine whether particular hydrochemical profiles produce reproducible metabolic effects.</p>
	]]></content:encoded>

	<dc:title>Beyond Hydration: Natural Mineral Water and Metabolic Health</dc:title>
			<dc:creator>Eleni Pavlidou</dc:creator>
			<dc:creator>Eleni Melenikioti</dc:creator>
			<dc:creator>Aristeidis Fasoulas</dc:creator>
			<dc:creator>Constantinos Giaginis</dc:creator>
			<dc:creator>Sousana K. Papadopoulou</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100208</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-21</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-21</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>208</prism:startingPage>
		<prism:doi>10.3390/diabetology7100208</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/208</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/207">

	<title>Diabetology, Vol. 7, Pages 207: Two Pathways to Glycaemic Control: Dietary Adherence, Physical Activity, and Their Independent Contributions Among Persons with Type 2 Diabetes in Urban Delhi&amp;mdash;A Community-Based Cross-Sectional Analytical Study</title>
	<link>https://www.mdpi.com/2673-4540/7/10/207</link>
	<description>Background: India bears one of the highest diabetes burdens globally, yet community-based evidence simultaneously examining the contributions of dietary adherence and physical activity to glycaemic control remains scarce. Most existing Indian studies are hospital-based and assess only one behavioural domain. Methods: A community-based cross-sectional analytical study was conducted among 320 persons with type 2 diabetes in Gokulpuri, North-East Delhi. Dietary adherence was assessed using the Perceived Dietary Adherence Questionnaire (PDAQ) and physical activity using the International Physical Activity Questionnaire (IPAQ). Glycaemic control was measured as random blood sugar (RBS). Sociodemographic and clinical determinants of each behavioural domain were examined using bivariate analyses, followed by multivariable linear regression. Three nested multiple linear regression models were estimated to quantify the independent and combined contributions of dietary adherence and physical activity to RBS. Results: The mean age was 58.09 years (SD 11.17); 65.3% were female. Mean RBS was 217.41 mg/dL (SD 82.21), mean PDAQ score was 47.01 out of 63 (SD 5.32), and mean IPAQ was 531.67 MET-min/week (SD 526.54). Higher household income was a significant positive predictor of dietary adherence (&amp;amp;beta; = 0.103, p = 0.009), while a positive family history of diabetes was a significant negative predictor (&amp;amp;beta; = &amp;amp;minus;2.203, p = 0.004). Male gender was the only significant predictor of greater physical activity (p &amp;amp;lt; 0.001). In nested regression models adjusted for age, gender, education, BMI, diabetes duration, and hypertension, both dietary adherence (&amp;amp;beta; = &amp;amp;minus;3.117, p = 0.001) and physical activity (&amp;amp;beta; = &amp;amp;minus;0.026, p = 0.004) were independently and significantly associated with lower RBS. The combined model demonstrated the best fit (Adjusted R2 = 0.078, F = 3.62), with the two predictors showing near-zero mutual correlation (r = 0.008), confirming their independence. Conclusions: In this cross-sectional analysis, dietary adherence and physical activity were independent additive predictors of lower random blood sugar (RBS) in community-dwelling persons with type 2 diabetes in urban Delhi. Income and diabetes fatalism are key modifiable determinants of dietary adherence, while gender-based disparities drive differences in physical activity. Integrated, dual-domain lifestyle interventions addressing these sociodemographic barriers are warranted within community-based NCD programmes in India.</description>
	<pubDate>2026-10-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 207: Two Pathways to Glycaemic Control: Dietary Adherence, Physical Activity, and Their Independent Contributions Among Persons with Type 2 Diabetes in Urban Delhi&amp;mdash;A Community-Based Cross-Sectional Analytical Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/207">doi: 10.3390/diabetology7100207</a></p>
	<p>Authors:
		Shivani Rao
		Aninda Debnath
		Mongjam Meghachandra Singh
		Himanshu Bachawandia
		Nandini Sharma
		</p>
	<p>Background: India bears one of the highest diabetes burdens globally, yet community-based evidence simultaneously examining the contributions of dietary adherence and physical activity to glycaemic control remains scarce. Most existing Indian studies are hospital-based and assess only one behavioural domain. Methods: A community-based cross-sectional analytical study was conducted among 320 persons with type 2 diabetes in Gokulpuri, North-East Delhi. Dietary adherence was assessed using the Perceived Dietary Adherence Questionnaire (PDAQ) and physical activity using the International Physical Activity Questionnaire (IPAQ). Glycaemic control was measured as random blood sugar (RBS). Sociodemographic and clinical determinants of each behavioural domain were examined using bivariate analyses, followed by multivariable linear regression. Three nested multiple linear regression models were estimated to quantify the independent and combined contributions of dietary adherence and physical activity to RBS. Results: The mean age was 58.09 years (SD 11.17); 65.3% were female. Mean RBS was 217.41 mg/dL (SD 82.21), mean PDAQ score was 47.01 out of 63 (SD 5.32), and mean IPAQ was 531.67 MET-min/week (SD 526.54). Higher household income was a significant positive predictor of dietary adherence (&amp;amp;beta; = 0.103, p = 0.009), while a positive family history of diabetes was a significant negative predictor (&amp;amp;beta; = &amp;amp;minus;2.203, p = 0.004). Male gender was the only significant predictor of greater physical activity (p &amp;amp;lt; 0.001). In nested regression models adjusted for age, gender, education, BMI, diabetes duration, and hypertension, both dietary adherence (&amp;amp;beta; = &amp;amp;minus;3.117, p = 0.001) and physical activity (&amp;amp;beta; = &amp;amp;minus;0.026, p = 0.004) were independently and significantly associated with lower RBS. The combined model demonstrated the best fit (Adjusted R2 = 0.078, F = 3.62), with the two predictors showing near-zero mutual correlation (r = 0.008), confirming their independence. Conclusions: In this cross-sectional analysis, dietary adherence and physical activity were independent additive predictors of lower random blood sugar (RBS) in community-dwelling persons with type 2 diabetes in urban Delhi. Income and diabetes fatalism are key modifiable determinants of dietary adherence, while gender-based disparities drive differences in physical activity. Integrated, dual-domain lifestyle interventions addressing these sociodemographic barriers are warranted within community-based NCD programmes in India.</p>
	]]></content:encoded>

	<dc:title>Two Pathways to Glycaemic Control: Dietary Adherence, Physical Activity, and Their Independent Contributions Among Persons with Type 2 Diabetes in Urban Delhi&amp;amp;mdash;A Community-Based Cross-Sectional Analytical Study</dc:title>
			<dc:creator>Shivani Rao</dc:creator>
			<dc:creator>Aninda Debnath</dc:creator>
			<dc:creator>Mongjam Meghachandra Singh</dc:creator>
			<dc:creator>Himanshu Bachawandia</dc:creator>
			<dc:creator>Nandini Sharma</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100207</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-21</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-21</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>207</prism:startingPage>
		<prism:doi>10.3390/diabetology7100207</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/207</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/206">

	<title>Diabetology, Vol. 7, Pages 206: A Phase III, Randomized, Double-Blind Clinical Trial of a Novel Triple Fixed-Dose Combination (Glimepiride/Vildagliptin/Metformin) in Mexican Adults with Uncontrolled Type 2 Diabetes After Dual Oral Therapy Failure</title>
	<link>https://www.mdpi.com/2673-4540/7/10/206</link>
	<description>Background/Objectives: Achieving glycaemic control remains challenging in patients with type 2 diabetes mellitus (T2DM). Fixed-dose combinations with complementary mechanisms may facilitate treatment intensification and improve adherence. This study evaluated the efficacy and safety of a dose-titrated fixed-dose combination (FDC) of glimepiride, vildagliptin, and metformin in this population. Methods: This phase III, randomized, double-blind, multicentre clinical trial enrolled adults with inadequate glycaemic control after dual oral therapy. Participants were randomly assigned to Sequence A (escalation to intermediate-dose FDC) or Sequence B (escalation to high-dose FDC), with all participants administered the low-dose FDC once daily. On days 45 and 90, participants meeting escalation criteria were up-titrated to their assigned target dose. The primary endpoint was HbA1c on day 180, expressed as the difference between sequences. Results: On day 180, mean HbA1c was 7.57% in Sequence A and 7.89% in Sequence B (p = 0.068). At the end of follow-up, 52.4% of participants achieved HbA1c &amp;amp;lt;7.0%: 24.1% with the low-dose FDC, 12.0% after escalation to the intermediate-dose FDC, and 16.3% with the high-dose FDC. A total of 133 adverse events were reported in 62 participants: 54.9% were mild, and none were severe. Hypoglycaemia was the most frequent event (13.5%; n = 18 episodes). Conclusions: The FDC was associated with glycaemic improvements after dual-therapy failure and was well tolerated across all dose levels. These findings suggest that a response-guided triple oral FDC strategy represents a potentially effective and accessible intensification option for patients with T2DM who remain inadequately controlled on dual oral therapy. Trial Registration: ClinicalTrials.gov, NCT04841096.</description>
	<pubDate>2026-10-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 206: A Phase III, Randomized, Double-Blind Clinical Trial of a Novel Triple Fixed-Dose Combination (Glimepiride/Vildagliptin/Metformin) in Mexican Adults with Uncontrolled Type 2 Diabetes After Dual Oral Therapy Failure</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/206">doi: 10.3390/diabetology7100206</a></p>
	<p>Authors:
		Ana Cristina García-Ulloa
		Victor Bohorquez-López
		Ana Flores-Barranco
		Salvador Pérez-Jaime
		Ivonne Bourget-Ontiveros
		Juan A. Becerra-Hernandez
		Kevin F. Rios-Brito
		Miguel A. Martinez-Hernandez
		Cuitlahuac Gasca-Chavez
		Daniel Muñiz-Galindo
		Laura A. Lugo-Sánchez
		Julio C. Mora-Villalobos
		Jorge González-Canudas
		</p>
	<p>Background/Objectives: Achieving glycaemic control remains challenging in patients with type 2 diabetes mellitus (T2DM). Fixed-dose combinations with complementary mechanisms may facilitate treatment intensification and improve adherence. This study evaluated the efficacy and safety of a dose-titrated fixed-dose combination (FDC) of glimepiride, vildagliptin, and metformin in this population. Methods: This phase III, randomized, double-blind, multicentre clinical trial enrolled adults with inadequate glycaemic control after dual oral therapy. Participants were randomly assigned to Sequence A (escalation to intermediate-dose FDC) or Sequence B (escalation to high-dose FDC), with all participants administered the low-dose FDC once daily. On days 45 and 90, participants meeting escalation criteria were up-titrated to their assigned target dose. The primary endpoint was HbA1c on day 180, expressed as the difference between sequences. Results: On day 180, mean HbA1c was 7.57% in Sequence A and 7.89% in Sequence B (p = 0.068). At the end of follow-up, 52.4% of participants achieved HbA1c &amp;amp;lt;7.0%: 24.1% with the low-dose FDC, 12.0% after escalation to the intermediate-dose FDC, and 16.3% with the high-dose FDC. A total of 133 adverse events were reported in 62 participants: 54.9% were mild, and none were severe. Hypoglycaemia was the most frequent event (13.5%; n = 18 episodes). Conclusions: The FDC was associated with glycaemic improvements after dual-therapy failure and was well tolerated across all dose levels. These findings suggest that a response-guided triple oral FDC strategy represents a potentially effective and accessible intensification option for patients with T2DM who remain inadequately controlled on dual oral therapy. Trial Registration: ClinicalTrials.gov, NCT04841096.</p>
	]]></content:encoded>

	<dc:title>A Phase III, Randomized, Double-Blind Clinical Trial of a Novel Triple Fixed-Dose Combination (Glimepiride/Vildagliptin/Metformin) in Mexican Adults with Uncontrolled Type 2 Diabetes After Dual Oral Therapy Failure</dc:title>
			<dc:creator>Ana Cristina García-Ulloa</dc:creator>
			<dc:creator>Victor Bohorquez-López</dc:creator>
			<dc:creator>Ana Flores-Barranco</dc:creator>
			<dc:creator>Salvador Pérez-Jaime</dc:creator>
			<dc:creator>Ivonne Bourget-Ontiveros</dc:creator>
			<dc:creator>Juan A. Becerra-Hernandez</dc:creator>
			<dc:creator>Kevin F. Rios-Brito</dc:creator>
			<dc:creator>Miguel A. Martinez-Hernandez</dc:creator>
			<dc:creator>Cuitlahuac Gasca-Chavez</dc:creator>
			<dc:creator>Daniel Muñiz-Galindo</dc:creator>
			<dc:creator>Laura A. Lugo-Sánchez</dc:creator>
			<dc:creator>Julio C. Mora-Villalobos</dc:creator>
			<dc:creator>Jorge González-Canudas</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100206</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-19</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-19</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>206</prism:startingPage>
		<prism:doi>10.3390/diabetology7100206</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/206</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/205">

	<title>Diabetology, Vol. 7, Pages 205: An Observational Comparison of Gestational Diabetes Mellitus Prevalence and Pregnancy Outcomes Before and During COVID-19 in the Australian Capital Territory, 2018&amp;ndash;2021</title>
	<link>https://www.mdpi.com/2673-4540/7/10/205</link>
	<description>Background: In the Australian Capital Territory (ACT) during the Coronavirus disease 2019 (COVID-19) pandemic, gestational diabetes mellitus (GDM) testing using the World Health Organization&amp;amp;rsquo;s (WHO) oral glucose tolerance test (OGTT) was replaced with temporary guidelines comprising two phases: the red phase, with fasting glucose &amp;amp;ge;5.1 mmol/L (diagnosed) and &amp;amp;lt;5.1 mmol/L (excluded); and the subsequent amber phase of screening with fasting &amp;amp;ge;5.1 mmol/L (diagnosed), &amp;amp;lt;4.7 mmol/L (excluded) and 4.7&amp;amp;ndash;5.0 mmol/L, requiring completion of an OGTT. Aims: Our aim was to determine whether there were differences in GDM prevalence, maternal characteristics or infant outcomes during the COVID-19 pandemic period, in association with implementation of the temporary guidelines. Methods: We performed a before&amp;amp;ndash;during observational analysis of 9686 singleton births between April 2018 and December 2019 (pre-COVID-19, group 1, n = 4879) or April 2020 and December 2021 (COVID-19, group 2, n = 4807). Group 2 comprised subgroups 2a (1 April&amp;amp;ndash;2 November 2020, n = 1845) and 2b (3 November 2020&amp;amp;ndash;31 December 2021, n = 2962). The GDM testing date was estimated at 26 weeks of gestation and used for group assignment. For GDM diagnosis, group 1 applied the WHO OGTT, and group 2 applied the temporary guidelines (2a the red phase; 2b the amber phase). Associations were tested using chi-square tests, pairwise z-tests and logistic regression. Results: Compared to group 1, GDM prevalence significantly decreased in subgroup 2a (26.7% vs. 21.7%) and significantly increased in subgroup 2b (26.7% vs. 31.7%) (all: p &amp;amp;lt; 0.001). For non-GDM pregnancies, there were no significant associations nor significant differences for infant outcomes when group 1 was compared to subgroups 2a and 2b. Subgroup 2a pregnancies with insulin-requiring GDM, compared to Group 1 counterparts, had significantly higher odds of infants with LGA (aOR = 1.73, 98.75% CI of 1.04&amp;amp;ndash;2.89, p = 0.008) and macrosomia (aOR = 2.05, 98.75% CI of 1.09&amp;amp;ndash;3.86, p = 0.004). Conclusions: The COVID-19 period and the temporary guidelines were associated with changes in GDM prevalence, which differed by phase. No increase was observed in adverse infant outcomes in non-GDM pregnancies. GDM pregnancies in the red phase had worse infant outcomes, which may have been due to enrichment of this group with elevated fasting GDM.</description>
	<pubDate>2026-10-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 205: An Observational Comparison of Gestational Diabetes Mellitus Prevalence and Pregnancy Outcomes Before and During COVID-19 in the Australian Capital Territory, 2018&amp;ndash;2021</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/205">doi: 10.3390/diabetology7100205</a></p>
	<p>Authors:
		Jennifer Hutchinson
		Matthew Hart
		Roisin Ashhurst
		Christopher J. Nolan
		Deborah Davis
		Catherine R. Knight-Agarwal
		</p>
	<p>Background: In the Australian Capital Territory (ACT) during the Coronavirus disease 2019 (COVID-19) pandemic, gestational diabetes mellitus (GDM) testing using the World Health Organization&amp;amp;rsquo;s (WHO) oral glucose tolerance test (OGTT) was replaced with temporary guidelines comprising two phases: the red phase, with fasting glucose &amp;amp;ge;5.1 mmol/L (diagnosed) and &amp;amp;lt;5.1 mmol/L (excluded); and the subsequent amber phase of screening with fasting &amp;amp;ge;5.1 mmol/L (diagnosed), &amp;amp;lt;4.7 mmol/L (excluded) and 4.7&amp;amp;ndash;5.0 mmol/L, requiring completion of an OGTT. Aims: Our aim was to determine whether there were differences in GDM prevalence, maternal characteristics or infant outcomes during the COVID-19 pandemic period, in association with implementation of the temporary guidelines. Methods: We performed a before&amp;amp;ndash;during observational analysis of 9686 singleton births between April 2018 and December 2019 (pre-COVID-19, group 1, n = 4879) or April 2020 and December 2021 (COVID-19, group 2, n = 4807). Group 2 comprised subgroups 2a (1 April&amp;amp;ndash;2 November 2020, n = 1845) and 2b (3 November 2020&amp;amp;ndash;31 December 2021, n = 2962). The GDM testing date was estimated at 26 weeks of gestation and used for group assignment. For GDM diagnosis, group 1 applied the WHO OGTT, and group 2 applied the temporary guidelines (2a the red phase; 2b the amber phase). Associations were tested using chi-square tests, pairwise z-tests and logistic regression. Results: Compared to group 1, GDM prevalence significantly decreased in subgroup 2a (26.7% vs. 21.7%) and significantly increased in subgroup 2b (26.7% vs. 31.7%) (all: p &amp;amp;lt; 0.001). For non-GDM pregnancies, there were no significant associations nor significant differences for infant outcomes when group 1 was compared to subgroups 2a and 2b. Subgroup 2a pregnancies with insulin-requiring GDM, compared to Group 1 counterparts, had significantly higher odds of infants with LGA (aOR = 1.73, 98.75% CI of 1.04&amp;amp;ndash;2.89, p = 0.008) and macrosomia (aOR = 2.05, 98.75% CI of 1.09&amp;amp;ndash;3.86, p = 0.004). Conclusions: The COVID-19 period and the temporary guidelines were associated with changes in GDM prevalence, which differed by phase. No increase was observed in adverse infant outcomes in non-GDM pregnancies. GDM pregnancies in the red phase had worse infant outcomes, which may have been due to enrichment of this group with elevated fasting GDM.</p>
	]]></content:encoded>

	<dc:title>An Observational Comparison of Gestational Diabetes Mellitus Prevalence and Pregnancy Outcomes Before and During COVID-19 in the Australian Capital Territory, 2018&amp;amp;ndash;2021</dc:title>
			<dc:creator>Jennifer Hutchinson</dc:creator>
			<dc:creator>Matthew Hart</dc:creator>
			<dc:creator>Roisin Ashhurst</dc:creator>
			<dc:creator>Christopher J. Nolan</dc:creator>
			<dc:creator>Deborah Davis</dc:creator>
			<dc:creator>Catherine R. Knight-Agarwal</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100205</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-16</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-16</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>205</prism:startingPage>
		<prism:doi>10.3390/diabetology7100205</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/205</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/204">

	<title>Diabetology, Vol. 7, Pages 204: Inpatient Hypoglycaemia&amp;mdash;The Next Prognostic Factor: A Retrospective Case&amp;ndash;Control Study of Hospital Inpatients with and Without Diabetes Mellitus</title>
	<link>https://www.mdpi.com/2673-4540/7/10/204</link>
	<description>Background: Hospital inpatient hypoglycaemia is a common complication associated with poor patient outcomes. With the rising prevalence of diabetes mellitus (DM) and approximately 20% of hospital beds occupied by patients with DM, inpatient hypoglycaemia is an important safety concern. We aimed to determine the incidence of and risk factors for inpatient hypoglycaemia and their association with mortality and hospital length of stay (LOS). Methods: A retrospective single-centre case&amp;amp;ndash;control study was conducted at Nepean Hospital, New South Wales, Australia, over 12 months (July 2018&amp;amp;ndash;June 2019). The cases were inpatients who experienced hypoglycaemia, defined as capillary blood glucose &amp;amp;lt;4 mmol/L. Patients with hypoglycaemia were stratified into those with and without DM. The controls were randomly selected inpatients with DM admitted during the same period who did not experience hypoglycaemia. Results: A total of 251 episodes of hypoglycaemia occurred in 234 patients; 202 events (80%) occurred in 187 patients with DM and 49 (20%) in 47 patients without DM. In the patients with DM, the factors associated with hypoglycaemia included basal&amp;amp;ndash;bolus insulin (aOR 26.6; 95% CI 7.9&amp;amp;ndash;106.6), premixed insulin (aOR 5.9; 95% CI 1.6&amp;amp;ndash;25.9), sulfonylureas (aOR 3.2; 95% CI 1.1&amp;amp;ndash;9.6), and malnutrition (aOR 4.2; 95% CI 1.2&amp;amp;ndash;18.0). Compared with the controls, patients with DM and hypoglycaemia had higher inpatient mortality (10.2% vs. 3.0%), 12-month mortality (20.9% vs. 5.5%), and a longer median LOS (12 vs. 4 days). The twelve-month mortality was 36.2% in patients without DM who experienced hypoglycaemia. Conclusions: Inpatient hypoglycaemia is associated with high mortality and increased LOS, highlighting the need for greater awareness and effective prevention strategies.</description>
	<pubDate>2026-10-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 204: Inpatient Hypoglycaemia&amp;mdash;The Next Prognostic Factor: A Retrospective Case&amp;ndash;Control Study of Hospital Inpatients with and Without Diabetes Mellitus</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/204">doi: 10.3390/diabetology7100204</a></p>
	<p>Authors:
		Nardeen S. Habashy
		Gary K. K. Low
		Emily J. Hibbert
		</p>
	<p>Background: Hospital inpatient hypoglycaemia is a common complication associated with poor patient outcomes. With the rising prevalence of diabetes mellitus (DM) and approximately 20% of hospital beds occupied by patients with DM, inpatient hypoglycaemia is an important safety concern. We aimed to determine the incidence of and risk factors for inpatient hypoglycaemia and their association with mortality and hospital length of stay (LOS). Methods: A retrospective single-centre case&amp;amp;ndash;control study was conducted at Nepean Hospital, New South Wales, Australia, over 12 months (July 2018&amp;amp;ndash;June 2019). The cases were inpatients who experienced hypoglycaemia, defined as capillary blood glucose &amp;amp;lt;4 mmol/L. Patients with hypoglycaemia were stratified into those with and without DM. The controls were randomly selected inpatients with DM admitted during the same period who did not experience hypoglycaemia. Results: A total of 251 episodes of hypoglycaemia occurred in 234 patients; 202 events (80%) occurred in 187 patients with DM and 49 (20%) in 47 patients without DM. In the patients with DM, the factors associated with hypoglycaemia included basal&amp;amp;ndash;bolus insulin (aOR 26.6; 95% CI 7.9&amp;amp;ndash;106.6), premixed insulin (aOR 5.9; 95% CI 1.6&amp;amp;ndash;25.9), sulfonylureas (aOR 3.2; 95% CI 1.1&amp;amp;ndash;9.6), and malnutrition (aOR 4.2; 95% CI 1.2&amp;amp;ndash;18.0). Compared with the controls, patients with DM and hypoglycaemia had higher inpatient mortality (10.2% vs. 3.0%), 12-month mortality (20.9% vs. 5.5%), and a longer median LOS (12 vs. 4 days). The twelve-month mortality was 36.2% in patients without DM who experienced hypoglycaemia. Conclusions: Inpatient hypoglycaemia is associated with high mortality and increased LOS, highlighting the need for greater awareness and effective prevention strategies.</p>
	]]></content:encoded>

	<dc:title>Inpatient Hypoglycaemia&amp;amp;mdash;The Next Prognostic Factor: A Retrospective Case&amp;amp;ndash;Control Study of Hospital Inpatients with and Without Diabetes Mellitus</dc:title>
			<dc:creator>Nardeen S. Habashy</dc:creator>
			<dc:creator>Gary K. K. Low</dc:creator>
			<dc:creator>Emily J. Hibbert</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100204</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-15</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-15</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>204</prism:startingPage>
		<prism:doi>10.3390/diabetology7100204</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/204</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/203">

	<title>Diabetology, Vol. 7, Pages 203: Long-Term Protection from Severe Hypoglycemia Following Pancreas Transplantation: A Single-Center Cohort Study</title>
	<link>https://www.mdpi.com/2673-4540/7/10/203</link>
	<description>Background: Patients with type 1 diabetes complicated by severe hypoglycemia and impaired awareness remain at high risk of mortality despite advances in diabetes treatment. Pancreas transplantation offers definitive &amp;amp;beta;-cell replacement; however, contemporary real-world data on hypoglycemia outcomes are limited. Methods: We performed a retrospective single-center cohort study of adult patients undergoing pancreas transplantation at The Mount Sinai Hospital between 1 January 2010 and 31 December 2024. Transplant types included simultaneous pancreas&amp;amp;ndash;kidney (SPK), pancreas after kidney (PAK), and pancreas transplant alone (PTA). The primary outcome was the incidence of severe hypoglycemia following transplantation, with secondary outcomes including graft survival, patient survival, biopsy-proven rejection, and infectious complications. Post-transplant HbA1c and continuous glucose monitoring data were not systematically captured and could not be analyzed. Results: A total of 100 pancreas transplants were performed (SPK 73%, PAK 26%, PTA 1%), over a median follow-up of 8.5 years (IQR 4.5&amp;amp;ndash;13.7). Pretransplant hypoglycemia or hypoglycemia unawareness was present in 63% of recipients. Documented impaired awareness specifically was recorded in a smaller subset (9%). No episodes of severe hypoglycemia occurred following transplantation, and hypoglycemia unawareness resolved in all patients with available follow-up. Two patients (2%) had a hypoglycemic episode recorded post-transplant; in one, the episode occurred after graft failure while on insulin, and neither was a severe (third-party-assisted) event in a functioning graft. Death-censored graft survival was 94.0% at 1 year, 91.6% at 3 years, 83.0% at 5 years, and 80.5% at 10 years, while patient survival was 95.0%, 89.5%, 88.2%, and 84.2% at the same time points. Rejection occurred in 21%, and infectious complications in 31% of recipients. Conclusions: Pancreas transplantation provided complete and durable protection from clinically documented severe hypoglycemia, with excellent long-term graft and patient survival. In the absence of systematic post-transplant HbA1c and continuous glucose monitoring data, these findings should be read as freedom from clinically recognized severe hypoglycemic events rather than as documented normoglycemia, supporting its role as the most definitive &amp;amp;beta;-cell replacement strategy in appropriately selected patients.</description>
	<pubDate>2026-10-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 203: Long-Term Protection from Severe Hypoglycemia Following Pancreas Transplantation: A Single-Center Cohort Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/203">doi: 10.3390/diabetology7100203</a></p>
	<p>Authors:
		Sara Shahrestani
		Rachel Todd
		Rafael Khaim
		Vikram Wadhera
		Fasika Tedla
		Matthew Holzner
		Ron Shapiro
		Sander Florman
		Kasi McCune
		</p>
	<p>Background: Patients with type 1 diabetes complicated by severe hypoglycemia and impaired awareness remain at high risk of mortality despite advances in diabetes treatment. Pancreas transplantation offers definitive &amp;amp;beta;-cell replacement; however, contemporary real-world data on hypoglycemia outcomes are limited. Methods: We performed a retrospective single-center cohort study of adult patients undergoing pancreas transplantation at The Mount Sinai Hospital between 1 January 2010 and 31 December 2024. Transplant types included simultaneous pancreas&amp;amp;ndash;kidney (SPK), pancreas after kidney (PAK), and pancreas transplant alone (PTA). The primary outcome was the incidence of severe hypoglycemia following transplantation, with secondary outcomes including graft survival, patient survival, biopsy-proven rejection, and infectious complications. Post-transplant HbA1c and continuous glucose monitoring data were not systematically captured and could not be analyzed. Results: A total of 100 pancreas transplants were performed (SPK 73%, PAK 26%, PTA 1%), over a median follow-up of 8.5 years (IQR 4.5&amp;amp;ndash;13.7). Pretransplant hypoglycemia or hypoglycemia unawareness was present in 63% of recipients. Documented impaired awareness specifically was recorded in a smaller subset (9%). No episodes of severe hypoglycemia occurred following transplantation, and hypoglycemia unawareness resolved in all patients with available follow-up. Two patients (2%) had a hypoglycemic episode recorded post-transplant; in one, the episode occurred after graft failure while on insulin, and neither was a severe (third-party-assisted) event in a functioning graft. Death-censored graft survival was 94.0% at 1 year, 91.6% at 3 years, 83.0% at 5 years, and 80.5% at 10 years, while patient survival was 95.0%, 89.5%, 88.2%, and 84.2% at the same time points. Rejection occurred in 21%, and infectious complications in 31% of recipients. Conclusions: Pancreas transplantation provided complete and durable protection from clinically documented severe hypoglycemia, with excellent long-term graft and patient survival. In the absence of systematic post-transplant HbA1c and continuous glucose monitoring data, these findings should be read as freedom from clinically recognized severe hypoglycemic events rather than as documented normoglycemia, supporting its role as the most definitive &amp;amp;beta;-cell replacement strategy in appropriately selected patients.</p>
	]]></content:encoded>

	<dc:title>Long-Term Protection from Severe Hypoglycemia Following Pancreas Transplantation: A Single-Center Cohort Study</dc:title>
			<dc:creator>Sara Shahrestani</dc:creator>
			<dc:creator>Rachel Todd</dc:creator>
			<dc:creator>Rafael Khaim</dc:creator>
			<dc:creator>Vikram Wadhera</dc:creator>
			<dc:creator>Fasika Tedla</dc:creator>
			<dc:creator>Matthew Holzner</dc:creator>
			<dc:creator>Ron Shapiro</dc:creator>
			<dc:creator>Sander Florman</dc:creator>
			<dc:creator>Kasi McCune</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100203</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-14</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-14</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>203</prism:startingPage>
		<prism:doi>10.3390/diabetology7100203</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/203</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/202">

	<title>Diabetology, Vol. 7, Pages 202: Organisational Health Literacy in Diabetes Healthcare: Protocol for a Multisite Implementation and Evaluation of OHL-Act</title>
	<link>https://www.mdpi.com/2673-4540/7/10/202</link>
	<description>Health literacy challenges are associated with greater risk and adverse outcomes of long-term conditions such as diabetes mellitus and contribute to persistent health inequalities. In response, increasing attention has been given to Organisational Health Literacy (OHL), which addresses how healthcare organisations can make health information and services more accessible and easier to navigate for users (def: people receiving care, treatment, education or health-related support from the organisation) with diverse health literacy needs. Despite the increased focus on the organisational perspective, most previous interventions have focused on individual health literacy. Thus, there is limited systematic evidence on organisational interventions designed to improve OHL and which mechanisms and contextual factors support and facilitate change. The aim of this paper is to describe the protocol for the implementation and evaluation of an OHL intervention (OHL-Act) across primary care and hospital settings caring for individuals with long-term conditions. The primary objective for the future project will be to evaluate whether the implementation of OHL-Act is associated with improvements in OHL across diverse healthcare organisations providing care and support for people living with long-term conditions. The OHL-Act comprises three workshops designed to strengthen OHL through facilitated reflections among staff and managers, a structured self-assessment of the organisation and identification and prioritisation of improvement ideas in a local action plan. The OHL-Act will be implemented in 8&amp;amp;ndash;10 Danish outpatient clinics and municipal units providing care and preventive services for people living with long-term conditions such as diabetes. A mixed-methods evaluation (2026&amp;amp;ndash;2029) will use the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework combined with the Practical, Robust Implementation and Sustainability Model (PRISM) to examine implementation processes, mechanisms of change and contextual factors. Data will be collected from surveys, organisational self-assessments, and implementation logs, as well as qualitative interview data. The study will generate insights into the implementation and effectiveness of the OHL-Act across healthcare settings and thereby give a deeper understanding of how OHL can be embedded in routine care and provide evidence of the development of more health literacy responsive and equitable healthcare systems.</description>
	<pubDate>2026-10-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 202: Organisational Health Literacy in Diabetes Healthcare: Protocol for a Multisite Implementation and Evaluation of OHL-Act</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/202">doi: 10.3390/diabetology7100202</a></p>
	<p>Authors:
		Maiken Meldgaard
		Helle Terkildsen Maindal
		Liv Stubbe Østergaard
		Mette Juel Rothmann
		Anna Aaby
		</p>
	<p>Health literacy challenges are associated with greater risk and adverse outcomes of long-term conditions such as diabetes mellitus and contribute to persistent health inequalities. In response, increasing attention has been given to Organisational Health Literacy (OHL), which addresses how healthcare organisations can make health information and services more accessible and easier to navigate for users (def: people receiving care, treatment, education or health-related support from the organisation) with diverse health literacy needs. Despite the increased focus on the organisational perspective, most previous interventions have focused on individual health literacy. Thus, there is limited systematic evidence on organisational interventions designed to improve OHL and which mechanisms and contextual factors support and facilitate change. The aim of this paper is to describe the protocol for the implementation and evaluation of an OHL intervention (OHL-Act) across primary care and hospital settings caring for individuals with long-term conditions. The primary objective for the future project will be to evaluate whether the implementation of OHL-Act is associated with improvements in OHL across diverse healthcare organisations providing care and support for people living with long-term conditions. The OHL-Act comprises three workshops designed to strengthen OHL through facilitated reflections among staff and managers, a structured self-assessment of the organisation and identification and prioritisation of improvement ideas in a local action plan. The OHL-Act will be implemented in 8&amp;amp;ndash;10 Danish outpatient clinics and municipal units providing care and preventive services for people living with long-term conditions such as diabetes. A mixed-methods evaluation (2026&amp;amp;ndash;2029) will use the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework combined with the Practical, Robust Implementation and Sustainability Model (PRISM) to examine implementation processes, mechanisms of change and contextual factors. Data will be collected from surveys, organisational self-assessments, and implementation logs, as well as qualitative interview data. The study will generate insights into the implementation and effectiveness of the OHL-Act across healthcare settings and thereby give a deeper understanding of how OHL can be embedded in routine care and provide evidence of the development of more health literacy responsive and equitable healthcare systems.</p>
	]]></content:encoded>

	<dc:title>Organisational Health Literacy in Diabetes Healthcare: Protocol for a Multisite Implementation and Evaluation of OHL-Act</dc:title>
			<dc:creator>Maiken Meldgaard</dc:creator>
			<dc:creator>Helle Terkildsen Maindal</dc:creator>
			<dc:creator>Liv Stubbe Østergaard</dc:creator>
			<dc:creator>Mette Juel Rothmann</dc:creator>
			<dc:creator>Anna Aaby</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100202</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-14</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-14</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Protocol</prism:section>
	<prism:startingPage>202</prism:startingPage>
		<prism:doi>10.3390/diabetology7100202</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/202</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/201">

	<title>Diabetology, Vol. 7, Pages 201: Development of the Digital Diabetes Education Platform for Type 1 Diabetes in Pakistan</title>
	<link>https://www.mdpi.com/2673-4540/7/10/201</link>
	<description>Objectives: This study aimed to develop a structured and culturally appropriate diabetes education platform to provide accessible education to individuals and caregivers of Type 1 Diabetes (T1D). Methods: In phase I, the digital tele-education platform, named T1Dbits, was formed by modifying and translating the existing content of DigiBete, a digital diabetes platform in the UK. First, an Expert Advisory Group (EAG, n = 13) selected 30 topics on six key areas of diabetes self-management and education. A co-design group (n = 30 TIDs and HCPs) tailored content according to the needs of the Pakistani population, in linguistically appropriate formats. In phase II, this digital resource was implemented in Digital Diabetes Education Centers in rural and urban areas (n = 30), employing a hybrid of in-person and online education delivery. Results: From December 2023 to March 2026, the platform achieved 46,000 new users and 4200 returning users. Following the implementation of T1DBits, an absolute change of 1.31% in HbA1c levels and an increase in self-reported knowledge scores were observed among T1D individuals (n = 60). HCP and community feedback highlights the platform&amp;amp;rsquo;s strong usability for daily T1D management. About 80.95% of HCPs reported that the content fulfills their need to practice. Overall, 61.4% of the community and 52.4% of HCPs recommended translations into regional languages. Conclusions: The platform achieved a high user rate and demonstrated its effectiveness in improving glycemic control and self-management knowledge scores of T1D individuals. The platform was found to be equally useful for the HCPs and T1D community members, indicating its strong feasibility to be integrated into the routine healthcare system of Pakistan.</description>
	<pubDate>2026-10-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 201: Development of the Digital Diabetes Education Platform for Type 1 Diabetes in Pakistan</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/201">doi: 10.3390/diabetology7100201</a></p>
	<p>Authors:
		Anum Anwar
		Sana Ajmal
		Abdul Wahab
		Aliza Fatima
		Salma Mehar
		Maddie Julian
		</p>
	<p>Objectives: This study aimed to develop a structured and culturally appropriate diabetes education platform to provide accessible education to individuals and caregivers of Type 1 Diabetes (T1D). Methods: In phase I, the digital tele-education platform, named T1Dbits, was formed by modifying and translating the existing content of DigiBete, a digital diabetes platform in the UK. First, an Expert Advisory Group (EAG, n = 13) selected 30 topics on six key areas of diabetes self-management and education. A co-design group (n = 30 TIDs and HCPs) tailored content according to the needs of the Pakistani population, in linguistically appropriate formats. In phase II, this digital resource was implemented in Digital Diabetes Education Centers in rural and urban areas (n = 30), employing a hybrid of in-person and online education delivery. Results: From December 2023 to March 2026, the platform achieved 46,000 new users and 4200 returning users. Following the implementation of T1DBits, an absolute change of 1.31% in HbA1c levels and an increase in self-reported knowledge scores were observed among T1D individuals (n = 60). HCP and community feedback highlights the platform&amp;amp;rsquo;s strong usability for daily T1D management. About 80.95% of HCPs reported that the content fulfills their need to practice. Overall, 61.4% of the community and 52.4% of HCPs recommended translations into regional languages. Conclusions: The platform achieved a high user rate and demonstrated its effectiveness in improving glycemic control and self-management knowledge scores of T1D individuals. The platform was found to be equally useful for the HCPs and T1D community members, indicating its strong feasibility to be integrated into the routine healthcare system of Pakistan.</p>
	]]></content:encoded>

	<dc:title>Development of the Digital Diabetes Education Platform for Type 1 Diabetes in Pakistan</dc:title>
			<dc:creator>Anum Anwar</dc:creator>
			<dc:creator>Sana Ajmal</dc:creator>
			<dc:creator>Abdul Wahab</dc:creator>
			<dc:creator>Aliza Fatima</dc:creator>
			<dc:creator>Salma Mehar</dc:creator>
			<dc:creator>Maddie Julian</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100201</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-14</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-14</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>201</prism:startingPage>
		<prism:doi>10.3390/diabetology7100201</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/201</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/200">

	<title>Diabetology, Vol. 7, Pages 200: UK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England</title>
	<link>https://www.mdpi.com/2673-4540/7/10/200</link>
	<description>Background/Objectives: In this retrospective aggregate pharmacovigilance study, we described UK Yellow Card reporting relative to partial English National Health Service (NHS) general practice (GP) prescribing for six glucagon-like peptide-1 (GLP-1)-based therapies. Methods: Primary overall reaction ratios used matching complete calendar years within each medicine: 2022&amp;amp;ndash;2025 for five medicines and 2024&amp;amp;ndash;2025 for tirzepatide. UK reaction counts were divided by English NHS GP items; geographical and product-coverage differences remain. Separate medicine estimates used conditional exact Poisson intervals without pooling. Annual models allowed for overdispersion. Outcome-specific extracts with unmatched windows and the combined GP plus estimated hospital denominator were secondary analyses. Results: Under the incomplete English NHS GP denominator, primary reaction ratios per million items were tirzepatide 23,808.48, semaglutide 5720.42, liraglutide 1700.45, exenatide 370.52, dulaglutide 258.11, and lixisenatide 87.70. Overall and severity report-based ratios were available for four medicines over their eligible periods. Temporal estimates were imprecise; tirzepatide had only two complete years, and lixisenatide had three reaction entries in its complete-year series, so neither received trend inference. Conclusions: Calendar matching improves the temporal definition of the overall ratios. Omitted private prescribing, UK&amp;amp;ndash;England population differences, uncertain product matching and reporting behaviour still prevent interpretation as incidence or comparative safety.</description>
	<pubDate>2026-10-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 200: UK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/200">doi: 10.3390/diabetology7100200</a></p>
	<p>Authors:
		Ahmed Asiri
		Rob Daniels
		Ahmed Nijim
		Hairil Abdul Razak
		Kinan Mokbel
		</p>
	<p>Background/Objectives: In this retrospective aggregate pharmacovigilance study, we described UK Yellow Card reporting relative to partial English National Health Service (NHS) general practice (GP) prescribing for six glucagon-like peptide-1 (GLP-1)-based therapies. Methods: Primary overall reaction ratios used matching complete calendar years within each medicine: 2022&amp;amp;ndash;2025 for five medicines and 2024&amp;amp;ndash;2025 for tirzepatide. UK reaction counts were divided by English NHS GP items; geographical and product-coverage differences remain. Separate medicine estimates used conditional exact Poisson intervals without pooling. Annual models allowed for overdispersion. Outcome-specific extracts with unmatched windows and the combined GP plus estimated hospital denominator were secondary analyses. Results: Under the incomplete English NHS GP denominator, primary reaction ratios per million items were tirzepatide 23,808.48, semaglutide 5720.42, liraglutide 1700.45, exenatide 370.52, dulaglutide 258.11, and lixisenatide 87.70. Overall and severity report-based ratios were available for four medicines over their eligible periods. Temporal estimates were imprecise; tirzepatide had only two complete years, and lixisenatide had three reaction entries in its complete-year series, so neither received trend inference. Conclusions: Calendar matching improves the temporal definition of the overall ratios. Omitted private prescribing, UK&amp;amp;ndash;England population differences, uncertain product matching and reporting behaviour still prevent interpretation as incidence or comparative safety.</p>
	]]></content:encoded>

	<dc:title>UK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England</dc:title>
			<dc:creator>Ahmed Asiri</dc:creator>
			<dc:creator>Rob Daniels</dc:creator>
			<dc:creator>Ahmed Nijim</dc:creator>
			<dc:creator>Hairil Abdul Razak</dc:creator>
			<dc:creator>Kinan Mokbel</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100200</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-13</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-13</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>200</prism:startingPage>
		<prism:doi>10.3390/diabetology7100200</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/200</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/199">

	<title>Diabetology, Vol. 7, Pages 199: The Clinical Spectrum and Significance of ABCC8 Gene Variants in the Diagnosis of Monogenic Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/10/199</link>
	<description>Background:&amp;amp;nbsp;ABCC8 gene variants have been linked to a range of conditions that affect insulin secretion, such as congenital hyperinsulinism, neonatal diabetes and maturity-onset diabetes of the young (MODY). This study aimed to characterise ABCC8 variants and to assess their relationship with clinical phenotypes and family segregation. Methods: Between 2017 and May 2026, tNGS (targeted next-generation sequencing) analysis was performed on the DNA of 1202 patients who were referred for suspected monogenic diabetes. The exons and flanking intronic regions of the ABCC8 gene were assessed for single nucleotide variants (SNVs) and small insertions and deletions (indels). Rare variants were prioritised based on population frequency, in silico predictions and clinical classification. Selected variants were confirmed, and segregation analysis was performed using Sanger sequencing. Results: We identified five patients carrying pathogenic or likely pathogenic ABCC8 variants. A frameshift ABCC8 variant had not been previously reported. All patients had diabetes, with some also presenting with a history of hypoglycaemia. Family studies also revealed intra-familial variability and enabled the identification of previously unrecognized affected relatives. Conclusions: Our findings support the broad clinical spectrum associated with ABCC8 variants and highlight the importance of family segregation analysis. Comprehensive molecular and clinical evaluation may improve the detection of patients with ABCC8-related diabetes and distinguish this condition from other forms of monogenic diabetes.</description>
	<pubDate>2026-10-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 199: The Clinical Spectrum and Significance of ABCC8 Gene Variants in the Diagnosis of Monogenic Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/199">doi: 10.3390/diabetology7100199</a></p>
	<p>Authors:
		Natalia Kapelan
		Piotr Tust
		Sebastian Skoczylas
		Tomasz Płoszaj
		Karolina Gadzalska
		Monika Gorządek
		Paulina Jakiel
		Ewa Juścińska
		Edyta Budzyńska
		Maciej Borowiec
		Agnieszka Szadkowska
		Renata Stawerska
		Agnieszka Zmysłowska
		</p>
	<p>Background:&amp;amp;nbsp;ABCC8 gene variants have been linked to a range of conditions that affect insulin secretion, such as congenital hyperinsulinism, neonatal diabetes and maturity-onset diabetes of the young (MODY). This study aimed to characterise ABCC8 variants and to assess their relationship with clinical phenotypes and family segregation. Methods: Between 2017 and May 2026, tNGS (targeted next-generation sequencing) analysis was performed on the DNA of 1202 patients who were referred for suspected monogenic diabetes. The exons and flanking intronic regions of the ABCC8 gene were assessed for single nucleotide variants (SNVs) and small insertions and deletions (indels). Rare variants were prioritised based on population frequency, in silico predictions and clinical classification. Selected variants were confirmed, and segregation analysis was performed using Sanger sequencing. Results: We identified five patients carrying pathogenic or likely pathogenic ABCC8 variants. A frameshift ABCC8 variant had not been previously reported. All patients had diabetes, with some also presenting with a history of hypoglycaemia. Family studies also revealed intra-familial variability and enabled the identification of previously unrecognized affected relatives. Conclusions: Our findings support the broad clinical spectrum associated with ABCC8 variants and highlight the importance of family segregation analysis. Comprehensive molecular and clinical evaluation may improve the detection of patients with ABCC8-related diabetes and distinguish this condition from other forms of monogenic diabetes.</p>
	]]></content:encoded>

	<dc:title>The Clinical Spectrum and Significance of ABCC8 Gene Variants in the Diagnosis of Monogenic Diabetes</dc:title>
			<dc:creator>Natalia Kapelan</dc:creator>
			<dc:creator>Piotr Tust</dc:creator>
			<dc:creator>Sebastian Skoczylas</dc:creator>
			<dc:creator>Tomasz Płoszaj</dc:creator>
			<dc:creator>Karolina Gadzalska</dc:creator>
			<dc:creator>Monika Gorządek</dc:creator>
			<dc:creator>Paulina Jakiel</dc:creator>
			<dc:creator>Ewa Juścińska</dc:creator>
			<dc:creator>Edyta Budzyńska</dc:creator>
			<dc:creator>Maciej Borowiec</dc:creator>
			<dc:creator>Agnieszka Szadkowska</dc:creator>
			<dc:creator>Renata Stawerska</dc:creator>
			<dc:creator>Agnieszka Zmysłowska</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100199</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-13</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-13</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>199</prism:startingPage>
		<prism:doi>10.3390/diabetology7100199</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/199</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/198">

	<title>Diabetology, Vol. 7, Pages 198: Exploratory Associations of Subjective Sleep Characteristics, Psychosocial Factors, and Glycemic Control in Adults with Type 1 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/10/198</link>
	<description>Background/Objectives: Sleep health contributes to glucose homeostasis and metabolic regulation. We explored associations between subjective sleep characteristics, glycemic control, and diabetes-related clinical factors in adults with type 1 diabetes mellitus (T1DM). Methods: This exploratory cross-sectional, pilot investigation included 30 adults with T1DM at the Emergency Clinical County Hospital of T&amp;amp;acirc;rgu Mure&amp;amp;#537; between April 2025 and March 2026. We analyzed subjective sleep parameters, 90- and 14-day continuous glucose monitoring (CGM) data, clinical and laboratory parameters, diabetes distress and depression symptom scores. Results: Mean age was 39.0 &amp;amp;plusmn; 12.87 years, and 56.7% were male. Mean HbA1c was 7.28 &amp;amp;plusmn; 1.24%, 90-day time in range (TIR) was 61.47 &amp;amp;plusmn; 17.90%, and the coefficient of variation (CV) was 35.91 &amp;amp;plusmn; 6.71%. Mean nocturnal sleep duration was 7.15 &amp;amp;plusmn; 0.89 h, which was negatively correlated with mean afternoon nap duration on both weekdays (Pearson&amp;amp;rsquo;s r = &amp;amp;minus;0.492, 95% CI &amp;amp;minus;0.739 to &amp;amp;minus;0.124, n = 30, p = 0.009) and weekends (Pearson&amp;amp;rsquo;s r = &amp;amp;minus;0.481, 95% CI &amp;amp;minus;0.736 to &amp;amp;minus;0.119, n = 30, p = 0.012). Moreover, weekend sleep duration (p = 0.032, r = &amp;amp;minus;0.401) was negatively correlated only with TIR assessed over 90 days. Social jetlag, self-reported sleep quality, the number of self-reported nocturnal awakenings, altered sleep duration on weekdays, and daytime napping were not significantly correlated with HbA1c or CGM-derived metrics (all p &amp;amp;gt; 0.05). Mean subjective sleep quality score was 3.22 &amp;amp;plusmn; 0.87 on a five-point Likert scale. Restful sleep was reported only on half of the monitored nights; 20% had high risk for obstructive sleep apnea (OSA). Physical activity was positively correlated with TIR assessed over both 90 days (Pearson&amp;amp;rsquo;s r = 0.446, 95% CI 0.144 to 0.606, n = 30, p = 0.025) and 14 days (Pearson&amp;amp;rsquo;s r = 0.464, 95% CI 0.345 to 0.704, n = 30 p = 0.037). Conclusions: Among the assessed sleep characteristics, only weekend sleep duration was significantly associated with historical 90-day TIR, whereas physical activity was positively associated with TIR over both monitoring periods. Given the exploratory nature and small sample size of this study, larger longitudinal studies are needed to clarify the relationships between sleep health and glycemic control in adults with type 1 diabetes.</description>
	<pubDate>2026-10-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 198: Exploratory Associations of Subjective Sleep Characteristics, Psychosocial Factors, and Glycemic Control in Adults with Type 1 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/198">doi: 10.3390/diabetology7100198</a></p>
	<p>Authors:
		Boglárka Varga
		Enikő Nemes-Nagy
		Csongor Aszalos
		Bianca-Larisa Abalașei
		Monica Iudita Maria Szabo
		Mariana Cornelia Tilinca
		</p>
	<p>Background/Objectives: Sleep health contributes to glucose homeostasis and metabolic regulation. We explored associations between subjective sleep characteristics, glycemic control, and diabetes-related clinical factors in adults with type 1 diabetes mellitus (T1DM). Methods: This exploratory cross-sectional, pilot investigation included 30 adults with T1DM at the Emergency Clinical County Hospital of T&amp;amp;acirc;rgu Mure&amp;amp;#537; between April 2025 and March 2026. We analyzed subjective sleep parameters, 90- and 14-day continuous glucose monitoring (CGM) data, clinical and laboratory parameters, diabetes distress and depression symptom scores. Results: Mean age was 39.0 &amp;amp;plusmn; 12.87 years, and 56.7% were male. Mean HbA1c was 7.28 &amp;amp;plusmn; 1.24%, 90-day time in range (TIR) was 61.47 &amp;amp;plusmn; 17.90%, and the coefficient of variation (CV) was 35.91 &amp;amp;plusmn; 6.71%. Mean nocturnal sleep duration was 7.15 &amp;amp;plusmn; 0.89 h, which was negatively correlated with mean afternoon nap duration on both weekdays (Pearson&amp;amp;rsquo;s r = &amp;amp;minus;0.492, 95% CI &amp;amp;minus;0.739 to &amp;amp;minus;0.124, n = 30, p = 0.009) and weekends (Pearson&amp;amp;rsquo;s r = &amp;amp;minus;0.481, 95% CI &amp;amp;minus;0.736 to &amp;amp;minus;0.119, n = 30, p = 0.012). Moreover, weekend sleep duration (p = 0.032, r = &amp;amp;minus;0.401) was negatively correlated only with TIR assessed over 90 days. Social jetlag, self-reported sleep quality, the number of self-reported nocturnal awakenings, altered sleep duration on weekdays, and daytime napping were not significantly correlated with HbA1c or CGM-derived metrics (all p &amp;amp;gt; 0.05). Mean subjective sleep quality score was 3.22 &amp;amp;plusmn; 0.87 on a five-point Likert scale. Restful sleep was reported only on half of the monitored nights; 20% had high risk for obstructive sleep apnea (OSA). Physical activity was positively correlated with TIR assessed over both 90 days (Pearson&amp;amp;rsquo;s r = 0.446, 95% CI 0.144 to 0.606, n = 30, p = 0.025) and 14 days (Pearson&amp;amp;rsquo;s r = 0.464, 95% CI 0.345 to 0.704, n = 30 p = 0.037). Conclusions: Among the assessed sleep characteristics, only weekend sleep duration was significantly associated with historical 90-day TIR, whereas physical activity was positively associated with TIR over both monitoring periods. Given the exploratory nature and small sample size of this study, larger longitudinal studies are needed to clarify the relationships between sleep health and glycemic control in adults with type 1 diabetes.</p>
	]]></content:encoded>

	<dc:title>Exploratory Associations of Subjective Sleep Characteristics, Psychosocial Factors, and Glycemic Control in Adults with Type 1 Diabetes</dc:title>
			<dc:creator>Boglárka Varga</dc:creator>
			<dc:creator>Enikő Nemes-Nagy</dc:creator>
			<dc:creator>Csongor Aszalos</dc:creator>
			<dc:creator>Bianca-Larisa Abalașei</dc:creator>
			<dc:creator>Monica Iudita Maria Szabo</dc:creator>
			<dc:creator>Mariana Cornelia Tilinca</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100198</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-12</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-12</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>198</prism:startingPage>
		<prism:doi>10.3390/diabetology7100198</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/198</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/197">

	<title>Diabetology, Vol. 7, Pages 197: A Robust and Explainable Framework for Predicting Hospital Readmission in Patients with Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/10/197</link>
	<description>Background: Hospital readmission among patients with diabetes remains a healthcare challenge, contributing to adverse clinical outcomes, increased healthcare expenditures, and reduced quality of care. This study presents a leakage-resistant and clinically interpretable machine learning framework for predicting hospital readmission risk using structured clinical and admission-related data. Methods: The framework incorporated preprocessing strategies to minimize information leakage, including duplicate-feature removal, categorical encoding, and feature normalization. Class imbalance was addressed using fold-specific strategies, including class-weighted learning and the Synthetic Minority Over-sampling Technique for Nominal and Continuous features (SMOTENC). Resampling was performed exclusively within each training fold, while validation and test data retained their original class distributions. Feature selection was conducted using correlation analysis and Recursive Feature Elimination (RFE). Principal Component Analysis (PCA) was used for exploratory variance analysis and visualization, preserving the interpretability of the predictive features Five models were evaluated: L2-regularized logistic regression, random forest, ANN, XGBoost, and Hybrid CNN&amp;amp;ndash;LSTM. SHAP and LIME provided global and local explanations. Results: The hybrid CNN-LSTM achieved the strongest performance, attaining an accuracy of 0.80 and an area under the receiver operating characteristic curve (ROC-AUC) of 0.86 on a hold-out dataset. Explainability analyses enhanced model transparency and supported clinical interpretation of predictions. Conclusions: Combining leakage-resistant preprocessing, balanced training, interpretable feature selection, and explainable deep learning provides a robust and clinically meaningful framework for diabetic readmission prediction.</description>
	<pubDate>2026-10-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 197: A Robust and Explainable Framework for Predicting Hospital Readmission in Patients with Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/197">doi: 10.3390/diabetology7100197</a></p>
	<p>Authors:
		Adil Ayaz Afridi
		Muhammad Usman
		Daniel J. Rubin
		Muhammad Rizwan Rashid Rana
		</p>
	<p>Background: Hospital readmission among patients with diabetes remains a healthcare challenge, contributing to adverse clinical outcomes, increased healthcare expenditures, and reduced quality of care. This study presents a leakage-resistant and clinically interpretable machine learning framework for predicting hospital readmission risk using structured clinical and admission-related data. Methods: The framework incorporated preprocessing strategies to minimize information leakage, including duplicate-feature removal, categorical encoding, and feature normalization. Class imbalance was addressed using fold-specific strategies, including class-weighted learning and the Synthetic Minority Over-sampling Technique for Nominal and Continuous features (SMOTENC). Resampling was performed exclusively within each training fold, while validation and test data retained their original class distributions. Feature selection was conducted using correlation analysis and Recursive Feature Elimination (RFE). Principal Component Analysis (PCA) was used for exploratory variance analysis and visualization, preserving the interpretability of the predictive features Five models were evaluated: L2-regularized logistic regression, random forest, ANN, XGBoost, and Hybrid CNN&amp;amp;ndash;LSTM. SHAP and LIME provided global and local explanations. Results: The hybrid CNN-LSTM achieved the strongest performance, attaining an accuracy of 0.80 and an area under the receiver operating characteristic curve (ROC-AUC) of 0.86 on a hold-out dataset. Explainability analyses enhanced model transparency and supported clinical interpretation of predictions. Conclusions: Combining leakage-resistant preprocessing, balanced training, interpretable feature selection, and explainable deep learning provides a robust and clinically meaningful framework for diabetic readmission prediction.</p>
	]]></content:encoded>

	<dc:title>A Robust and Explainable Framework for Predicting Hospital Readmission in Patients with Diabetes</dc:title>
			<dc:creator>Adil Ayaz Afridi</dc:creator>
			<dc:creator>Muhammad Usman</dc:creator>
			<dc:creator>Daniel J. Rubin</dc:creator>
			<dc:creator>Muhammad Rizwan Rashid Rana</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100197</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-12</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-12</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>197</prism:startingPage>
		<prism:doi>10.3390/diabetology7100197</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/197</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/196">

	<title>Diabetology, Vol. 7, Pages 196: Non-Biomedical Factors in Diabetic Foot Prevention in Ulcer-Free Patients: A Delphi Consensus Study</title>
	<link>https://www.mdpi.com/2673-4540/7/10/196</link>
	<description>Background/Objectives: Diabetic foot disease is associated with high rates of ulceration, amputation and premature mortality. While biomedical risk factors are systematically assessed in clinical practice, non-biomedical determinants&amp;amp;mdash;psychological, behavioural, social and socioeconomic&amp;amp;mdash;remain largely absent from existing risk stratification models. This study aimed to achieve expert consensus on the relevance of non-biomedical factors in the prevention of diabetic foot disease in people with diabetes without prior ulceration. Methods: A two-round Delphi consensus study was conducted with a multidisciplinary panel of 21 experts. A 24-item questionnaire, developed through narrative literature review and tested for content validity, was administered. Items were rated on a nine-point Likert scale, with consensus defined a priori as at least 70% of ratings falling within the 7&amp;amp;ndash;9 range. The study was prospectively registered on the Open Science Framework. Results: Of the 24 items presented in Round 1, 21 (87.5%) reached consensus. Six items were re-rated in Round 2, of which two crossed the threshold, giving 23 of 24 items (95.8%) endorsed as highly relevant after two rounds. No active disagreement was detected for any item, and all 21 panellists completed both rounds. One item did not reach consensus: shame or stigma associated with diabetes (14/21; 66.7%). Conclusions: Expert consensus supports the relevance of 23 non-biomedical factors in the prevention of diabetic foot disease in ulcer-free patients. These factors constitute a candidate framework for the development of risk screening tools complementing existing biomedical assessment models; their predictive value and clinical utility require prospective validation.</description>
	<pubDate>2026-10-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 196: Non-Biomedical Factors in Diabetic Foot Prevention in Ulcer-Free Patients: A Delphi Consensus Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/196">doi: 10.3390/diabetology7100196</a></p>
	<p>Authors:
		Raúl Fernández-Torres
		Francisco Javier Martínez-Barrios
		Luis Ignacio Rodríguez-Pérez
		Álvaro Amores-Ternero
		María Ruiz-Muñoz
		</p>
	<p>Background/Objectives: Diabetic foot disease is associated with high rates of ulceration, amputation and premature mortality. While biomedical risk factors are systematically assessed in clinical practice, non-biomedical determinants&amp;amp;mdash;psychological, behavioural, social and socioeconomic&amp;amp;mdash;remain largely absent from existing risk stratification models. This study aimed to achieve expert consensus on the relevance of non-biomedical factors in the prevention of diabetic foot disease in people with diabetes without prior ulceration. Methods: A two-round Delphi consensus study was conducted with a multidisciplinary panel of 21 experts. A 24-item questionnaire, developed through narrative literature review and tested for content validity, was administered. Items were rated on a nine-point Likert scale, with consensus defined a priori as at least 70% of ratings falling within the 7&amp;amp;ndash;9 range. The study was prospectively registered on the Open Science Framework. Results: Of the 24 items presented in Round 1, 21 (87.5%) reached consensus. Six items were re-rated in Round 2, of which two crossed the threshold, giving 23 of 24 items (95.8%) endorsed as highly relevant after two rounds. No active disagreement was detected for any item, and all 21 panellists completed both rounds. One item did not reach consensus: shame or stigma associated with diabetes (14/21; 66.7%). Conclusions: Expert consensus supports the relevance of 23 non-biomedical factors in the prevention of diabetic foot disease in ulcer-free patients. These factors constitute a candidate framework for the development of risk screening tools complementing existing biomedical assessment models; their predictive value and clinical utility require prospective validation.</p>
	]]></content:encoded>

	<dc:title>Non-Biomedical Factors in Diabetic Foot Prevention in Ulcer-Free Patients: A Delphi Consensus Study</dc:title>
			<dc:creator>Raúl Fernández-Torres</dc:creator>
			<dc:creator>Francisco Javier Martínez-Barrios</dc:creator>
			<dc:creator>Luis Ignacio Rodríguez-Pérez</dc:creator>
			<dc:creator>Álvaro Amores-Ternero</dc:creator>
			<dc:creator>María Ruiz-Muñoz</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100196</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-09</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-09</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>196</prism:startingPage>
		<prism:doi>10.3390/diabetology7100196</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/196</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/195">

	<title>Diabetology, Vol. 7, Pages 195: Metabolic Rejuvenation in Type 2 Diabetes: A Network Biology Perspective on Functional Restoration and Disease Modification</title>
	<link>https://www.mdpi.com/2673-4540/7/10/195</link>
	<description>Type 2 diabetes (T2D) is increasingly recognized as a systemic network disorder in which impaired communication among endocrine, neural, immune, and microbial systems drives metabolic dysfunction and accelerates biological aging. Extending DeFronzo&amp;amp;rsquo;s &amp;amp;ldquo;Ominous Octet,&amp;amp;rdquo; contemporary advances in immunometabolism, mitochondrial biology, circadian physiology, and incretin signaling demonstrate that metabolic homeostasis depends on the structural and functional integrity of dynamic inter-organ networks. Their progressive disruption contributes not only to classical insulin resistance and &amp;amp;beta;-cell failure, but also to chronic low-grade inflammation (inflammaging), mitochondrial decay, autonomic dysregulation, and epigenetic age acceleration. Crucially, modern disease-modifying interventions&amp;amp;mdash;including multi-incretin receptor agonists, SGLT2 inhibitors, metabolic/bariatric surgery, and circadian-aligned lifestyle programs&amp;amp;mdash;produce pleiotropic benefits that extend far beyond simple glycemic control. These convergent effects suggest partial restoration of impaired metabolic networks rather than isolated correction of glucose abnormalities. In this review, we propose &amp;amp;ldquo;Metabolic Rejuvenation&amp;amp;rdquo; as a novel, unifying operational framework describing the systemic restoration of metabolic network integrity, physiological resilience, and biological adaptability. Mechanistically, we discuss how reactive aldehyde-driven glycative stress operates within a multifactorial cascade&amp;amp;mdash;together with chronic inflammation and organelle dysfunction&amp;amp;mdash;to drive metabolic network collapse and accelerate biological aging. Finally, we outline a multidimensional assessment framework spanning five measurable domains (Inflammatory, Energetic &amp;amp;amp; Mitochondrial, Autonomic &amp;amp;amp; Neuroendocrine, Clinical &amp;amp;amp; Metabolic, and Digital &amp;amp;amp; Behavioral) to quantify disease modification, &amp;amp;beta;-cell preservation, and diabetes remission potential toward healthy metabolic longevity.</description>
	<pubDate>2026-10-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 195: Metabolic Rejuvenation in Type 2 Diabetes: A Network Biology Perspective on Functional Restoration and Disease Modification</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/195">doi: 10.3390/diabetology7100195</a></p>
	<p>Authors:
		Hiroshi Yamamoto
		Yoshikazu Yonei
		Teruyoshi Tanaka
		</p>
	<p>Type 2 diabetes (T2D) is increasingly recognized as a systemic network disorder in which impaired communication among endocrine, neural, immune, and microbial systems drives metabolic dysfunction and accelerates biological aging. Extending DeFronzo&amp;amp;rsquo;s &amp;amp;ldquo;Ominous Octet,&amp;amp;rdquo; contemporary advances in immunometabolism, mitochondrial biology, circadian physiology, and incretin signaling demonstrate that metabolic homeostasis depends on the structural and functional integrity of dynamic inter-organ networks. Their progressive disruption contributes not only to classical insulin resistance and &amp;amp;beta;-cell failure, but also to chronic low-grade inflammation (inflammaging), mitochondrial decay, autonomic dysregulation, and epigenetic age acceleration. Crucially, modern disease-modifying interventions&amp;amp;mdash;including multi-incretin receptor agonists, SGLT2 inhibitors, metabolic/bariatric surgery, and circadian-aligned lifestyle programs&amp;amp;mdash;produce pleiotropic benefits that extend far beyond simple glycemic control. These convergent effects suggest partial restoration of impaired metabolic networks rather than isolated correction of glucose abnormalities. In this review, we propose &amp;amp;ldquo;Metabolic Rejuvenation&amp;amp;rdquo; as a novel, unifying operational framework describing the systemic restoration of metabolic network integrity, physiological resilience, and biological adaptability. Mechanistically, we discuss how reactive aldehyde-driven glycative stress operates within a multifactorial cascade&amp;amp;mdash;together with chronic inflammation and organelle dysfunction&amp;amp;mdash;to drive metabolic network collapse and accelerate biological aging. Finally, we outline a multidimensional assessment framework spanning five measurable domains (Inflammatory, Energetic &amp;amp;amp; Mitochondrial, Autonomic &amp;amp;amp; Neuroendocrine, Clinical &amp;amp;amp; Metabolic, and Digital &amp;amp;amp; Behavioral) to quantify disease modification, &amp;amp;beta;-cell preservation, and diabetes remission potential toward healthy metabolic longevity.</p>
	]]></content:encoded>

	<dc:title>Metabolic Rejuvenation in Type 2 Diabetes: A Network Biology Perspective on Functional Restoration and Disease Modification</dc:title>
			<dc:creator>Hiroshi Yamamoto</dc:creator>
			<dc:creator>Yoshikazu Yonei</dc:creator>
			<dc:creator>Teruyoshi Tanaka</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100195</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-09</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-09</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>195</prism:startingPage>
		<prism:doi>10.3390/diabetology7100195</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/195</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/194">

	<title>Diabetology, Vol. 7, Pages 194: Glycemic Improvement Despite Limited Weight-Loss Response in Adults with Obesity and High Cardiometabolic Burden: A Real-World Study from the Brazilian Amazon</title>
	<link>https://www.mdpi.com/2673-4540/7/10/194</link>
	<description>Objective: Obesity and type 2 diabetes mellitus frequently coexist and require therapeutic strategies capable of addressing both excess adiposity and cardiometabolic risk. However, real-world evidence on whether improvements in cardiometabolic parameters are accompanied by clinically meaningful weight loss remains limited, particularly in public healthcare settings in the Brazilian Amazon. This study evaluated longitudinal changes in body weight and cardiometabolic parameters among adults with obesity receiving routine outpatient endocrinology care within the Brazilian Unified Health System and investigated the relationship between weight change, glycemic response, and factors associated with therapeutic target achievement. As a complementary metabolic analysis, longitudinal changes in the triglyceride&amp;amp;ndash;glucose (TyG) index, as a surrogate marker of insulin resistance, were also evaluated. Methods: This retrospective longitudinal observational study included 90 adults with obesity receiving routine outpatient endocrinology care within the Brazilian Unified Health System in Marab&amp;amp;aacute;, Par&amp;amp;aacute;, Brazil. Participants had at least six months of follow-up, with a mean follow-up duration of 14.3 &amp;amp;plusmn; 4.0 months. Changes in anthropometric, glycemic, blood pressure, and lipid parameters were evaluated between baseline and follow-up. The TyG index was calculated from fasting plasma glucose and triglyceride concentrations, with longitudinal TyG analysis restricted to participants with paired measurements available at baseline and follow-up. Standardized within-participant effect sizes were estimated using Cohen&amp;amp;rsquo;s dz with bootstrap 95% confidence intervals (CIs). Spearman correlations were used to examine associations between percentage weight change and cardiometabolic changes. Multivariable logistic regression models evaluated factors associated with achieving HbA1c &amp;amp;lt; 7.0% among participants with type 2 diabetes mellitus and &amp;amp;ge;5% weight loss in the overall cohort. Results: Body weight changed minimally during follow-up (mean &amp;amp;Delta; = &amp;amp;minus;0.47 kg; dz = &amp;amp;minus;0.072; 95% CI &amp;amp;minus;0.306 to 0.126), whereas HbA1c decreased by 1.00 percentage point (dz = &amp;amp;minus;0.441; 95% CI &amp;amp;minus;0.751 to &amp;amp;minus;0.219). Small reductions were also observed in fasting plasma glucose (&amp;amp;Delta; = &amp;amp;minus;31.53 mg/dL), LDL cholesterol (&amp;amp;Delta; = &amp;amp;minus;15.79 mg/dL), and triglycerides (&amp;amp;Delta; = &amp;amp;minus;35.30 mg/dL). Among 51 participants with complete paired fasting plasma glucose and triglyceride measurements, mean TyG decreased from 9.68 &amp;amp;plusmn; 0.85 to 9.29 &amp;amp;plusmn; 0.79 (mean &amp;amp;Delta; = &amp;amp;minus;0.39; 95% CI &amp;amp;minus;0.58 to &amp;amp;minus;0.20; p &amp;amp;lt; 0.001), with a moderate standardized within-participant effect (dz = &amp;amp;minus;0.569; bootstrap 95% CI &amp;amp;minus;0.881 to &amp;amp;minus;0.301). Only 21/90 participants (23.3%) achieved &amp;amp;ge;5% weight loss, while 44/90 (48.9%) gained weight. Among participants with paired HbA1c measurements, the proportion with HbA1c &amp;amp;ge;7.0% decreased from 72.9% to 52.9%. Percentage weight change was not significantly correlated with changes in HbA1c (rs = &amp;amp;minus;0.018; p = 0.882), fasting plasma glucose, or lipid parameters, nor with change in TyG (rs = &amp;amp;minus;0.041; p = 0.776). Self-reported medication adherence was associated with a greater median reduction in HbA1c (&amp;amp;minus;1.55 vs. 0.00 percentage points; p = 0.003) and higher adjusted odds of achieving HbA1c &amp;amp;lt; 7.0% (OR = 3.58; 95% CI 1.08&amp;amp;ndash;11.86; p = 0.037) but was not associated with weight-loss response. No evaluated baseline characteristic was significantly associated with achieving &amp;amp;ge;5% weight loss. Conclusions: In adults with obesity receiving routine outpatient endocrinology care within the Brazilian Unified Health System in the Brazilian Amazon, longitudinal follow-up was accompanied by modest improvements in glycemic and selected lipid parameters but minimal average weight reduction. The TyG index also decreased significantly among participants with paired measurements, consistent with improvement in this surrogate marker of insulin resistance; however, this finding should not be interpreted as direct evidence of improved insulin sensitivity or reduced cardiovascular risk. Clinically meaningful weight loss was achieved by fewer than one quarter of participants, and nearly half gained weight. Medication adherence was associated with better glycemic control but not with weight loss. These findings indicate that improvements in conventional and surrogate metabolic markers were not consistently accompanied by meaningful reductions in body weight and support the incorporation of weight-specific outcomes and comprehensive obesity-directed strategies into chronic disease care.</description>
	<pubDate>2026-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 194: Glycemic Improvement Despite Limited Weight-Loss Response in Adults with Obesity and High Cardiometabolic Burden: A Real-World Study from the Brazilian Amazon</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/194">doi: 10.3390/diabetology7100194</a></p>
	<p>Authors:
		Alana Ferreira de Oliveira
		Laila de Castro Araújo
		Tatiana Cristina Dias de Oliveira
		Valéria de Castro Fagundes
		Lorena dos Reis Rabelo
		Dulcinéia Sampaio Azeredo
		Angelica Arêa Leão Martins
		Francywagner Silva Vargas
		Harbi Amjad Nabih Othman
		Luciana Gonçalves de Oliveira
		Alfredina dos Santos
		Marília Vieira Miranda
		Fabio de França Silva
		Luana Pereira Margalho
		Carolina Heitmann Mares Azevedo Ribeiro
		Ana Cristina Lo Prete
		Érica dos Santos Sarges
		Ana Cristina dos Santos Baetas
		Jorgete Carneiro Chaves
		Amanda Gabryelle Nunes Cardoso Mello
		José Luiz Fernandes Vieira
		Maria Pantoja Moreira de Sena
		Luann Wendel Pereira de Sena
		</p>
	<p>Objective: Obesity and type 2 diabetes mellitus frequently coexist and require therapeutic strategies capable of addressing both excess adiposity and cardiometabolic risk. However, real-world evidence on whether improvements in cardiometabolic parameters are accompanied by clinically meaningful weight loss remains limited, particularly in public healthcare settings in the Brazilian Amazon. This study evaluated longitudinal changes in body weight and cardiometabolic parameters among adults with obesity receiving routine outpatient endocrinology care within the Brazilian Unified Health System and investigated the relationship between weight change, glycemic response, and factors associated with therapeutic target achievement. As a complementary metabolic analysis, longitudinal changes in the triglyceride&amp;amp;ndash;glucose (TyG) index, as a surrogate marker of insulin resistance, were also evaluated. Methods: This retrospective longitudinal observational study included 90 adults with obesity receiving routine outpatient endocrinology care within the Brazilian Unified Health System in Marab&amp;amp;aacute;, Par&amp;amp;aacute;, Brazil. Participants had at least six months of follow-up, with a mean follow-up duration of 14.3 &amp;amp;plusmn; 4.0 months. Changes in anthropometric, glycemic, blood pressure, and lipid parameters were evaluated between baseline and follow-up. The TyG index was calculated from fasting plasma glucose and triglyceride concentrations, with longitudinal TyG analysis restricted to participants with paired measurements available at baseline and follow-up. Standardized within-participant effect sizes were estimated using Cohen&amp;amp;rsquo;s dz with bootstrap 95% confidence intervals (CIs). Spearman correlations were used to examine associations between percentage weight change and cardiometabolic changes. Multivariable logistic regression models evaluated factors associated with achieving HbA1c &amp;amp;lt; 7.0% among participants with type 2 diabetes mellitus and &amp;amp;ge;5% weight loss in the overall cohort. Results: Body weight changed minimally during follow-up (mean &amp;amp;Delta; = &amp;amp;minus;0.47 kg; dz = &amp;amp;minus;0.072; 95% CI &amp;amp;minus;0.306 to 0.126), whereas HbA1c decreased by 1.00 percentage point (dz = &amp;amp;minus;0.441; 95% CI &amp;amp;minus;0.751 to &amp;amp;minus;0.219). Small reductions were also observed in fasting plasma glucose (&amp;amp;Delta; = &amp;amp;minus;31.53 mg/dL), LDL cholesterol (&amp;amp;Delta; = &amp;amp;minus;15.79 mg/dL), and triglycerides (&amp;amp;Delta; = &amp;amp;minus;35.30 mg/dL). Among 51 participants with complete paired fasting plasma glucose and triglyceride measurements, mean TyG decreased from 9.68 &amp;amp;plusmn; 0.85 to 9.29 &amp;amp;plusmn; 0.79 (mean &amp;amp;Delta; = &amp;amp;minus;0.39; 95% CI &amp;amp;minus;0.58 to &amp;amp;minus;0.20; p &amp;amp;lt; 0.001), with a moderate standardized within-participant effect (dz = &amp;amp;minus;0.569; bootstrap 95% CI &amp;amp;minus;0.881 to &amp;amp;minus;0.301). Only 21/90 participants (23.3%) achieved &amp;amp;ge;5% weight loss, while 44/90 (48.9%) gained weight. Among participants with paired HbA1c measurements, the proportion with HbA1c &amp;amp;ge;7.0% decreased from 72.9% to 52.9%. Percentage weight change was not significantly correlated with changes in HbA1c (rs = &amp;amp;minus;0.018; p = 0.882), fasting plasma glucose, or lipid parameters, nor with change in TyG (rs = &amp;amp;minus;0.041; p = 0.776). Self-reported medication adherence was associated with a greater median reduction in HbA1c (&amp;amp;minus;1.55 vs. 0.00 percentage points; p = 0.003) and higher adjusted odds of achieving HbA1c &amp;amp;lt; 7.0% (OR = 3.58; 95% CI 1.08&amp;amp;ndash;11.86; p = 0.037) but was not associated with weight-loss response. No evaluated baseline characteristic was significantly associated with achieving &amp;amp;ge;5% weight loss. Conclusions: In adults with obesity receiving routine outpatient endocrinology care within the Brazilian Unified Health System in the Brazilian Amazon, longitudinal follow-up was accompanied by modest improvements in glycemic and selected lipid parameters but minimal average weight reduction. The TyG index also decreased significantly among participants with paired measurements, consistent with improvement in this surrogate marker of insulin resistance; however, this finding should not be interpreted as direct evidence of improved insulin sensitivity or reduced cardiovascular risk. Clinically meaningful weight loss was achieved by fewer than one quarter of participants, and nearly half gained weight. Medication adherence was associated with better glycemic control but not with weight loss. These findings indicate that improvements in conventional and surrogate metabolic markers were not consistently accompanied by meaningful reductions in body weight and support the incorporation of weight-specific outcomes and comprehensive obesity-directed strategies into chronic disease care.</p>
	]]></content:encoded>

	<dc:title>Glycemic Improvement Despite Limited Weight-Loss Response in Adults with Obesity and High Cardiometabolic Burden: A Real-World Study from the Brazilian Amazon</dc:title>
			<dc:creator>Alana Ferreira de Oliveira</dc:creator>
			<dc:creator>Laila de Castro Araújo</dc:creator>
			<dc:creator>Tatiana Cristina Dias de Oliveira</dc:creator>
			<dc:creator>Valéria de Castro Fagundes</dc:creator>
			<dc:creator>Lorena dos Reis Rabelo</dc:creator>
			<dc:creator>Dulcinéia Sampaio Azeredo</dc:creator>
			<dc:creator>Angelica Arêa Leão Martins</dc:creator>
			<dc:creator>Francywagner Silva Vargas</dc:creator>
			<dc:creator>Harbi Amjad Nabih Othman</dc:creator>
			<dc:creator>Luciana Gonçalves de Oliveira</dc:creator>
			<dc:creator>Alfredina dos Santos</dc:creator>
			<dc:creator>Marília Vieira Miranda</dc:creator>
			<dc:creator>Fabio de França Silva</dc:creator>
			<dc:creator>Luana Pereira Margalho</dc:creator>
			<dc:creator>Carolina Heitmann Mares Azevedo Ribeiro</dc:creator>
			<dc:creator>Ana Cristina Lo Prete</dc:creator>
			<dc:creator>Érica dos Santos Sarges</dc:creator>
			<dc:creator>Ana Cristina dos Santos Baetas</dc:creator>
			<dc:creator>Jorgete Carneiro Chaves</dc:creator>
			<dc:creator>Amanda Gabryelle Nunes Cardoso Mello</dc:creator>
			<dc:creator>José Luiz Fernandes Vieira</dc:creator>
			<dc:creator>Maria Pantoja Moreira de Sena</dc:creator>
			<dc:creator>Luann Wendel Pereira de Sena</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100194</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-08</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-08</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>194</prism:startingPage>
		<prism:doi>10.3390/diabetology7100194</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/194</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/193">

	<title>Diabetology, Vol. 7, Pages 193: 11&amp;beta;-HSD1-Mediated Cortisol Signalling in Fibrosis and Impaired Diabetic Wound Healing: Current Evidence and Emerging Mechanisms</title>
	<link>https://www.mdpi.com/2673-4540/7/10/193</link>
	<description>Diabetic wound healing is characterised by persistent inflammation, impaired angiogenesis, extracellular matrix (ECM) dysregulation, and defective tissue remodelling, frequently resulting in chronic wounds such as diabetic foot ulcers (DFUs). Fibrosis, characterised by excessive ECM deposition and sustained fibroblast activation, is increasingly recognised as an important barrier to effective wound repair in patients with diabetes. Emerging evidence suggests that glucocorticoid signalling, particularly through the stress hormone cortisol and its activating enzyme 11&amp;amp;beta;-hydroxysteroid dehydrogenase type 1 (11&amp;amp;beta;-HSD1), may contribute to pathological and fibrotic changes in diabetic skin by altering inflammation, extracellular matrix turnover, angiogenesis, and cellular behaviour. In parallel, connective tissue growth factor (CTGF) and insulin-like growth factor binding protein-5 (IGFBP-5) have been associated with profibrotic processes, although the evidence for their roles in diabetic wound healing is limited, particularly for IGFBP-5. This review examines current evidence regarding the role of 11&amp;amp;beta;-HSD1-mediated cortisol signalling in fibrosis and impaired diabetic wound healing, with particular emphasis on its potential interactions with CTGF and IGFBP-5. However, whether and how these mediators interact with cortisol signalling in diabetic wounds remains poorly understood. Evidence from preclinical and early clinical studies suggests that inhibition of 11&amp;amp;beta;-HSD1 may improve wound repair and tissue integrity; however, many existing studies rely on acute wound models and do not fully reflect the chronic inflammatory and fibrotic environment of diabetic wounds.</description>
	<pubDate>2026-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 193: 11&amp;beta;-HSD1-Mediated Cortisol Signalling in Fibrosis and Impaired Diabetic Wound Healing: Current Evidence and Emerging Mechanisms</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/193">doi: 10.3390/diabetology7100193</a></p>
	<p>Authors:
		Carol-Ann Lao
		Begonya Alcacer-Pitarch
		Steven Patterson
		Ana Tiganescu
		Catherine S. Wright
		</p>
	<p>Diabetic wound healing is characterised by persistent inflammation, impaired angiogenesis, extracellular matrix (ECM) dysregulation, and defective tissue remodelling, frequently resulting in chronic wounds such as diabetic foot ulcers (DFUs). Fibrosis, characterised by excessive ECM deposition and sustained fibroblast activation, is increasingly recognised as an important barrier to effective wound repair in patients with diabetes. Emerging evidence suggests that glucocorticoid signalling, particularly through the stress hormone cortisol and its activating enzyme 11&amp;amp;beta;-hydroxysteroid dehydrogenase type 1 (11&amp;amp;beta;-HSD1), may contribute to pathological and fibrotic changes in diabetic skin by altering inflammation, extracellular matrix turnover, angiogenesis, and cellular behaviour. In parallel, connective tissue growth factor (CTGF) and insulin-like growth factor binding protein-5 (IGFBP-5) have been associated with profibrotic processes, although the evidence for their roles in diabetic wound healing is limited, particularly for IGFBP-5. This review examines current evidence regarding the role of 11&amp;amp;beta;-HSD1-mediated cortisol signalling in fibrosis and impaired diabetic wound healing, with particular emphasis on its potential interactions with CTGF and IGFBP-5. However, whether and how these mediators interact with cortisol signalling in diabetic wounds remains poorly understood. Evidence from preclinical and early clinical studies suggests that inhibition of 11&amp;amp;beta;-HSD1 may improve wound repair and tissue integrity; however, many existing studies rely on acute wound models and do not fully reflect the chronic inflammatory and fibrotic environment of diabetic wounds.</p>
	]]></content:encoded>

	<dc:title>11&amp;amp;beta;-HSD1-Mediated Cortisol Signalling in Fibrosis and Impaired Diabetic Wound Healing: Current Evidence and Emerging Mechanisms</dc:title>
			<dc:creator>Carol-Ann Lao</dc:creator>
			<dc:creator>Begonya Alcacer-Pitarch</dc:creator>
			<dc:creator>Steven Patterson</dc:creator>
			<dc:creator>Ana Tiganescu</dc:creator>
			<dc:creator>Catherine S. Wright</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100193</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-08</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-08</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>193</prism:startingPage>
		<prism:doi>10.3390/diabetology7100193</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/193</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/192">

	<title>Diabetology, Vol. 7, Pages 192: Points to Consider Regarding Biomarker Measurement and Evaluation in Diabetes Screening</title>
	<link>https://www.mdpi.com/2673-4540/7/10/192</link>
	<description>The prevalences of overweight, obesity, prediabetes, and diabetes are rapidly increasing worldwide, accompanied by increased insulin resistance (IR). Although the proportions of these populations vary greatly by region, a common trend across all areas is the increasing the prevalence of overweight, obesity, impaired glucose tolerance (IGT)/prediabetes and diabetes throughout all income levels. Based on the international baseline standards provided by the World Health Organization, national health and hygiene agencies and local expert organizations are implementing more proactive screening protocols tailored to local circumstances. These indicators are based on anthropometric measurements and do not include measurements of blood or urine biomarkers. However, evidence-based screening methods utilizing measurements of blood biomarkers, such as blood glucose levels and hemoglobin A1c, generally target individuals aged 40 and older. Therefore, screening based on anthropometric indices, adjusted for regional and racial characteristics and targeting individuals under 40 years old, can fail to identify individuals at relatively high risk for metabolic disorders, such as IGT or prediabetes, even when their measurements fall within the reference range. There are important points to consider regarding the measurement and interpretation of biomarkers used for diabetes screening. This review outlines the limitations and key considerations associated with biomarker measurement for screening IGT/prediabetes, diabetes, and elevated IR.</description>
	<pubDate>2026-10-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 192: Points to Consider Regarding Biomarker Measurement and Evaluation in Diabetes Screening</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/192">doi: 10.3390/diabetology7100192</a></p>
	<p>Authors:
		Takao Kimura
		</p>
	<p>The prevalences of overweight, obesity, prediabetes, and diabetes are rapidly increasing worldwide, accompanied by increased insulin resistance (IR). Although the proportions of these populations vary greatly by region, a common trend across all areas is the increasing the prevalence of overweight, obesity, impaired glucose tolerance (IGT)/prediabetes and diabetes throughout all income levels. Based on the international baseline standards provided by the World Health Organization, national health and hygiene agencies and local expert organizations are implementing more proactive screening protocols tailored to local circumstances. These indicators are based on anthropometric measurements and do not include measurements of blood or urine biomarkers. However, evidence-based screening methods utilizing measurements of blood biomarkers, such as blood glucose levels and hemoglobin A1c, generally target individuals aged 40 and older. Therefore, screening based on anthropometric indices, adjusted for regional and racial characteristics and targeting individuals under 40 years old, can fail to identify individuals at relatively high risk for metabolic disorders, such as IGT or prediabetes, even when their measurements fall within the reference range. There are important points to consider regarding the measurement and interpretation of biomarkers used for diabetes screening. This review outlines the limitations and key considerations associated with biomarker measurement for screening IGT/prediabetes, diabetes, and elevated IR.</p>
	]]></content:encoded>

	<dc:title>Points to Consider Regarding Biomarker Measurement and Evaluation in Diabetes Screening</dc:title>
			<dc:creator>Takao Kimura</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100192</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-01</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-01</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>192</prism:startingPage>
		<prism:doi>10.3390/diabetology7100192</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/192</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/191">

	<title>Diabetology, Vol. 7, Pages 191: Pancreatic &amp;beta;-Cell Dysfunction and Protection: Emerging Insights from Glucocorticoid Signaling and Islet Microcirculation</title>
	<link>https://www.mdpi.com/2673-4540/7/10/191</link>
	<description>PDX-1 and MafA are insulin gene transcription factors and maintain mature pancreatic &amp;amp;beta;-cell function. After chronic exposure to hyperglycemia, however, the expression levels of PDX-1 and MafA are substantially suppressed by provoked oxidative stress and the activation of the JNK/c-Jun pathway, which further aggravates &amp;amp;beta;-cell function. In addition, glucocorticoids are often used to treat a variety of diseases, but they often induce hyperglycemia, not only by increasing insulin resistance, but also by directly impairing insulin biosynthesis in &amp;amp;beta;-cells. Glucocorticoids bind and activate the glucocorticoid receptor in &amp;amp;beta;-cells, while PDX-1 and MafA expression levels are substantially suppressed through the activation of the JNK/c-Jun pathway, which could explain the molecular mechanism behind glucocorticoid-induced &amp;amp;beta;-cell dysfunction. There are similarities in the molecular mechanism for &amp;amp;beta;-cell dysfunction induced by chronic hyperglycemia and glucocorticoid administration. On the other hand, a GLP-1 receptor agonist rapidly enhances microvascular flow in pancreatic islets in a NO-dependent manner. Such phenomena show that the islet microenvironment is substantially regulated by GLP-1 receptor signaling. Also, based on these data, it is likely that rapid microvascular adaptation contributes to the maintenance of &amp;amp;beta;-cell function under diabetic conditions.</description>
	<pubDate>2026-10-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 191: Pancreatic &amp;beta;-Cell Dysfunction and Protection: Emerging Insights from Glucocorticoid Signaling and Islet Microcirculation</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/191">doi: 10.3390/diabetology7100191</a></p>
	<p>Authors:
		Hideaki Kaneto
		Tomohiko Kimura
		Yuichiro Iwamoto
		Junpei Sanada
		Masashi Shimoda
		Kohei Kaku
		</p>
	<p>PDX-1 and MafA are insulin gene transcription factors and maintain mature pancreatic &amp;amp;beta;-cell function. After chronic exposure to hyperglycemia, however, the expression levels of PDX-1 and MafA are substantially suppressed by provoked oxidative stress and the activation of the JNK/c-Jun pathway, which further aggravates &amp;amp;beta;-cell function. In addition, glucocorticoids are often used to treat a variety of diseases, but they often induce hyperglycemia, not only by increasing insulin resistance, but also by directly impairing insulin biosynthesis in &amp;amp;beta;-cells. Glucocorticoids bind and activate the glucocorticoid receptor in &amp;amp;beta;-cells, while PDX-1 and MafA expression levels are substantially suppressed through the activation of the JNK/c-Jun pathway, which could explain the molecular mechanism behind glucocorticoid-induced &amp;amp;beta;-cell dysfunction. There are similarities in the molecular mechanism for &amp;amp;beta;-cell dysfunction induced by chronic hyperglycemia and glucocorticoid administration. On the other hand, a GLP-1 receptor agonist rapidly enhances microvascular flow in pancreatic islets in a NO-dependent manner. Such phenomena show that the islet microenvironment is substantially regulated by GLP-1 receptor signaling. Also, based on these data, it is likely that rapid microvascular adaptation contributes to the maintenance of &amp;amp;beta;-cell function under diabetic conditions.</p>
	]]></content:encoded>

	<dc:title>Pancreatic &amp;amp;beta;-Cell Dysfunction and Protection: Emerging Insights from Glucocorticoid Signaling and Islet Microcirculation</dc:title>
			<dc:creator>Hideaki Kaneto</dc:creator>
			<dc:creator>Tomohiko Kimura</dc:creator>
			<dc:creator>Yuichiro Iwamoto</dc:creator>
			<dc:creator>Junpei Sanada</dc:creator>
			<dc:creator>Masashi Shimoda</dc:creator>
			<dc:creator>Kohei Kaku</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100191</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-10-01</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-10-01</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>191</prism:startingPage>
		<prism:doi>10.3390/diabetology7100191</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/191</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/190">

	<title>Diabetology, Vol. 7, Pages 190: Tirzepatide Failed to Improve Neuropathy in a Murine Nonobese Streptozotocin-Induced Type 1 Diabetes Model, Despite Alleviating Systemic Inflammation</title>
	<link>https://www.mdpi.com/2673-4540/7/10/190</link>
	<description>Background/Objectives: This study aimed to assess the effect of tirzepatide on systemic inflammation in a diabetic neuropathy (DN) model in mice. Methods: Type 1 diabetes was induced with streptozotocin 180 mg/kg i.p. One month later, we injected two doses of tirzepatide (5 or 15 mcg/kg BW s.c. e3d) over the next 4 weeks, then performed a battery of neurological tests and measured blood cytokines with the Simple Plex&amp;amp;reg; platform CE-IVD version. Data were compared with na&amp;amp;iuml;ve controls with or without diabetes induction. Results: Tirzepatide treatment failed to improve both glycemia and neuropathic behavior post-streptozotocin treatment. Higher-dose tirzepatide-treated mice had significantly decreased grip strength (p = 0.013) and higher cold (p = 0.04) and mechanical (p &amp;amp;lt; 0.001) sensitivity, despite substantially lower systemic inflammation, as assessed by TNF-&amp;amp;alpha; and IL-6. An exploratory composite inflammatory index (ECII) derived from IL-6 and TNF-&amp;amp;alpha; showed statistically significantly lower systemic inflammation in the group treated with a higher tirzepatide dose vs. the treatment-na&amp;amp;iuml;ve control (p &amp;amp;lt; 0.05), the diabetic group (p &amp;amp;lt; 0.05), and the diabetic group treated with lower-dose tirzepatide (p &amp;amp;lt; 0.05). Conclusions: Tirzepatide failed to improve DN in a streptozotocin-induced murine nonobese model of type 1 diabetes, although it substantially decreased systemic inflammation. Testing tirzepatide for potential protection against DN in non-streptozotocin-based DN animal models is warranted.</description>
	<pubDate>2026-09-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 190: Tirzepatide Failed to Improve Neuropathy in a Murine Nonobese Streptozotocin-Induced Type 1 Diabetes Model, Despite Alleviating Systemic Inflammation</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/190">doi: 10.3390/diabetology7100190</a></p>
	<p>Authors:
		Pavlina Andreeva-Gateva
		Milen Hristov
		Dragomira Nikolova
		Ilyan Bogdanov
		Zafer Sabit
		Ivanka Dimova
		</p>
	<p>Background/Objectives: This study aimed to assess the effect of tirzepatide on systemic inflammation in a diabetic neuropathy (DN) model in mice. Methods: Type 1 diabetes was induced with streptozotocin 180 mg/kg i.p. One month later, we injected two doses of tirzepatide (5 or 15 mcg/kg BW s.c. e3d) over the next 4 weeks, then performed a battery of neurological tests and measured blood cytokines with the Simple Plex&amp;amp;reg; platform CE-IVD version. Data were compared with na&amp;amp;iuml;ve controls with or without diabetes induction. Results: Tirzepatide treatment failed to improve both glycemia and neuropathic behavior post-streptozotocin treatment. Higher-dose tirzepatide-treated mice had significantly decreased grip strength (p = 0.013) and higher cold (p = 0.04) and mechanical (p &amp;amp;lt; 0.001) sensitivity, despite substantially lower systemic inflammation, as assessed by TNF-&amp;amp;alpha; and IL-6. An exploratory composite inflammatory index (ECII) derived from IL-6 and TNF-&amp;amp;alpha; showed statistically significantly lower systemic inflammation in the group treated with a higher tirzepatide dose vs. the treatment-na&amp;amp;iuml;ve control (p &amp;amp;lt; 0.05), the diabetic group (p &amp;amp;lt; 0.05), and the diabetic group treated with lower-dose tirzepatide (p &amp;amp;lt; 0.05). Conclusions: Tirzepatide failed to improve DN in a streptozotocin-induced murine nonobese model of type 1 diabetes, although it substantially decreased systemic inflammation. Testing tirzepatide for potential protection against DN in non-streptozotocin-based DN animal models is warranted.</p>
	]]></content:encoded>

	<dc:title>Tirzepatide Failed to Improve Neuropathy in a Murine Nonobese Streptozotocin-Induced Type 1 Diabetes Model, Despite Alleviating Systemic Inflammation</dc:title>
			<dc:creator>Pavlina Andreeva-Gateva</dc:creator>
			<dc:creator>Milen Hristov</dc:creator>
			<dc:creator>Dragomira Nikolova</dc:creator>
			<dc:creator>Ilyan Bogdanov</dc:creator>
			<dc:creator>Zafer Sabit</dc:creator>
			<dc:creator>Ivanka Dimova</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100190</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-29</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-29</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>190</prism:startingPage>
		<prism:doi>10.3390/diabetology7100190</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/190</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/189">

	<title>Diabetology, Vol. 7, Pages 189: Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin-Dose Reduction, Metabolic Outcomes and Safety Assessment</title>
	<link>https://www.mdpi.com/2673-4540/7/10/189</link>
	<description>Background: Semaglutide and tirzepatide are not approved for type 1 diabetes (T1D), and their real-world effects on insulin requirements, metabolic outcomes, and safety are uncertain. Methods: Using de-identified electronic health record data from a federated U.S. network (2018&amp;amp;ndash;2025), adults with T1D who initiated semaglutide (n = 1447) or tirzepatide (n = 568) were matched 1:1 to unexposed adults with T1D on demographics, comorbidities, glycated hemoglobin (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), T1D duration, healthcare utilization, and calendar year (Cohort A). Insulin total daily dose (TDD) was analyzed in a second cohort additionally matched on baseline TDD and insulin delivery modality (Cohort B; 337 semaglutide and 117 tirzepatide pairs). Results: At 12 months, TDD changed by &amp;amp;minus;12.9% with semaglutide versus &amp;amp;minus;2.6% in matched controls (difference &amp;amp;minus;10.4 percentage points [pp]; p &amp;amp;lt; 0.001) and by &amp;amp;minus;10.4% with tirzepatide versus +13.3% (difference &amp;amp;minus;23.7 pp; p = 0.02); a &amp;amp;ge;10% TDD reduction was reached by 41% versus 21% of patients with semaglutide and 47% versus 11% with tirzepatide (both p &amp;amp;lt; 0.001). Among semaglutide-treated patients, 6-month-TDD reduction was &amp;amp;minus;24.1%, &amp;amp;minus;12.6%, and &amp;amp;minus;5.6% with &amp;amp;ge;10% weight loss, 0 to &amp;amp;lt;10% loss, and weight gain (p &amp;amp;lt; 0.001), but did not vary with HbA1c change (p = 0.95) or semaglutide dose (p = 0.50). At 12 months, HbA1c fell 0.31 pp more with semaglutide than in controls (p &amp;amp;lt; 0.001) and 0.19 pp more with tirzepatide (p = 0.07); body weight fell 3.3 pp and 5.1 pp more with semaglutide and tirzepatide, respectively (both p &amp;amp;lt; 0.001). Relative to matched controls, the 365-day risk of nausea or vomiting rose 8.6 pp after semaglutide or tirzepatide initiation (p &amp;amp;lt; 0.001) and constipation rose 3.4 pp (p = 0.003), whereas diabetic ketoacidosis (+0.3 pp; p = 0.63) and severe hypoglycemia (&amp;amp;minus;0.8 pp; p = 0.39) did not change significantly. Conclusions: In routine care, adjunctive semaglutide and tirzepatide were associated with lower insulin requirements, modest HbA1c improvement, and weight loss in adults with T1D, with a gastrointestinal-predominant adverse-event profile. Randomized trials are needed to establish efficacy and safety.</description>
	<pubDate>2026-09-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 189: Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin-Dose Reduction, Metabolic Outcomes and Safety Assessment</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/189">doi: 10.3390/diabetology7100189</a></p>
	<p>Authors:
		Robert Matson
		Karthik Murugadoss
		A. J. Venkatakrishnan
		Venky Soundararajan
		</p>
	<p>Background: Semaglutide and tirzepatide are not approved for type 1 diabetes (T1D), and their real-world effects on insulin requirements, metabolic outcomes, and safety are uncertain. Methods: Using de-identified electronic health record data from a federated U.S. network (2018&amp;amp;ndash;2025), adults with T1D who initiated semaglutide (n = 1447) or tirzepatide (n = 568) were matched 1:1 to unexposed adults with T1D on demographics, comorbidities, glycated hemoglobin (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), T1D duration, healthcare utilization, and calendar year (Cohort A). Insulin total daily dose (TDD) was analyzed in a second cohort additionally matched on baseline TDD and insulin delivery modality (Cohort B; 337 semaglutide and 117 tirzepatide pairs). Results: At 12 months, TDD changed by &amp;amp;minus;12.9% with semaglutide versus &amp;amp;minus;2.6% in matched controls (difference &amp;amp;minus;10.4 percentage points [pp]; p &amp;amp;lt; 0.001) and by &amp;amp;minus;10.4% with tirzepatide versus +13.3% (difference &amp;amp;minus;23.7 pp; p = 0.02); a &amp;amp;ge;10% TDD reduction was reached by 41% versus 21% of patients with semaglutide and 47% versus 11% with tirzepatide (both p &amp;amp;lt; 0.001). Among semaglutide-treated patients, 6-month-TDD reduction was &amp;amp;minus;24.1%, &amp;amp;minus;12.6%, and &amp;amp;minus;5.6% with &amp;amp;ge;10% weight loss, 0 to &amp;amp;lt;10% loss, and weight gain (p &amp;amp;lt; 0.001), but did not vary with HbA1c change (p = 0.95) or semaglutide dose (p = 0.50). At 12 months, HbA1c fell 0.31 pp more with semaglutide than in controls (p &amp;amp;lt; 0.001) and 0.19 pp more with tirzepatide (p = 0.07); body weight fell 3.3 pp and 5.1 pp more with semaglutide and tirzepatide, respectively (both p &amp;amp;lt; 0.001). Relative to matched controls, the 365-day risk of nausea or vomiting rose 8.6 pp after semaglutide or tirzepatide initiation (p &amp;amp;lt; 0.001) and constipation rose 3.4 pp (p = 0.003), whereas diabetic ketoacidosis (+0.3 pp; p = 0.63) and severe hypoglycemia (&amp;amp;minus;0.8 pp; p = 0.39) did not change significantly. Conclusions: In routine care, adjunctive semaglutide and tirzepatide were associated with lower insulin requirements, modest HbA1c improvement, and weight loss in adults with T1D, with a gastrointestinal-predominant adverse-event profile. Randomized trials are needed to establish efficacy and safety.</p>
	]]></content:encoded>

	<dc:title>Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin-Dose Reduction, Metabolic Outcomes and Safety Assessment</dc:title>
			<dc:creator>Robert Matson</dc:creator>
			<dc:creator>Karthik Murugadoss</dc:creator>
			<dc:creator>A. J. Venkatakrishnan</dc:creator>
			<dc:creator>Venky Soundararajan</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100189</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-25</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-25</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>189</prism:startingPage>
		<prism:doi>10.3390/diabetology7100189</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/189</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/188">

	<title>Diabetology, Vol. 7, Pages 188: Diabetic Bone Disease and Fracture Healing: Molecular Mechanisms, Skeletal Fragility, and Emerging Orthopedic Therapeutic Strategies</title>
	<link>https://www.mdpi.com/2673-4540/7/10/188</link>
	<description>Diabetes mellitus is increasingly recognized as a disorder of skeletal quality in addition to metabolic dysregulation. Both type 1 and type 2 diabetes are associated with increased fracture risk, impaired fracture healing, and higher rates of orthopedic complications despite preserved or even elevated bone mineral density, highlighting the limitations of conventional densitometric assessment alone. Diabetic bone disease arises through complex and interconnected mechanisms involving osteoblast, osteocyte, and osteoclast dysfunction, accumulation of advanced glycation end products, oxidative stress, chronic inflammation, impaired insulin and insulin-like growth factor-1 signaling, and disruption of bone&amp;amp;ndash;pancreas and bone&amp;amp;ndash;adipose crosstalk. Here, we review the cellular, molecular, genetic, and epigenetic mechanisms that contribute to diabetic skeletal fragility and examine how these abnormalities impair bone remodeling, fracture healing, and orthopedic outcomes. Particular emphasis is placed on the disconnect between bone mineral density and bone quality, describing how alterations in bone microarchitecture and matrix integrity contribute to skeletal fragility beyond the conventional measures of bone mass. We further review emerging strategies for fracture risk assessment, including advanced imaging modalities and biomarkers that more accurately characterize diabetic bone disease, and discuss the influence of antidiabetic therapies, perioperative glycemic optimization, and emerging biologic and epigenetic therapeutic approaches on fracture healing and musculoskeletal outcomes. By integrating molecular mechanisms with clinical and orthopedic evidence, this review provides a comprehensive overview of diabetic bone disease while highlighting priorities for future research and clinical translation.</description>
	<pubDate>2026-09-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 188: Diabetic Bone Disease and Fracture Healing: Molecular Mechanisms, Skeletal Fragility, and Emerging Orthopedic Therapeutic Strategies</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/188">doi: 10.3390/diabetology7100188</a></p>
	<p>Authors:
		Maxwell J. Latshaw
		Aaron J. Gillespie
		Hasan Pracha
		Shawn J. Yates
		Anoop Sunkara
		Arun K. Movva
		Albert T. Anastasio
		</p>
	<p>Diabetes mellitus is increasingly recognized as a disorder of skeletal quality in addition to metabolic dysregulation. Both type 1 and type 2 diabetes are associated with increased fracture risk, impaired fracture healing, and higher rates of orthopedic complications despite preserved or even elevated bone mineral density, highlighting the limitations of conventional densitometric assessment alone. Diabetic bone disease arises through complex and interconnected mechanisms involving osteoblast, osteocyte, and osteoclast dysfunction, accumulation of advanced glycation end products, oxidative stress, chronic inflammation, impaired insulin and insulin-like growth factor-1 signaling, and disruption of bone&amp;amp;ndash;pancreas and bone&amp;amp;ndash;adipose crosstalk. Here, we review the cellular, molecular, genetic, and epigenetic mechanisms that contribute to diabetic skeletal fragility and examine how these abnormalities impair bone remodeling, fracture healing, and orthopedic outcomes. Particular emphasis is placed on the disconnect between bone mineral density and bone quality, describing how alterations in bone microarchitecture and matrix integrity contribute to skeletal fragility beyond the conventional measures of bone mass. We further review emerging strategies for fracture risk assessment, including advanced imaging modalities and biomarkers that more accurately characterize diabetic bone disease, and discuss the influence of antidiabetic therapies, perioperative glycemic optimization, and emerging biologic and epigenetic therapeutic approaches on fracture healing and musculoskeletal outcomes. By integrating molecular mechanisms with clinical and orthopedic evidence, this review provides a comprehensive overview of diabetic bone disease while highlighting priorities for future research and clinical translation.</p>
	]]></content:encoded>

	<dc:title>Diabetic Bone Disease and Fracture Healing: Molecular Mechanisms, Skeletal Fragility, and Emerging Orthopedic Therapeutic Strategies</dc:title>
			<dc:creator>Maxwell J. Latshaw</dc:creator>
			<dc:creator>Aaron J. Gillespie</dc:creator>
			<dc:creator>Hasan Pracha</dc:creator>
			<dc:creator>Shawn J. Yates</dc:creator>
			<dc:creator>Anoop Sunkara</dc:creator>
			<dc:creator>Arun K. Movva</dc:creator>
			<dc:creator>Albert T. Anastasio</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100188</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-24</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-24</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>188</prism:startingPage>
		<prism:doi>10.3390/diabetology7100188</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/188</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/10/187">

	<title>Diabetology, Vol. 7, Pages 187: The GLP-1&amp;ndash;Gut Microbiota&amp;ndash;Autoimmunity Axis in Type 1 Diabetes: Emerging Evidence and Mechanistic Perspectives</title>
	<link>https://www.mdpi.com/2673-4540/7/10/187</link>
	<description>Type 1 diabetes (T1D) is an autoimmune disease in which genetic susceptibility interacts with environmental and immunometabolic factors. Growing evidence implicates gut dysbiosis, impaired intestinal barrier integrity, and altered microbial metabolites in the loss of immune tolerance and &amp;amp;beta;-cell autoimmunity. Microbiota-derived metabolites regulate enteroendocrine glucagon-like peptide-1 (GLP-1) secretion, epithelial barrier function, and immune responses. Conversely, GLP-1 signaling and incretin-based therapies may modify the intestinal environment and microbial composition. Overall, the GLP-1&amp;amp;ndash;gut microbiota axis is a promising therapeutic target. Activation of the GLP-1 receptor suppresses pro-inflammatory pathways while promoting anti-inflammatory ones; all these effects may protect &amp;amp;beta;-cells. Caveolin-1 may represent a molecular hub linking the GLP-1&amp;amp;ndash;gut microbiota&amp;amp;ndash;autoimmunity axis in T1D. This narrative review examines the bidirectional relationship between GLP-1 signaling and the gut microbiota and its potential relevance to T1D.</description>
	<pubDate>2026-09-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 187: The GLP-1&amp;ndash;Gut Microbiota&amp;ndash;Autoimmunity Axis in Type 1 Diabetes: Emerging Evidence and Mechanistic Perspectives</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/10/187">doi: 10.3390/diabetology7100187</a></p>
	<p>Authors:
		Anna Arecco
		Grazia Piras
		Francesco Cocchiara
		Davide Carlo Maggi
		Alessandra Puddu
		</p>
	<p>Type 1 diabetes (T1D) is an autoimmune disease in which genetic susceptibility interacts with environmental and immunometabolic factors. Growing evidence implicates gut dysbiosis, impaired intestinal barrier integrity, and altered microbial metabolites in the loss of immune tolerance and &amp;amp;beta;-cell autoimmunity. Microbiota-derived metabolites regulate enteroendocrine glucagon-like peptide-1 (GLP-1) secretion, epithelial barrier function, and immune responses. Conversely, GLP-1 signaling and incretin-based therapies may modify the intestinal environment and microbial composition. Overall, the GLP-1&amp;amp;ndash;gut microbiota axis is a promising therapeutic target. Activation of the GLP-1 receptor suppresses pro-inflammatory pathways while promoting anti-inflammatory ones; all these effects may protect &amp;amp;beta;-cells. Caveolin-1 may represent a molecular hub linking the GLP-1&amp;amp;ndash;gut microbiota&amp;amp;ndash;autoimmunity axis in T1D. This narrative review examines the bidirectional relationship between GLP-1 signaling and the gut microbiota and its potential relevance to T1D.</p>
	]]></content:encoded>

	<dc:title>The GLP-1&amp;amp;ndash;Gut Microbiota&amp;amp;ndash;Autoimmunity Axis in Type 1 Diabetes: Emerging Evidence and Mechanistic Perspectives</dc:title>
			<dc:creator>Anna Arecco</dc:creator>
			<dc:creator>Grazia Piras</dc:creator>
			<dc:creator>Francesco Cocchiara</dc:creator>
			<dc:creator>Davide Carlo Maggi</dc:creator>
			<dc:creator>Alessandra Puddu</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7100187</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-23</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-23</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>187</prism:startingPage>
		<prism:doi>10.3390/diabetology7100187</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/10/187</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/186">

	<title>Diabetology, Vol. 7, Pages 186: Association of Insulin Resistance and Metabolic Syndrome with Cognitive Impairment in Nonobese, Nondiabetic Older Adults: A Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/9/186</link>
	<description>Background/Objectives: Insulin resistance (IR) and metabolic Syndrome (MSy) have been linked to cognitive decline, but their presence in mild cognitive impairment (MCI) and Alzheimer disease (AD) remains unclear. We evaluated MSy and IR in nonobese, nondiabetic older adults with cognitive dysfunction. Methods: The cross-sectional study included 143 participants aged 65&amp;amp;ndash;90 years: 62 with AD, 41 with MCI, and 40 cognitively preserved controls. Anthropometric measures, blood pressure, fasting glucose, insulin, and lipid levels were assessed. Diabetes was excluded by oral glucose tolerance testing. IR was estimated using HOMA-IR, and MSy was diagnosed according to International Diabetes Federation (IDF) criteria. Group differences and associations with cognitive impairment were assessed using analysis of variance and regression analyses. Results: Fasting insulin increased from controls to MCI and AD (7.18 &amp;amp;plusmn; 4.32, 13.76 &amp;amp;plusmn; 6.89, and 18.58 &amp;amp;plusmn; 8.19 mU/L), as did HOMA-IR (1.49 &amp;amp;plusmn; 0.98, 3.35 &amp;amp;plusmn; 1.72, and 4.59 &amp;amp;plusmn; 2.19, p &amp;amp;lt; 0.05). Compared with controls, both cognitively impaired groups had higher fasting glucose, TCh, LDL-ch and lower HDL-ch (all p &amp;amp;lt; 0.05), whereas triglycerides did not differ (p = 0.266). MSy prevalence was 22.5% in controls, 46.3% in MCI, and 35.5% in AD; however, the overall difference was not statistically significant (p = 0.079). In binary logistic regression analysis, sex, age, LDL-ch, and HOMA-IR were independently associated with cognitive impairment (all p &amp;amp;lt; 0.05). Conclusions: Increased IR was more consistently associated with cognitive impairment than the presence of MSy, with the highest degree of IR observed in AD. These findings support an association between metabolic dysfunction and cognitive impairment and suggest that IR may represent a potential target for preventive and therapeutic strategies.</description>
	<pubDate>2026-09-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 186: Association of Insulin Resistance and Metabolic Syndrome with Cognitive Impairment in Nonobese, Nondiabetic Older Adults: A Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/186">doi: 10.3390/diabetology7090186</a></p>
	<p>Authors:
		Marija Macesic
		Katarina Lalic
		Ljiljana Lukic
		Tanja Milicic
		Gorana Mandic Stojmenovic
		Tanja Stojkovic
		Jelena Stanarcic Gajovic
		Milica Stoiljkovic
		Jelena Milin
		Mina Bozic
		Djurdja Rafailovic
		Stefan Maric
		Milica Vujasevic
		Aleksandra Jotic
		</p>
	<p>Background/Objectives: Insulin resistance (IR) and metabolic Syndrome (MSy) have been linked to cognitive decline, but their presence in mild cognitive impairment (MCI) and Alzheimer disease (AD) remains unclear. We evaluated MSy and IR in nonobese, nondiabetic older adults with cognitive dysfunction. Methods: The cross-sectional study included 143 participants aged 65&amp;amp;ndash;90 years: 62 with AD, 41 with MCI, and 40 cognitively preserved controls. Anthropometric measures, blood pressure, fasting glucose, insulin, and lipid levels were assessed. Diabetes was excluded by oral glucose tolerance testing. IR was estimated using HOMA-IR, and MSy was diagnosed according to International Diabetes Federation (IDF) criteria. Group differences and associations with cognitive impairment were assessed using analysis of variance and regression analyses. Results: Fasting insulin increased from controls to MCI and AD (7.18 &amp;amp;plusmn; 4.32, 13.76 &amp;amp;plusmn; 6.89, and 18.58 &amp;amp;plusmn; 8.19 mU/L), as did HOMA-IR (1.49 &amp;amp;plusmn; 0.98, 3.35 &amp;amp;plusmn; 1.72, and 4.59 &amp;amp;plusmn; 2.19, p &amp;amp;lt; 0.05). Compared with controls, both cognitively impaired groups had higher fasting glucose, TCh, LDL-ch and lower HDL-ch (all p &amp;amp;lt; 0.05), whereas triglycerides did not differ (p = 0.266). MSy prevalence was 22.5% in controls, 46.3% in MCI, and 35.5% in AD; however, the overall difference was not statistically significant (p = 0.079). In binary logistic regression analysis, sex, age, LDL-ch, and HOMA-IR were independently associated with cognitive impairment (all p &amp;amp;lt; 0.05). Conclusions: Increased IR was more consistently associated with cognitive impairment than the presence of MSy, with the highest degree of IR observed in AD. These findings support an association between metabolic dysfunction and cognitive impairment and suggest that IR may represent a potential target for preventive and therapeutic strategies.</p>
	]]></content:encoded>

	<dc:title>Association of Insulin Resistance and Metabolic Syndrome with Cognitive Impairment in Nonobese, Nondiabetic Older Adults: A Cross-Sectional Study</dc:title>
			<dc:creator>Marija Macesic</dc:creator>
			<dc:creator>Katarina Lalic</dc:creator>
			<dc:creator>Ljiljana Lukic</dc:creator>
			<dc:creator>Tanja Milicic</dc:creator>
			<dc:creator>Gorana Mandic Stojmenovic</dc:creator>
			<dc:creator>Tanja Stojkovic</dc:creator>
			<dc:creator>Jelena Stanarcic Gajovic</dc:creator>
			<dc:creator>Milica Stoiljkovic</dc:creator>
			<dc:creator>Jelena Milin</dc:creator>
			<dc:creator>Mina Bozic</dc:creator>
			<dc:creator>Djurdja Rafailovic</dc:creator>
			<dc:creator>Stefan Maric</dc:creator>
			<dc:creator>Milica Vujasevic</dc:creator>
			<dc:creator>Aleksandra Jotic</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090186</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-20</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-20</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>186</prism:startingPage>
		<prism:doi>10.3390/diabetology7090186</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/186</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/185">

	<title>Diabetology, Vol. 7, Pages 185: The Physiological Importance of Free Fatty Acid Receptors in the Maintenance of Metabolic Health</title>
	<link>https://www.mdpi.com/2673-4540/7/9/185</link>
	<description>Recently, a subset of G protein-coupled receptors (GPCRs) has been deorphanized as nutrient-sensing receptors activated by free fatty acids (FFAs). These GPCRs, termed free fatty acid receptors (FFARs), change their conformation in response to fatty acid binding and transmit extracellular signals into cells to maintain physiological homeostasis. Therefore, FFAs serve a dual role as energy substrates for most body tissues and as signaling molecules. Signaling through FFARs affects various physiological functions, such as metabolic and immune responses. In particular, their role in metabolic regulation has been extensively studied. Thus, FFARs have gained attention as key therapeutic targets for the treatment of obesity and type 2 diabetes. To date, many synthetic agonists for FFARs have been designed and have entered clinical trials, but no agonists have received approval for clinical use. In this review, we summarize and discuss the current knowledge of nutrient signaling mediated by FFARs. We also review the biological importance of FFARs in maintaining metabolic health and recent advances in the translational research of FFAR1 agonists. A better understanding of how FFARs maintain metabolic health may help address global public health problems such as obesity and type 2 diabetes.</description>
	<pubDate>2026-09-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 185: The Physiological Importance of Free Fatty Acid Receptors in the Maintenance of Metabolic Health</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/185">doi: 10.3390/diabetology7090185</a></p>
	<p>Authors:
		Takako Ikeda
		Ikuo Kimura
		</p>
	<p>Recently, a subset of G protein-coupled receptors (GPCRs) has been deorphanized as nutrient-sensing receptors activated by free fatty acids (FFAs). These GPCRs, termed free fatty acid receptors (FFARs), change their conformation in response to fatty acid binding and transmit extracellular signals into cells to maintain physiological homeostasis. Therefore, FFAs serve a dual role as energy substrates for most body tissues and as signaling molecules. Signaling through FFARs affects various physiological functions, such as metabolic and immune responses. In particular, their role in metabolic regulation has been extensively studied. Thus, FFARs have gained attention as key therapeutic targets for the treatment of obesity and type 2 diabetes. To date, many synthetic agonists for FFARs have been designed and have entered clinical trials, but no agonists have received approval for clinical use. In this review, we summarize and discuss the current knowledge of nutrient signaling mediated by FFARs. We also review the biological importance of FFARs in maintaining metabolic health and recent advances in the translational research of FFAR1 agonists. A better understanding of how FFARs maintain metabolic health may help address global public health problems such as obesity and type 2 diabetes.</p>
	]]></content:encoded>

	<dc:title>The Physiological Importance of Free Fatty Acid Receptors in the Maintenance of Metabolic Health</dc:title>
			<dc:creator>Takako Ikeda</dc:creator>
			<dc:creator>Ikuo Kimura</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090185</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-20</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-20</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>185</prism:startingPage>
		<prism:doi>10.3390/diabetology7090185</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/185</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/184">

	<title>Diabetology, Vol. 7, Pages 184: Clinical Outcomes and Hospital Resource Utilization Among Hospitalized Patients with Diabetes Mellitus and COVID-19 Infection: Insights from United States National Inpatient Sample, 2020&amp;ndash;2022</title>
	<link>https://www.mdpi.com/2673-4540/7/9/184</link>
	<description>Background: Diabetes mellitus (DM) is highly prevalent in the United States and increases the risk of severe illness in patients with COVID-19. We compared outcomes among adult COVID-19 hospitalizations with and without DM. Methods: We compared the National Inpatient Sample (2020&amp;amp;ndash;2022), using multivariate regression to adjust for potential confounders. Results: Among 5,934,565 hospitalizations for COVID-19, 2,155,978 (36.3%) had concomitant DM. The DM group had higher unadjusted in-hospital mortality (13.5% vs. 10.1%) and was associated with higher mortality after adjustment (aOR 1.17; 95% CI, 1.15&amp;amp;ndash;1.19; p &amp;amp;lt; 0.001). DM was also independently associated with higher odds of acute respiratory failure (46.1% vs. 42.3%; aOR 1.12; 95% CI, 1.11&amp;amp;ndash;1.13; p &amp;amp;lt; 0.001), greater use of invasive mechanical ventilation (aOR 1.35; 95% CI, 1.33&amp;amp;ndash;1.37; p &amp;amp;lt; 0.001) and non-invasive ventilation (NIV; aOR 1.42; 95% CI, 1.40&amp;amp;ndash;1.45; p &amp;amp;lt; 0.001). COVID-19 hospitalizations with DM also had higher rates of acute respiratory distress syndrome, acute kidney injury, renal replacement therapy, sepsis, septic shock, and vasopressor use, along with longer length of hospital stay and higher total hospitalization charges. In-hospital mortality among COVID-19 hospitalizations with DM was lower in 2022 than in 2020 and 2021. Conclusions: DM was associated with higher in-hospital mortality and greater respiratory, renal, and hemodynamic complications and hospital resource utilization.</description>
	<pubDate>2026-09-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 184: Clinical Outcomes and Hospital Resource Utilization Among Hospitalized Patients with Diabetes Mellitus and COVID-19 Infection: Insights from United States National Inpatient Sample, 2020&amp;ndash;2022</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/184">doi: 10.3390/diabetology7090184</a></p>
	<p>Authors:
		Antony Arumairaj
		Poojaben Dhorajiya
		Jayesh Mittal
		Manikya Kuriti
		Vimala Sravanthi Vajjala
		Divya Korpu
		Dili Dhanani
		</p>
	<p>Background: Diabetes mellitus (DM) is highly prevalent in the United States and increases the risk of severe illness in patients with COVID-19. We compared outcomes among adult COVID-19 hospitalizations with and without DM. Methods: We compared the National Inpatient Sample (2020&amp;amp;ndash;2022), using multivariate regression to adjust for potential confounders. Results: Among 5,934,565 hospitalizations for COVID-19, 2,155,978 (36.3%) had concomitant DM. The DM group had higher unadjusted in-hospital mortality (13.5% vs. 10.1%) and was associated with higher mortality after adjustment (aOR 1.17; 95% CI, 1.15&amp;amp;ndash;1.19; p &amp;amp;lt; 0.001). DM was also independently associated with higher odds of acute respiratory failure (46.1% vs. 42.3%; aOR 1.12; 95% CI, 1.11&amp;amp;ndash;1.13; p &amp;amp;lt; 0.001), greater use of invasive mechanical ventilation (aOR 1.35; 95% CI, 1.33&amp;amp;ndash;1.37; p &amp;amp;lt; 0.001) and non-invasive ventilation (NIV; aOR 1.42; 95% CI, 1.40&amp;amp;ndash;1.45; p &amp;amp;lt; 0.001). COVID-19 hospitalizations with DM also had higher rates of acute respiratory distress syndrome, acute kidney injury, renal replacement therapy, sepsis, septic shock, and vasopressor use, along with longer length of hospital stay and higher total hospitalization charges. In-hospital mortality among COVID-19 hospitalizations with DM was lower in 2022 than in 2020 and 2021. Conclusions: DM was associated with higher in-hospital mortality and greater respiratory, renal, and hemodynamic complications and hospital resource utilization.</p>
	]]></content:encoded>

	<dc:title>Clinical Outcomes and Hospital Resource Utilization Among Hospitalized Patients with Diabetes Mellitus and COVID-19 Infection: Insights from United States National Inpatient Sample, 2020&amp;amp;ndash;2022</dc:title>
			<dc:creator>Antony Arumairaj</dc:creator>
			<dc:creator>Poojaben Dhorajiya</dc:creator>
			<dc:creator>Jayesh Mittal</dc:creator>
			<dc:creator>Manikya Kuriti</dc:creator>
			<dc:creator>Vimala Sravanthi Vajjala</dc:creator>
			<dc:creator>Divya Korpu</dc:creator>
			<dc:creator>Dili Dhanani</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090184</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-20</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-20</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>184</prism:startingPage>
		<prism:doi>10.3390/diabetology7090184</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/184</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/183">

	<title>Diabetology, Vol. 7, Pages 183: Incidence of Thiamine Deficiency and Severity of Lactataemia in Patients with Diabetic Ketoacidosis: A Systematic Review</title>
	<link>https://www.mdpi.com/2673-4540/7/9/183</link>
	<description>Objective: To perform a systematic literature review summarising current evidence of the incidence and clinical outcomes of thiamine deficiency in patients with diabetic ketoacidosis (DKA). Due to inconsistent and variable measurement of thiamine levels, hyperlactataemia in DKA was included as a potential surrogate for thiamine deficiency. Methods: The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO). MEDLINE, EMBASE, Cochrane, CINAHL and ClinicalTrials.gov were searched using medical subject headings from database inception to 26 June 2026. Two independent reviewers screened results, and studies were included if they were original research that assessed lactate and/or thiamine in DKA, with subsequent forward citation searching. Risk of bias was assessed using the Cochrane Risk of Bias 2 Tool and the Newcastle-Ottawa Scale, and the data was analysed using a systematic review without meta-analysis (SWIM) approach. Results: Of 2122 screened studies, 31 were included in the final manuscript. Six studies assessed thiamine levels and deficiency, one assessed thiamine replacement, and the remainder assessed hyperlactataemia in patients with DKA. The incidence of thiamine deficiency ranged from 23.8&amp;amp;ndash;78%, with two studies demonstrating an inverse correlation between thiamine levels and lactate. The incidence of hyperlactataemia in patients with DKA ranged from 37.5&amp;amp;ndash;92%, with inconsistent findings regarding clinical outcomes. Conclusions: The available evidence suggests that thiamine deficiency and hyperlactataemia are common among patients with DKA. However, the association of both with clinical outcomes remains uncertain, with limited data making it difficult to draw significant conclusions, highlighting the need for further research.</description>
	<pubDate>2026-09-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 183: Incidence of Thiamine Deficiency and Severity of Lactataemia in Patients with Diabetic Ketoacidosis: A Systematic Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/183">doi: 10.3390/diabetology7090183</a></p>
	<p>Authors:
		Aashish Kumar
		Amanda Zahumensky
		Rahima Habibullah
		Jana Waldmann
		Mahesh Ramanan
		</p>
	<p>Objective: To perform a systematic literature review summarising current evidence of the incidence and clinical outcomes of thiamine deficiency in patients with diabetic ketoacidosis (DKA). Due to inconsistent and variable measurement of thiamine levels, hyperlactataemia in DKA was included as a potential surrogate for thiamine deficiency. Methods: The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO). MEDLINE, EMBASE, Cochrane, CINAHL and ClinicalTrials.gov were searched using medical subject headings from database inception to 26 June 2026. Two independent reviewers screened results, and studies were included if they were original research that assessed lactate and/or thiamine in DKA, with subsequent forward citation searching. Risk of bias was assessed using the Cochrane Risk of Bias 2 Tool and the Newcastle-Ottawa Scale, and the data was analysed using a systematic review without meta-analysis (SWIM) approach. Results: Of 2122 screened studies, 31 were included in the final manuscript. Six studies assessed thiamine levels and deficiency, one assessed thiamine replacement, and the remainder assessed hyperlactataemia in patients with DKA. The incidence of thiamine deficiency ranged from 23.8&amp;amp;ndash;78%, with two studies demonstrating an inverse correlation between thiamine levels and lactate. The incidence of hyperlactataemia in patients with DKA ranged from 37.5&amp;amp;ndash;92%, with inconsistent findings regarding clinical outcomes. Conclusions: The available evidence suggests that thiamine deficiency and hyperlactataemia are common among patients with DKA. However, the association of both with clinical outcomes remains uncertain, with limited data making it difficult to draw significant conclusions, highlighting the need for further research.</p>
	]]></content:encoded>

	<dc:title>Incidence of Thiamine Deficiency and Severity of Lactataemia in Patients with Diabetic Ketoacidosis: A Systematic Review</dc:title>
			<dc:creator>Aashish Kumar</dc:creator>
			<dc:creator>Amanda Zahumensky</dc:creator>
			<dc:creator>Rahima Habibullah</dc:creator>
			<dc:creator>Jana Waldmann</dc:creator>
			<dc:creator>Mahesh Ramanan</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090183</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-18</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-18</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>183</prism:startingPage>
		<prism:doi>10.3390/diabetology7090183</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/183</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/182">

	<title>Diabetology, Vol. 7, Pages 182: The Role of a Moderately Low-Carbohydrate Diet (LOCABO&amp;reg;) in Glycemic Control and Type 2 Diabetes Management: Current Evidence and Future Perspectives</title>
	<link>https://www.mdpi.com/2673-4540/7/9/182</link>
	<description>Medical nutrition therapy is a cornerstone of type 2 diabetes mellitus (T2DM) management. Current guidelines emphasize individualized nutrition therapy rather than a single universal dietary approach. This narrative review summarizes current dietary strategies for T2DM and examines moderate carbohydrate restriction and the Japanese LOCABO&amp;amp;reg; approach, which combines meal-based carbohydrate targets (20&amp;amp;ndash;40 g/meal), a daily target (70&amp;amp;ndash;130 g/day), and limited discretionary carbohydrate intake. Research was identified from major diabetes guidelines and peer-reviewed publications, including randomized controlled trials and long-term observational studies. Evidence supporting moderate carbohydrate restriction in general is substantially broader than evidence specifically evaluating LOCABO&amp;amp;reg;. LOCABO&amp;amp;reg;-specific evidence comprises one small RCT and several observational or uncontrolled studies conducted in Japan. These studies provide preliminary signals regarding glycemic efficacy and longer-term metabolic outcomes and have also examined restaurant availability of compatible meals and renal function. However, validated evidence regarding dietary adherence, acceptability, nutritional adequacy, adverse events, long-term cardiovascular outcomes, and international generalizability remains insufficient. Moderate carbohydrate restriction may therefore be considered one evidence-based option within individualized medical nutrition therapy for T2DM, whereas LOCABO&amp;amp;reg; should be regarded as a pragmatic meal-based implementation that requires independent, multicenter, and long-term validation.</description>
	<pubDate>2026-09-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 182: The Role of a Moderately Low-Carbohydrate Diet (LOCABO&amp;reg;) in Glycemic Control and Type 2 Diabetes Management: Current Evidence and Future Perspectives</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/182">doi: 10.3390/diabetology7090182</a></p>
	<p>Authors:
		Satoru Yamada
		</p>
	<p>Medical nutrition therapy is a cornerstone of type 2 diabetes mellitus (T2DM) management. Current guidelines emphasize individualized nutrition therapy rather than a single universal dietary approach. This narrative review summarizes current dietary strategies for T2DM and examines moderate carbohydrate restriction and the Japanese LOCABO&amp;amp;reg; approach, which combines meal-based carbohydrate targets (20&amp;amp;ndash;40 g/meal), a daily target (70&amp;amp;ndash;130 g/day), and limited discretionary carbohydrate intake. Research was identified from major diabetes guidelines and peer-reviewed publications, including randomized controlled trials and long-term observational studies. Evidence supporting moderate carbohydrate restriction in general is substantially broader than evidence specifically evaluating LOCABO&amp;amp;reg;. LOCABO&amp;amp;reg;-specific evidence comprises one small RCT and several observational or uncontrolled studies conducted in Japan. These studies provide preliminary signals regarding glycemic efficacy and longer-term metabolic outcomes and have also examined restaurant availability of compatible meals and renal function. However, validated evidence regarding dietary adherence, acceptability, nutritional adequacy, adverse events, long-term cardiovascular outcomes, and international generalizability remains insufficient. Moderate carbohydrate restriction may therefore be considered one evidence-based option within individualized medical nutrition therapy for T2DM, whereas LOCABO&amp;amp;reg; should be regarded as a pragmatic meal-based implementation that requires independent, multicenter, and long-term validation.</p>
	]]></content:encoded>

	<dc:title>The Role of a Moderately Low-Carbohydrate Diet (LOCABO&amp;amp;reg;) in Glycemic Control and Type 2 Diabetes Management: Current Evidence and Future Perspectives</dc:title>
			<dc:creator>Satoru Yamada</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090182</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-16</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-16</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>182</prism:startingPage>
		<prism:doi>10.3390/diabetology7090182</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/182</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/181">

	<title>Diabetology, Vol. 7, Pages 181: Cardio-Neurovascular Multimorbidity in Diabetes: Real-World Overlap of Heart Failure, Peripheral Neuropathy, and Lower-Limb Amputation</title>
	<link>https://www.mdpi.com/2673-4540/7/9/181</link>
	<description>Background: Diabetes mellitus is frequently complicated by cardiovascular, neurological, and limb-threatening conditions, yet these complications are often evaluated separately. Heart failure, peripheral neuropathy, and lower-limb amputation may coexist in patients with advanced diabetes and may define a clinically severe cardio-neurovascular multimorbidity phenotype. This study evaluated the real-world overlap between these complications. Methods: This retrospective hospital-based study used four routinely generated patient-level exports from the electronic diabetes registry/clinical information system of the Clinical County Emergency Hospital Bihor, Oradea, Romania. The primary cohort comprised 2246 unique patients with diabetes and a recorded heart failure diagnosis; linked exports identified peripheral neuropathy and below- or above-ankle amputation. Results: Peripheral neuropathy was documented in 1028 patients (45.8%). Patients with neuropathy were older (median 70 [IQR 63&amp;amp;ndash;76] vs. 67 [IQR 59&amp;amp;ndash;73] years, p &amp;amp;lt; 0.001) and had longer diabetes duration (15 [IQR 9&amp;amp;ndash;21] vs. 6 [IQR 1&amp;amp;ndash;11] years, p &amp;amp;lt; 0.001) than patients without neuropathy. Any lower-limb amputation occurred in 35 patients (1.6%) and was more frequent among patients with neuropathy than among those without neuropathy (2.6% vs. 0.7%, p &amp;amp;lt; 0.001). In the adjusted analysis, male sex, diabetes duration, and insulin therapy were independently associated with lower-limb amputation, whereas the association with neuropathy was attenuated. Conclusions: In this hospital-based retrospective cohort, peripheral neuropathy was common and identified a subgroup with longer-standing diabetes, more intensive therapy, and greater amputation burden. The findings indicate associations within a selected clinical population and should not be interpreted as causal or population-based estimates.</description>
	<pubDate>2026-09-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 181: Cardio-Neurovascular Multimorbidity in Diabetes: Real-World Overlap of Heart Failure, Peripheral Neuropathy, and Lower-Limb Amputation</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/181">doi: 10.3390/diabetology7090181</a></p>
	<p>Authors:
		Anca Cristina Ferician
		Timea Claudia Ghitea
		Mihaela Simona Popoviciu
		</p>
	<p>Background: Diabetes mellitus is frequently complicated by cardiovascular, neurological, and limb-threatening conditions, yet these complications are often evaluated separately. Heart failure, peripheral neuropathy, and lower-limb amputation may coexist in patients with advanced diabetes and may define a clinically severe cardio-neurovascular multimorbidity phenotype. This study evaluated the real-world overlap between these complications. Methods: This retrospective hospital-based study used four routinely generated patient-level exports from the electronic diabetes registry/clinical information system of the Clinical County Emergency Hospital Bihor, Oradea, Romania. The primary cohort comprised 2246 unique patients with diabetes and a recorded heart failure diagnosis; linked exports identified peripheral neuropathy and below- or above-ankle amputation. Results: Peripheral neuropathy was documented in 1028 patients (45.8%). Patients with neuropathy were older (median 70 [IQR 63&amp;amp;ndash;76] vs. 67 [IQR 59&amp;amp;ndash;73] years, p &amp;amp;lt; 0.001) and had longer diabetes duration (15 [IQR 9&amp;amp;ndash;21] vs. 6 [IQR 1&amp;amp;ndash;11] years, p &amp;amp;lt; 0.001) than patients without neuropathy. Any lower-limb amputation occurred in 35 patients (1.6%) and was more frequent among patients with neuropathy than among those without neuropathy (2.6% vs. 0.7%, p &amp;amp;lt; 0.001). In the adjusted analysis, male sex, diabetes duration, and insulin therapy were independently associated with lower-limb amputation, whereas the association with neuropathy was attenuated. Conclusions: In this hospital-based retrospective cohort, peripheral neuropathy was common and identified a subgroup with longer-standing diabetes, more intensive therapy, and greater amputation burden. The findings indicate associations within a selected clinical population and should not be interpreted as causal or population-based estimates.</p>
	]]></content:encoded>

	<dc:title>Cardio-Neurovascular Multimorbidity in Diabetes: Real-World Overlap of Heart Failure, Peripheral Neuropathy, and Lower-Limb Amputation</dc:title>
			<dc:creator>Anca Cristina Ferician</dc:creator>
			<dc:creator>Timea Claudia Ghitea</dc:creator>
			<dc:creator>Mihaela Simona Popoviciu</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090181</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-15</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-15</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>181</prism:startingPage>
		<prism:doi>10.3390/diabetology7090181</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/181</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/180">

	<title>Diabetology, Vol. 7, Pages 180: The Friendly Neighbourhood Hospital: Rethinking Diabetes Care Beyond the Consultation: A Conceptual Perspective</title>
	<link>https://www.mdpi.com/2673-4540/7/9/180</link>
	<description>Contemporary diabetes care is largely organised around one-to-one clinical consultations and the regulation of biomedical outcomes. While such approaches remain essential, they may be insufficient for addressing the social and behavioural aspects of chronic disease management. Based on this conceptual perspective, we propose the Friendly Neighbourhood Hospital as an approach to supporting peer contact and self-management, complementing clinical care. Drawing on affordance theory, social architecture, and urban social geography, we argue that hospital environments can shape participation, learning, and behavioural change through mechanisms including peer interaction, tacit knowledge, situated learning, and institutional trust. We illustrate this approach using five settings: communal cooking, movement and social interaction, public and cultural events, flexible access, and digital participation. These examples are illustrative and not evaluated interventions, and their anticipated effects, ranging from immediate participation and belonging to longer-term behavioural change, remain hypotheses for future testing. From this perspective, we do not advocate for replacing individual consultations but rather for repositioning them within a broader social and spatial context.</description>
	<pubDate>2026-09-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 180: The Friendly Neighbourhood Hospital: Rethinking Diabetes Care Beyond the Consultation: A Conceptual Perspective</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/180">doi: 10.3390/diabetology7090180</a></p>
	<p>Authors:
		Zandra Overgaard Pedersen
		Bryan Cleal
		Kristoffer Marsaa
		</p>
	<p>Contemporary diabetes care is largely organised around one-to-one clinical consultations and the regulation of biomedical outcomes. While such approaches remain essential, they may be insufficient for addressing the social and behavioural aspects of chronic disease management. Based on this conceptual perspective, we propose the Friendly Neighbourhood Hospital as an approach to supporting peer contact and self-management, complementing clinical care. Drawing on affordance theory, social architecture, and urban social geography, we argue that hospital environments can shape participation, learning, and behavioural change through mechanisms including peer interaction, tacit knowledge, situated learning, and institutional trust. We illustrate this approach using five settings: communal cooking, movement and social interaction, public and cultural events, flexible access, and digital participation. These examples are illustrative and not evaluated interventions, and their anticipated effects, ranging from immediate participation and belonging to longer-term behavioural change, remain hypotheses for future testing. From this perspective, we do not advocate for replacing individual consultations but rather for repositioning them within a broader social and spatial context.</p>
	]]></content:encoded>

	<dc:title>The Friendly Neighbourhood Hospital: Rethinking Diabetes Care Beyond the Consultation: A Conceptual Perspective</dc:title>
			<dc:creator>Zandra Overgaard Pedersen</dc:creator>
			<dc:creator>Bryan Cleal</dc:creator>
			<dc:creator>Kristoffer Marsaa</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090180</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-11</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-11</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>180</prism:startingPage>
		<prism:doi>10.3390/diabetology7090180</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/180</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/179">

	<title>Diabetology, Vol. 7, Pages 179: w&amp;icirc;cihitowin: Helping Each Other with Type 2 Diabetes Education Program in One Canadian Province</title>
	<link>https://www.mdpi.com/2673-4540/7/9/179</link>
	<description>Background/Objectives: Type 2 diabetes (T2D) is one of the fastest growing chronic pediatric conditions worldwide. Indigenous children tend to be diagnosed younger, have severe progression of disease, and poorer health outcomes. While biomedical advancements have yielded more effective treatment outcomes, few resources have been implemented to prevent T2D in Indigenous youth. Therefore, an exploratory pilot study was conducted in one Canadian province with an overall purpose of co-creating, pilot-testing, and evaluating an Indigenous community-led T2D education resource called the w&amp;amp;icirc;cihitowin: Helping Each Other with Type 2 Diabetes Education Program. Methods: Data for this analysis were derived from a pre- and post-test evaluation of the digital education resource with a purposeful sample of Indigenous youth (n = 87) from two Cree communities living in a western Canadian province. Descriptive statistics, paired t-tests, and correlations were used to measure the differences from pre- to post-participation in the education program. Results: The youth had moderate knowledge baseline scores of diabetes, nutrition, and physical activity. Participants reported improved knowledge on all the education topics after participating in the w&amp;amp;icirc;cihitowin: Helping Each Other with Type 2 Diabetes Program. Significant positive correlations were found between all knowledge areas. Conclusions: The digital education resource effectively enhanced youths&amp;amp;rsquo; knowledge of diabetes, nutrition, and physical activity. Additionally, these findings highlighted the importance of culturally safe teachings for Indigenous peoples, emphasizing the need for T2D education to be community and culturally driven. These results are particularly important given the lack of existing evidence evaluating the effectiveness of T2D education among Indigenous youth.</description>
	<pubDate>2026-09-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 179: w&amp;icirc;cihitowin: Helping Each Other with Type 2 Diabetes Education Program in One Canadian Province</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/179">doi: 10.3390/diabetology7090179</a></p>
	<p>Authors:
		Shelley Spurr
		Jill M. G. Bally
		Kali McNair
		Helen Tootoosis
		</p>
	<p>Background/Objectives: Type 2 diabetes (T2D) is one of the fastest growing chronic pediatric conditions worldwide. Indigenous children tend to be diagnosed younger, have severe progression of disease, and poorer health outcomes. While biomedical advancements have yielded more effective treatment outcomes, few resources have been implemented to prevent T2D in Indigenous youth. Therefore, an exploratory pilot study was conducted in one Canadian province with an overall purpose of co-creating, pilot-testing, and evaluating an Indigenous community-led T2D education resource called the w&amp;amp;icirc;cihitowin: Helping Each Other with Type 2 Diabetes Education Program. Methods: Data for this analysis were derived from a pre- and post-test evaluation of the digital education resource with a purposeful sample of Indigenous youth (n = 87) from two Cree communities living in a western Canadian province. Descriptive statistics, paired t-tests, and correlations were used to measure the differences from pre- to post-participation in the education program. Results: The youth had moderate knowledge baseline scores of diabetes, nutrition, and physical activity. Participants reported improved knowledge on all the education topics after participating in the w&amp;amp;icirc;cihitowin: Helping Each Other with Type 2 Diabetes Program. Significant positive correlations were found between all knowledge areas. Conclusions: The digital education resource effectively enhanced youths&amp;amp;rsquo; knowledge of diabetes, nutrition, and physical activity. Additionally, these findings highlighted the importance of culturally safe teachings for Indigenous peoples, emphasizing the need for T2D education to be community and culturally driven. These results are particularly important given the lack of existing evidence evaluating the effectiveness of T2D education among Indigenous youth.</p>
	]]></content:encoded>

	<dc:title>w&amp;amp;icirc;cihitowin: Helping Each Other with Type 2 Diabetes Education Program in One Canadian Province</dc:title>
			<dc:creator>Shelley Spurr</dc:creator>
			<dc:creator>Jill M. G. Bally</dc:creator>
			<dc:creator>Kali McNair</dc:creator>
			<dc:creator>Helen Tootoosis</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090179</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-10</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-10</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>179</prism:startingPage>
		<prism:doi>10.3390/diabetology7090179</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/179</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/178">

	<title>Diabetology, Vol. 7, Pages 178: Diabetes Care Inequities and Culturally Grounded Management Among African American and Native American Communities: A Narrative Review</title>
	<link>https://www.mdpi.com/2673-4540/7/9/178</link>
	<description>Diabetes disproportionately affects African American and Native American populations in the United States; however, diabetes disparities are frequently examined either collectively across minority populations or within individual groups, limiting understanding of the distinct mechanisms that drive inequities. This narrative review compares differences in diabetes diagnosis, culturally grounded management, diabetes self-management education and support (DSMES), and diabetes-related complications among African American and Native American adults in the United States to identify both shared and population-specific pathways contributing to disparities. A narrative review of peer-reviewed literature published between 2010 and 2025 was conducted using PubMed, Scopus, and Google Scholar. Studies addressing diabetes diagnosis, management, diabetes education, or complications among African American and Native American adults were included and synthesized using a comparative thematic approach. Disparities were evident across the continuum of diabetes care, but their underlying drivers differed substantially between populations. Among African Americans, diagnostic challenges reflected both structural inequities and limitations of commonly used glycemic markers such as hemoglobin A1c. Among Native Americans, delayed diagnosis was more closely associated with geographic isolation and under-resourced healthcare systems. Culturally grounded management also differed, with Native American communities demonstrating greater integration of Indigenous frameworks and traditional practices, whereas African American communities relied more heavily on family- and faith-based support systems. DSMES remained underutilized in both populations because of referral gaps, structural barriers, and limited cultural tailoring, with access barriers particularly pronounced in rural and tribal settings. Both populations experienced disproportionately high rates of diabetes-related complications, although Native Americans frequently exhibited earlier onset while African Americans often experienced greater severity of outcomes. Findings suggest that similar diabetes disparities emerge through different structural, cultural, and healthcare system pathways. Recognizing these differences can inform the development of more targeted clinical interventions, community-based programs, and health policies aimed at reducing diabetes inequities in underserved populations.</description>
	<pubDate>2026-09-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 178: Diabetes Care Inequities and Culturally Grounded Management Among African American and Native American Communities: A Narrative Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/178">doi: 10.3390/diabetology7090178</a></p>
	<p>Authors:
		Kwaku Karikari Manu
		Seth Appiah-Opoku
		Cassandra Ford
		Joe Weber
		Selima Sultana
		Amobichukwu Chukwudi Amanambu
		</p>
	<p>Diabetes disproportionately affects African American and Native American populations in the United States; however, diabetes disparities are frequently examined either collectively across minority populations or within individual groups, limiting understanding of the distinct mechanisms that drive inequities. This narrative review compares differences in diabetes diagnosis, culturally grounded management, diabetes self-management education and support (DSMES), and diabetes-related complications among African American and Native American adults in the United States to identify both shared and population-specific pathways contributing to disparities. A narrative review of peer-reviewed literature published between 2010 and 2025 was conducted using PubMed, Scopus, and Google Scholar. Studies addressing diabetes diagnosis, management, diabetes education, or complications among African American and Native American adults were included and synthesized using a comparative thematic approach. Disparities were evident across the continuum of diabetes care, but their underlying drivers differed substantially between populations. Among African Americans, diagnostic challenges reflected both structural inequities and limitations of commonly used glycemic markers such as hemoglobin A1c. Among Native Americans, delayed diagnosis was more closely associated with geographic isolation and under-resourced healthcare systems. Culturally grounded management also differed, with Native American communities demonstrating greater integration of Indigenous frameworks and traditional practices, whereas African American communities relied more heavily on family- and faith-based support systems. DSMES remained underutilized in both populations because of referral gaps, structural barriers, and limited cultural tailoring, with access barriers particularly pronounced in rural and tribal settings. Both populations experienced disproportionately high rates of diabetes-related complications, although Native Americans frequently exhibited earlier onset while African Americans often experienced greater severity of outcomes. Findings suggest that similar diabetes disparities emerge through different structural, cultural, and healthcare system pathways. Recognizing these differences can inform the development of more targeted clinical interventions, community-based programs, and health policies aimed at reducing diabetes inequities in underserved populations.</p>
	]]></content:encoded>

	<dc:title>Diabetes Care Inequities and Culturally Grounded Management Among African American and Native American Communities: A Narrative Review</dc:title>
			<dc:creator>Kwaku Karikari Manu</dc:creator>
			<dc:creator>Seth Appiah-Opoku</dc:creator>
			<dc:creator>Cassandra Ford</dc:creator>
			<dc:creator>Joe Weber</dc:creator>
			<dc:creator>Selima Sultana</dc:creator>
			<dc:creator>Amobichukwu Chukwudi Amanambu</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090178</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-10</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-10</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>178</prism:startingPage>
		<prism:doi>10.3390/diabetology7090178</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/178</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/177">

	<title>Diabetology, Vol. 7, Pages 177: Diabetic Calcaneal Osteomyelitis: Outcomes Before and After the Introduction of Bone Graft Substitutes&amp;mdash;A Retrospective Cohort Study</title>
	<link>https://www.mdpi.com/2673-4540/7/9/177</link>
	<description>Background: Calcaneal osteomyelitis is a severe form of diabetic foot osteomyelitis associated with poor healing, major amputation, and increased mortality. Evidence on the use of bone graft substitutes in this setting remains limited. Methods: We conducted a retrospective single-center cohort study including 103 consecutive patients with diabetic calcaneal osteomyelitis treated at a tertiary diabetic foot center. In total, 29 patients received bone graft substitutes following surgical debridement, while 74 underwent conventional surgical treatment. Outcomes included healing, time to healing, major amputation, and mortality for all-cause. Results: Overall healing rates were similar between the bone graft and control groups (58.6% vs. 54.1%; p = 0.83). However, healing within one year was more frequent in patients treated with bone graft substitutes (65.4% vs. 45.8%). In multivariable analysis, bone graft substitute treatment was independently associated with healing within one year (OR 4.96, 95% CI 1.18&amp;amp;ndash;20.79; p = 0.029). Median healing time was significantly shorter in the bone graft group (90 [IQR 60&amp;amp;ndash;120] vs. 210 [IQR 150&amp;amp;ndash;370] days; p &amp;amp;lt; 0.001), corresponding to a 67% reduction after adjustment. Major amputation rates were low and comparable between groups (10.3% vs. 13.5%; p = 0.75). Observed three-year mortality was lower in the bone graft group (33.3% vs. 54.8%), and bone graft substitute treatment remained independently associated with reduced 3-year mortality (OR 0.29, 95% CI 0.09&amp;amp;ndash;0.88; p = 0.028). Conclusions: In diabetic calcaneal osteomyelitis, bone graft substitutes were associated with faster healing, improved 1-year healing outcomes, and lower long-term mortality, while maintaining high limb-salvage rates. These findings suggest that bone graft substitutes may represent a promising adjunct to surgical treatment and warrant confirmation in prospective studies.</description>
	<pubDate>2026-09-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 177: Diabetic Calcaneal Osteomyelitis: Outcomes Before and After the Introduction of Bone Graft Substitutes&amp;mdash;A Retrospective Cohort Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/177">doi: 10.3390/diabetology7090177</a></p>
	<p>Authors:
		Roberto Da Ros
		Enrica Barro
		Andrea Michelli
		Roberta Assaloni
		Barbara Brunato
		Marta Nardi
		Cesare Miranda
		</p>
	<p>Background: Calcaneal osteomyelitis is a severe form of diabetic foot osteomyelitis associated with poor healing, major amputation, and increased mortality. Evidence on the use of bone graft substitutes in this setting remains limited. Methods: We conducted a retrospective single-center cohort study including 103 consecutive patients with diabetic calcaneal osteomyelitis treated at a tertiary diabetic foot center. In total, 29 patients received bone graft substitutes following surgical debridement, while 74 underwent conventional surgical treatment. Outcomes included healing, time to healing, major amputation, and mortality for all-cause. Results: Overall healing rates were similar between the bone graft and control groups (58.6% vs. 54.1%; p = 0.83). However, healing within one year was more frequent in patients treated with bone graft substitutes (65.4% vs. 45.8%). In multivariable analysis, bone graft substitute treatment was independently associated with healing within one year (OR 4.96, 95% CI 1.18&amp;amp;ndash;20.79; p = 0.029). Median healing time was significantly shorter in the bone graft group (90 [IQR 60&amp;amp;ndash;120] vs. 210 [IQR 150&amp;amp;ndash;370] days; p &amp;amp;lt; 0.001), corresponding to a 67% reduction after adjustment. Major amputation rates were low and comparable between groups (10.3% vs. 13.5%; p = 0.75). Observed three-year mortality was lower in the bone graft group (33.3% vs. 54.8%), and bone graft substitute treatment remained independently associated with reduced 3-year mortality (OR 0.29, 95% CI 0.09&amp;amp;ndash;0.88; p = 0.028). Conclusions: In diabetic calcaneal osteomyelitis, bone graft substitutes were associated with faster healing, improved 1-year healing outcomes, and lower long-term mortality, while maintaining high limb-salvage rates. These findings suggest that bone graft substitutes may represent a promising adjunct to surgical treatment and warrant confirmation in prospective studies.</p>
	]]></content:encoded>

	<dc:title>Diabetic Calcaneal Osteomyelitis: Outcomes Before and After the Introduction of Bone Graft Substitutes&amp;amp;mdash;A Retrospective Cohort Study</dc:title>
			<dc:creator>Roberto Da Ros</dc:creator>
			<dc:creator>Enrica Barro</dc:creator>
			<dc:creator>Andrea Michelli</dc:creator>
			<dc:creator>Roberta Assaloni</dc:creator>
			<dc:creator>Barbara Brunato</dc:creator>
			<dc:creator>Marta Nardi</dc:creator>
			<dc:creator>Cesare Miranda</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090177</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-09</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-09</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>177</prism:startingPage>
		<prism:doi>10.3390/diabetology7090177</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/177</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/176">

	<title>Diabetology, Vol. 7, Pages 176: Shifting the Paradigm in Global Diabetes Management: Beyond Glycohemoglobinism and Toward Etiological Mitigation via Minimizing Insulin Resistance on the Basis of Pharmacogenetics</title>
	<link>https://www.mdpi.com/2673-4540/7/9/176</link>
	<description>Several decades of intensive research into antidiabetic therapeutics have yielded an expansive, mechanism-driven pharmacopeia. Yet, the clinical endpoint for these diverse agents remains singular and superficial: the reduction in glycated hemoglobin (HbA1c). By focusing primarily on downstream glucose lowering, current therapeutic paradigms treat the symptom rather than the etiology. This approach persists despite definitive consensus that the foundational pathology of type 2 diabetes is much more complex which paves the way to insulin resistance, not merely the spillover of glucose into the bloodstream. This systemic misalignment raises a critical question for the scientific community: are we collectively &amp;amp;ldquo;agreeing to disagree&amp;amp;rdquo; on a biological fact or a clinical myth? The Myth is that &amp;amp;lsquo;Persistent hyperglycemia&amp;amp;rsquo; is the disease itself, but the fact is: hyperglycemia is a late-stage biomarker of systemic insulin resistance. By managing the biomarker rather than the root cause, clinical medicine has normalized an incomplete treatment model. This review aims to deliberately provoke a shift in rational thinking. We challenge the comfortable status quo of accepting hyperglycemia as the primary definition of diabetes. True therapeutic innovation requires moving past this consensus of convenience. We must reorient basic and clinical science toward reversing the cellular mechanisms of insulin resistance itself, rather than settling for the cosmetic management of blood glucose levels. Rather than merely recounting established therapeutic mechanisms, this review systematically bridges classical antidiabetic pharmacology with the specific pharmacogenomic determinants likely driving hyperglycemia and phenotypic insulin resistance. Mechanisms of action and pharmacogenomic perspectives of &amp;amp;alpha;-glucosidase inhibitors, Sulfonylureas, SGLT2 inhibitors, GLP-1 agonists, Meglitinides, Insulins, Metformin, Thiazolidinediones, and DPP4 inhibitors are discussed in this review. In conclusion, mapping the pharmacogenetic landscape of antidiabetic therapies reveals how distinct genetic variations likely dictate drug metabolism and insulin receptor kinetics. Decoding these patient-specific mechanisms is essential to reverse tissue-specific insulin resistance and transition from empirical prescribing to precise, genotype-directed diabetes management.</description>
	<pubDate>2026-09-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 176: Shifting the Paradigm in Global Diabetes Management: Beyond Glycohemoglobinism and Toward Etiological Mitigation via Minimizing Insulin Resistance on the Basis of Pharmacogenetics</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/176">doi: 10.3390/diabetology7090176</a></p>
	<p>Authors:
		Sidhartha D. Ray
		Lining Liang He
		Stratton Rottersmann
		Christina Hand
		Maria Di Leo
		Alec Chunilall
		Ian G. Gray
		Ngo Tsun Siu
		Sonia Jong
		Nigel Sirois
		Kaitlin M. McNeely
		Margarett A. Costes
		</p>
	<p>Several decades of intensive research into antidiabetic therapeutics have yielded an expansive, mechanism-driven pharmacopeia. Yet, the clinical endpoint for these diverse agents remains singular and superficial: the reduction in glycated hemoglobin (HbA1c). By focusing primarily on downstream glucose lowering, current therapeutic paradigms treat the symptom rather than the etiology. This approach persists despite definitive consensus that the foundational pathology of type 2 diabetes is much more complex which paves the way to insulin resistance, not merely the spillover of glucose into the bloodstream. This systemic misalignment raises a critical question for the scientific community: are we collectively &amp;amp;ldquo;agreeing to disagree&amp;amp;rdquo; on a biological fact or a clinical myth? The Myth is that &amp;amp;lsquo;Persistent hyperglycemia&amp;amp;rsquo; is the disease itself, but the fact is: hyperglycemia is a late-stage biomarker of systemic insulin resistance. By managing the biomarker rather than the root cause, clinical medicine has normalized an incomplete treatment model. This review aims to deliberately provoke a shift in rational thinking. We challenge the comfortable status quo of accepting hyperglycemia as the primary definition of diabetes. True therapeutic innovation requires moving past this consensus of convenience. We must reorient basic and clinical science toward reversing the cellular mechanisms of insulin resistance itself, rather than settling for the cosmetic management of blood glucose levels. Rather than merely recounting established therapeutic mechanisms, this review systematically bridges classical antidiabetic pharmacology with the specific pharmacogenomic determinants likely driving hyperglycemia and phenotypic insulin resistance. Mechanisms of action and pharmacogenomic perspectives of &amp;amp;alpha;-glucosidase inhibitors, Sulfonylureas, SGLT2 inhibitors, GLP-1 agonists, Meglitinides, Insulins, Metformin, Thiazolidinediones, and DPP4 inhibitors are discussed in this review. In conclusion, mapping the pharmacogenetic landscape of antidiabetic therapies reveals how distinct genetic variations likely dictate drug metabolism and insulin receptor kinetics. Decoding these patient-specific mechanisms is essential to reverse tissue-specific insulin resistance and transition from empirical prescribing to precise, genotype-directed diabetes management.</p>
	]]></content:encoded>

	<dc:title>Shifting the Paradigm in Global Diabetes Management: Beyond Glycohemoglobinism and Toward Etiological Mitigation via Minimizing Insulin Resistance on the Basis of Pharmacogenetics</dc:title>
			<dc:creator>Sidhartha D. Ray</dc:creator>
			<dc:creator>Lining Liang He</dc:creator>
			<dc:creator>Stratton Rottersmann</dc:creator>
			<dc:creator>Christina Hand</dc:creator>
			<dc:creator>Maria Di Leo</dc:creator>
			<dc:creator>Alec Chunilall</dc:creator>
			<dc:creator>Ian G. Gray</dc:creator>
			<dc:creator>Ngo Tsun Siu</dc:creator>
			<dc:creator>Sonia Jong</dc:creator>
			<dc:creator>Nigel Sirois</dc:creator>
			<dc:creator>Kaitlin M. McNeely</dc:creator>
			<dc:creator>Margarett A. Costes</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090176</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-08</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-08</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>176</prism:startingPage>
		<prism:doi>10.3390/diabetology7090176</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/176</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/174">

	<title>Diabetology, Vol. 7, Pages 174: Potential Biomarkers for the Early Prediction of Prediabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/9/174</link>
	<description>Background/Objective: Prediabetes is increasingly recognized as a state of chronic, low-grade inflammation that contributes to early &amp;amp;beta;-cell dysfunction, insulin resistance, and progression to type 2 diabetes (T2D). This review synthesizes mechanistic and clinical evidence to characterize the inflammatory landscape of prediabetes, evaluate the consistency of candidate biomarkers, and assess potential for clinical translation. Methods: We conducted a structured narrative review and assessed 22 studies investigating inflammatory and metabolic biomarkers for prediabetes across experimental animal models, human pancreatic islets, and clinical cohorts. Biomarkers included cytokines, oxidative stress indicators, microRNAs, and immune-cell-associated factors. Studies included cross-sectional, longitudinal, and mechanistic designs. Results: Clinical studies generally reported higher CRP and hsCRP. In several cohorts, IL-6 and other inflammatory mediators were increased in individuals with prediabetes. However, inflammatory responses were not uniform across studies. One study reported elevated IL-10 and IL-4 in addition to hsCRP, while TNF-&amp;amp;alpha; and IL-6 were not significantly different. Overall, CRP and hsCRP demonstrated the strongest clinical translational evidence, with findings replicated across multiple cohorts and longitudinal evidence linking higher baseline hsCRP or CRP with increased risk of progression to T2D. Other candidates, including IL-6, TNF-&amp;amp;alpha;, adiponectin, SFRP4, oxidative stress markers, and microRNAs, remain promising but have more limited or inconsistent evidence for clinical application. Conclusions: Prediabetes is characterized by a multifaceted inflammatory response involving innate and adaptive immune pathways, altered cytokine and microRNA profiles, oxidative stress, and adipose&amp;amp;ndash;pancreatic interactions. Although inflammatory biomarkers may enhance conventional metabolic measures for risk stratification, current evidence does not establish any inflammatory marker as a standalone diagnostic test for prediabetes.</description>
	<pubDate>2026-09-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 174: Potential Biomarkers for the Early Prediction of Prediabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/174">doi: 10.3390/diabetology7090174</a></p>
	<p>Authors:
		Luisa V. Gracia Mazuca
		Bibiana Mancera
		</p>
	<p>Background/Objective: Prediabetes is increasingly recognized as a state of chronic, low-grade inflammation that contributes to early &amp;amp;beta;-cell dysfunction, insulin resistance, and progression to type 2 diabetes (T2D). This review synthesizes mechanistic and clinical evidence to characterize the inflammatory landscape of prediabetes, evaluate the consistency of candidate biomarkers, and assess potential for clinical translation. Methods: We conducted a structured narrative review and assessed 22 studies investigating inflammatory and metabolic biomarkers for prediabetes across experimental animal models, human pancreatic islets, and clinical cohorts. Biomarkers included cytokines, oxidative stress indicators, microRNAs, and immune-cell-associated factors. Studies included cross-sectional, longitudinal, and mechanistic designs. Results: Clinical studies generally reported higher CRP and hsCRP. In several cohorts, IL-6 and other inflammatory mediators were increased in individuals with prediabetes. However, inflammatory responses were not uniform across studies. One study reported elevated IL-10 and IL-4 in addition to hsCRP, while TNF-&amp;amp;alpha; and IL-6 were not significantly different. Overall, CRP and hsCRP demonstrated the strongest clinical translational evidence, with findings replicated across multiple cohorts and longitudinal evidence linking higher baseline hsCRP or CRP with increased risk of progression to T2D. Other candidates, including IL-6, TNF-&amp;amp;alpha;, adiponectin, SFRP4, oxidative stress markers, and microRNAs, remain promising but have more limited or inconsistent evidence for clinical application. Conclusions: Prediabetes is characterized by a multifaceted inflammatory response involving innate and adaptive immune pathways, altered cytokine and microRNA profiles, oxidative stress, and adipose&amp;amp;ndash;pancreatic interactions. Although inflammatory biomarkers may enhance conventional metabolic measures for risk stratification, current evidence does not establish any inflammatory marker as a standalone diagnostic test for prediabetes.</p>
	]]></content:encoded>

	<dc:title>Potential Biomarkers for the Early Prediction of Prediabetes</dc:title>
			<dc:creator>Luisa V. Gracia Mazuca</dc:creator>
			<dc:creator>Bibiana Mancera</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090174</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-07</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-07</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>174</prism:startingPage>
		<prism:doi>10.3390/diabetology7090174</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/174</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/175">

	<title>Diabetology, Vol. 7, Pages 175: Understanding Psychological Functioning in Type 1 Diabetes: Toward an Integrated Framework</title>
	<link>https://www.mdpi.com/2673-4540/7/9/175</link>
	<description>Type 1 diabetes mellitus (T1DM) is increasingly recognized as a condition in which psychological processes play an important role in disease management, adaptation, and clinical outcomes. Although research has identified a growing number of relevant psychological constructs, these have largely been investigated independently, limiting understanding of their interactions with behavioral and biological processes. This contribution discusses the principal conceptual gaps that currently constrain theoretical integration and proposes an integrative psychobiological framework in which individual and contextual factors, psychological processes, self-management behaviors, and biological and metabolic dimensions are conceptualized as components of a dynamic and temporally embedded system. The framework emphasizes potentially mediated, moderated, and reciprocal pathways whose relative contribution may vary across individuals, life stages, and the disease trajectory. By providing a structure through which these processes can be jointly operationalized and empirically investigated, this perspective may support more coherent research strategies and help identify individual and evolving assessment and intervention priorities in diabetes care.</description>
	<pubDate>2026-09-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 175: Understanding Psychological Functioning in Type 1 Diabetes: Toward an Integrated Framework</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/175">doi: 10.3390/diabetology7090175</a></p>
	<p>Authors:
		Emanuele Maria Merlo
		</p>
	<p>Type 1 diabetes mellitus (T1DM) is increasingly recognized as a condition in which psychological processes play an important role in disease management, adaptation, and clinical outcomes. Although research has identified a growing number of relevant psychological constructs, these have largely been investigated independently, limiting understanding of their interactions with behavioral and biological processes. This contribution discusses the principal conceptual gaps that currently constrain theoretical integration and proposes an integrative psychobiological framework in which individual and contextual factors, psychological processes, self-management behaviors, and biological and metabolic dimensions are conceptualized as components of a dynamic and temporally embedded system. The framework emphasizes potentially mediated, moderated, and reciprocal pathways whose relative contribution may vary across individuals, life stages, and the disease trajectory. By providing a structure through which these processes can be jointly operationalized and empirically investigated, this perspective may support more coherent research strategies and help identify individual and evolving assessment and intervention priorities in diabetes care.</p>
	]]></content:encoded>

	<dc:title>Understanding Psychological Functioning in Type 1 Diabetes: Toward an Integrated Framework</dc:title>
			<dc:creator>Emanuele Maria Merlo</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090175</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-07</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-07</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>175</prism:startingPage>
		<prism:doi>10.3390/diabetology7090175</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/175</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/173">

	<title>Diabetology, Vol. 7, Pages 173: Impact of Personal Health Record Use on HbA1c Improvement in People with Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/9/173</link>
	<description>Objective: This study aimed to evaluate how using personal health records (PHRs; Health2Sync&amp;amp;reg;) impacts long-term glycemic management and body weight in people with type 2 diabetes (T2DM) and to identify factors associated with glycated hemoglobin (HbA1c) changes. Methods: This single-center, retrospective observational study included 154 patients with T2DM (76 PHR users and 78 non-users [control]; mean age: 57.9 and 65.0 years, respectively) between April 2022 and June 2024. Clinical parameters (HbA1c, body weight; BW), nutritional support, and antidiabetic medications were collected at the index date and at 3, 6, and 12 months. The between-group difference in HbA1c change (&amp;amp;Delta;HbA1c) from the index date to 12 months was the primary outcome, and the between-group difference in body weight change (&amp;amp;Delta;BW) was the secondary outcome. Factors associated with &amp;amp;Delta;HbA1c were explored using multivariate analysis in the PHR group. Results: In the PHR group, &amp;amp;Delta;HbA1c from the index date showed a significant reduction as early as 3 months, and this decrease was sustained at 6 and 12 months (p &amp;amp;lt; 0.001). Furthermore, a similar trend was observed for &amp;amp;Delta;BW (p &amp;amp;lt; 0.001). Moreover, multivariable regression analysis revealed an independent association between nutritional support and improvement in HbA1c. Conclusions: PHR use was associated with improved glycemic control and weight reduction in people with T2DM, and together with nutritional support, it may further enhance self-management and clinical outcomes.</description>
	<pubDate>2026-09-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 173: Impact of Personal Health Record Use on HbA1c Improvement in People with Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/173">doi: 10.3390/diabetology7090173</a></p>
	<p>Authors:
		Isaki Hanamura
		Norio Abiru
		Toshifumi Sakamoto
		Akie Moriuchi
		Nobuko Sera
		</p>
	<p>Objective: This study aimed to evaluate how using personal health records (PHRs; Health2Sync&amp;amp;reg;) impacts long-term glycemic management and body weight in people with type 2 diabetes (T2DM) and to identify factors associated with glycated hemoglobin (HbA1c) changes. Methods: This single-center, retrospective observational study included 154 patients with T2DM (76 PHR users and 78 non-users [control]; mean age: 57.9 and 65.0 years, respectively) between April 2022 and June 2024. Clinical parameters (HbA1c, body weight; BW), nutritional support, and antidiabetic medications were collected at the index date and at 3, 6, and 12 months. The between-group difference in HbA1c change (&amp;amp;Delta;HbA1c) from the index date to 12 months was the primary outcome, and the between-group difference in body weight change (&amp;amp;Delta;BW) was the secondary outcome. Factors associated with &amp;amp;Delta;HbA1c were explored using multivariate analysis in the PHR group. Results: In the PHR group, &amp;amp;Delta;HbA1c from the index date showed a significant reduction as early as 3 months, and this decrease was sustained at 6 and 12 months (p &amp;amp;lt; 0.001). Furthermore, a similar trend was observed for &amp;amp;Delta;BW (p &amp;amp;lt; 0.001). Moreover, multivariable regression analysis revealed an independent association between nutritional support and improvement in HbA1c. Conclusions: PHR use was associated with improved glycemic control and weight reduction in people with T2DM, and together with nutritional support, it may further enhance self-management and clinical outcomes.</p>
	]]></content:encoded>

	<dc:title>Impact of Personal Health Record Use on HbA1c Improvement in People with Type 2 Diabetes</dc:title>
			<dc:creator>Isaki Hanamura</dc:creator>
			<dc:creator>Norio Abiru</dc:creator>
			<dc:creator>Toshifumi Sakamoto</dc:creator>
			<dc:creator>Akie Moriuchi</dc:creator>
			<dc:creator>Nobuko Sera</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090173</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-04</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-04</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>173</prism:startingPage>
		<prism:doi>10.3390/diabetology7090173</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/173</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/172">

	<title>Diabetology, Vol. 7, Pages 172: Prevalence of Antiphospholipid Antibodies in Greek Individuals with Type 1 Diabetes and Their Association with Diabetes-Related Complications</title>
	<link>https://www.mdpi.com/2673-4540/7/9/172</link>
	<description>Background/Objectives: Antiphospholipid antibodies (aPL) comprise anticardiolipin antibodies (aCL), antibodies against &amp;amp;beta;2 glycoprotein I (anti-&amp;amp;beta;2GPI) and lupus anticoagulant (LA). LA is an established risk factor for thrombosis and pregnancy morbidity in the general population. In people with type 1 diabetes (T1D), aPL have been proposed as potential predictors of microvascular and macrovascular diabetes-related complications. The aim of the present prospective, observational study was to investigate the prevalence of aPL in a well-defined cohort of adults presenting with uncomplicated T1D compared with healthy controls. In addition, we prospectively examined whether aPL titers or positivity were potentially associated with the subsequent development of diabetes-related complications. Methods: Two hundred (200) adults with T1D and without microvascular or macrovascular complications participated (mean age, 37.9 &amp;amp;plusmn; 10.6 years; mean diabetes duration, 21.00 &amp;amp;plusmn; 9.20 years). We also included 200 age- and sex-matched healthy controls (mean age, 37.7 &amp;amp;plusmn; 10.1 years) without diabetes mellitus or other autoimmune diseases. The aPL panel, including aCL &amp;amp;Iota;gG/IgM, anti- &amp;amp;beta;2GPI IgG/IgM, and LA, was assessed using standardized laboratory methods. Participants with T1D were re-evaluated after a mean follow-up of 7.6 years. Results: Titers of aCL IgG/IgM and anti-&amp;amp;beta;2GPI IgG, as well as positivity of aCL-IgG and aCL-IgM, were higher in participants with T1D compared with healthy controls, whereas LA positivity was very low in both groups. In the T1D group, aCL-IgG titers significantly correlated with age and diabetes duration. Neither aCL-IgG titers nor positivity was associated with the development of microvascular or macrovascular complications or with all-cause mortality during follow-up. Conclusions: In adults with long-standing, uncomplicated T1D, most aPL titers and positivity rates were higher than those observed in healthy controls. However, aCL-IgG titers and positivity were not associated with the subsequent development of diabetes-related complications. Larger prospective studies are required to determine whether aPL have predictive value for diabetes-related complications and to identify subgroups of people with T1D who may benefit from aPL testing.</description>
	<pubDate>2026-09-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 172: Prevalence of Antiphospholipid Antibodies in Greek Individuals with Type 1 Diabetes and Their Association with Diabetes-Related Complications</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/172">doi: 10.3390/diabetology7090172</a></p>
	<p>Authors:
		Stavroula-Panagiota Lontou
		Ioanna A. Anastasiou
		Nikolitsa Kafasi
		Anestis Chanos
		Vasiliki Mamakou
		Paraskevas Stamopoulos
		Dimitrios Chronopoulos
		Maria Tektonidou
		Helen Gogas
		Nikolaos Papanas
		Aris Polyzos
		Nikolaos Tentolouris
		</p>
	<p>Background/Objectives: Antiphospholipid antibodies (aPL) comprise anticardiolipin antibodies (aCL), antibodies against &amp;amp;beta;2 glycoprotein I (anti-&amp;amp;beta;2GPI) and lupus anticoagulant (LA). LA is an established risk factor for thrombosis and pregnancy morbidity in the general population. In people with type 1 diabetes (T1D), aPL have been proposed as potential predictors of microvascular and macrovascular diabetes-related complications. The aim of the present prospective, observational study was to investigate the prevalence of aPL in a well-defined cohort of adults presenting with uncomplicated T1D compared with healthy controls. In addition, we prospectively examined whether aPL titers or positivity were potentially associated with the subsequent development of diabetes-related complications. Methods: Two hundred (200) adults with T1D and without microvascular or macrovascular complications participated (mean age, 37.9 &amp;amp;plusmn; 10.6 years; mean diabetes duration, 21.00 &amp;amp;plusmn; 9.20 years). We also included 200 age- and sex-matched healthy controls (mean age, 37.7 &amp;amp;plusmn; 10.1 years) without diabetes mellitus or other autoimmune diseases. The aPL panel, including aCL &amp;amp;Iota;gG/IgM, anti- &amp;amp;beta;2GPI IgG/IgM, and LA, was assessed using standardized laboratory methods. Participants with T1D were re-evaluated after a mean follow-up of 7.6 years. Results: Titers of aCL IgG/IgM and anti-&amp;amp;beta;2GPI IgG, as well as positivity of aCL-IgG and aCL-IgM, were higher in participants with T1D compared with healthy controls, whereas LA positivity was very low in both groups. In the T1D group, aCL-IgG titers significantly correlated with age and diabetes duration. Neither aCL-IgG titers nor positivity was associated with the development of microvascular or macrovascular complications or with all-cause mortality during follow-up. Conclusions: In adults with long-standing, uncomplicated T1D, most aPL titers and positivity rates were higher than those observed in healthy controls. However, aCL-IgG titers and positivity were not associated with the subsequent development of diabetes-related complications. Larger prospective studies are required to determine whether aPL have predictive value for diabetes-related complications and to identify subgroups of people with T1D who may benefit from aPL testing.</p>
	]]></content:encoded>

	<dc:title>Prevalence of Antiphospholipid Antibodies in Greek Individuals with Type 1 Diabetes and Their Association with Diabetes-Related Complications</dc:title>
			<dc:creator>Stavroula-Panagiota Lontou</dc:creator>
			<dc:creator>Ioanna A. Anastasiou</dc:creator>
			<dc:creator>Nikolitsa Kafasi</dc:creator>
			<dc:creator>Anestis Chanos</dc:creator>
			<dc:creator>Vasiliki Mamakou</dc:creator>
			<dc:creator>Paraskevas Stamopoulos</dc:creator>
			<dc:creator>Dimitrios Chronopoulos</dc:creator>
			<dc:creator>Maria Tektonidou</dc:creator>
			<dc:creator>Helen Gogas</dc:creator>
			<dc:creator>Nikolaos Papanas</dc:creator>
			<dc:creator>Aris Polyzos</dc:creator>
			<dc:creator>Nikolaos Tentolouris</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090172</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-03</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-03</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>172</prism:startingPage>
		<prism:doi>10.3390/diabetology7090172</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/172</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/171">

	<title>Diabetology, Vol. 7, Pages 171: Clinical Outcomes of Urinary Tract Infection and Pneumonia in Hospitalized Patients with Type 1 and Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/9/171</link>
	<description>Background: Individuals with diabetes have an increased risk of infection-related hospitalization; however, whether type 1 diabetes (T1D) and type 2 diabetes (T2D) differentially influence outcomes following hospitalization remains unclear. We compared mortality, metabolic complications, and hospital outcomes among adults with T1D, T2D, or no documented diabetes admitted with urinary tract infection (UTI) or pneumonia. Methods: We performed a retrospective cohort study using electronic health records from a tertiary 1500-bed medical center (2018&amp;amp;ndash;2026). Eligible adult hospital admissions for UTI or pneumonia were classified according to documented T1D, T2D, or no diabetes. The study included 22,475 UTI admissions (211 with T1D, 9230 with T2D, and 13,034 without diabetes) and 32,703 pneumonia admissions (208 with T1D, 15,112 with T2D, and 17,383 without diabetes). Multivariable logistic regression was used to evaluate the association between diabetes status and 30-day mortality, with adjustment for age, sex, BMI, CCI, and MEWS. Because individuals could contribute multiple eligible admissions, the primary mortality models used patient-level cluster-robust standard errors to account for within-patient correlation. Results: T1D admissions involved substantially younger individuals than T2D or non-diabetes admissions but were associated with the greatest metabolic instability during hospitalization. Hypoglycemia occurred in 41.2% of T1D admissions for UTI and 19.7% for pneumonia, compared with 19.6% and 4.1% in T2D, respectively (both p &amp;amp;lt; 0.001). Hyperglycemia was also markedly more frequent in T1D, affecting 88.6% of UTI and 72.6% of pneumonia admissions. ICU transfer was nearly threefold higher in T1D than T2D during UTI hospitalization (10.0% vs. 3.5%, p &amp;amp;lt; 0.001). After adjustment, T1D was not independently associated with 30-day mortality, whereas T2D was associated with modestly lower adjusted odds of 30-day mortality compared with patients without documented diabetes. No significant mortality differences were observed between T1D and T2D. Conclusions: Diabetes type was not independently associated with higher short-term mortality following hospitalization for UTI or pneumonia after adjustment for measured confounders. However, T1D was associated with substantially greater glycemic instability and increased intensive care utilization, suggesting that diabetes type may influence the metabolic complexity and intensity of inpatient management more than short-term survival.</description>
	<pubDate>2026-09-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 171: Clinical Outcomes of Urinary Tract Infection and Pneumonia in Hospitalized Patients with Type 1 and Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/171">doi: 10.3390/diabetology7090171</a></p>
	<p>Authors:
		Eugene Feigin
		Hussein Zaitoon
		</p>
	<p>Background: Individuals with diabetes have an increased risk of infection-related hospitalization; however, whether type 1 diabetes (T1D) and type 2 diabetes (T2D) differentially influence outcomes following hospitalization remains unclear. We compared mortality, metabolic complications, and hospital outcomes among adults with T1D, T2D, or no documented diabetes admitted with urinary tract infection (UTI) or pneumonia. Methods: We performed a retrospective cohort study using electronic health records from a tertiary 1500-bed medical center (2018&amp;amp;ndash;2026). Eligible adult hospital admissions for UTI or pneumonia were classified according to documented T1D, T2D, or no diabetes. The study included 22,475 UTI admissions (211 with T1D, 9230 with T2D, and 13,034 without diabetes) and 32,703 pneumonia admissions (208 with T1D, 15,112 with T2D, and 17,383 without diabetes). Multivariable logistic regression was used to evaluate the association between diabetes status and 30-day mortality, with adjustment for age, sex, BMI, CCI, and MEWS. Because individuals could contribute multiple eligible admissions, the primary mortality models used patient-level cluster-robust standard errors to account for within-patient correlation. Results: T1D admissions involved substantially younger individuals than T2D or non-diabetes admissions but were associated with the greatest metabolic instability during hospitalization. Hypoglycemia occurred in 41.2% of T1D admissions for UTI and 19.7% for pneumonia, compared with 19.6% and 4.1% in T2D, respectively (both p &amp;amp;lt; 0.001). Hyperglycemia was also markedly more frequent in T1D, affecting 88.6% of UTI and 72.6% of pneumonia admissions. ICU transfer was nearly threefold higher in T1D than T2D during UTI hospitalization (10.0% vs. 3.5%, p &amp;amp;lt; 0.001). After adjustment, T1D was not independently associated with 30-day mortality, whereas T2D was associated with modestly lower adjusted odds of 30-day mortality compared with patients without documented diabetes. No significant mortality differences were observed between T1D and T2D. Conclusions: Diabetes type was not independently associated with higher short-term mortality following hospitalization for UTI or pneumonia after adjustment for measured confounders. However, T1D was associated with substantially greater glycemic instability and increased intensive care utilization, suggesting that diabetes type may influence the metabolic complexity and intensity of inpatient management more than short-term survival.</p>
	]]></content:encoded>

	<dc:title>Clinical Outcomes of Urinary Tract Infection and Pneumonia in Hospitalized Patients with Type 1 and Type 2 Diabetes</dc:title>
			<dc:creator>Eugene Feigin</dc:creator>
			<dc:creator>Hussein Zaitoon</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090171</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-03</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-03</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>171</prism:startingPage>
		<prism:doi>10.3390/diabetology7090171</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/171</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/170">

	<title>Diabetology, Vol. 7, Pages 170: Baseline Eating Behaviors and Responsiveness to TelePhysio in Older Patients with Type 2 Diabetes: An Exploratory Secondary Analysis of the TelePhysioT2D Trial</title>
	<link>https://www.mdpi.com/2673-4540/7/9/170</link>
	<description>Background/Objectives: Telerehabilitation for physiotherapy programs (TelePhysio) has been shown to improve knee extension force (KEF) in older patients with type 2 diabetes mellitus (T2DM), but factors associated with responsiveness remain unclear. This exploratory secondary analysis investigated whether baseline eating behaviors modified the effectiveness of TelePhysio in KEF. Methods: This secondary analysis included 74 older patients with T2DM enrolled in a randomized controlled trial. The participants were assigned to the TelePhysio (n = 39) or non-intervention group (n = 35). Baseline eating behaviors were assessed using an Eating Behavior Questionnaire. Multiple regression analysis was performed using 6-month KEF as the dependent variable, adjusting for baseline KEF, age, sex, body mass index, diabetic polyneuropathy, intervention group, baseline eating behavior score, and their interactions. The original trial was prospectively registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; UMIN000024416; registered on 15 October 2016). Results: A significant interaction was found between the intervention group and baseline eating behavior score (B = &amp;amp;minus;0.0064, p = 0.0352). Estimated TelePhysio effects on eating behavior scores corresponding to mean &amp;amp;minus; 1 standard deviation (SD), mean, and mean + 1 SD were +0.36, +0.12, and &amp;amp;minus;0.12 Nm/kg, respectively. None of the seven domain-specific group-by-domain interactions reached statistical significance. Sensitivity analyses using KEF changes showed a similar directional trend but were not statistically significant (p = 0.2913). Conclusions: Baseline eating behaviors may be associated with differential responsiveness to TelePhysio in older adults with T2DM. The estimated effect of TelePhysio on KEF was smaller at higher baseline Eating Behavior Questionnaire scores. These findings should be cautiously interpreted because the interaction was not confirmed using sensitivity analysis regarding changes in the KEF.</description>
	<pubDate>2026-09-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 170: Baseline Eating Behaviors and Responsiveness to TelePhysio in Older Patients with Type 2 Diabetes: An Exploratory Secondary Analysis of the TelePhysioT2D Trial</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/170">doi: 10.3390/diabetology7090170</a></p>
	<p>Authors:
		Hiroaki Kataoka
		Takuo Nomura
		Hiroyuki Oka
		Yukio Ikeda
		</p>
	<p>Background/Objectives: Telerehabilitation for physiotherapy programs (TelePhysio) has been shown to improve knee extension force (KEF) in older patients with type 2 diabetes mellitus (T2DM), but factors associated with responsiveness remain unclear. This exploratory secondary analysis investigated whether baseline eating behaviors modified the effectiveness of TelePhysio in KEF. Methods: This secondary analysis included 74 older patients with T2DM enrolled in a randomized controlled trial. The participants were assigned to the TelePhysio (n = 39) or non-intervention group (n = 35). Baseline eating behaviors were assessed using an Eating Behavior Questionnaire. Multiple regression analysis was performed using 6-month KEF as the dependent variable, adjusting for baseline KEF, age, sex, body mass index, diabetic polyneuropathy, intervention group, baseline eating behavior score, and their interactions. The original trial was prospectively registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; UMIN000024416; registered on 15 October 2016). Results: A significant interaction was found between the intervention group and baseline eating behavior score (B = &amp;amp;minus;0.0064, p = 0.0352). Estimated TelePhysio effects on eating behavior scores corresponding to mean &amp;amp;minus; 1 standard deviation (SD), mean, and mean + 1 SD were +0.36, +0.12, and &amp;amp;minus;0.12 Nm/kg, respectively. None of the seven domain-specific group-by-domain interactions reached statistical significance. Sensitivity analyses using KEF changes showed a similar directional trend but were not statistically significant (p = 0.2913). Conclusions: Baseline eating behaviors may be associated with differential responsiveness to TelePhysio in older adults with T2DM. The estimated effect of TelePhysio on KEF was smaller at higher baseline Eating Behavior Questionnaire scores. These findings should be cautiously interpreted because the interaction was not confirmed using sensitivity analysis regarding changes in the KEF.</p>
	]]></content:encoded>

	<dc:title>Baseline Eating Behaviors and Responsiveness to TelePhysio in Older Patients with Type 2 Diabetes: An Exploratory Secondary Analysis of the TelePhysioT2D Trial</dc:title>
			<dc:creator>Hiroaki Kataoka</dc:creator>
			<dc:creator>Takuo Nomura</dc:creator>
			<dc:creator>Hiroyuki Oka</dc:creator>
			<dc:creator>Yukio Ikeda</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090170</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-02</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-02</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>170</prism:startingPage>
		<prism:doi>10.3390/diabetology7090170</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/170</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/169">

	<title>Diabetology, Vol. 7, Pages 169: Cutaneous Manifestations as a Clinical Screening Index for Diabetic Microvascular Involvement: A Pilot Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/9/169</link>
	<description>Background and objectives: Diabetic microangiopathy is a frequent complication of diabetes mellitus, and its early identification remains challenging, particularly in resource-limited settings. This study aimed to develop a simple clinical scoring system based on cutaneous manifestations to estimate the risk of microangiopathy. Methods: An observational cross-sectional pilot study was conducted in 30 adults with diabetes mellitus attending a specialized diabetic foot unit. Lower-limb cutaneous manifestations (xerosis, absence of hair, hyperpigmentation, nail-plate thickening, skin atrophy and hypertrophy) were assessed during physical examination. Cutaneous findings significantly associated with clinically established microangiopathy were incorporated into a preliminary clinical screening index. Its discriminative ability was evaluated using receiver operating characteristic (ROC) analysis. As a secondary exploratory analysis, the relationship between the index and transcutaneous oxygen pressure (TcPO2) was investigated. Results: Five cutaneous manifestations were included in the final clinical screening index. The index demonstrated excellent discriminative ability for identifying clinically established microangiopathy (AUC = 0.95; 95% CI: 0.88&amp;amp;ndash;1.00). A cut-off value of &amp;amp;ge;4 points yielded a sensitivity of 76.2% and a specificity of 100%. Higher index scores showed a trend towards lower TcPO2 values and a greater frequency of reduced tissue oxygenation, although these exploratory associations were not statistically significant. Conclusions: The proposed score shows promising discriminative performance. Although physiological associations were not statistically significant, observed trends support its potential clinical relevance. Further validation in larger cohorts is required.</description>
	<pubDate>2026-09-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 169: Cutaneous Manifestations as a Clinical Screening Index for Diabetic Microvascular Involvement: A Pilot Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/169">doi: 10.3390/diabetology7090169</a></p>
	<p>Authors:
		Laura Palacios-Abril
		Aroa Tardáguila-García
		Francisco Javier Álvaro-Afonso
		Sol Tejeda-Ramírez
		Yolanda García-Álvarez
		José Luis Lázaro-Martínez
		</p>
	<p>Background and objectives: Diabetic microangiopathy is a frequent complication of diabetes mellitus, and its early identification remains challenging, particularly in resource-limited settings. This study aimed to develop a simple clinical scoring system based on cutaneous manifestations to estimate the risk of microangiopathy. Methods: An observational cross-sectional pilot study was conducted in 30 adults with diabetes mellitus attending a specialized diabetic foot unit. Lower-limb cutaneous manifestations (xerosis, absence of hair, hyperpigmentation, nail-plate thickening, skin atrophy and hypertrophy) were assessed during physical examination. Cutaneous findings significantly associated with clinically established microangiopathy were incorporated into a preliminary clinical screening index. Its discriminative ability was evaluated using receiver operating characteristic (ROC) analysis. As a secondary exploratory analysis, the relationship between the index and transcutaneous oxygen pressure (TcPO2) was investigated. Results: Five cutaneous manifestations were included in the final clinical screening index. The index demonstrated excellent discriminative ability for identifying clinically established microangiopathy (AUC = 0.95; 95% CI: 0.88&amp;amp;ndash;1.00). A cut-off value of &amp;amp;ge;4 points yielded a sensitivity of 76.2% and a specificity of 100%. Higher index scores showed a trend towards lower TcPO2 values and a greater frequency of reduced tissue oxygenation, although these exploratory associations were not statistically significant. Conclusions: The proposed score shows promising discriminative performance. Although physiological associations were not statistically significant, observed trends support its potential clinical relevance. Further validation in larger cohorts is required.</p>
	]]></content:encoded>

	<dc:title>Cutaneous Manifestations as a Clinical Screening Index for Diabetic Microvascular Involvement: A Pilot Cross-Sectional Study</dc:title>
			<dc:creator>Laura Palacios-Abril</dc:creator>
			<dc:creator>Aroa Tardáguila-García</dc:creator>
			<dc:creator>Francisco Javier Álvaro-Afonso</dc:creator>
			<dc:creator>Sol Tejeda-Ramírez</dc:creator>
			<dc:creator>Yolanda García-Álvarez</dc:creator>
			<dc:creator>José Luis Lázaro-Martínez</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090169</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-01</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-01</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>169</prism:startingPage>
		<prism:doi>10.3390/diabetology7090169</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/169</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/168">

	<title>Diabetology, Vol. 7, Pages 168: Skeletal Health in Premenopausal Women with Type 1 Diabetes: A Scoping Review</title>
	<link>https://www.mdpi.com/2673-4540/7/9/168</link>
	<description>Background: Type 1 diabetes (T1D) is increasingly recognized as a condition associated with impaired skeletal health and increased fracture risk. Although osteoporosis is usually considered more clinically relevant after menopause, diabetes-related skeletal alterations may begin earlier in life. This scoping review aimed to map the available evidence on bone-health outcomes in premenopausal women with T1D. Methods: A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). PubMed/MEDLINE, Scopus, Web of Science, CINAHL and the Cochrane Library were searched, supplemented by Google Scholar and manual screening of reference lists. Eligible studies examined bone mineral density (BMD), fracture history or fracture risk, bone turnover markers, quantitative ultrasound parameters, bone microarchitecture, or other skeletal outcomes in premenopausal women or women with T1D. Results: Seven studies met the eligibility criteria. The included studies were mainly observational and varied in sample size, age range, diabetes duration, skeletal sites assessed, and bone-assessment methods. Most studies reported lower BMD or less favorable skeletal parameters in premenopausal women with T1D compared with women without diabetes, particularly at peripheral or hip-related skeletal sites. Quantitative ultrasound studies suggested impaired peripheral skeletal properties, while one MRI-based study identified trabecular microarchitectural deficits. Several studies also reported altered bone turnover markers and associations between poorer glycemic control, adverse health behaviors or diabetes-related complications, and poorer bone outcomes. Fracture data were limited and were based on previous or self-reported fractures. Potential determinants of skeletal health were variably reported across studies, with more consistent consideration of body mass index and selected lifestyle or reproductive factors than of autoimmune, nutritional, medication-related, and detailed reproductive variables. Conclusions: Available evidence indicates that premenopausal women with T1D may exhibit early alterations in skeletal health, including differences in BMD, peripheral bone measures, bone turnover, and microarchitecture. These findings highlight the potential importance of considering bone health before the menopausal transition. However, prospective data on fragility fractures remain limited, and further longitudinal studies incorporating detailed reproductive, metabolic, and clinical factors are needed to clarify the long-term skeletal implications and inform future risk-assessment strategies.</description>
	<pubDate>2026-09-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 168: Skeletal Health in Premenopausal Women with Type 1 Diabetes: A Scoping Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/168">doi: 10.3390/diabetology7090168</a></p>
	<p>Authors:
		Eugenia Vlachou
		Anastasia Ntikoudi
		Dimitra Anna Owens
		Despoina Rizikou
		Afroditi Tsalkitzi
		Eleni Evangelou
		Athanasios N. Tsartsalis
		</p>
	<p>Background: Type 1 diabetes (T1D) is increasingly recognized as a condition associated with impaired skeletal health and increased fracture risk. Although osteoporosis is usually considered more clinically relevant after menopause, diabetes-related skeletal alterations may begin earlier in life. This scoping review aimed to map the available evidence on bone-health outcomes in premenopausal women with T1D. Methods: A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). PubMed/MEDLINE, Scopus, Web of Science, CINAHL and the Cochrane Library were searched, supplemented by Google Scholar and manual screening of reference lists. Eligible studies examined bone mineral density (BMD), fracture history or fracture risk, bone turnover markers, quantitative ultrasound parameters, bone microarchitecture, or other skeletal outcomes in premenopausal women or women with T1D. Results: Seven studies met the eligibility criteria. The included studies were mainly observational and varied in sample size, age range, diabetes duration, skeletal sites assessed, and bone-assessment methods. Most studies reported lower BMD or less favorable skeletal parameters in premenopausal women with T1D compared with women without diabetes, particularly at peripheral or hip-related skeletal sites. Quantitative ultrasound studies suggested impaired peripheral skeletal properties, while one MRI-based study identified trabecular microarchitectural deficits. Several studies also reported altered bone turnover markers and associations between poorer glycemic control, adverse health behaviors or diabetes-related complications, and poorer bone outcomes. Fracture data were limited and were based on previous or self-reported fractures. Potential determinants of skeletal health were variably reported across studies, with more consistent consideration of body mass index and selected lifestyle or reproductive factors than of autoimmune, nutritional, medication-related, and detailed reproductive variables. Conclusions: Available evidence indicates that premenopausal women with T1D may exhibit early alterations in skeletal health, including differences in BMD, peripheral bone measures, bone turnover, and microarchitecture. These findings highlight the potential importance of considering bone health before the menopausal transition. However, prospective data on fragility fractures remain limited, and further longitudinal studies incorporating detailed reproductive, metabolic, and clinical factors are needed to clarify the long-term skeletal implications and inform future risk-assessment strategies.</p>
	]]></content:encoded>

	<dc:title>Skeletal Health in Premenopausal Women with Type 1 Diabetes: A Scoping Review</dc:title>
			<dc:creator>Eugenia Vlachou</dc:creator>
			<dc:creator>Anastasia Ntikoudi</dc:creator>
			<dc:creator>Dimitra Anna Owens</dc:creator>
			<dc:creator>Despoina Rizikou</dc:creator>
			<dc:creator>Afroditi Tsalkitzi</dc:creator>
			<dc:creator>Eleni Evangelou</dc:creator>
			<dc:creator>Athanasios N. Tsartsalis</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090168</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-09-01</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-09-01</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>168</prism:startingPage>
		<prism:doi>10.3390/diabetology7090168</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/168</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/167">

	<title>Diabetology, Vol. 7, Pages 167: Prevalence of Hypertension and Associated Factors Among Patients with Type 2 Diabetes Mellitus at Lira Regional Referral Hospital, Uganda: A Hospital-Based Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/9/167</link>
	<description>Background: Hypertension commonly complicates Type 2 diabetes mellitus (T2DM), contributing significantly to increased morbidity and mortality. This study determined the prevalence and factors associated with hypertension among people with T2DM at a tertiary health facility in Northern Uganda. Methods: A hospital-based cross-sectional study was conducted from 18 July to 24 October 2024. Participants with confirmed T2DM were selected through systematic random sampling at Lira Regional Referral Hospital (LRRH) in Lira City, Uganda. Data were collected using a structured questionnaire adapted from the WHO STEPS (2022) tool. Patient charts and registers were used to verify information. Data were analyzed using STATA version 16. Multivariable logistic regression was performed, and p-values &amp;amp;lt; 0.05 were considered statistically significant. Results: A total of 340 participants were enrolled in the study; the median age was 55 years; 244 (71.8%) were female; and nearly half of the participants (163, 47.9%) had attained primary education. Overall, 67.1% (228/340) of the participants with T2DM had hypertension. Factors independently associated with higher odds of hypertension were as follows: age 61+ years (aOR = 5.55, 95% CI: 1.34&amp;amp;ndash;23.1, p = 0.018), being overweight (aOR = 3.77, 95%CI: 1.05&amp;amp;ndash;13.57, p = 0.042), T2DM duration of more than five years (aOR = 2.51, 95% CI: 1.41&amp;amp;ndash;4.67, p = 0.002), and being widowed (aOR = 8.04, 95% CI: 1.87&amp;amp;ndash;34.61, p = 0.005). Earning UGX 50,001&amp;amp;ndash;100,000 per month (aOR = 0.35, 95% CI: 0.13&amp;amp;ndash;0.93, p = 0.037) was associated with 65% lower odds of having hypertension. Conclusions: Two-thirds of patients with T2DM had hypertension, and factors such as older age, being overweight, a longer T2DM duration, and marital status significantly increased hypertension risk; meanwhile, moderate-income status offered a protective effect. The high burden of hypertension among patients with T2DM demonstrates the necessity for targeted public health interventions such as comprehensive lifestyle modification programs, routine screening for hypertension, early detection, and its management among patients with T2DM through enhanced healthcare access. These interventions should focus on integrated care approaches that monitor and manage T2DM alongside hypertension.</description>
	<pubDate>2026-08-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 167: Prevalence of Hypertension and Associated Factors Among Patients with Type 2 Diabetes Mellitus at Lira Regional Referral Hospital, Uganda: A Hospital-Based Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/167">doi: 10.3390/diabetology7090167</a></p>
	<p>Authors:
		Geoffrey Ezama
		Marc Sam Opollo
		Bosco Opio
		Felix Bongomin
		Francis Kiweewa
		Beth Namukwana
		Solomon Icel
		Gasthony Alobo
		Bernard Omech
		</p>
	<p>Background: Hypertension commonly complicates Type 2 diabetes mellitus (T2DM), contributing significantly to increased morbidity and mortality. This study determined the prevalence and factors associated with hypertension among people with T2DM at a tertiary health facility in Northern Uganda. Methods: A hospital-based cross-sectional study was conducted from 18 July to 24 October 2024. Participants with confirmed T2DM were selected through systematic random sampling at Lira Regional Referral Hospital (LRRH) in Lira City, Uganda. Data were collected using a structured questionnaire adapted from the WHO STEPS (2022) tool. Patient charts and registers were used to verify information. Data were analyzed using STATA version 16. Multivariable logistic regression was performed, and p-values &amp;amp;lt; 0.05 were considered statistically significant. Results: A total of 340 participants were enrolled in the study; the median age was 55 years; 244 (71.8%) were female; and nearly half of the participants (163, 47.9%) had attained primary education. Overall, 67.1% (228/340) of the participants with T2DM had hypertension. Factors independently associated with higher odds of hypertension were as follows: age 61+ years (aOR = 5.55, 95% CI: 1.34&amp;amp;ndash;23.1, p = 0.018), being overweight (aOR = 3.77, 95%CI: 1.05&amp;amp;ndash;13.57, p = 0.042), T2DM duration of more than five years (aOR = 2.51, 95% CI: 1.41&amp;amp;ndash;4.67, p = 0.002), and being widowed (aOR = 8.04, 95% CI: 1.87&amp;amp;ndash;34.61, p = 0.005). Earning UGX 50,001&amp;amp;ndash;100,000 per month (aOR = 0.35, 95% CI: 0.13&amp;amp;ndash;0.93, p = 0.037) was associated with 65% lower odds of having hypertension. Conclusions: Two-thirds of patients with T2DM had hypertension, and factors such as older age, being overweight, a longer T2DM duration, and marital status significantly increased hypertension risk; meanwhile, moderate-income status offered a protective effect. The high burden of hypertension among patients with T2DM demonstrates the necessity for targeted public health interventions such as comprehensive lifestyle modification programs, routine screening for hypertension, early detection, and its management among patients with T2DM through enhanced healthcare access. These interventions should focus on integrated care approaches that monitor and manage T2DM alongside hypertension.</p>
	]]></content:encoded>

	<dc:title>Prevalence of Hypertension and Associated Factors Among Patients with Type 2 Diabetes Mellitus at Lira Regional Referral Hospital, Uganda: A Hospital-Based Cross-Sectional Study</dc:title>
			<dc:creator>Geoffrey Ezama</dc:creator>
			<dc:creator>Marc Sam Opollo</dc:creator>
			<dc:creator>Bosco Opio</dc:creator>
			<dc:creator>Felix Bongomin</dc:creator>
			<dc:creator>Francis Kiweewa</dc:creator>
			<dc:creator>Beth Namukwana</dc:creator>
			<dc:creator>Solomon Icel</dc:creator>
			<dc:creator>Gasthony Alobo</dc:creator>
			<dc:creator>Bernard Omech</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090167</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-31</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-31</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>167</prism:startingPage>
		<prism:doi>10.3390/diabetology7090167</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/167</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/166">

	<title>Diabetology, Vol. 7, Pages 166: Relationships Between Body Mass Index, Diabetes Mellitus and Peripheral Haemodynamic Parameters: A Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/9/166</link>
	<description>Background/Objectives: The ankle&amp;amp;ndash;brachial index (ABI) is a low-cost, non-invasive screening tool for peripheral artery disease (PAD) and an independent predictor of cardiovascular events, which makes it suitable for primary care. Peripheral haemodynamic data across body mass index (BMI) gradients remain scarce, and BMI and diabetes are seldom modelled together despite their frequent co-occurrence. We investigated their associations with peripheral haemodynamic parameters. Methods: We performed a cross-sectional study in 147 primary care users, twenty-seven of whom had a self-reported diagnosis of diabetes mellitus (DM). Systolic pressure was obtained by auscultation, with Doppler being unavailable. The ABI was calculated per leg from unrounded pressure, and the lower index was adopted and classified according to American Heart Association thresholds (abnormal: &amp;amp;le;0.90; borderline: 0.91&amp;amp;ndash;0.99; normal: 1.00&amp;amp;ndash;1.40; elevated: &amp;amp;gt;1.40). Nested linear models with robust standard errors estimated the adjusted association of DM with each outcome. Results: The DM group was older (62 vs. 44 years; p &amp;amp;lt; 0.001), with greater rates of excess weight (77.8% vs. 54.2%), hypertension (59.3% vs. 25.8%), dyslipidaemia (48.1% vs. 11.7%), and smoking (30.8% vs. 10.1%). Crude upper-limb systolic pressure was 10.1 mmHg higher in the DM group (95% confidence interval [CI]: &amp;amp;minus;0.5 to 20.6) but fell to 1.3 mmHg upon adjustment for age (p = 0.82 fully adjusted). The ABI did not differ between the groups (mean difference of 0.02, 95%CI: &amp;amp;minus;0.06 to 0.11; p = 0.59) and showed no gradient across BMI. An abnormal ABI was present in 14.4% of participants and a borderline ABI in 18.5%, so that 32.9% had an ABI below 1.00. Conclusions: The crude blood pressure difference was attenuated after adjustment, chiefly for age, and DM was not independently associated with any outcome; residual confounding cannot be excluded. No ABI difference was detected, but power reached 80% only for a difference of about 0.12 units. The fact that one-third of participants had an ABI below 1.00 warrants further investigation of risk-based vascular peripheral assessment in primary care.</description>
	<pubDate>2026-08-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 166: Relationships Between Body Mass Index, Diabetes Mellitus and Peripheral Haemodynamic Parameters: A Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/166">doi: 10.3390/diabetology7090166</a></p>
	<p>Authors:
		Djenane Cristovam Souza
		Rejane Cristiany Lins de França Pereira
		Rogério Fabiano Gonçalves
		Paulo Adriano Schwingel
		Manoel da Cunha Costa
		</p>
	<p>Background/Objectives: The ankle&amp;amp;ndash;brachial index (ABI) is a low-cost, non-invasive screening tool for peripheral artery disease (PAD) and an independent predictor of cardiovascular events, which makes it suitable for primary care. Peripheral haemodynamic data across body mass index (BMI) gradients remain scarce, and BMI and diabetes are seldom modelled together despite their frequent co-occurrence. We investigated their associations with peripheral haemodynamic parameters. Methods: We performed a cross-sectional study in 147 primary care users, twenty-seven of whom had a self-reported diagnosis of diabetes mellitus (DM). Systolic pressure was obtained by auscultation, with Doppler being unavailable. The ABI was calculated per leg from unrounded pressure, and the lower index was adopted and classified according to American Heart Association thresholds (abnormal: &amp;amp;le;0.90; borderline: 0.91&amp;amp;ndash;0.99; normal: 1.00&amp;amp;ndash;1.40; elevated: &amp;amp;gt;1.40). Nested linear models with robust standard errors estimated the adjusted association of DM with each outcome. Results: The DM group was older (62 vs. 44 years; p &amp;amp;lt; 0.001), with greater rates of excess weight (77.8% vs. 54.2%), hypertension (59.3% vs. 25.8%), dyslipidaemia (48.1% vs. 11.7%), and smoking (30.8% vs. 10.1%). Crude upper-limb systolic pressure was 10.1 mmHg higher in the DM group (95% confidence interval [CI]: &amp;amp;minus;0.5 to 20.6) but fell to 1.3 mmHg upon adjustment for age (p = 0.82 fully adjusted). The ABI did not differ between the groups (mean difference of 0.02, 95%CI: &amp;amp;minus;0.06 to 0.11; p = 0.59) and showed no gradient across BMI. An abnormal ABI was present in 14.4% of participants and a borderline ABI in 18.5%, so that 32.9% had an ABI below 1.00. Conclusions: The crude blood pressure difference was attenuated after adjustment, chiefly for age, and DM was not independently associated with any outcome; residual confounding cannot be excluded. No ABI difference was detected, but power reached 80% only for a difference of about 0.12 units. The fact that one-third of participants had an ABI below 1.00 warrants further investigation of risk-based vascular peripheral assessment in primary care.</p>
	]]></content:encoded>

	<dc:title>Relationships Between Body Mass Index, Diabetes Mellitus and Peripheral Haemodynamic Parameters: A Cross-Sectional Study</dc:title>
			<dc:creator>Djenane Cristovam Souza</dc:creator>
			<dc:creator>Rejane Cristiany Lins de França Pereira</dc:creator>
			<dc:creator>Rogério Fabiano Gonçalves</dc:creator>
			<dc:creator>Paulo Adriano Schwingel</dc:creator>
			<dc:creator>Manoel da Cunha Costa</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090166</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-28</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-28</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>166</prism:startingPage>
		<prism:doi>10.3390/diabetology7090166</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/166</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/165">

	<title>Diabetology, Vol. 7, Pages 165: Association Between Diabetic Retinopathy and Skin Autofluorescence in Individuals with Long-Standing Type 1 Diabetes and No History of Atherosclerotic Cardiovascular Disease</title>
	<link>https://www.mdpi.com/2673-4540/7/9/165</link>
	<description>Introduction: Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus (DM). Among the established risk factors for DR, &amp;amp;ldquo;metabolic memory&amp;amp;rdquo; plays a key role. Its development is mainly driven by advanced glycation end-products (AGEs), some of which possess characteristic fluorescent properties. Aims: To examine the relationship between skin AGEs, noninvasively assessed through skin autofluorescence (SAF), and the presence and severity of DR in subjects with long-standing type 1 DM (T1DM) and no history of atherosclerotic cardiovascular disease. Methods: 81 subjects with T1DM and 45 healthy controls were included. All individuals underwent SAF measurements and fundus photographs were taken in subjects with T1DM. Associations between SAF, its change over time and the presence and severity of DR were analyzed. Results: A significant positive correlation was found between SAF and the severity of DR. Only SAF and renal parameters showed a significant positive association with the presence of sight-threatening DR (STDR). There was a statistically significant increase in SAF levels over 3 years in STDR. Conclusions: SAF, but not HbA1c or diabetes duration, was associated with the severity of DR. SAF may therefore represent a promising, rapid, and non-invasive biomarker for identifying individuals at increased risk of STDR.</description>
	<pubDate>2026-08-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 165: Association Between Diabetic Retinopathy and Skin Autofluorescence in Individuals with Long-Standing Type 1 Diabetes and No History of Atherosclerotic Cardiovascular Disease</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/165">doi: 10.3390/diabetology7090165</a></p>
	<p>Authors:
		Elitsa Hadzhieva
		Mila Boyadzhieva
		Zornitsa Zlatarova
		Violeta Iotova
		Lidiya Zaduryan
		Natalya Usheva
		Sevim Shefket
		Yoto Yotov
		</p>
	<p>Introduction: Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus (DM). Among the established risk factors for DR, &amp;amp;ldquo;metabolic memory&amp;amp;rdquo; plays a key role. Its development is mainly driven by advanced glycation end-products (AGEs), some of which possess characteristic fluorescent properties. Aims: To examine the relationship between skin AGEs, noninvasively assessed through skin autofluorescence (SAF), and the presence and severity of DR in subjects with long-standing type 1 DM (T1DM) and no history of atherosclerotic cardiovascular disease. Methods: 81 subjects with T1DM and 45 healthy controls were included. All individuals underwent SAF measurements and fundus photographs were taken in subjects with T1DM. Associations between SAF, its change over time and the presence and severity of DR were analyzed. Results: A significant positive correlation was found between SAF and the severity of DR. Only SAF and renal parameters showed a significant positive association with the presence of sight-threatening DR (STDR). There was a statistically significant increase in SAF levels over 3 years in STDR. Conclusions: SAF, but not HbA1c or diabetes duration, was associated with the severity of DR. SAF may therefore represent a promising, rapid, and non-invasive biomarker for identifying individuals at increased risk of STDR.</p>
	]]></content:encoded>

	<dc:title>Association Between Diabetic Retinopathy and Skin Autofluorescence in Individuals with Long-Standing Type 1 Diabetes and No History of Atherosclerotic Cardiovascular Disease</dc:title>
			<dc:creator>Elitsa Hadzhieva</dc:creator>
			<dc:creator>Mila Boyadzhieva</dc:creator>
			<dc:creator>Zornitsa Zlatarova</dc:creator>
			<dc:creator>Violeta Iotova</dc:creator>
			<dc:creator>Lidiya Zaduryan</dc:creator>
			<dc:creator>Natalya Usheva</dc:creator>
			<dc:creator>Sevim Shefket</dc:creator>
			<dc:creator>Yoto Yotov</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090165</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-27</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-27</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>165</prism:startingPage>
		<prism:doi>10.3390/diabetology7090165</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/165</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/164">

	<title>Diabetology, Vol. 7, Pages 164: Reply to Klonoff et al. Limitations of a Recent Study on Insulin Pen Needle Preferences in People with Diabetes. Comment on &amp;ldquo;Gentile et al. Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer? Diabetology 2026, 7, 56&amp;rdquo;</title>
	<link>https://www.mdpi.com/2673-4540/7/9/164</link>
	<description>This response letter addresses criticisms from a recent commentary regarding a real-world survey on insulin pen needle preferences. The authors clarify that their study was purposefully designed as an observational survey to capture genuine patient perceptions under routine clinical conditions, rather than functioning as a randomized controlled trial. Consequently, methodological constraints such as blinding were fundamentally inapplicable. Furthermore, the authors emphasize the limited relevance of the Hawthorne effect in this context. While originally described in industrial settings, recent systematic reviews in the medical literature indicate that its magnitude and impact on modern clinical research are highly uncertain and generally modest. Ultimately, the study effectively highlights real-world patient experiences with the shortest and thinnest needles currently available, aligning with advances in injection technology.</description>
	<pubDate>2026-08-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 164: Reply to Klonoff et al. Limitations of a Recent Study on Insulin Pen Needle Preferences in People with Diabetes. Comment on &amp;ldquo;Gentile et al. Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer? Diabetology 2026, 7, 56&amp;rdquo;</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/164">doi: 10.3390/diabetology7090164</a></p>
	<p>Authors:
		Sandro Gentile
		Raffaella Fiorentino
		Maddalena Lettieri
		Giuseppina Guarino
		Giampiero Marino
		Elisabetta Tommasi
		Vera Frison
		Ersilia Satta
		Maria Chiarello
		Giuseppe Caccavale
		Emilia Masuccio
		Felice Strollo
		</p>
	<p>This response letter addresses criticisms from a recent commentary regarding a real-world survey on insulin pen needle preferences. The authors clarify that their study was purposefully designed as an observational survey to capture genuine patient perceptions under routine clinical conditions, rather than functioning as a randomized controlled trial. Consequently, methodological constraints such as blinding were fundamentally inapplicable. Furthermore, the authors emphasize the limited relevance of the Hawthorne effect in this context. While originally described in industrial settings, recent systematic reviews in the medical literature indicate that its magnitude and impact on modern clinical research are highly uncertain and generally modest. Ultimately, the study effectively highlights real-world patient experiences with the shortest and thinnest needles currently available, aligning with advances in injection technology.</p>
	]]></content:encoded>

	<dc:title>Reply to Klonoff et al. Limitations of a Recent Study on Insulin Pen Needle Preferences in People with Diabetes. Comment on &amp;amp;ldquo;Gentile et al. Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer? Diabetology 2026, 7, 56&amp;amp;rdquo;</dc:title>
			<dc:creator>Sandro Gentile</dc:creator>
			<dc:creator>Raffaella Fiorentino</dc:creator>
			<dc:creator>Maddalena Lettieri</dc:creator>
			<dc:creator>Giuseppina Guarino</dc:creator>
			<dc:creator>Giampiero Marino</dc:creator>
			<dc:creator>Elisabetta Tommasi</dc:creator>
			<dc:creator>Vera Frison</dc:creator>
			<dc:creator>Ersilia Satta</dc:creator>
			<dc:creator>Maria Chiarello</dc:creator>
			<dc:creator>Giuseppe Caccavale</dc:creator>
			<dc:creator>Emilia Masuccio</dc:creator>
			<dc:creator>Felice Strollo</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090164</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-27</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-27</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Reply</prism:section>
	<prism:startingPage>164</prism:startingPage>
		<prism:doi>10.3390/diabetology7090164</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/164</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/163">

	<title>Diabetology, Vol. 7, Pages 163: Limitations of a Recent Study on Insulin Pen Needle Preferences in People with Diabetes. Comment on Gentile et al. Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer? Diabetology 2026, 7, 56</title>
	<link>https://www.mdpi.com/2673-4540/7/9/163</link>
	<description>We read with interest a recent article in Diabetology titled &amp;amp;ldquo;Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer [...]</description>
	<pubDate>2026-08-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 163: Limitations of a Recent Study on Insulin Pen Needle Preferences in People with Diabetes. Comment on Gentile et al. Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer? Diabetology 2026, 7, 56</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/163">doi: 10.3390/diabetology7090163</a></p>
	<p>Authors:
		David C. Klonoff
		Mandy M. Shao
		Agatha F. Scheideman
		</p>
	<p>We read with interest a recent article in Diabetology titled &amp;amp;ldquo;Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer [...]</p>
	]]></content:encoded>

	<dc:title>Limitations of a Recent Study on Insulin Pen Needle Preferences in People with Diabetes. Comment on Gentile et al. Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer? Diabetology 2026, 7, 56</dc:title>
			<dc:creator>David C. Klonoff</dc:creator>
			<dc:creator>Mandy M. Shao</dc:creator>
			<dc:creator>Agatha F. Scheideman</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090163</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-26</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-26</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Comment</prism:section>
	<prism:startingPage>163</prism:startingPage>
		<prism:doi>10.3390/diabetology7090163</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/163</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/162">

	<title>Diabetology, Vol. 7, Pages 162: Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease</title>
	<link>https://www.mdpi.com/2673-4540/7/9/162</link>
	<description>Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2DM) have been associated with dyslipidemia. This study aimed to investigate the association between lipid values and markers of hepatic steatosis and fibrosis in patients with T2DM. Methods: This is a post hoc analysis of the AleCardio randomized controlled trial in patients with T2DM and recent acute coronary syndrome. Risk of liver steatosis was estimated with the Hepatic Steatosis Index (HSI), risk of liver fibrosis with the NAFLD Fibrosis Score (NFS). Results: Of 7226 participants, 526 were untreated with lipid-lowering medication and formed the analysis cohort. Mean age was 61 &amp;amp;plusmn; 10 years, and body mass index (BMI) was 28.5 &amp;amp;plusmn; 5.8 kg/m2. A total of 75% of individuals had an HSI score &amp;amp;gt; 36, associated with high risk of liver steatosis, elevated NFS scores &amp;amp;gt; 0.67, associated with high risk of liver fibrosis, were present in 15%. Patients with elevated HSI scores had higher BMI, HOMA IR, triglycerides, remnant cholesterol, and lower high-density lipoprotein compared to those with lower scores. Patients with elevated NFS scores had greater BMI and HOMA IR, and had lower triglycerides, remnant cholesterol, and apolipoprotein B in linear regression analyses. Conclusion: Patients with T2DM, cardiovascular disease, and blood-based indices suggesting liver steatosis or fibrosis differed significantly with respect to the lipid profile. An elevated HSI score, suggesting steatosis, was associated with dyslipidemia, an elevated NFS score, suggesting fibrosis, was not. A possible explanation for the latter findings is reduced very-low-density lipoprotein (VLDL-C) synthesis or secretion accompanying advanced hepatocellular dysfunction.</description>
	<pubDate>2026-08-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 162: Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/162">doi: 10.3390/diabetology7090162</a></p>
	<p>Authors:
		Laura A. M. Konings
		Weiwei Xu
		Vivian D. de Jong
		Marco Alings
		Jean-Claude Tardif
		Abraham M. Lincoff
		Gregory G. Schwartz
		Diederick E. Grobbee
		Manuel Castro Cabezas
		</p>
	<p>Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2DM) have been associated with dyslipidemia. This study aimed to investigate the association between lipid values and markers of hepatic steatosis and fibrosis in patients with T2DM. Methods: This is a post hoc analysis of the AleCardio randomized controlled trial in patients with T2DM and recent acute coronary syndrome. Risk of liver steatosis was estimated with the Hepatic Steatosis Index (HSI), risk of liver fibrosis with the NAFLD Fibrosis Score (NFS). Results: Of 7226 participants, 526 were untreated with lipid-lowering medication and formed the analysis cohort. Mean age was 61 &amp;amp;plusmn; 10 years, and body mass index (BMI) was 28.5 &amp;amp;plusmn; 5.8 kg/m2. A total of 75% of individuals had an HSI score &amp;amp;gt; 36, associated with high risk of liver steatosis, elevated NFS scores &amp;amp;gt; 0.67, associated with high risk of liver fibrosis, were present in 15%. Patients with elevated HSI scores had higher BMI, HOMA IR, triglycerides, remnant cholesterol, and lower high-density lipoprotein compared to those with lower scores. Patients with elevated NFS scores had greater BMI and HOMA IR, and had lower triglycerides, remnant cholesterol, and apolipoprotein B in linear regression analyses. Conclusion: Patients with T2DM, cardiovascular disease, and blood-based indices suggesting liver steatosis or fibrosis differed significantly with respect to the lipid profile. An elevated HSI score, suggesting steatosis, was associated with dyslipidemia, an elevated NFS score, suggesting fibrosis, was not. A possible explanation for the latter findings is reduced very-low-density lipoprotein (VLDL-C) synthesis or secretion accompanying advanced hepatocellular dysfunction.</p>
	]]></content:encoded>

	<dc:title>Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease</dc:title>
			<dc:creator>Laura A. M. Konings</dc:creator>
			<dc:creator>Weiwei Xu</dc:creator>
			<dc:creator>Vivian D. de Jong</dc:creator>
			<dc:creator>Marco Alings</dc:creator>
			<dc:creator>Jean-Claude Tardif</dc:creator>
			<dc:creator>Abraham M. Lincoff</dc:creator>
			<dc:creator>Gregory G. Schwartz</dc:creator>
			<dc:creator>Diederick E. Grobbee</dc:creator>
			<dc:creator>Manuel Castro Cabezas</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090162</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-26</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-26</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>162</prism:startingPage>
		<prism:doi>10.3390/diabetology7090162</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/162</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/9/161">

	<title>Diabetology, Vol. 7, Pages 161: Local Action, Systemic Reach: A Topical Desiccating Agent in Diabetic Foot-Related Necrotizing Fasciitis&amp;mdash;A Retrospective Cohort Study</title>
	<link>https://www.mdpi.com/2673-4540/7/9/161</link>
	<description>Background: Necrotizing fasciitis complicating diabetic foot infection requires rapid source control and is associated with substantial morbidity. A topical desiccating agent (TDA) may assist debridement by dehydrating necrotic tissue and potentially disrupting biofilm, but comparative clinical evidence is limited. Methods: We conducted a retrospective, single-center cohort study of 87 patients who underwent emergency surgery for diabetic foot-related necrotizing fasciitis between July 2023 and February 2026. Nineteen patients received a single application of TDA at the index operation in addition to standard care, and 68 received standard care without TDA. Treatment allocation was non-random and occurred in routine clinical practice. The primary outcome was the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score at Day 7. The primary analysis used linear regression adjusted for baseline LRINEC score and baseline septic status, with heteroskedasticity-consistent type 3 (HC3) standard errors. LRINEC was treated as a laboratory-based surrogate rather than as a validated treatment-response measure. C-reactive protein (CRP), white blood cell count, and glucose at Day 0 and Day 7 were summarized descriptively. Secondary clinical outcomes were 30-day major amputation and all-cause mortality. Results: The mean LRINEC score decreased from 8.58 to 2.95 in the TDA group and from 7.51 to 5.51 in the control group. The mean change was &amp;amp;minus;5.63 in the TDA group and &amp;amp;minus;2.00 in the control group, an unadjusted between-group difference of &amp;amp;minus;3.63 points (95% confidence interval [CI], &amp;amp;minus;4.83 to &amp;amp;minus;2.43; p &amp;amp;lt; 0.001). Baseline sepsis was more frequent in the TDA group than in the control group (89.5% vs. 51.5%). After adjustment for baseline LRINEC score and septic status, TDA exposure was associated with a 3.01-point lower Day-7 LRINEC score (95% CI, &amp;amp;minus;4.00 to &amp;amp;minus;2.02; p &amp;amp;lt; 0.001). At Day 7, 18 of 19 TDA-treated patients (94.7%) and 34 of 68 controls (50.0%) had an LRINEC score below 6; this threshold analysis was exploratory. CRP, white blood cell count, and glucose decreased descriptively in both groups, with numerically larger reductions in the TDA group. No major amputations or deaths occurred within 30 days in either group. No TDA-related adverse event was documented in the retrospective clinical records. Conclusions: Adjunctive TDA use was associated with a lower Day-7 LRINEC score and a greater reduction from baseline. Because treatment was not randomized, baseline severity differed between groups, LRINEC is not a validated longitudinal treatment-response measure, and assessment of clinical outcomes was limited, the findings should be interpreted as exploratory associations and confirmed in prospective multicenter studies.</description>
	<pubDate>2026-08-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 161: Local Action, Systemic Reach: A Topical Desiccating Agent in Diabetic Foot-Related Necrotizing Fasciitis&amp;mdash;A Retrospective Cohort Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/9/161">doi: 10.3390/diabetology7090161</a></p>
	<p>Authors:
		Hikmet Erhan Güven
		Lara Kavasoğlu
		George Theodorakopoulos
		</p>
	<p>Background: Necrotizing fasciitis complicating diabetic foot infection requires rapid source control and is associated with substantial morbidity. A topical desiccating agent (TDA) may assist debridement by dehydrating necrotic tissue and potentially disrupting biofilm, but comparative clinical evidence is limited. Methods: We conducted a retrospective, single-center cohort study of 87 patients who underwent emergency surgery for diabetic foot-related necrotizing fasciitis between July 2023 and February 2026. Nineteen patients received a single application of TDA at the index operation in addition to standard care, and 68 received standard care without TDA. Treatment allocation was non-random and occurred in routine clinical practice. The primary outcome was the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score at Day 7. The primary analysis used linear regression adjusted for baseline LRINEC score and baseline septic status, with heteroskedasticity-consistent type 3 (HC3) standard errors. LRINEC was treated as a laboratory-based surrogate rather than as a validated treatment-response measure. C-reactive protein (CRP), white blood cell count, and glucose at Day 0 and Day 7 were summarized descriptively. Secondary clinical outcomes were 30-day major amputation and all-cause mortality. Results: The mean LRINEC score decreased from 8.58 to 2.95 in the TDA group and from 7.51 to 5.51 in the control group. The mean change was &amp;amp;minus;5.63 in the TDA group and &amp;amp;minus;2.00 in the control group, an unadjusted between-group difference of &amp;amp;minus;3.63 points (95% confidence interval [CI], &amp;amp;minus;4.83 to &amp;amp;minus;2.43; p &amp;amp;lt; 0.001). Baseline sepsis was more frequent in the TDA group than in the control group (89.5% vs. 51.5%). After adjustment for baseline LRINEC score and septic status, TDA exposure was associated with a 3.01-point lower Day-7 LRINEC score (95% CI, &amp;amp;minus;4.00 to &amp;amp;minus;2.02; p &amp;amp;lt; 0.001). At Day 7, 18 of 19 TDA-treated patients (94.7%) and 34 of 68 controls (50.0%) had an LRINEC score below 6; this threshold analysis was exploratory. CRP, white blood cell count, and glucose decreased descriptively in both groups, with numerically larger reductions in the TDA group. No major amputations or deaths occurred within 30 days in either group. No TDA-related adverse event was documented in the retrospective clinical records. Conclusions: Adjunctive TDA use was associated with a lower Day-7 LRINEC score and a greater reduction from baseline. Because treatment was not randomized, baseline severity differed between groups, LRINEC is not a validated longitudinal treatment-response measure, and assessment of clinical outcomes was limited, the findings should be interpreted as exploratory associations and confirmed in prospective multicenter studies.</p>
	]]></content:encoded>

	<dc:title>Local Action, Systemic Reach: A Topical Desiccating Agent in Diabetic Foot-Related Necrotizing Fasciitis&amp;amp;mdash;A Retrospective Cohort Study</dc:title>
			<dc:creator>Hikmet Erhan Güven</dc:creator>
			<dc:creator>Lara Kavasoğlu</dc:creator>
			<dc:creator>George Theodorakopoulos</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7090161</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-24</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-24</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>161</prism:startingPage>
		<prism:doi>10.3390/diabetology7090161</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/9/161</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/160">

	<title>Diabetology, Vol. 7, Pages 160: Diabetic Cardiomyopathy: Distinct Clinical Entity or Manifestation of Metabolic Heart Disease?</title>
	<link>https://www.mdpi.com/2673-4540/7/8/160</link>
	<description>Background/Objectives: Type 2 diabetes mellitus (T2DM) is a global epidemic strongly associated with an increased risk of heart failure, independent of coronary artery disease or hypertension. This condition, historically termed diabetic cardiomyopathy (DCM) and recently redefined as &amp;amp;ldquo;diabetic myocardial disorder,&amp;amp;rdquo; remains frequently underdiagnosed in its subclinical stages. The objective of this non-systematic review is to synthesize current evidence on the pathophysiological mechanisms, diagnostic advancements, and evolving therapeutic strategies for diabetic myocardial involvement. Methods: A comprehensive review of contemporary literature was conducted, focusing on recent consensus statements from the ESC and AHA, large-scale epidemiological data (IDF/WHO), and pivotal clinical trials (EMPA-REG, DAPA-HF, and LEADER). We analyzed the role of multimodal imaging&amp;amp;mdash;specifically speckle-tracking echocardiography (STE) and multiparametric cardiac magnetic resonance (CMR)&amp;amp;mdash;and circulating biomarkers in early phenotyping. Results: Pathophysiological drivers include lipotoxicity, oxidative stress, and AGE-mediated fibrosis. Advanced imaging techniques, such as global longitudinal strain (GLS) and CMR T1-mapping/ECV quantification, demonstrate superior sensitivity over LVEF in detecting early subendocardial dysfunction and diffuse fibrosis. Furthermore, NT-proBNP serves as a robust prognostic marker for the HFpEF-like trajectory typical of diabetes. Clinically, the therapeutic landscape has shifted with SGLT2 inhibitors and GLP-1 receptor agonists, which provide significant cardioprotection and reduction in heart failure hospitalizations through mechanisms beyond glycemic control. Conclusions: Diabetic myocardial disorder represents a complex continuum within the cardiometabolic spectrum. Early detection through multimodal imaging and biomarkers is essential for risk stratification. Integrating novel glucose-lowering therapies with proven cardiovascular benefits is now mandatory to alter the natural history of the disease and prevent progression to overt heart failure.</description>
	<pubDate>2026-08-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 160: Diabetic Cardiomyopathy: Distinct Clinical Entity or Manifestation of Metabolic Heart Disease?</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/160">doi: 10.3390/diabetology7080160</a></p>
	<p>Authors:
		Saverio D’Elia
		Rosa Franzese
		Ettore Luisi
		Mariarosaria Morello
		Gisella Titolo
		Chiara Serpico
		Achille Solimene
		Granata Matteo
		Acampora Benito
		Francesco Loffredo
		Paolo Golino
		Francesco Natale
		Giovanni Cimmino
		</p>
	<p>Background/Objectives: Type 2 diabetes mellitus (T2DM) is a global epidemic strongly associated with an increased risk of heart failure, independent of coronary artery disease or hypertension. This condition, historically termed diabetic cardiomyopathy (DCM) and recently redefined as &amp;amp;ldquo;diabetic myocardial disorder,&amp;amp;rdquo; remains frequently underdiagnosed in its subclinical stages. The objective of this non-systematic review is to synthesize current evidence on the pathophysiological mechanisms, diagnostic advancements, and evolving therapeutic strategies for diabetic myocardial involvement. Methods: A comprehensive review of contemporary literature was conducted, focusing on recent consensus statements from the ESC and AHA, large-scale epidemiological data (IDF/WHO), and pivotal clinical trials (EMPA-REG, DAPA-HF, and LEADER). We analyzed the role of multimodal imaging&amp;amp;mdash;specifically speckle-tracking echocardiography (STE) and multiparametric cardiac magnetic resonance (CMR)&amp;amp;mdash;and circulating biomarkers in early phenotyping. Results: Pathophysiological drivers include lipotoxicity, oxidative stress, and AGE-mediated fibrosis. Advanced imaging techniques, such as global longitudinal strain (GLS) and CMR T1-mapping/ECV quantification, demonstrate superior sensitivity over LVEF in detecting early subendocardial dysfunction and diffuse fibrosis. Furthermore, NT-proBNP serves as a robust prognostic marker for the HFpEF-like trajectory typical of diabetes. Clinically, the therapeutic landscape has shifted with SGLT2 inhibitors and GLP-1 receptor agonists, which provide significant cardioprotection and reduction in heart failure hospitalizations through mechanisms beyond glycemic control. Conclusions: Diabetic myocardial disorder represents a complex continuum within the cardiometabolic spectrum. Early detection through multimodal imaging and biomarkers is essential for risk stratification. Integrating novel glucose-lowering therapies with proven cardiovascular benefits is now mandatory to alter the natural history of the disease and prevent progression to overt heart failure.</p>
	]]></content:encoded>

	<dc:title>Diabetic Cardiomyopathy: Distinct Clinical Entity or Manifestation of Metabolic Heart Disease?</dc:title>
			<dc:creator>Saverio D’Elia</dc:creator>
			<dc:creator>Rosa Franzese</dc:creator>
			<dc:creator>Ettore Luisi</dc:creator>
			<dc:creator>Mariarosaria Morello</dc:creator>
			<dc:creator>Gisella Titolo</dc:creator>
			<dc:creator>Chiara Serpico</dc:creator>
			<dc:creator>Achille Solimene</dc:creator>
			<dc:creator>Granata Matteo</dc:creator>
			<dc:creator>Acampora Benito</dc:creator>
			<dc:creator>Francesco Loffredo</dc:creator>
			<dc:creator>Paolo Golino</dc:creator>
			<dc:creator>Francesco Natale</dc:creator>
			<dc:creator>Giovanni Cimmino</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080160</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-18</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-18</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>160</prism:startingPage>
		<prism:doi>10.3390/diabetology7080160</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/160</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/159">

	<title>Diabetology, Vol. 7, Pages 159: Association Between Glycemic Burden, Diabetes Duration, and MMSE-Defined Cognitive Impairment in Middle-Aged and Older Adults: A Comparative Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/8/159</link>
	<description>Background/Objectives: Diabetes mellitus is associated with cognitive impairment, but evidence from southern Morocco remains limited. This study examined the associations of diabetes status, HbA1c, and diabetes duration with Mini-Mental State Examination (MMSE) performance among adults aged 45 years or older in Dakhla. Methods: This hospital-based comparative cross-sectional study included 100 participants (50 with diabetes and 50 without diabetes). Data were collected through a structured bilingual questionnaire and medical records. MMSE scores below 27 defined MMSE-based cognitive impairment. Crude and age-, sex-, and education-adjusted linear regression models with HC3 robust standard errors were complemented by correlation, subgroup, chi-square, and odds-ratio analyses. Results: Mean MMSE scores were lower in participants with diabetes than in those without diabetes (24.4 &amp;amp;plusmn; 5.39 vs. 28.8 &amp;amp;plusmn; 2.08). After adjustment, diabetes remained associated with a 4.13-point lower score (&amp;amp;beta; = &amp;amp;minus;4.13; 95% CI: &amp;amp;minus;5.57 to &amp;amp;minus;2.69; p &amp;amp;lt; 0.001). MMSE-defined impairment occurred in 54% and 14% of the diabetic and non-diabetic groups, respectively (OR = 7.21; 95% CI: 2.72&amp;amp;ndash;19.05; p &amp;amp;lt; 0.001). Within the diabetic group, MMSE scores correlated inversely with diabetes duration (r = &amp;amp;minus;0.523; p &amp;amp;lt; 0.001) and HbA1c (r = &amp;amp;minus;0.393; p = 0.005), but neither remained independently associated after adjustment. Participants with type 1 diabetes had lower median MMSE scores and longer disease duration than those with type 2 diabetes, although this subgroup comparison was exploratory. Conclusions: Diabetes was strongly associated with lower MMSE performance and a higher prevalence of MMSE-defined impairment in this hospital-based sample. The cross-sectional design precludes causal interpretation, and the findings require confirmation in larger prospective studies.</description>
	<pubDate>2026-08-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 159: Association Between Glycemic Burden, Diabetes Duration, and MMSE-Defined Cognitive Impairment in Middle-Aged and Older Adults: A Comparative Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/159">doi: 10.3390/diabetology7080159</a></p>
	<p>Authors:
		Rachid Aithammou
		Mohamed Ben-El-Caid
		</p>
	<p>Background/Objectives: Diabetes mellitus is associated with cognitive impairment, but evidence from southern Morocco remains limited. This study examined the associations of diabetes status, HbA1c, and diabetes duration with Mini-Mental State Examination (MMSE) performance among adults aged 45 years or older in Dakhla. Methods: This hospital-based comparative cross-sectional study included 100 participants (50 with diabetes and 50 without diabetes). Data were collected through a structured bilingual questionnaire and medical records. MMSE scores below 27 defined MMSE-based cognitive impairment. Crude and age-, sex-, and education-adjusted linear regression models with HC3 robust standard errors were complemented by correlation, subgroup, chi-square, and odds-ratio analyses. Results: Mean MMSE scores were lower in participants with diabetes than in those without diabetes (24.4 &amp;amp;plusmn; 5.39 vs. 28.8 &amp;amp;plusmn; 2.08). After adjustment, diabetes remained associated with a 4.13-point lower score (&amp;amp;beta; = &amp;amp;minus;4.13; 95% CI: &amp;amp;minus;5.57 to &amp;amp;minus;2.69; p &amp;amp;lt; 0.001). MMSE-defined impairment occurred in 54% and 14% of the diabetic and non-diabetic groups, respectively (OR = 7.21; 95% CI: 2.72&amp;amp;ndash;19.05; p &amp;amp;lt; 0.001). Within the diabetic group, MMSE scores correlated inversely with diabetes duration (r = &amp;amp;minus;0.523; p &amp;amp;lt; 0.001) and HbA1c (r = &amp;amp;minus;0.393; p = 0.005), but neither remained independently associated after adjustment. Participants with type 1 diabetes had lower median MMSE scores and longer disease duration than those with type 2 diabetes, although this subgroup comparison was exploratory. Conclusions: Diabetes was strongly associated with lower MMSE performance and a higher prevalence of MMSE-defined impairment in this hospital-based sample. The cross-sectional design precludes causal interpretation, and the findings require confirmation in larger prospective studies.</p>
	]]></content:encoded>

	<dc:title>Association Between Glycemic Burden, Diabetes Duration, and MMSE-Defined Cognitive Impairment in Middle-Aged and Older Adults: A Comparative Cross-Sectional Study</dc:title>
			<dc:creator>Rachid Aithammou</dc:creator>
			<dc:creator>Mohamed Ben-El-Caid</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080159</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-18</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-18</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>159</prism:startingPage>
		<prism:doi>10.3390/diabetology7080159</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/159</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/158">

	<title>Diabetology, Vol. 7, Pages 158: Validation of Prostate Cancer Diagnosis and Cause of Death in a National Cohort of Male Veterans with Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/8/158</link>
	<description>Background: Accurate diagnosis and cause of death ascertainment are essential for effective disease surveillance and epidemiological research. This study aimed to validate prostate cancer diagnostic accuracy (PCa) and the accuracy of cause of death information among veterans with type 2 diabetes mellitus (T2DM). Methods: We conducted a retrospective cohort study of veterans with T2DM diagnosed during the baseline period (2008&amp;amp;ndash;2009) and followed from 2010 to 2019 using data from the Veterans Health Administration (VHA) Corporate Data Warehouse (CDW). Diagnostic codes and cause of death data were obtained from the Prostate Cancer Data Core (PCDC) and the National Death Index (NDI), which served as the gold standards for validating PCa diagnosis and mortality information in the CDW. Concordance between data sources was assessed using Cohen&amp;amp;rsquo;s Kappa statistic. Results: Among 763,424 veterans with T2DM, 37,048 (4.9%) were diagnosed with PCa in the CDW and 36,861 (4.8%) in the PCDC, with a concordance rate of 36,361 (98.6% of patients diagnosed in the PCDC). Mortality data from the NDI identified 2723 deaths with PCa listed as the underlying cause of death, of whom 75.4% had a corresponding PCa diagnosis recorded in the CDW. For all-cause mortality, 328,165 veterans were identified as deceased in the CDW Vital Status File (VSF), compared with 326,707 deaths recorded in the NDI. Of these, 324,567 deaths were concordant between the two sources, representing 99.3% of NDI-recorded deaths. Compared with the PCDC, the CDW demonstrated high accuracy for identifying incident PCa diagnosis, with a sensitivity of 98.6% and a specificity of 99.9%. Conclusions: The findings demonstrated a high level of concordance in key outcomes, including PCa diagnosis between the CDW and PCDC, and all-cause mortality between the CDW VSF and NDI.</description>
	<pubDate>2026-08-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 158: Validation of Prostate Cancer Diagnosis and Cause of Death in a National Cohort of Male Veterans with Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/158">doi: 10.3390/diabetology7080158</a></p>
	<p>Authors:
		Kinfe G. Bishu
		Andrew D. Schreiner
		David J. Taber
		Matvey Tsivian
		Mulugeta Gebregziabher
		</p>
	<p>Background: Accurate diagnosis and cause of death ascertainment are essential for effective disease surveillance and epidemiological research. This study aimed to validate prostate cancer diagnostic accuracy (PCa) and the accuracy of cause of death information among veterans with type 2 diabetes mellitus (T2DM). Methods: We conducted a retrospective cohort study of veterans with T2DM diagnosed during the baseline period (2008&amp;amp;ndash;2009) and followed from 2010 to 2019 using data from the Veterans Health Administration (VHA) Corporate Data Warehouse (CDW). Diagnostic codes and cause of death data were obtained from the Prostate Cancer Data Core (PCDC) and the National Death Index (NDI), which served as the gold standards for validating PCa diagnosis and mortality information in the CDW. Concordance between data sources was assessed using Cohen&amp;amp;rsquo;s Kappa statistic. Results: Among 763,424 veterans with T2DM, 37,048 (4.9%) were diagnosed with PCa in the CDW and 36,861 (4.8%) in the PCDC, with a concordance rate of 36,361 (98.6% of patients diagnosed in the PCDC). Mortality data from the NDI identified 2723 deaths with PCa listed as the underlying cause of death, of whom 75.4% had a corresponding PCa diagnosis recorded in the CDW. For all-cause mortality, 328,165 veterans were identified as deceased in the CDW Vital Status File (VSF), compared with 326,707 deaths recorded in the NDI. Of these, 324,567 deaths were concordant between the two sources, representing 99.3% of NDI-recorded deaths. Compared with the PCDC, the CDW demonstrated high accuracy for identifying incident PCa diagnosis, with a sensitivity of 98.6% and a specificity of 99.9%. Conclusions: The findings demonstrated a high level of concordance in key outcomes, including PCa diagnosis between the CDW and PCDC, and all-cause mortality between the CDW VSF and NDI.</p>
	]]></content:encoded>

	<dc:title>Validation of Prostate Cancer Diagnosis and Cause of Death in a National Cohort of Male Veterans with Type 2 Diabetes</dc:title>
			<dc:creator>Kinfe G. Bishu</dc:creator>
			<dc:creator>Andrew D. Schreiner</dc:creator>
			<dc:creator>David J. Taber</dc:creator>
			<dc:creator>Matvey Tsivian</dc:creator>
			<dc:creator>Mulugeta Gebregziabher</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080158</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-17</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-17</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>158</prism:startingPage>
		<prism:doi>10.3390/diabetology7080158</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/158</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/157">

	<title>Diabetology, Vol. 7, Pages 157: Residual Recurrence Risk in Diabetic Foot Ulcer Remission: A Narrative Review</title>
	<link>https://www.mdpi.com/2673-4540/7/8/157</link>
	<description>Background: Diabetic foot ulcer (DFU) recurrence remains a primary challenge in diabetes care. Although wound closure is the conventional therapeutic endpoint, it does not equate to risk resolution. Despite the implementation of evidence-based preventive strategies, a significant proportion of patients experience recurrent ulceration, highlighting an efficacy gap in current management. Objectives: This narrative review aims to quantify the residual recurrence risk and to provide a clinical framework for risk stratification in patients in remission. Methods: A structured narrative review of PubMed and Google Scholar (up to May 2026) was conducted to evaluate the residual burden associated with standard preventive interventions. Only English-language publications were considered. Results: Our analysis reveals that even with optimal adherence to established preventive protocols, a substantial residual risk persists, ranging from 16.7% to 41.4%. Clinical data indicate that the frequency of podiatric follow-up is a critical determinant of outcomes, with a 4-week screening interval limiting residual risk to 18.4%, significantly outperforming less frequent assessments. Conclusions: The persistence of residual risk mandates a paradigm shift in diabetic foot management: from a &amp;amp;ldquo;healing-centered&amp;amp;rdquo; approach to a &amp;amp;ldquo;remission-focused&amp;amp;rdquo; model. We propose an integrated, multidisciplinary strategy&amp;amp;mdash;anchored by 4-week podiatric surveillance&amp;amp;mdash;to mitigate the multifactorial drivers of recurrence and narrow the efficacy gap in clinical practice.</description>
	<pubDate>2026-08-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 157: Residual Recurrence Risk in Diabetic Foot Ulcer Remission: A Narrative Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/157">doi: 10.3390/diabetology7080157</a></p>
	<p>Authors:
		Cesare Miranda
		Valerio Velardi
		Roberto Da Ros
		</p>
	<p>Background: Diabetic foot ulcer (DFU) recurrence remains a primary challenge in diabetes care. Although wound closure is the conventional therapeutic endpoint, it does not equate to risk resolution. Despite the implementation of evidence-based preventive strategies, a significant proportion of patients experience recurrent ulceration, highlighting an efficacy gap in current management. Objectives: This narrative review aims to quantify the residual recurrence risk and to provide a clinical framework for risk stratification in patients in remission. Methods: A structured narrative review of PubMed and Google Scholar (up to May 2026) was conducted to evaluate the residual burden associated with standard preventive interventions. Only English-language publications were considered. Results: Our analysis reveals that even with optimal adherence to established preventive protocols, a substantial residual risk persists, ranging from 16.7% to 41.4%. Clinical data indicate that the frequency of podiatric follow-up is a critical determinant of outcomes, with a 4-week screening interval limiting residual risk to 18.4%, significantly outperforming less frequent assessments. Conclusions: The persistence of residual risk mandates a paradigm shift in diabetic foot management: from a &amp;amp;ldquo;healing-centered&amp;amp;rdquo; approach to a &amp;amp;ldquo;remission-focused&amp;amp;rdquo; model. We propose an integrated, multidisciplinary strategy&amp;amp;mdash;anchored by 4-week podiatric surveillance&amp;amp;mdash;to mitigate the multifactorial drivers of recurrence and narrow the efficacy gap in clinical practice.</p>
	]]></content:encoded>

	<dc:title>Residual Recurrence Risk in Diabetic Foot Ulcer Remission: A Narrative Review</dc:title>
			<dc:creator>Cesare Miranda</dc:creator>
			<dc:creator>Valerio Velardi</dc:creator>
			<dc:creator>Roberto Da Ros</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080157</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-17</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-17</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>157</prism:startingPage>
		<prism:doi>10.3390/diabetology7080157</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/157</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/156">

	<title>Diabetology, Vol. 7, Pages 156: Effect of Metformin on Progression from Prediabetes to Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis</title>
	<link>https://www.mdpi.com/2673-4540/7/8/156</link>
	<description>Background/Objectives: Prediabetes is a highly prevalent metabolic condition associated with an increased risk of progression to type 2 diabetes mellitus (T2DM) and related cardiometabolic complications. Although lifestyle modification remains the cornerstone of diabetes prevention, long-term adherence is often challenging in routine clinical practice. This systematic review and meta-analysis aimed to evaluate the effect of metformin therapy on progression from prediabetes to T2DM and its impact on glycemic and metabolic outcomes. Methods: A systematic literature search was conducted in PubMed, MEDLINE, and Web of Science in accordance with the PRISMA 2020 guidelines. Studies involving adults with prediabetes that evaluated metformin therapy and reported diabetes-related outcomes were eligible for inclusion. Risk of bias was assessed using the RoB 2 tool and the NOS. Where appropriate, quantitative meta-analysis was performed using a random-effects model. Results: Forty-one publications were included in the systematic review, with eligible subsets contributing to the quantitative analyses. Overall, the available evidence suggested that metformin was associated with a reduced risk of progression from prediabetes to T2DM compared with placebo, usual care, or lifestyle intervention alone. Long-term follow-up studies demonstrated sustained preventive effects extending beyond 10 years. Meta-analysis demonstrated a significant reduction in BMI among metformin-treated participants (MD = &amp;amp;minus;2.06, 95% CI &amp;amp;minus;2.53 to &amp;amp;minus;1.60; I2 = 0%; p &amp;amp;lt; 0.001). Findings for glycated hemoglobin and fasting plasma glucose were variable across studies and did not consistently reach statistical significance. Some studies reported additional improvements in insulin sensitivity and other cardiometabolic outcomes, although these findings were not consistently reported across the evidence base. Conclusions: The available evidence supports metformin as an effective adjunctive pharmacological strategy for reducing progression from prediabetes to T2DM, particularly among selected high-risk adults. When used alongside lifestyle modification, metformin may provide additional benefits in body weight and metabolic health. However, lifestyle intervention should remain the first-line preventive strategy. Further high-quality studies are needed to optimize patient selection, dose, treatment duration, and long-term clinical outcomes.</description>
	<pubDate>2026-08-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 156: Effect of Metformin on Progression from Prediabetes to Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/156">doi: 10.3390/diabetology7080156</a></p>
	<p>Authors:
		Lara Osama Al Hartany
		Marya Aref Alghorab
		Maya Faissal Alhomieed
		Reema Saleh Albalawi
		A’laa Abdullah Almowallad
		Abdulaziz Alsharif
		Ayesha Shrouq Amin
		Saud Faisal Alamri
		Taif Khalid Aljabal
		Abdulrhman Abdulaziz Alkthiry
		</p>
	<p>Background/Objectives: Prediabetes is a highly prevalent metabolic condition associated with an increased risk of progression to type 2 diabetes mellitus (T2DM) and related cardiometabolic complications. Although lifestyle modification remains the cornerstone of diabetes prevention, long-term adherence is often challenging in routine clinical practice. This systematic review and meta-analysis aimed to evaluate the effect of metformin therapy on progression from prediabetes to T2DM and its impact on glycemic and metabolic outcomes. Methods: A systematic literature search was conducted in PubMed, MEDLINE, and Web of Science in accordance with the PRISMA 2020 guidelines. Studies involving adults with prediabetes that evaluated metformin therapy and reported diabetes-related outcomes were eligible for inclusion. Risk of bias was assessed using the RoB 2 tool and the NOS. Where appropriate, quantitative meta-analysis was performed using a random-effects model. Results: Forty-one publications were included in the systematic review, with eligible subsets contributing to the quantitative analyses. Overall, the available evidence suggested that metformin was associated with a reduced risk of progression from prediabetes to T2DM compared with placebo, usual care, or lifestyle intervention alone. Long-term follow-up studies demonstrated sustained preventive effects extending beyond 10 years. Meta-analysis demonstrated a significant reduction in BMI among metformin-treated participants (MD = &amp;amp;minus;2.06, 95% CI &amp;amp;minus;2.53 to &amp;amp;minus;1.60; I2 = 0%; p &amp;amp;lt; 0.001). Findings for glycated hemoglobin and fasting plasma glucose were variable across studies and did not consistently reach statistical significance. Some studies reported additional improvements in insulin sensitivity and other cardiometabolic outcomes, although these findings were not consistently reported across the evidence base. Conclusions: The available evidence supports metformin as an effective adjunctive pharmacological strategy for reducing progression from prediabetes to T2DM, particularly among selected high-risk adults. When used alongside lifestyle modification, metformin may provide additional benefits in body weight and metabolic health. However, lifestyle intervention should remain the first-line preventive strategy. Further high-quality studies are needed to optimize patient selection, dose, treatment duration, and long-term clinical outcomes.</p>
	]]></content:encoded>

	<dc:title>Effect of Metformin on Progression from Prediabetes to Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis</dc:title>
			<dc:creator>Lara Osama Al Hartany</dc:creator>
			<dc:creator>Marya Aref Alghorab</dc:creator>
			<dc:creator>Maya Faissal Alhomieed</dc:creator>
			<dc:creator>Reema Saleh Albalawi</dc:creator>
			<dc:creator>A’laa Abdullah Almowallad</dc:creator>
			<dc:creator>Abdulaziz Alsharif</dc:creator>
			<dc:creator>Ayesha Shrouq Amin</dc:creator>
			<dc:creator>Saud Faisal Alamri</dc:creator>
			<dc:creator>Taif Khalid Aljabal</dc:creator>
			<dc:creator>Abdulrhman Abdulaziz Alkthiry</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080156</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-11</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-11</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>156</prism:startingPage>
		<prism:doi>10.3390/diabetology7080156</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/156</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/155">

	<title>Diabetology, Vol. 7, Pages 155: Weight and Glycemic Outcomes Following GLP-1 Receptor Agonist Therapy in People Living with HIV: A Retrospective Study at a Bronx Hospital</title>
	<link>https://www.mdpi.com/2673-4540/7/8/155</link>
	<description>Background/Objectives: People living with HIV (PLWH) who undergo prolonged antiretroviral therapy (ART) may experience weight gain as a potential side effect. Many of these individuals are prescribed glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), or dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RAs, which are known for their weight-reducing effects and positive impact on metabolic health. However, studies investigating their effects on PLWH are limited. Methods: We conducted a retrospective study at a public hospital in the Bronx, New York, among PLWH with obesity and/or type 2 diabetes mellitus (T2DM) prescribed GLP-1 or dual GLP-1/GIP RAs between August 2020 to March 2024. We collected baseline measurements of weight, body mass index (BMI), glycated hemoglobin (HbA1c), and lipid panel, before and after initiation of treatment, to assess the potential metabolic changes associated with the therapy. Logistic regression was used to analyze the factors associated with reductions in HbA1c and weight. Results: A total of 202 patients were included in the final study, with a mean duration of 24.2 months of GLP-1 or GLP-1/GIP RA therapy. A mean HbA1c reduction of 1.0% (p &amp;amp;lt; 0.001), a mean BMI reduction of 0.7 kg/m2 (p &amp;amp;lt; 0.001), and an average mean weight loss of 3.55% were observed. In the univariate analysis, the duration of GLP-1 or GLP-1/GIP RA use was the only factor independently associated with HbA1c reduction greater than 1% (p = 0.027). However, no correlation was found between the duration of their use and the percentage of weight loss (p = 0.126). Insulin use was associated with less weight loss (p = 0.048), while younger age was associated with greater weight loss (p = 0.048). No significant differences in weight loss were observed when the population was stratified by sex, race, comorbidities, type of GLP-1 RA therapy, or other antidiabetic or ART regimens. Conclusions: Use of GLP-1 RAs among PLWH with obesity and/or T2DM is associated with reductions in HbA1c and BMI. In this diverse cohort, which predominantly consists of Black and Hispanic individuals, longer duration of treatment was associated with reductions in HbA1c greater than 1%. These findings encourage GLP-1 RA-related treatment for PLWH with obesity and/or T2DM. Further prospective studies with larger cohorts are needed to confirm these benefits and better define their effects on long-term metabolic health.</description>
	<pubDate>2026-08-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 155: Weight and Glycemic Outcomes Following GLP-1 Receptor Agonist Therapy in People Living with HIV: A Retrospective Study at a Bronx Hospital</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/155">doi: 10.3390/diabetology7080155</a></p>
	<p>Authors:
		Dimitrios Raptis
		Natalia Nazarenko
		Raksheeth Agarwal
		Mandar Kalpesh Shah
		Yiqi Gao
		Panagiotis Theodoropoulos
		Pawel Borkowski
		Maisha Maliha
		Maria Alyssa Yee Policarpio
		Shreyas Yakkali
		Yi-Yun Chen
		Jason Leider
		Preeti Kishore
		Naomi Friedman
		</p>
	<p>Background/Objectives: People living with HIV (PLWH) who undergo prolonged antiretroviral therapy (ART) may experience weight gain as a potential side effect. Many of these individuals are prescribed glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), or dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RAs, which are known for their weight-reducing effects and positive impact on metabolic health. However, studies investigating their effects on PLWH are limited. Methods: We conducted a retrospective study at a public hospital in the Bronx, New York, among PLWH with obesity and/or type 2 diabetes mellitus (T2DM) prescribed GLP-1 or dual GLP-1/GIP RAs between August 2020 to March 2024. We collected baseline measurements of weight, body mass index (BMI), glycated hemoglobin (HbA1c), and lipid panel, before and after initiation of treatment, to assess the potential metabolic changes associated with the therapy. Logistic regression was used to analyze the factors associated with reductions in HbA1c and weight. Results: A total of 202 patients were included in the final study, with a mean duration of 24.2 months of GLP-1 or GLP-1/GIP RA therapy. A mean HbA1c reduction of 1.0% (p &amp;amp;lt; 0.001), a mean BMI reduction of 0.7 kg/m2 (p &amp;amp;lt; 0.001), and an average mean weight loss of 3.55% were observed. In the univariate analysis, the duration of GLP-1 or GLP-1/GIP RA use was the only factor independently associated with HbA1c reduction greater than 1% (p = 0.027). However, no correlation was found between the duration of their use and the percentage of weight loss (p = 0.126). Insulin use was associated with less weight loss (p = 0.048), while younger age was associated with greater weight loss (p = 0.048). No significant differences in weight loss were observed when the population was stratified by sex, race, comorbidities, type of GLP-1 RA therapy, or other antidiabetic or ART regimens. Conclusions: Use of GLP-1 RAs among PLWH with obesity and/or T2DM is associated with reductions in HbA1c and BMI. In this diverse cohort, which predominantly consists of Black and Hispanic individuals, longer duration of treatment was associated with reductions in HbA1c greater than 1%. These findings encourage GLP-1 RA-related treatment for PLWH with obesity and/or T2DM. Further prospective studies with larger cohorts are needed to confirm these benefits and better define their effects on long-term metabolic health.</p>
	]]></content:encoded>

	<dc:title>Weight and Glycemic Outcomes Following GLP-1 Receptor Agonist Therapy in People Living with HIV: A Retrospective Study at a Bronx Hospital</dc:title>
			<dc:creator>Dimitrios Raptis</dc:creator>
			<dc:creator>Natalia Nazarenko</dc:creator>
			<dc:creator>Raksheeth Agarwal</dc:creator>
			<dc:creator>Mandar Kalpesh Shah</dc:creator>
			<dc:creator>Yiqi Gao</dc:creator>
			<dc:creator>Panagiotis Theodoropoulos</dc:creator>
			<dc:creator>Pawel Borkowski</dc:creator>
			<dc:creator>Maisha Maliha</dc:creator>
			<dc:creator>Maria Alyssa Yee Policarpio</dc:creator>
			<dc:creator>Shreyas Yakkali</dc:creator>
			<dc:creator>Yi-Yun Chen</dc:creator>
			<dc:creator>Jason Leider</dc:creator>
			<dc:creator>Preeti Kishore</dc:creator>
			<dc:creator>Naomi Friedman</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080155</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-11</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-11</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>155</prism:startingPage>
		<prism:doi>10.3390/diabetology7080155</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/155</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/154">

	<title>Diabetology, Vol. 7, Pages 154: Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus</title>
	<link>https://www.mdpi.com/2673-4540/7/8/154</link>
	<description>Background: The most appropriate management of glucose-lowering therapies in patients exposed to iodinated contrast media (ICM) is still debated. The recent development of antidiabetic drugs that improve cardiovascular and renal outcomes leads to questions regarding their impact on the risk of contrast-associated acute kidney injury (CA-AKI). The present study aimed to assess the effect of different glucose-lowering therapies on the rate of CA-AKI among patients undergoing coronary angiography and/or angioplasty. Methods: Diabetic patients exposed to ICM for coronary procedures were retrospectively identified and divided according to the strategy for the management of diabetes mellitus. The use of a new antidiabetic drug (NAD) was defined for patients treated with SGLT2-I, DDP4-I or GLP-1 receptor agonists on admission. The primary endpoint was the occurrence of CA-AKI within 72 h after contrast medium exposure. Results: We included 462 patients with diabetes mellitus, 51.5% treated with insulin, 44.4% treated with metformin and 50.9% receiving NAD. Among them, 48 (10.4%) experienced CA-AKI. Patients experiencing acute renal injury were more often treated with calcium channel blockers (p = 0.04) and diuretics (p = 0.004), and less often P2Y12 inhibitors (p = 0.04), and presented lower levels of hemoglobin (p = 0.02). Patients receiving NADs displayed a significantly lower occurrence of CA-AKI (33.3% vs. 53.6%, p = 0.009), mainly for those treated with SGLT2-I. On the contrary, patients treated with sulfonylureas and meglitinides displayed a significant increase in the rate of CA-AKI (10.4% vs. 3.9%, p = 0.05). The results were confirmed via multivariable analysis, with NADs and diuretics emerging as the only independent predictors of CA-AKI (NAD: adjusted OR = 0.42 [0.21&amp;amp;ndash;0.81], p = 0.01; diuretics: adjusted OR = 2.22 [1.14&amp;amp;ndash;4.35], p = 0.02). The independent predictors of CA-AKI were the use of NADs (adjusted OR = 0.45 [0.24&amp;amp;ndash;0.86], p = 0.02) and diuretics (adjusted OR = 2.57 [1.33&amp;amp;ndash;4.97], p = 0.005). Conclusions: Among patients with diabetes mellitus undergoing coronary angiographic procedures, the use of diuretics, sulfonylureas and meglitinides is associated with an increased occurrence of CA-AKI, whereas the rate of events was significantly lower among users of new antidiabetic drugs and especially SGLT2-I.</description>
	<pubDate>2026-08-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 154: Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/154">doi: 10.3390/diabetology7080154</a></p>
	<p>Authors:
		Monica Verdoia
		Matteo Nardin
		Giuseppe Ciliberti
		Marta Leverone
		Jari Paternoster
		Aron Faraguna
		Emanuel Barnoffi
		Domenico Lorusso
		Gennaro Ciliberti
		Tommaso Piva
		Elisa Nicolini
		Marco Marini
		Antonio Dello Russo
		Rocco Mollace
		Gaia Gasparini
		Eligio Miccichè
		Roberto Bonmassari
		Orazio Viola
		Davide Cao
		Andrea Rognoni
		Filippo Zilio
		</p>
	<p>Background: The most appropriate management of glucose-lowering therapies in patients exposed to iodinated contrast media (ICM) is still debated. The recent development of antidiabetic drugs that improve cardiovascular and renal outcomes leads to questions regarding their impact on the risk of contrast-associated acute kidney injury (CA-AKI). The present study aimed to assess the effect of different glucose-lowering therapies on the rate of CA-AKI among patients undergoing coronary angiography and/or angioplasty. Methods: Diabetic patients exposed to ICM for coronary procedures were retrospectively identified and divided according to the strategy for the management of diabetes mellitus. The use of a new antidiabetic drug (NAD) was defined for patients treated with SGLT2-I, DDP4-I or GLP-1 receptor agonists on admission. The primary endpoint was the occurrence of CA-AKI within 72 h after contrast medium exposure. Results: We included 462 patients with diabetes mellitus, 51.5% treated with insulin, 44.4% treated with metformin and 50.9% receiving NAD. Among them, 48 (10.4%) experienced CA-AKI. Patients experiencing acute renal injury were more often treated with calcium channel blockers (p = 0.04) and diuretics (p = 0.004), and less often P2Y12 inhibitors (p = 0.04), and presented lower levels of hemoglobin (p = 0.02). Patients receiving NADs displayed a significantly lower occurrence of CA-AKI (33.3% vs. 53.6%, p = 0.009), mainly for those treated with SGLT2-I. On the contrary, patients treated with sulfonylureas and meglitinides displayed a significant increase in the rate of CA-AKI (10.4% vs. 3.9%, p = 0.05). The results were confirmed via multivariable analysis, with NADs and diuretics emerging as the only independent predictors of CA-AKI (NAD: adjusted OR = 0.42 [0.21&amp;amp;ndash;0.81], p = 0.01; diuretics: adjusted OR = 2.22 [1.14&amp;amp;ndash;4.35], p = 0.02). The independent predictors of CA-AKI were the use of NADs (adjusted OR = 0.45 [0.24&amp;amp;ndash;0.86], p = 0.02) and diuretics (adjusted OR = 2.57 [1.33&amp;amp;ndash;4.97], p = 0.005). Conclusions: Among patients with diabetes mellitus undergoing coronary angiographic procedures, the use of diuretics, sulfonylureas and meglitinides is associated with an increased occurrence of CA-AKI, whereas the rate of events was significantly lower among users of new antidiabetic drugs and especially SGLT2-I.</p>
	]]></content:encoded>

	<dc:title>Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus</dc:title>
			<dc:creator>Monica Verdoia</dc:creator>
			<dc:creator>Matteo Nardin</dc:creator>
			<dc:creator>Giuseppe Ciliberti</dc:creator>
			<dc:creator>Marta Leverone</dc:creator>
			<dc:creator>Jari Paternoster</dc:creator>
			<dc:creator>Aron Faraguna</dc:creator>
			<dc:creator>Emanuel Barnoffi</dc:creator>
			<dc:creator>Domenico Lorusso</dc:creator>
			<dc:creator>Gennaro Ciliberti</dc:creator>
			<dc:creator>Tommaso Piva</dc:creator>
			<dc:creator>Elisa Nicolini</dc:creator>
			<dc:creator>Marco Marini</dc:creator>
			<dc:creator>Antonio Dello Russo</dc:creator>
			<dc:creator>Rocco Mollace</dc:creator>
			<dc:creator>Gaia Gasparini</dc:creator>
			<dc:creator>Eligio Miccichè</dc:creator>
			<dc:creator>Roberto Bonmassari</dc:creator>
			<dc:creator>Orazio Viola</dc:creator>
			<dc:creator>Davide Cao</dc:creator>
			<dc:creator>Andrea Rognoni</dc:creator>
			<dc:creator>Filippo Zilio</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080154</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-11</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-11</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>154</prism:startingPage>
		<prism:doi>10.3390/diabetology7080154</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/154</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/153">

	<title>Diabetology, Vol. 7, Pages 153: Gut Microbiota in Type 2 Diabetes and Metabolic Disorders: Sources of Heterogeneity and Ways to Resolve Contradictions in Research</title>
	<link>https://www.mdpi.com/2673-4540/7/8/153</link>
	<description>Metabolic diseases, including obesity and type 2 diabetes mellitus, represent a major global health burden and are closely linked to the composition and function of the gut microbiota. Advances in molecular methods have enabled detailed characterization of microbial communities and their interactions with diet, medications, and host physiology, positioning the microbiome as an active metabolic organ. However, the field faces persistent challenges in distinguishing causal relationships from associations, largely owing to substantial biological, exposure-related, and methodological heterogeneity. This review systematizes the principal lines of evidence connecting the gut microbiome to metabolic disorders and critically examines the sources of variability that limit reproducibility and cross-cohort transferability of these findings. We discuss the taxonomic, functional, and metabolite-based levels of microbiome analysis, evaluate the strengths and limitations of cross-sectional, case&amp;amp;ndash;control, cohort, and interventional study designs, and consider approaches for establishing causality, including fecal microbiota transplantation, Mendelian randomization, mediation analysis, causal diagrams, and triangulation of evidence. We conclude that only a comprehensive, standardized, and causally informed approach will allow reliable discrimination between true microbiota-driven effects and methodological artifacts, thereby advancing the integration of microbiome science into the management of metabolic diseases and diabetes.</description>
	<pubDate>2026-08-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 153: Gut Microbiota in Type 2 Diabetes and Metabolic Disorders: Sources of Heterogeneity and Ways to Resolve Contradictions in Research</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/153">doi: 10.3390/diabetology7080153</a></p>
	<p>Authors:
		Ekaterina Nesterova
		Maria Gladkikh
		Inna Burakova
		Olga Korneeva
		Polina Morozova
		Mikhail Syromyatnikov
		</p>
	<p>Metabolic diseases, including obesity and type 2 diabetes mellitus, represent a major global health burden and are closely linked to the composition and function of the gut microbiota. Advances in molecular methods have enabled detailed characterization of microbial communities and their interactions with diet, medications, and host physiology, positioning the microbiome as an active metabolic organ. However, the field faces persistent challenges in distinguishing causal relationships from associations, largely owing to substantial biological, exposure-related, and methodological heterogeneity. This review systematizes the principal lines of evidence connecting the gut microbiome to metabolic disorders and critically examines the sources of variability that limit reproducibility and cross-cohort transferability of these findings. We discuss the taxonomic, functional, and metabolite-based levels of microbiome analysis, evaluate the strengths and limitations of cross-sectional, case&amp;amp;ndash;control, cohort, and interventional study designs, and consider approaches for establishing causality, including fecal microbiota transplantation, Mendelian randomization, mediation analysis, causal diagrams, and triangulation of evidence. We conclude that only a comprehensive, standardized, and causally informed approach will allow reliable discrimination between true microbiota-driven effects and methodological artifacts, thereby advancing the integration of microbiome science into the management of metabolic diseases and diabetes.</p>
	]]></content:encoded>

	<dc:title>Gut Microbiota in Type 2 Diabetes and Metabolic Disorders: Sources of Heterogeneity and Ways to Resolve Contradictions in Research</dc:title>
			<dc:creator>Ekaterina Nesterova</dc:creator>
			<dc:creator>Maria Gladkikh</dc:creator>
			<dc:creator>Inna Burakova</dc:creator>
			<dc:creator>Olga Korneeva</dc:creator>
			<dc:creator>Polina Morozova</dc:creator>
			<dc:creator>Mikhail Syromyatnikov</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080153</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-11</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-11</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>153</prism:startingPage>
		<prism:doi>10.3390/diabetology7080153</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/153</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/152">

	<title>Diabetology, Vol. 7, Pages 152: Association of Obesity with Cardiovascular Procedures and In-Hospital Outcomes in Adults with Diabetes Mellitus and Acute Myocardial Infarction Complicated by Cardiogenic Shock</title>
	<link>https://www.mdpi.com/2673-4540/7/8/152</link>
	<description>Background/Objectives: Obesity and diabetes mellitus coexist, but the association of obesity with invasive management and in-hospital outcomes in acute myocardial infarction (AMI) complicated by cardiogenic shock is uncertain. We evaluated these associations among adults with diabetes mellitus. Methods: We performed a retrospective discharge-level analysis of the National Inpatient Sample for 2016&amp;amp;ndash;2021. Obesity was identified from ICD-10-CM codes. Survey-design logistic regression accounted for weights, strata, hospital clusters, and prespecified covariates. Results: The cohort comprised 19,399 discharges, representing 96,995 hospitalizations; 24.1% had obesity. Angiography and coronary artery bypass grafting (CABG) were more frequent with obesity, whereas percutaneous coronary intervention (PCI) was less frequent. After adjustment, obesity was associated with higher odds of angiography (adjusted odds ratio [aOR] 1.12, 95% confidence interval [CI] 1.03&amp;amp;ndash;1.21) and CABG (aOR 1.49, 95% CI 1.35&amp;amp;ndash;1.63), lower odds of PCI (aOR 0.90, 95% CI 0.84&amp;amp;ndash;0.97), and similar odds of circulatory support (aOR 1.00, 95% CI 0.93&amp;amp;ndash;1.07). Adjusted odds were lower for major adverse cardiovascular and cerebrovascular events (aOR 0.88, 95% CI 0.82&amp;amp;ndash;0.95), in-hospital mortality (aOR 0.90, 95% CI 0.83&amp;amp;ndash;0.98), acute ischemic stroke (aOR 0.78, 95% CI 0.64&amp;amp;ndash;0.95), and major bleeding (aOR 0.86, 95% CI 0.76&amp;amp;ndash;0.98). Procedure adjustment attenuated mortality and major bleeding. Conclusions: Obesity was associated with a different invasive-management pattern and lower adjusted odds of several short-term outcomes, consistent with an apparent in-hospital obesity paradox in this high-risk population.</description>
	<pubDate>2026-08-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 152: Association of Obesity with Cardiovascular Procedures and In-Hospital Outcomes in Adults with Diabetes Mellitus and Acute Myocardial Infarction Complicated by Cardiogenic Shock</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/152">doi: 10.3390/diabetology7080152</a></p>
	<p>Authors:
		Kirill Berezhnoi
		Ilan Merdler
		Adam Folman
		Maguli Barel
		Rami Abu-Fanne
		Ariel Roguin
		Ofer Kobo
		</p>
	<p>Background/Objectives: Obesity and diabetes mellitus coexist, but the association of obesity with invasive management and in-hospital outcomes in acute myocardial infarction (AMI) complicated by cardiogenic shock is uncertain. We evaluated these associations among adults with diabetes mellitus. Methods: We performed a retrospective discharge-level analysis of the National Inpatient Sample for 2016&amp;amp;ndash;2021. Obesity was identified from ICD-10-CM codes. Survey-design logistic regression accounted for weights, strata, hospital clusters, and prespecified covariates. Results: The cohort comprised 19,399 discharges, representing 96,995 hospitalizations; 24.1% had obesity. Angiography and coronary artery bypass grafting (CABG) were more frequent with obesity, whereas percutaneous coronary intervention (PCI) was less frequent. After adjustment, obesity was associated with higher odds of angiography (adjusted odds ratio [aOR] 1.12, 95% confidence interval [CI] 1.03&amp;amp;ndash;1.21) and CABG (aOR 1.49, 95% CI 1.35&amp;amp;ndash;1.63), lower odds of PCI (aOR 0.90, 95% CI 0.84&amp;amp;ndash;0.97), and similar odds of circulatory support (aOR 1.00, 95% CI 0.93&amp;amp;ndash;1.07). Adjusted odds were lower for major adverse cardiovascular and cerebrovascular events (aOR 0.88, 95% CI 0.82&amp;amp;ndash;0.95), in-hospital mortality (aOR 0.90, 95% CI 0.83&amp;amp;ndash;0.98), acute ischemic stroke (aOR 0.78, 95% CI 0.64&amp;amp;ndash;0.95), and major bleeding (aOR 0.86, 95% CI 0.76&amp;amp;ndash;0.98). Procedure adjustment attenuated mortality and major bleeding. Conclusions: Obesity was associated with a different invasive-management pattern and lower adjusted odds of several short-term outcomes, consistent with an apparent in-hospital obesity paradox in this high-risk population.</p>
	]]></content:encoded>

	<dc:title>Association of Obesity with Cardiovascular Procedures and In-Hospital Outcomes in Adults with Diabetes Mellitus and Acute Myocardial Infarction Complicated by Cardiogenic Shock</dc:title>
			<dc:creator>Kirill Berezhnoi</dc:creator>
			<dc:creator>Ilan Merdler</dc:creator>
			<dc:creator>Adam Folman</dc:creator>
			<dc:creator>Maguli Barel</dc:creator>
			<dc:creator>Rami Abu-Fanne</dc:creator>
			<dc:creator>Ariel Roguin</dc:creator>
			<dc:creator>Ofer Kobo</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080152</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-11</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-11</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>152</prism:startingPage>
		<prism:doi>10.3390/diabetology7080152</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/152</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/151">

	<title>Diabetology, Vol. 7, Pages 151: Non-Invasive Sociodemographic Cues for Type 2 Diabetes Risk Stratification in South Africa</title>
	<link>https://www.mdpi.com/2673-4540/7/8/151</link>
	<description>Background/Objectives: Type 2 diabetes mellitus (T2DM) is a growing burden in low- and middle-income countries, and non-invasive risk tools have been proposed where laboratory screening is not feasible. Fast-and-frugal decision trees (FFDTs) are transparent, non-compensatory rules that make sensitivity&amp;amp;ndash;specificity trade-offs explicit. We asked how far five routinely collected sociodemographic cues can go for classifying self-reported diabetes status and benchmarked FFDTs against the simplest possible alternatives. Methods: A cross-sectional secondary analysis of the 2016 South Africa Demographic and Health Survey Adult Health recode (N = 10,292; 459 self-reported cases, 4.46%) was carried out. Five binary cues were derived: age category, household wealth, employment, education and sex. Data were split 70/30 into development and a locked hold-out set. Three purpose-specific FFDTs were selected by 5 &amp;amp;times; 10-fold cross-validation within the development data only, frozen, and then evaluated once on the hold-out set. Comparators were a pre-specified age-only rule and logistic regression using the same five predictors at a development-derived Youden threshold. We report survey-weighted estimates, internal&amp;amp;ndash;external cross-validation across nine provinces, external validation in 12 further DHS, subgroup performance, and a log&amp;amp;ndash;log analysis of error against training sample size. Results: On the hold-out set the balanced screening FFDT achieved sensitivity 0.920 (95% CI 0.862&amp;amp;ndash;0.959), specificity 0.585 (0.567&amp;amp;ndash;0.602) and balanced accuracy 0.752 (0.727&amp;amp;ndash;0.776). The pre-specified age-only rule achieved balanced accuracy 0.751 (0.724&amp;amp;ndash;0.775), while logistic regression at the development-derived Youden threshold achieved 0.766 (0.735&amp;amp;ndash;0.797). Across 50 independent splits, the case-finding FFDT was arithmetically identical to the age-only rule in every split; the balanced FFDT exceeded it by a median of 0.001 (95% range &amp;amp;minus;0.004 to +0.025); the referral-minimisation FFDT was worse by a median of 0.124. Performance was stable across provinces (balanced accuracy 0.731&amp;amp;ndash;0.801) but degraded across countries (0.508&amp;amp;ndash;0.724), with referral rate ranging from 0.225 to 0.806. Error scaled with training size as beta = &amp;amp;minus;0.044 (95% CI &amp;amp;minus;0.063 to &amp;amp;minus;0.025). Conclusions: Transparent decision trees built from non-invasive sociodemographic cues classify self-reported diabetes status no better than a single question about age, do not transport reliably across countries, and are unlikely to be materially improved by simply increasing the training sample size. Their value lies in auditability rather than accuracy. Progress in low-burden risk stratification for T2DM in these settings will require cues that carry a biological rather than health system signal.</description>
	<pubDate>2026-08-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 151: Non-Invasive Sociodemographic Cues for Type 2 Diabetes Risk Stratification in South Africa</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/151">doi: 10.3390/diabetology7080151</a></p>
	<p>Authors:
		Reza Fahimi
		Abdulaziz Alrubayyi
		Habibullah Muhammad Kamal
		Ibrahim Khalil Ja’afar
		Mohanad Alhothify
		Thomas M. Barber
		Olalekan A. Uthman
		</p>
	<p>Background/Objectives: Type 2 diabetes mellitus (T2DM) is a growing burden in low- and middle-income countries, and non-invasive risk tools have been proposed where laboratory screening is not feasible. Fast-and-frugal decision trees (FFDTs) are transparent, non-compensatory rules that make sensitivity&amp;amp;ndash;specificity trade-offs explicit. We asked how far five routinely collected sociodemographic cues can go for classifying self-reported diabetes status and benchmarked FFDTs against the simplest possible alternatives. Methods: A cross-sectional secondary analysis of the 2016 South Africa Demographic and Health Survey Adult Health recode (N = 10,292; 459 self-reported cases, 4.46%) was carried out. Five binary cues were derived: age category, household wealth, employment, education and sex. Data were split 70/30 into development and a locked hold-out set. Three purpose-specific FFDTs were selected by 5 &amp;amp;times; 10-fold cross-validation within the development data only, frozen, and then evaluated once on the hold-out set. Comparators were a pre-specified age-only rule and logistic regression using the same five predictors at a development-derived Youden threshold. We report survey-weighted estimates, internal&amp;amp;ndash;external cross-validation across nine provinces, external validation in 12 further DHS, subgroup performance, and a log&amp;amp;ndash;log analysis of error against training sample size. Results: On the hold-out set the balanced screening FFDT achieved sensitivity 0.920 (95% CI 0.862&amp;amp;ndash;0.959), specificity 0.585 (0.567&amp;amp;ndash;0.602) and balanced accuracy 0.752 (0.727&amp;amp;ndash;0.776). The pre-specified age-only rule achieved balanced accuracy 0.751 (0.724&amp;amp;ndash;0.775), while logistic regression at the development-derived Youden threshold achieved 0.766 (0.735&amp;amp;ndash;0.797). Across 50 independent splits, the case-finding FFDT was arithmetically identical to the age-only rule in every split; the balanced FFDT exceeded it by a median of 0.001 (95% range &amp;amp;minus;0.004 to +0.025); the referral-minimisation FFDT was worse by a median of 0.124. Performance was stable across provinces (balanced accuracy 0.731&amp;amp;ndash;0.801) but degraded across countries (0.508&amp;amp;ndash;0.724), with referral rate ranging from 0.225 to 0.806. Error scaled with training size as beta = &amp;amp;minus;0.044 (95% CI &amp;amp;minus;0.063 to &amp;amp;minus;0.025). Conclusions: Transparent decision trees built from non-invasive sociodemographic cues classify self-reported diabetes status no better than a single question about age, do not transport reliably across countries, and are unlikely to be materially improved by simply increasing the training sample size. Their value lies in auditability rather than accuracy. Progress in low-burden risk stratification for T2DM in these settings will require cues that carry a biological rather than health system signal.</p>
	]]></content:encoded>

	<dc:title>Non-Invasive Sociodemographic Cues for Type 2 Diabetes Risk Stratification in South Africa</dc:title>
			<dc:creator>Reza Fahimi</dc:creator>
			<dc:creator>Abdulaziz Alrubayyi</dc:creator>
			<dc:creator>Habibullah Muhammad Kamal</dc:creator>
			<dc:creator>Ibrahim Khalil Ja’afar</dc:creator>
			<dc:creator>Mohanad Alhothify</dc:creator>
			<dc:creator>Thomas M. Barber</dc:creator>
			<dc:creator>Olalekan A. Uthman</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080151</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-07</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-07</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>151</prism:startingPage>
		<prism:doi>10.3390/diabetology7080151</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/151</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/150">

	<title>Diabetology, Vol. 7, Pages 150: Cerebrospinal Fluid Biomarkers of Neuroinflammation and Neuroplasticity in Type 2 Diabetes Mellitus: Association with Cognitive Performance</title>
	<link>https://www.mdpi.com/2673-4540/7/8/150</link>
	<description>Background: Type 2 Diabetes Mellitus (T2DM) is associated with cognitive decline, potentially mediated by neuroinflammatory processes and altered neuroplasticity. This study investigated cerebrospinal fluid (CSF) biomarkers of neuroinflammation and neuroplasticity in T2DM individuals versus controls, and their relationship with cognitive performance. Methods: This cross-sectional study included 56 T2DM individuals and 26 controls (aged 37&amp;amp;ndash;70 years; 48% male). CSF concentrations of leptin, IL-6, VEGF, BDNF, TNF-&amp;amp;alpha;, IGF-1, and IL-1&amp;amp;beta; were measured using ELISA. Cognitive function was assessed using MMSE, the Stroop test, SDMT, RCFT, and TAAV. Group comparisons used Mann&amp;amp;ndash;Whitney U or t-tests; Spearman correlations examined variable relationships. Results: No statistically significant differences in CSF biomarkers were observed between groups. However, T2DM patients showed lower word recall (4.66 &amp;amp;plusmn; 1.48 vs. 5.81 &amp;amp;plusmn; 1.52; p = 0.002), reduced Symbol&amp;amp;ndash;Digit performance (17.82 &amp;amp;plusmn; 12.16 vs. 24.92 &amp;amp;plusmn; 12.10; p = 0.016), and higher Complex Figure Test scores (19.94 &amp;amp;plusmn; 9.32 vs. 15.94 &amp;amp;plusmn; 5.02; p = 0.009). IL-6 was negatively correlated with MMSE (r = &amp;amp;minus;0.33, p = 0.005). Significant correlations emerged between MMSE and Symbol&amp;amp;ndash;Digit scores (r = 0.40, p &amp;amp;lt; 0.001) and among biomarkers. Conclusions: &amp;amp;ldquo;No statistically significant differences in CSF biomarkers were observed between groups and unadjusted CSF biomarker concentrations did not differ significantly between groups; however, after adjustment for age and BMI, IL-6 was significantly elevated in T2DM patients, indicating that covariate-adjusted analyses may be more sensitive for detecting subtle neuroinflammatory differences in this population.</description>
	<pubDate>2026-08-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 150: Cerebrospinal Fluid Biomarkers of Neuroinflammation and Neuroplasticity in Type 2 Diabetes Mellitus: Association with Cognitive Performance</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/150">doi: 10.3390/diabetology7080150</a></p>
	<p>Authors:
		César Mauricio Baracaldo Barrera
		Martha Cecilia Jiménez Martínez
		Sandra Rojas Vega
		</p>
	<p>Background: Type 2 Diabetes Mellitus (T2DM) is associated with cognitive decline, potentially mediated by neuroinflammatory processes and altered neuroplasticity. This study investigated cerebrospinal fluid (CSF) biomarkers of neuroinflammation and neuroplasticity in T2DM individuals versus controls, and their relationship with cognitive performance. Methods: This cross-sectional study included 56 T2DM individuals and 26 controls (aged 37&amp;amp;ndash;70 years; 48% male). CSF concentrations of leptin, IL-6, VEGF, BDNF, TNF-&amp;amp;alpha;, IGF-1, and IL-1&amp;amp;beta; were measured using ELISA. Cognitive function was assessed using MMSE, the Stroop test, SDMT, RCFT, and TAAV. Group comparisons used Mann&amp;amp;ndash;Whitney U or t-tests; Spearman correlations examined variable relationships. Results: No statistically significant differences in CSF biomarkers were observed between groups. However, T2DM patients showed lower word recall (4.66 &amp;amp;plusmn; 1.48 vs. 5.81 &amp;amp;plusmn; 1.52; p = 0.002), reduced Symbol&amp;amp;ndash;Digit performance (17.82 &amp;amp;plusmn; 12.16 vs. 24.92 &amp;amp;plusmn; 12.10; p = 0.016), and higher Complex Figure Test scores (19.94 &amp;amp;plusmn; 9.32 vs. 15.94 &amp;amp;plusmn; 5.02; p = 0.009). IL-6 was negatively correlated with MMSE (r = &amp;amp;minus;0.33, p = 0.005). Significant correlations emerged between MMSE and Symbol&amp;amp;ndash;Digit scores (r = 0.40, p &amp;amp;lt; 0.001) and among biomarkers. Conclusions: &amp;amp;ldquo;No statistically significant differences in CSF biomarkers were observed between groups and unadjusted CSF biomarker concentrations did not differ significantly between groups; however, after adjustment for age and BMI, IL-6 was significantly elevated in T2DM patients, indicating that covariate-adjusted analyses may be more sensitive for detecting subtle neuroinflammatory differences in this population.</p>
	]]></content:encoded>

	<dc:title>Cerebrospinal Fluid Biomarkers of Neuroinflammation and Neuroplasticity in Type 2 Diabetes Mellitus: Association with Cognitive Performance</dc:title>
			<dc:creator>César Mauricio Baracaldo Barrera</dc:creator>
			<dc:creator>Martha Cecilia Jiménez Martínez</dc:creator>
			<dc:creator>Sandra Rojas Vega</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080150</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-07</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-07</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>150</prism:startingPage>
		<prism:doi>10.3390/diabetology7080150</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/150</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/149">

	<title>Diabetology, Vol. 7, Pages 149: Clinical Performance of Phase Angle in Screening for Osteosarcopenia Among Older Adults with Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/8/149</link>
	<description>Background: This study aimed to determine the prevalence of osteosarcopenia and evaluate the diagnostic performance of phase angle, derived from bioelectrical impedance analysis, in identifying osteosarcopenia among older adults with type 2 diabetes mellitus. Method: A cross-sectional study was conducted with 147 participants aged 60 years or older, recruited from an outpatient clinic in Thailand between during 2024. Osteosarcopenia was diagnosed when criteria for both sarcopenia, defined by low skeletal muscle mass and either reduced handgrip strength or impaired physical performance, and osteoporosis, defined by a T-score of &amp;amp;minus;2.5 or lower on dual-energy X-ray absorptiometry, were met. Participant characteristics, physical function, laboratory values, and body composition data were collected. Univariable Firth&amp;amp;rsquo;s penalized logistic regression identified low body mass index and a lower phase angle as independent predictors of osteosarcopenia. Results: The overall prevalence of osteosarcopenia was 7.5 percent. Receiver operating characteristic curve analysis showed strong diagnostic performance of phase angle, with an area under the curve of 0.865. A cutoff value of less than 4.0 degrees achieved 100% sensitivity, 62.5% specificity, and 100% negative predictive value. These findings suggest that phase angle may be a practical, noninvasive screening tool for identifying older adults with type 2 diabetes mellitus who are at risk for osteosarcopenia. Its application in routine clinical settings could enable earlier intervention and reduce long-term complications associated with musculoskeletal decline in this vulnerable population.</description>
	<pubDate>2026-08-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 149: Clinical Performance of Phase Angle in Screening for Osteosarcopenia Among Older Adults with Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/149">doi: 10.3390/diabetology7080149</a></p>
	<p>Authors:
		Thanapat Limpaarayakul
		Jakkrit Palapinyo
		Methavee Poochanasri
		Kasidid Lawongsa
		Chanittha Buakhao
		Thawee Songpatanasilp
		Parinya Samakkarnthai
		</p>
	<p>Background: This study aimed to determine the prevalence of osteosarcopenia and evaluate the diagnostic performance of phase angle, derived from bioelectrical impedance analysis, in identifying osteosarcopenia among older adults with type 2 diabetes mellitus. Method: A cross-sectional study was conducted with 147 participants aged 60 years or older, recruited from an outpatient clinic in Thailand between during 2024. Osteosarcopenia was diagnosed when criteria for both sarcopenia, defined by low skeletal muscle mass and either reduced handgrip strength or impaired physical performance, and osteoporosis, defined by a T-score of &amp;amp;minus;2.5 or lower on dual-energy X-ray absorptiometry, were met. Participant characteristics, physical function, laboratory values, and body composition data were collected. Univariable Firth&amp;amp;rsquo;s penalized logistic regression identified low body mass index and a lower phase angle as independent predictors of osteosarcopenia. Results: The overall prevalence of osteosarcopenia was 7.5 percent. Receiver operating characteristic curve analysis showed strong diagnostic performance of phase angle, with an area under the curve of 0.865. A cutoff value of less than 4.0 degrees achieved 100% sensitivity, 62.5% specificity, and 100% negative predictive value. These findings suggest that phase angle may be a practical, noninvasive screening tool for identifying older adults with type 2 diabetes mellitus who are at risk for osteosarcopenia. Its application in routine clinical settings could enable earlier intervention and reduce long-term complications associated with musculoskeletal decline in this vulnerable population.</p>
	]]></content:encoded>

	<dc:title>Clinical Performance of Phase Angle in Screening for Osteosarcopenia Among Older Adults with Type 2 Diabetes</dc:title>
			<dc:creator>Thanapat Limpaarayakul</dc:creator>
			<dc:creator>Jakkrit Palapinyo</dc:creator>
			<dc:creator>Methavee Poochanasri</dc:creator>
			<dc:creator>Kasidid Lawongsa</dc:creator>
			<dc:creator>Chanittha Buakhao</dc:creator>
			<dc:creator>Thawee Songpatanasilp</dc:creator>
			<dc:creator>Parinya Samakkarnthai</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080149</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-07</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-07</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>149</prism:startingPage>
		<prism:doi>10.3390/diabetology7080149</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/149</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/148">

	<title>Diabetology, Vol. 7, Pages 148: Targeting Pathogenic Effector T Cells with a Novel Small-Peptide Approach in Type 1 Diabetes: A First-in-Human, Randomized, Double-Blind, Phase 1b Clinical Trial</title>
	<link>https://www.mdpi.com/2673-4540/7/8/148</link>
	<description>Background: Type 1 diabetes (T1D) is a complex autoimmune disease demonstrating substantial heterogeneity in age of onset, residual C-peptide levels, clinical outcomes, and therapeutic response. Although the autoimmune classification of T1D has traditionally relied on detection of autoantibodies indicating B-cell involvement, studies targeting total CD3+ T cells have underscored the importance of T-cell regulation. Th40 cells, a pathogenic subset of CD3+ T cells, first identified in NOD mice, become significantly increased during diabetogenesis. Human subjects with T1D exhibit variable but significantly elevated Th40 levels in peripheral blood. Methods: To target pathogenic effector Th40 cells, we developed OPT101, a 15-mer peptide, and found that it interacts with CD40 in association with an activated integrin, identifying a novel inflammatory receptor complex. We conducted a phase 1b, double-blind, first-in-human clinical trial to evaluate OPT101 and met the primary objectives of safety and tolerability. Results: OPT101 generated only Grade 1 and 2 adverse events. Across eight doses, administered over six weeks, no product-related immune suppression was observed. Secondary objectives included immunologic outcomes and potential efficacy. Subjects with higher Th40 levels had low or undetectable C-peptide, higher (&amp;amp;gt;7.0%) HbA1c, and elevated inflammatory cytokines. Th40 levels were significantly higher in subjects diagnosed before age eighteen. OPT101 treatment significantly reduced Th40 percentages without cell ablation, increased Treg levels, and decreased inflammatory cytokines. Serum blood glucose levels and HbA1c were significantly reduced by visit 8 in treated subjects. In two subjects, 11 and 13 years post-diagnosis, with undetectable C-peptide at screening, C-peptide became detectable post-treatment. Conclusions: OPT101 proved safe and effective in human T1D subjects with only mild and a few moderate adverse events. In this short-term study, OPT101 improved beta cell functions thus warranting further exploration.</description>
	<pubDate>2026-08-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 148: Targeting Pathogenic Effector T Cells with a Novel Small-Peptide Approach in Type 1 Diabetes: A First-in-Human, Randomized, Double-Blind, Phase 1b Clinical Trial</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/148">doi: 10.3390/diabetology7080148</a></p>
	<p>Authors:
		Gisela M. Vaitaitis
		Martin G. Yussman
		Dan M. Waid
		Ronald Brazg
		David H. Wagner
		</p>
	<p>Background: Type 1 diabetes (T1D) is a complex autoimmune disease demonstrating substantial heterogeneity in age of onset, residual C-peptide levels, clinical outcomes, and therapeutic response. Although the autoimmune classification of T1D has traditionally relied on detection of autoantibodies indicating B-cell involvement, studies targeting total CD3+ T cells have underscored the importance of T-cell regulation. Th40 cells, a pathogenic subset of CD3+ T cells, first identified in NOD mice, become significantly increased during diabetogenesis. Human subjects with T1D exhibit variable but significantly elevated Th40 levels in peripheral blood. Methods: To target pathogenic effector Th40 cells, we developed OPT101, a 15-mer peptide, and found that it interacts with CD40 in association with an activated integrin, identifying a novel inflammatory receptor complex. We conducted a phase 1b, double-blind, first-in-human clinical trial to evaluate OPT101 and met the primary objectives of safety and tolerability. Results: OPT101 generated only Grade 1 and 2 adverse events. Across eight doses, administered over six weeks, no product-related immune suppression was observed. Secondary objectives included immunologic outcomes and potential efficacy. Subjects with higher Th40 levels had low or undetectable C-peptide, higher (&amp;amp;gt;7.0%) HbA1c, and elevated inflammatory cytokines. Th40 levels were significantly higher in subjects diagnosed before age eighteen. OPT101 treatment significantly reduced Th40 percentages without cell ablation, increased Treg levels, and decreased inflammatory cytokines. Serum blood glucose levels and HbA1c were significantly reduced by visit 8 in treated subjects. In two subjects, 11 and 13 years post-diagnosis, with undetectable C-peptide at screening, C-peptide became detectable post-treatment. Conclusions: OPT101 proved safe and effective in human T1D subjects with only mild and a few moderate adverse events. In this short-term study, OPT101 improved beta cell functions thus warranting further exploration.</p>
	]]></content:encoded>

	<dc:title>Targeting Pathogenic Effector T Cells with a Novel Small-Peptide Approach in Type 1 Diabetes: A First-in-Human, Randomized, Double-Blind, Phase 1b Clinical Trial</dc:title>
			<dc:creator>Gisela M. Vaitaitis</dc:creator>
			<dc:creator>Martin G. Yussman</dc:creator>
			<dc:creator>Dan M. Waid</dc:creator>
			<dc:creator>Ronald Brazg</dc:creator>
			<dc:creator>David H. Wagner</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080148</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-06</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-06</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>148</prism:startingPage>
		<prism:doi>10.3390/diabetology7080148</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/148</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/147">

	<title>Diabetology, Vol. 7, Pages 147: Clinical Utility of Genetic Testing in Obesity: A Case-Based Review in the Context of Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/8/147</link>
	<description>Background: Obesity has a significant genetic component, accounting for up to an estimated 70% of individual susceptibility. Advances in genome-wide association studies (GWASs) and next-generation sequencing (NGS) have enhanced identification and characterization of genetic forms of obesity, facilitating more precise and individualized treatment approaches. The phenotypic heterogenicity of the disease of obesity, along with the limited predictive value of clinical features, hinders the accurate identification of genetic forms of the disease. Therefore, genetic testing represents a critical diagnostic modality to confirm etiology and inform precision-based therapeutic strategies. Aim: To compare the clinical utility, interpretation and potential impact of direct-to-consumer (DTC-GT) and clinician-directed genetic testing for obesity in the context of type 2 diabetes. Methods: This case-based review evaluated a patient with severe obesity and type 2 diabetes who underwent both DTC-GT and clinician-directed genetic testing for obesity. A structured literature review using PubMed, Scopus, Web of Science, and Google was undertaken to identify the resources of both testing approaches. Tables and a schematic figure were developed to summarize the findings. Results: Neither testing approach identified clinically actionable obesity-associated genetic variants or a monogenic cause of obesity. However, the DTC-GT report concluded that the patient was at &amp;amp;ldquo;high risk&amp;amp;rdquo; of obesity and was provided to the patient without a referral to genetic counseling which contributed to patient misunderstanding. Conclusions: This case, interpreted alongside the reviewed literature, suggests that clinician-directed genetic testing may better support reliable interpretation of obesity-associated genetic findings and disease management than DTC-GT. Larger studies are warranted to confirm these observations.</description>
	<pubDate>2026-08-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 147: Clinical Utility of Genetic Testing in Obesity: A Case-Based Review in the Context of Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/147">doi: 10.3390/diabetology7080147</a></p>
	<p>Authors:
		Ahmed W. Al-Humadi
		Claire H. Parker
		Marcela Rodríguez-Flores
		Daniah A. Alwash
		Charis Liapi
		</p>
	<p>Background: Obesity has a significant genetic component, accounting for up to an estimated 70% of individual susceptibility. Advances in genome-wide association studies (GWASs) and next-generation sequencing (NGS) have enhanced identification and characterization of genetic forms of obesity, facilitating more precise and individualized treatment approaches. The phenotypic heterogenicity of the disease of obesity, along with the limited predictive value of clinical features, hinders the accurate identification of genetic forms of the disease. Therefore, genetic testing represents a critical diagnostic modality to confirm etiology and inform precision-based therapeutic strategies. Aim: To compare the clinical utility, interpretation and potential impact of direct-to-consumer (DTC-GT) and clinician-directed genetic testing for obesity in the context of type 2 diabetes. Methods: This case-based review evaluated a patient with severe obesity and type 2 diabetes who underwent both DTC-GT and clinician-directed genetic testing for obesity. A structured literature review using PubMed, Scopus, Web of Science, and Google was undertaken to identify the resources of both testing approaches. Tables and a schematic figure were developed to summarize the findings. Results: Neither testing approach identified clinically actionable obesity-associated genetic variants or a monogenic cause of obesity. However, the DTC-GT report concluded that the patient was at &amp;amp;ldquo;high risk&amp;amp;rdquo; of obesity and was provided to the patient without a referral to genetic counseling which contributed to patient misunderstanding. Conclusions: This case, interpreted alongside the reviewed literature, suggests that clinician-directed genetic testing may better support reliable interpretation of obesity-associated genetic findings and disease management than DTC-GT. Larger studies are warranted to confirm these observations.</p>
	]]></content:encoded>

	<dc:title>Clinical Utility of Genetic Testing in Obesity: A Case-Based Review in the Context of Type 2 Diabetes</dc:title>
			<dc:creator>Ahmed W. Al-Humadi</dc:creator>
			<dc:creator>Claire H. Parker</dc:creator>
			<dc:creator>Marcela Rodríguez-Flores</dc:creator>
			<dc:creator>Daniah A. Alwash</dc:creator>
			<dc:creator>Charis Liapi</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080147</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-06</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-06</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>147</prism:startingPage>
		<prism:doi>10.3390/diabetology7080147</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/147</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/146">

	<title>Diabetology, Vol. 7, Pages 146: Impact of a History of Obesity on Diabetic Microvascular Complications in Patients with Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/8/146</link>
	<description>Background/Objectives: The prevalence of obesity is increasing among Japanese patients with type 2 diabetes (T2D); however, the impact of obesity history and severity on microvascular complications remains poorly understood. This study aimed to investigate the association of lifetime maximum body mass index (BMI) and BMI at the first clinical visit with the development and progression of diabetic nephropathy and retinopathy. Methods: This retrospective cohort study included T2D patients who first visited the clinic of the Institute for Medical Sciences, Asahi Life Foundation between 2005 and 2022. Patients were categorized into five groups based on both lifetime maximum and first-visit BMI: underweight, normal weight, class I obesity, class II obesity, and severe obesity. The primary endpoints were renal events (sustained increase in proteinuria or &amp;amp;ge;40% decline in eGFR) and retinal events (worsening of diabetic retinopathy by &amp;amp;ge;1 stage). Results: A history of severe obesity, based on the lifetime maximum BMI, was an independent risk factor for proteinuria progression. While a history of severe obesity was associated with all endpoints in unadjusted analyses, these associations with eGFR decline and retinopathy were not significant after adjusting for covariates. In contrast, the BMI at the first visit was significantly associated with retinal events but not with renal events. Conclusions: A history of maximum lifetime obesity is a critical predictor of the proteinuria progression. A history of obesity, a simple clinical metric, is a valuable tool for identifying high-risk patients and may contribute to more effective preventative strategies.</description>
	<pubDate>2026-08-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 146: Impact of a History of Obesity on Diabetic Microvascular Complications in Patients with Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/146">doi: 10.3390/diabetology7080146</a></p>
	<p>Authors:
		Akifumi Kushiyama
		Haruka Ota
		Kaho Higashi
		Iori Yamazaki
		Momoka Kojima
		Takako Kikuchi
		</p>
	<p>Background/Objectives: The prevalence of obesity is increasing among Japanese patients with type 2 diabetes (T2D); however, the impact of obesity history and severity on microvascular complications remains poorly understood. This study aimed to investigate the association of lifetime maximum body mass index (BMI) and BMI at the first clinical visit with the development and progression of diabetic nephropathy and retinopathy. Methods: This retrospective cohort study included T2D patients who first visited the clinic of the Institute for Medical Sciences, Asahi Life Foundation between 2005 and 2022. Patients were categorized into five groups based on both lifetime maximum and first-visit BMI: underweight, normal weight, class I obesity, class II obesity, and severe obesity. The primary endpoints were renal events (sustained increase in proteinuria or &amp;amp;ge;40% decline in eGFR) and retinal events (worsening of diabetic retinopathy by &amp;amp;ge;1 stage). Results: A history of severe obesity, based on the lifetime maximum BMI, was an independent risk factor for proteinuria progression. While a history of severe obesity was associated with all endpoints in unadjusted analyses, these associations with eGFR decline and retinopathy were not significant after adjusting for covariates. In contrast, the BMI at the first visit was significantly associated with retinal events but not with renal events. Conclusions: A history of maximum lifetime obesity is a critical predictor of the proteinuria progression. A history of obesity, a simple clinical metric, is a valuable tool for identifying high-risk patients and may contribute to more effective preventative strategies.</p>
	]]></content:encoded>

	<dc:title>Impact of a History of Obesity on Diabetic Microvascular Complications in Patients with Type 2 Diabetes</dc:title>
			<dc:creator>Akifumi Kushiyama</dc:creator>
			<dc:creator>Haruka Ota</dc:creator>
			<dc:creator>Kaho Higashi</dc:creator>
			<dc:creator>Iori Yamazaki</dc:creator>
			<dc:creator>Momoka Kojima</dc:creator>
			<dc:creator>Takako Kikuchi</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080146</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-03</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-03</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>146</prism:startingPage>
		<prism:doi>10.3390/diabetology7080146</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/146</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/145">

	<title>Diabetology, Vol. 7, Pages 145: Patterns of Antidiabetic Therapy and Associated Metabolic Profiles in Routine Clinical Practice</title>
	<link>https://www.mdpi.com/2673-4540/7/8/145</link>
	<description>Background: Contemporary antidiabetic therapy has evolved from a glucose-centered approach toward integrated cardiometabolic risk reduction. However, real-world evidence regarding treatment patterns and their association with glycemic and cardiovascular&amp;amp;ndash;renal profiles remain limited. Methods: This retrospective observational study included 250 adults with type 2 diabetes mellitus receiving non-insulin glucose-lowering therapy in routine specialist clinical practice. Demographic, clinical, biochemical, and pharmacological data were extracted from medical records. Glycemic control was assessed using HbA1c levels and HbA1c variation, while cardiovascular&amp;amp;ndash;renal parameters included estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), lipid profile, blood pressure, and heart failure prevalence. Comparative analyses and multivariate logistic regression were performed. Results: The cohort had a mean age of 61.8 &amp;amp;plusmn; 11.3 years, and all patients had type 2 diabetes mellitus (100.0%). Obesity, metabolic syndrome, hypertension, ischemic heart disease, and chronic kidney disease were highly prevalent. Metformin was the most frequently prescribed therapy (58.8%), followed by GLP-1 receptor agonists (28.8%) and SGLT-2 inhibitors (27.6%). Patients receiving GLP-1 receptor agonists or SGLT-2 inhibitors showed numerically lower HbA1c values and greater HbA1c reductions compared with conventional therapies. However, differences in HbA1c, CRP, and eGFR were not statistically significant after correction for multiple comparisons. Longer diabetes duration independently predicted poor glycemic control, whereas increasing age was associated with a lower probability of HbA1c &amp;amp;gt; 7%. Conclusions: Contemporary antidiabetic therapies were associated with favorable numerical cardiometabolic trends, although these associations did not remain statistically significant after multiple-comparison correction. The findings should therefore be considered exploratory and hypothesis-generating.</description>
	<pubDate>2026-08-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 145: Patterns of Antidiabetic Therapy and Associated Metabolic Profiles in Routine Clinical Practice</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/145">doi: 10.3390/diabetology7080145</a></p>
	<p>Authors:
		Madalina Ioana Moisi
		Cosmin Mihai Vesa
		Florica Ramona Dorobantu
		Corina Cinezan
		Timea Claudia Ghitea
		Roxana Daniela Brata
		</p>
	<p>Background: Contemporary antidiabetic therapy has evolved from a glucose-centered approach toward integrated cardiometabolic risk reduction. However, real-world evidence regarding treatment patterns and their association with glycemic and cardiovascular&amp;amp;ndash;renal profiles remain limited. Methods: This retrospective observational study included 250 adults with type 2 diabetes mellitus receiving non-insulin glucose-lowering therapy in routine specialist clinical practice. Demographic, clinical, biochemical, and pharmacological data were extracted from medical records. Glycemic control was assessed using HbA1c levels and HbA1c variation, while cardiovascular&amp;amp;ndash;renal parameters included estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), lipid profile, blood pressure, and heart failure prevalence. Comparative analyses and multivariate logistic regression were performed. Results: The cohort had a mean age of 61.8 &amp;amp;plusmn; 11.3 years, and all patients had type 2 diabetes mellitus (100.0%). Obesity, metabolic syndrome, hypertension, ischemic heart disease, and chronic kidney disease were highly prevalent. Metformin was the most frequently prescribed therapy (58.8%), followed by GLP-1 receptor agonists (28.8%) and SGLT-2 inhibitors (27.6%). Patients receiving GLP-1 receptor agonists or SGLT-2 inhibitors showed numerically lower HbA1c values and greater HbA1c reductions compared with conventional therapies. However, differences in HbA1c, CRP, and eGFR were not statistically significant after correction for multiple comparisons. Longer diabetes duration independently predicted poor glycemic control, whereas increasing age was associated with a lower probability of HbA1c &amp;amp;gt; 7%. Conclusions: Contemporary antidiabetic therapies were associated with favorable numerical cardiometabolic trends, although these associations did not remain statistically significant after multiple-comparison correction. The findings should therefore be considered exploratory and hypothesis-generating.</p>
	]]></content:encoded>

	<dc:title>Patterns of Antidiabetic Therapy and Associated Metabolic Profiles in Routine Clinical Practice</dc:title>
			<dc:creator>Madalina Ioana Moisi</dc:creator>
			<dc:creator>Cosmin Mihai Vesa</dc:creator>
			<dc:creator>Florica Ramona Dorobantu</dc:creator>
			<dc:creator>Corina Cinezan</dc:creator>
			<dc:creator>Timea Claudia Ghitea</dc:creator>
			<dc:creator>Roxana Daniela Brata</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080145</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-08-01</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-08-01</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>145</prism:startingPage>
		<prism:doi>10.3390/diabetology7080145</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/145</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/144">

	<title>Diabetology, Vol. 7, Pages 144: Psychiatric Safety of GLP-1 Receptor Agonists Across Type 2 Diabetes and Obesity: An Integrative Review</title>
	<link>https://www.mdpi.com/2673-4540/7/8/144</link>
	<description>Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become first-line pharmacotherapy for eligible patients with type 2 diabetes mellitus and obesity. Soon after their broad uptake, spontaneous reports of suicidal ideation, depression, and anxiety prompted regulatory investigations and a contentious debate about the neuropsychiatric safety of the class. Objective: We aimed to synthesize emerging evidence on psychiatric adverse outcomes associated with GLP-1 RAs by integrating mechanistic, pharmacovigilance, observational, and regulatory data; to trace how the evidence and regulatory assessments evolved chronologically from initial signal detection toward subsequent controlled refutation; and to translate the current balance of evidence into practical clinical guidance. Methods: We conducted a narrative integrative synthesis of peer-reviewed pharmacovigilance studies, cohort and case&amp;amp;ndash;control analyses, systematic reviews and meta-analyses, mechanistic literature, and regulatory communications identified through targeted searches of the published record through early 2026. Results: Disproportionality analyses of spontaneous-reporting databases have generated modest, semaglutide-predominant signals for depression and suicidality, whereas liraglutide and tirzepatide have generally not. Anxiety signals parallel those for depression, and emerging data also indicate potential benefits for substance-use, binge-eating, and sleep-disordered breathing. In contrast, large propensity-matched cohort studies, a nationwide case&amp;amp;ndash;time&amp;amp;ndash;control analysis, an administrative-claims cohort exceeding two million users, and a meta-analysis of 91 placebo-controlled trials enrolling 107,910 participants found no increased risk and, in some analyses, lower risk of suicidal ideation. The principal exception is an amplified reporting signal among patients co-prescribed antidepressants or benzodiazepines, indicating effect modification by psychiatric vulnerability. Conclusions: The preponderance of controlled evidence has not demonstrated a causal relationship between GLP-1 RAs and suicidality or major psychiatric harm, a conclusion reflected in 2024&amp;amp;ndash;2026 regulatory determinations. Residual uncertainty persists for psychiatrically vulnerable subgroups, justifying continued individualized monitoring rather than restriction of access.</description>
	<pubDate>2026-07-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 144: Psychiatric Safety of GLP-1 Receptor Agonists Across Type 2 Diabetes and Obesity: An Integrative Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/144">doi: 10.3390/diabetology7080144</a></p>
	<p>Authors:
		Kavita Batra
		Jagdish Khubchandani
		Ravi Batra
		Syed Aman Ali
		</p>
	<p>Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become first-line pharmacotherapy for eligible patients with type 2 diabetes mellitus and obesity. Soon after their broad uptake, spontaneous reports of suicidal ideation, depression, and anxiety prompted regulatory investigations and a contentious debate about the neuropsychiatric safety of the class. Objective: We aimed to synthesize emerging evidence on psychiatric adverse outcomes associated with GLP-1 RAs by integrating mechanistic, pharmacovigilance, observational, and regulatory data; to trace how the evidence and regulatory assessments evolved chronologically from initial signal detection toward subsequent controlled refutation; and to translate the current balance of evidence into practical clinical guidance. Methods: We conducted a narrative integrative synthesis of peer-reviewed pharmacovigilance studies, cohort and case&amp;amp;ndash;control analyses, systematic reviews and meta-analyses, mechanistic literature, and regulatory communications identified through targeted searches of the published record through early 2026. Results: Disproportionality analyses of spontaneous-reporting databases have generated modest, semaglutide-predominant signals for depression and suicidality, whereas liraglutide and tirzepatide have generally not. Anxiety signals parallel those for depression, and emerging data also indicate potential benefits for substance-use, binge-eating, and sleep-disordered breathing. In contrast, large propensity-matched cohort studies, a nationwide case&amp;amp;ndash;time&amp;amp;ndash;control analysis, an administrative-claims cohort exceeding two million users, and a meta-analysis of 91 placebo-controlled trials enrolling 107,910 participants found no increased risk and, in some analyses, lower risk of suicidal ideation. The principal exception is an amplified reporting signal among patients co-prescribed antidepressants or benzodiazepines, indicating effect modification by psychiatric vulnerability. Conclusions: The preponderance of controlled evidence has not demonstrated a causal relationship between GLP-1 RAs and suicidality or major psychiatric harm, a conclusion reflected in 2024&amp;amp;ndash;2026 regulatory determinations. Residual uncertainty persists for psychiatrically vulnerable subgroups, justifying continued individualized monitoring rather than restriction of access.</p>
	]]></content:encoded>

	<dc:title>Psychiatric Safety of GLP-1 Receptor Agonists Across Type 2 Diabetes and Obesity: An Integrative Review</dc:title>
			<dc:creator>Kavita Batra</dc:creator>
			<dc:creator>Jagdish Khubchandani</dc:creator>
			<dc:creator>Ravi Batra</dc:creator>
			<dc:creator>Syed Aman Ali</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080144</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-30</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-30</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>144</prism:startingPage>
		<prism:doi>10.3390/diabetology7080144</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/144</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/143">

	<title>Diabetology, Vol. 7, Pages 143: Physical Activity Patterns Among Adults in the United States with Diabetes and Prediabetes: Differences by Country of Birth</title>
	<link>https://www.mdpi.com/2673-4540/7/8/143</link>
	<description>Background: Physical activity is a crucial component of diabetes prevention and management, yet participation varies across populations. Differences by country of birth may reflect cultural, socioeconomic, and structural factors that influence health behaviors among individuals with diabetic conditions. Objective: To examine the relationship between country of birth, diabetes status, and physical activity, and to assess whether country of birth is associated with diabetes prevalence. Methods: A cross-sectional analysis was conducted using U.S.-nationally representative data from the National Health and Nutrition Examination Survey (NHANES). Adults were categorized as having diabetes/prediabetes or no diabetes based on self-reported diagnosis. Physical activity was assessed using self-reported levels of moderate and vigorous leisure-time physical activity (LTPA). Sociodemographic characteristics were compared across groups. Stratified analyses were conducted to evaluate differences by country of birth and statistical tests were used to identify significant associations between diabetes status, physical activity, and sociodemographic variables. Results: Significant differences in sociodemographic characteristics were observed across diabetes status groups, particularly by age. There was no significant difference in physical activity levels between adults with diabetes compared to those without. Individuals with diabetes reported higher levels of sedentary time before adjustment for sociodemographic factors. Differences in physical activity behaviors were also observed in unadjusted analyses by country of birth, with foreign-born groups demonstrating lower levels of vigorous activity. Conclusions: Physical activity disparities exist among adults in the United States with diabetes and prediabetes and differ by country of birth, although they can be largely explained by sociodemographic factors. These findings highlight the need for culturally and socioeconomically tailored interventions to promote physical activity and support chronic disease management in diverse populations.</description>
	<pubDate>2026-07-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 143: Physical Activity Patterns Among Adults in the United States with Diabetes and Prediabetes: Differences by Country of Birth</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/143">doi: 10.3390/diabetology7080143</a></p>
	<p>Authors:
		Rebecca Duarte
		Jeegan Parikh
		Ismael Hoare
		</p>
	<p>Background: Physical activity is a crucial component of diabetes prevention and management, yet participation varies across populations. Differences by country of birth may reflect cultural, socioeconomic, and structural factors that influence health behaviors among individuals with diabetic conditions. Objective: To examine the relationship between country of birth, diabetes status, and physical activity, and to assess whether country of birth is associated with diabetes prevalence. Methods: A cross-sectional analysis was conducted using U.S.-nationally representative data from the National Health and Nutrition Examination Survey (NHANES). Adults were categorized as having diabetes/prediabetes or no diabetes based on self-reported diagnosis. Physical activity was assessed using self-reported levels of moderate and vigorous leisure-time physical activity (LTPA). Sociodemographic characteristics were compared across groups. Stratified analyses were conducted to evaluate differences by country of birth and statistical tests were used to identify significant associations between diabetes status, physical activity, and sociodemographic variables. Results: Significant differences in sociodemographic characteristics were observed across diabetes status groups, particularly by age. There was no significant difference in physical activity levels between adults with diabetes compared to those without. Individuals with diabetes reported higher levels of sedentary time before adjustment for sociodemographic factors. Differences in physical activity behaviors were also observed in unadjusted analyses by country of birth, with foreign-born groups demonstrating lower levels of vigorous activity. Conclusions: Physical activity disparities exist among adults in the United States with diabetes and prediabetes and differ by country of birth, although they can be largely explained by sociodemographic factors. These findings highlight the need for culturally and socioeconomically tailored interventions to promote physical activity and support chronic disease management in diverse populations.</p>
	]]></content:encoded>

	<dc:title>Physical Activity Patterns Among Adults in the United States with Diabetes and Prediabetes: Differences by Country of Birth</dc:title>
			<dc:creator>Rebecca Duarte</dc:creator>
			<dc:creator>Jeegan Parikh</dc:creator>
			<dc:creator>Ismael Hoare</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080143</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-29</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-29</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>143</prism:startingPage>
		<prism:doi>10.3390/diabetology7080143</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/143</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/8/142">

	<title>Diabetology, Vol. 7, Pages 142: Fecal Short-Chain Fatty Acid Profiling in Type 2 Diabetes Mellitus Using GC&amp;ndash;MS: A Comparative Study in a South African Population</title>
	<link>https://www.mdpi.com/2673-4540/7/8/142</link>
	<description>Background: Type 2 diabetes mellitus (T2DM) is associated with altered gut microbiota and reduced short-chain fatty acid production, which may contribute to insulin resistance. However, evidence on fecal Short Chain Fatty Acid (SCFA) profiles in African populations remains limited. This study quantified fecal SCFAs in individuals with and without T2DM using Gas Chromatography&amp;amp;ndash;Mass Spectrophotometry (GC-MS) with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) derivatization. Methods: A cross-sectional study included 140 adults (92 non-diabetic and 48 T2DM). Fecal SCFAs were extracted, derivatized using BSTFA, and analysed by GC&amp;amp;ndash;MS. Associations between SCFAs, diabetes status, and HbA1c were evaluated using non-parametric statistics. Results: The GC&amp;amp;ndash;MS method demonstrated strong linearity (R2 = 0.9917&amp;amp;ndash;0.9978), acceptable recovery, and reproducibility. Acetic, propionic, butyric, pentanoic, hexanoic, and heptanoic acids were detected, with acetic acid being most abundant in both groups. T2DM participants had higher median SCFA levels, although only butyric acid differed significantly (p = 0.027). HbA1c was significantly higher in the T2DM group (p &amp;amp;lt; 0.001). No significant associations were observed between SCFAs and HbA1c in either group. Age differed significantly between groups, with T2DM participants older than non-diabetic controls. Conclusions: Most fecal SCFA profiles were comparable between individuals with T2DM and healthy controls. However, butyric acid was significantly elevated in the T2DM group, indicating that not all SCFAs exhibited similar patterns between the study groups. These findings suggest that fecal SCFAs alone may not serve as reliable biomarkers of T2DM in this population and highlight the influence of complex host&amp;amp;ndash;microbiome&amp;amp;ndash;environment interactions suggesting that dietary and microbial factors may outweigh disease status in determining SCFA variability in this cohort setting.</description>
	<pubDate>2026-07-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 142: Fecal Short-Chain Fatty Acid Profiling in Type 2 Diabetes Mellitus Using GC&amp;ndash;MS: A Comparative Study in a South African Population</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/8/142">doi: 10.3390/diabetology7080142</a></p>
	<p>Authors:
		Scelo Khumalo
		Zamathombeni Duma
		Lizette Bekker
		Puleng Matatiele
		Lesibana Sethoga
		Sara Mosima Pheeha
		</p>
	<p>Background: Type 2 diabetes mellitus (T2DM) is associated with altered gut microbiota and reduced short-chain fatty acid production, which may contribute to insulin resistance. However, evidence on fecal Short Chain Fatty Acid (SCFA) profiles in African populations remains limited. This study quantified fecal SCFAs in individuals with and without T2DM using Gas Chromatography&amp;amp;ndash;Mass Spectrophotometry (GC-MS) with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) derivatization. Methods: A cross-sectional study included 140 adults (92 non-diabetic and 48 T2DM). Fecal SCFAs were extracted, derivatized using BSTFA, and analysed by GC&amp;amp;ndash;MS. Associations between SCFAs, diabetes status, and HbA1c were evaluated using non-parametric statistics. Results: The GC&amp;amp;ndash;MS method demonstrated strong linearity (R2 = 0.9917&amp;amp;ndash;0.9978), acceptable recovery, and reproducibility. Acetic, propionic, butyric, pentanoic, hexanoic, and heptanoic acids were detected, with acetic acid being most abundant in both groups. T2DM participants had higher median SCFA levels, although only butyric acid differed significantly (p = 0.027). HbA1c was significantly higher in the T2DM group (p &amp;amp;lt; 0.001). No significant associations were observed between SCFAs and HbA1c in either group. Age differed significantly between groups, with T2DM participants older than non-diabetic controls. Conclusions: Most fecal SCFA profiles were comparable between individuals with T2DM and healthy controls. However, butyric acid was significantly elevated in the T2DM group, indicating that not all SCFAs exhibited similar patterns between the study groups. These findings suggest that fecal SCFAs alone may not serve as reliable biomarkers of T2DM in this population and highlight the influence of complex host&amp;amp;ndash;microbiome&amp;amp;ndash;environment interactions suggesting that dietary and microbial factors may outweigh disease status in determining SCFA variability in this cohort setting.</p>
	]]></content:encoded>

	<dc:title>Fecal Short-Chain Fatty Acid Profiling in Type 2 Diabetes Mellitus Using GC&amp;amp;ndash;MS: A Comparative Study in a South African Population</dc:title>
			<dc:creator>Scelo Khumalo</dc:creator>
			<dc:creator>Zamathombeni Duma</dc:creator>
			<dc:creator>Lizette Bekker</dc:creator>
			<dc:creator>Puleng Matatiele</dc:creator>
			<dc:creator>Lesibana Sethoga</dc:creator>
			<dc:creator>Sara Mosima Pheeha</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7080142</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-23</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-23</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>142</prism:startingPage>
		<prism:doi>10.3390/diabetology7080142</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/8/142</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/141">

	<title>Diabetology, Vol. 7, Pages 141: A Potential Role of Psoralea corylifolia L. Seed Extract in Diabetic Nephropathy</title>
	<link>https://www.mdpi.com/2673-4540/7/7/141</link>
	<description>Diabetic nephropathy (DN) is a major microvascular complication of diabetes mellitus, and a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. It is characterized by proteinuria, mesangial expansion, glomerulosclerosis and progressive loss of renal function. Current therapeutic strategies of DN, including renin&amp;amp;ndash;angiotensin&amp;amp;ndash;aldosterone system (RAAS) blockade, glucagon-like peptide-1 receptor agonists, non-steroidal mineralocorticoid receptor, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, only slow the progression of the disease rather than reversing the pathology. Therefore, there is a growing interest in identifying alternative or complementary therapeutic agents, particularly those derived from natural products with multi-targeted activities. Psoralea corylifolia Linn (PCL) is a medicinal herb commonly used in traditional Asian medicine. It has known pharmacological properties on oxidative stress, inflammation, fibrosis and metabolic disorders. Accumulating recent studies indicated that PCL and its bioactive compounds, such as psoralen, bakuchiol, and corylin, mitigate pathological conditions in various diseases. Here, the current review will provide our current knowledge of major identified and characterized PCL focusing on their biological activity and function, particularly in DN.</description>
	<pubDate>2026-07-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 141: A Potential Role of Psoralea corylifolia L. Seed Extract in Diabetic Nephropathy</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/141">doi: 10.3390/diabetology7070141</a></p>
	<p>Authors:
		Jong Han Lee
		</p>
	<p>Diabetic nephropathy (DN) is a major microvascular complication of diabetes mellitus, and a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. It is characterized by proteinuria, mesangial expansion, glomerulosclerosis and progressive loss of renal function. Current therapeutic strategies of DN, including renin&amp;amp;ndash;angiotensin&amp;amp;ndash;aldosterone system (RAAS) blockade, glucagon-like peptide-1 receptor agonists, non-steroidal mineralocorticoid receptor, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, only slow the progression of the disease rather than reversing the pathology. Therefore, there is a growing interest in identifying alternative or complementary therapeutic agents, particularly those derived from natural products with multi-targeted activities. Psoralea corylifolia Linn (PCL) is a medicinal herb commonly used in traditional Asian medicine. It has known pharmacological properties on oxidative stress, inflammation, fibrosis and metabolic disorders. Accumulating recent studies indicated that PCL and its bioactive compounds, such as psoralen, bakuchiol, and corylin, mitigate pathological conditions in various diseases. Here, the current review will provide our current knowledge of major identified and characterized PCL focusing on their biological activity and function, particularly in DN.</p>
	]]></content:encoded>

	<dc:title>A Potential Role of Psoralea corylifolia L. Seed Extract in Diabetic Nephropathy</dc:title>
			<dc:creator>Jong Han Lee</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070141</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-22</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-22</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>141</prism:startingPage>
		<prism:doi>10.3390/diabetology7070141</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/141</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/140">

	<title>Diabetology, Vol. 7, Pages 140: Reliability, Criterion Validity, and Agreement of the Global Physical Activity Questionnaire Against Accelerometry Among High-Risk Individuals for Type 2 Diabetes in India</title>
	<link>https://www.mdpi.com/2673-4540/7/7/140</link>
	<description>Objectives: We assessed the test&amp;amp;ndash;retest reliability, criterion validity, and agreement of the Global Physical Activity Questionnaire (GPAQ) against accelerometry for estimating physical activity (PA) and sedentary behaviour (SB) among Indian adults at high risk of type 2 diabetes. Methods: We validated the original GPAQ in a subsample of 196 participants from the Kerala Diabetes Prevention Program. Participants were identified as being at high risk based on an Indian Diabetes Risk Score (IDRS) &amp;amp;ge; 60 and the absence of diabetes on an oral glucose tolerance test. To assess test&amp;amp;ndash;retest reliability, participants completed the GPAQ on two occasions, one week apart. Criterion validity and agreement were evaluated by comparing GPAQ responses with seven days of concurrent ActiGraph GT3X accelerometer data. Statistical analyses included intraclass correlation coefficients (ICCs) for reliability, Spearman&amp;amp;rsquo;s correlation coefficients (&amp;amp;rho;) for criterion validity, and Bland&amp;amp;ndash;Altman plots for agreement. Results: The mean (SD) age of participants was 47.0 (7.4) years, and 51% were female. ICCs for test&amp;amp;ndash;retest reliability ranged from 0.37 for moderate-intensity PA to 0.61 for vigorous-intensity PA. Spearman&amp;amp;rsquo;s &amp;amp;rho; for criterion validity ranged from 0.14 for SB to 0.38 for overall moderate-to-vigorous PA. Bland&amp;amp;ndash;Altman plots showed that the GPAQ consistently overestimated PA across all intensity levels while underestimating SB. Conclusions: The GPAQ demonstrated poor-to-moderate test&amp;amp;ndash;retest reliability, low criterion validity, and poor agreement with accelerometry for assessing PA and SB among Indian adults at high risk of type 2 diabetes.</description>
	<pubDate>2026-07-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 140: Reliability, Criterion Validity, and Agreement of the Global Physical Activity Questionnaire Against Accelerometry Among High-Risk Individuals for Type 2 Diabetes in India</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/140">doi: 10.3390/diabetology7070140</a></p>
	<p>Authors:
		Sathish Thirunavukkarasu
		Kai Wallens
		Gabrielli T. De Mello
		Yingting Cao
		Emma E. Thomas
		Natasha Reid
		Kavumpurathu Raman Thankappan
		Brian Oldenburg
		Elezebeth Mathews
		</p>
	<p>Objectives: We assessed the test&amp;amp;ndash;retest reliability, criterion validity, and agreement of the Global Physical Activity Questionnaire (GPAQ) against accelerometry for estimating physical activity (PA) and sedentary behaviour (SB) among Indian adults at high risk of type 2 diabetes. Methods: We validated the original GPAQ in a subsample of 196 participants from the Kerala Diabetes Prevention Program. Participants were identified as being at high risk based on an Indian Diabetes Risk Score (IDRS) &amp;amp;ge; 60 and the absence of diabetes on an oral glucose tolerance test. To assess test&amp;amp;ndash;retest reliability, participants completed the GPAQ on two occasions, one week apart. Criterion validity and agreement were evaluated by comparing GPAQ responses with seven days of concurrent ActiGraph GT3X accelerometer data. Statistical analyses included intraclass correlation coefficients (ICCs) for reliability, Spearman&amp;amp;rsquo;s correlation coefficients (&amp;amp;rho;) for criterion validity, and Bland&amp;amp;ndash;Altman plots for agreement. Results: The mean (SD) age of participants was 47.0 (7.4) years, and 51% were female. ICCs for test&amp;amp;ndash;retest reliability ranged from 0.37 for moderate-intensity PA to 0.61 for vigorous-intensity PA. Spearman&amp;amp;rsquo;s &amp;amp;rho; for criterion validity ranged from 0.14 for SB to 0.38 for overall moderate-to-vigorous PA. Bland&amp;amp;ndash;Altman plots showed that the GPAQ consistently overestimated PA across all intensity levels while underestimating SB. Conclusions: The GPAQ demonstrated poor-to-moderate test&amp;amp;ndash;retest reliability, low criterion validity, and poor agreement with accelerometry for assessing PA and SB among Indian adults at high risk of type 2 diabetes.</p>
	]]></content:encoded>

	<dc:title>Reliability, Criterion Validity, and Agreement of the Global Physical Activity Questionnaire Against Accelerometry Among High-Risk Individuals for Type 2 Diabetes in India</dc:title>
			<dc:creator>Sathish Thirunavukkarasu</dc:creator>
			<dc:creator>Kai Wallens</dc:creator>
			<dc:creator>Gabrielli T. De Mello</dc:creator>
			<dc:creator>Yingting Cao</dc:creator>
			<dc:creator>Emma E. Thomas</dc:creator>
			<dc:creator>Natasha Reid</dc:creator>
			<dc:creator>Kavumpurathu Raman Thankappan</dc:creator>
			<dc:creator>Brian Oldenburg</dc:creator>
			<dc:creator>Elezebeth Mathews</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070140</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-21</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-21</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>140</prism:startingPage>
		<prism:doi>10.3390/diabetology7070140</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/140</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/139">

	<title>Diabetology, Vol. 7, Pages 139: Nutritional Knowledge, Attitude, Eating Behavior, and Dietary Intake in Relation to Glycemic Control Among Patients with Type 2 Diabetes in Rural Thailand</title>
	<link>https://www.mdpi.com/2673-4540/7/7/139</link>
	<description>Objectives: Type 2 diabetes mellitus (T2DM) is an increasing public health concern in Thailand, particularly in rural communities where dietary practices and contextual factors may influence glycemic control. This study aimed to assess nutritional knowledge, attitude, and eating behavior using the Knowledge&amp;amp;ndash;Attitude&amp;amp;ndash;Practice (KAP) framework and to compare nutritional intake profiles between patients with controlled and uncontrolled glycemic status. Methods: A cross-sectional study was conducted among 70 patients with T2DM attending a health-promoting hospital in northeastern Thailand. Participants were classified into glycemic-controlled (GC; HbA1c &amp;amp;lt; 7%, n = 36) and glycemic-uncontrolled (UC; HbA1c &amp;amp;ge; 7%, n = 34) groups. Data were collected using a semi-structured questionnaire covering demographics, anthropometry, body composition, biochemical parameters, and KAP domains. Dietary intake was assessed using three-day food records (two weekdays and one weekend day) and analyzed with the INMUCAL Nutrients program. Statistical analyses included descriptive statistics, group comparisons, logistic regression, and Spearman&amp;amp;rsquo;s correlation. Results: Overall, participants demonstrated high levels of nutritional knowledge (71.4%) and fair attitude (52.9%), but moderate levels of appropriate eating behavior (58.6%). Eating behavior differed significantly between GC and UC groups (p = 0.038). The UC group consumed significantly higher amounts of total energy, carbohydrates, simple carbohydrates, and protein than the GC group. HbA1c and fasting blood glucose were positively correlated with total energy, carbohydrate, simple carbohydrate, and zinc intake, while protein and phosphorus intake were positively associated with fasting blood glucose only. Logistic regression analysis showed no significant associations between KAP domains and glycemic control. Conclusions: Glycemic control among rural Thai patients with T2DM was more closely related to dietary intake patterns than to nutritional knowledge or attitude alone, highlighting the need for context-specific, community-based dietary interventions.</description>
	<pubDate>2026-07-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 139: Nutritional Knowledge, Attitude, Eating Behavior, and Dietary Intake in Relation to Glycemic Control Among Patients with Type 2 Diabetes in Rural Thailand</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/139">doi: 10.3390/diabetology7070139</a></p>
	<p>Authors:
		Sirapat Khodseewong
		Thidarat Somdee
		Ploypailin Aneknan
		Rujira Nonsa-ard
		</p>
	<p>Objectives: Type 2 diabetes mellitus (T2DM) is an increasing public health concern in Thailand, particularly in rural communities where dietary practices and contextual factors may influence glycemic control. This study aimed to assess nutritional knowledge, attitude, and eating behavior using the Knowledge&amp;amp;ndash;Attitude&amp;amp;ndash;Practice (KAP) framework and to compare nutritional intake profiles between patients with controlled and uncontrolled glycemic status. Methods: A cross-sectional study was conducted among 70 patients with T2DM attending a health-promoting hospital in northeastern Thailand. Participants were classified into glycemic-controlled (GC; HbA1c &amp;amp;lt; 7%, n = 36) and glycemic-uncontrolled (UC; HbA1c &amp;amp;ge; 7%, n = 34) groups. Data were collected using a semi-structured questionnaire covering demographics, anthropometry, body composition, biochemical parameters, and KAP domains. Dietary intake was assessed using three-day food records (two weekdays and one weekend day) and analyzed with the INMUCAL Nutrients program. Statistical analyses included descriptive statistics, group comparisons, logistic regression, and Spearman&amp;amp;rsquo;s correlation. Results: Overall, participants demonstrated high levels of nutritional knowledge (71.4%) and fair attitude (52.9%), but moderate levels of appropriate eating behavior (58.6%). Eating behavior differed significantly between GC and UC groups (p = 0.038). The UC group consumed significantly higher amounts of total energy, carbohydrates, simple carbohydrates, and protein than the GC group. HbA1c and fasting blood glucose were positively correlated with total energy, carbohydrate, simple carbohydrate, and zinc intake, while protein and phosphorus intake were positively associated with fasting blood glucose only. Logistic regression analysis showed no significant associations between KAP domains and glycemic control. Conclusions: Glycemic control among rural Thai patients with T2DM was more closely related to dietary intake patterns than to nutritional knowledge or attitude alone, highlighting the need for context-specific, community-based dietary interventions.</p>
	]]></content:encoded>

	<dc:title>Nutritional Knowledge, Attitude, Eating Behavior, and Dietary Intake in Relation to Glycemic Control Among Patients with Type 2 Diabetes in Rural Thailand</dc:title>
			<dc:creator>Sirapat Khodseewong</dc:creator>
			<dc:creator>Thidarat Somdee</dc:creator>
			<dc:creator>Ploypailin Aneknan</dc:creator>
			<dc:creator>Rujira Nonsa-ard</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070139</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-20</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-20</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>139</prism:startingPage>
		<prism:doi>10.3390/diabetology7070139</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/139</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/138">

	<title>Diabetology, Vol. 7, Pages 138: Determinants of Health Status in Adult Diabetic Patients: From Anthropometric and Biological Indicators to Individual Perception</title>
	<link>https://www.mdpi.com/2673-4540/7/7/138</link>
	<description>Background/Objectives: In Romania, diabetes mellitus remains a significant public health challenge, characterized by high prevalence and significant undiagnosed cases. This study assessed the prevalence of elevated glycated hemoglobin (HbA1c) levels within the adult population participating in the European Health Examination Survey (EHES) and examined their associations with major cardiometabolic risk factors, subjective health perception, and patient awareness of previously diagnosed chronic conditions. Methods: This cross-sectional study analyzed data from the EHES in Romania, including systematic, population-weighted sample of adults aged 25&amp;amp;ndash;64 years. Data were analyzed using the Complex Samples module in SPSS, version 29.0 (IBM Corp., Armonk, NY, USA). HbA1c levels were measured through standardized clinical examination, with values of 5.7&amp;amp;ndash;6.4% classified as at risk for diabetes mellitus, and values &amp;amp;ge;6.5% as diabetes mellitus. Results: Among 5380 representative adults, the prevalence of elevated HbA1c (&amp;amp;ge;6.5%) was 7.1%, while prediabetes (HbA1c 5.7&amp;amp;ndash;6.4%) affected 35.4% of participants; both conditions were significantly more prevalent in men than in women. Elevated HbA1c and prediabetes were substantially more frequent among individuals with hypertension and hypercholesterolemia, and glycemic control among participants with previously diagnosed diabetes was generally poor (all p &amp;amp;le; 0.05). Individuals who are aware of having a chronic health condition appear to engage more actively in self-care practices, including increased physical activity and more frequent monitoring of key biological parameters. Conclusions: Elevated HbA1c and prediabetes were more prevalent than estimates reported in other studies using HbA1c-based diagnostic criteria. These observations highlight the importance of early detection and timely diagnosis, as awareness of one&amp;amp;rsquo;s health status may facilitate healthier behaviors that mitigate metabolic complications.</description>
	<pubDate>2026-07-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 138: Determinants of Health Status in Adult Diabetic Patients: From Anthropometric and Biological Indicators to Individual Perception</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/138">doi: 10.3390/diabetology7070138</a></p>
	<p>Authors:
		Lăcrămioara Aurelia Brîndușe
		Corina Vicol
		Maria Alexandra Cucu
		Eugenia Claudia Bratu
		</p>
	<p>Background/Objectives: In Romania, diabetes mellitus remains a significant public health challenge, characterized by high prevalence and significant undiagnosed cases. This study assessed the prevalence of elevated glycated hemoglobin (HbA1c) levels within the adult population participating in the European Health Examination Survey (EHES) and examined their associations with major cardiometabolic risk factors, subjective health perception, and patient awareness of previously diagnosed chronic conditions. Methods: This cross-sectional study analyzed data from the EHES in Romania, including systematic, population-weighted sample of adults aged 25&amp;amp;ndash;64 years. Data were analyzed using the Complex Samples module in SPSS, version 29.0 (IBM Corp., Armonk, NY, USA). HbA1c levels were measured through standardized clinical examination, with values of 5.7&amp;amp;ndash;6.4% classified as at risk for diabetes mellitus, and values &amp;amp;ge;6.5% as diabetes mellitus. Results: Among 5380 representative adults, the prevalence of elevated HbA1c (&amp;amp;ge;6.5%) was 7.1%, while prediabetes (HbA1c 5.7&amp;amp;ndash;6.4%) affected 35.4% of participants; both conditions were significantly more prevalent in men than in women. Elevated HbA1c and prediabetes were substantially more frequent among individuals with hypertension and hypercholesterolemia, and glycemic control among participants with previously diagnosed diabetes was generally poor (all p &amp;amp;le; 0.05). Individuals who are aware of having a chronic health condition appear to engage more actively in self-care practices, including increased physical activity and more frequent monitoring of key biological parameters. Conclusions: Elevated HbA1c and prediabetes were more prevalent than estimates reported in other studies using HbA1c-based diagnostic criteria. These observations highlight the importance of early detection and timely diagnosis, as awareness of one&amp;amp;rsquo;s health status may facilitate healthier behaviors that mitigate metabolic complications.</p>
	]]></content:encoded>

	<dc:title>Determinants of Health Status in Adult Diabetic Patients: From Anthropometric and Biological Indicators to Individual Perception</dc:title>
			<dc:creator>Lăcrămioara Aurelia Brîndușe</dc:creator>
			<dc:creator>Corina Vicol</dc:creator>
			<dc:creator>Maria Alexandra Cucu</dc:creator>
			<dc:creator>Eugenia Claudia Bratu</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070138</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-17</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-17</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>138</prism:startingPage>
		<prism:doi>10.3390/diabetology7070138</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/138</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/137">

	<title>Diabetology, Vol. 7, Pages 137: Association Between Physical Activity and Peripheral Arterial Disease in Patients with Diabetes: A Multicentre Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/7/137</link>
	<description>Background and Objectives: Physical inactivity is a modifiable risk factor for vascular complications in individuals with diabetes mellitus. The aim of this study was to evaluate the predictive capacity of physical activity level for peripheral arterial disease (PAD) in patients with diabetes. Methods: A multicentre cross-sectional study was conducted in adults with diabetes undergoing vascular screening. Physical activity was assessed using the Spanish short version of the Minnesota Leisure-Time Physical Activity Questionnaire (VREM), with energy expenditure expressed as metabolic equivalents (MET-min/14 days). PAD was defined according to standard vascular criteria. Analyses included bivariate tests, Spearman correlation, multivariable logistic regression, and receiver operating characteristic (ROC) curve analysis. Results: Fifty-four participants were included, with a mean energy expenditure of 4031.8 &amp;amp;plusmn; 3986.9 MET-min/14 days. Physical activity was inversely correlated with PAD (&amp;amp;rho; = &amp;amp;minus;0.380; p = 0.005). Participants without PAD had significantly higher activity levels than those with PAD (p = 0.006). After adjustment for age, body mass index, glycated haemoglobin, and diabetes duration, higher physical activity remained independently associated with lower odds of PAD (OR = 0.621; 95% CI: 0.392&amp;amp;ndash;0.983; p = 0.042). The model showed good discrimination (AUC = 0.840). Conclusions: Higher leisure-time physical activity is associated with a reduced likelihood of PAD in individuals with diabetes, although the findings should be interpreted cautiously due to the study design and sample size.</description>
	<pubDate>2026-07-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 137: Association Between Physical Activity and Peripheral Arterial Disease in Patients with Diabetes: A Multicentre Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/137">doi: 10.3390/diabetology7070137</a></p>
	<p>Authors:
		Laura Palacios-Abril
		Aroa Tardáguila-García
		Francisco Javier Álvaro-Afonso
		Sol Tejeda-Ramírez
		Mateo López-Moral
		José Luis Lázaro-Martínez
		</p>
	<p>Background and Objectives: Physical inactivity is a modifiable risk factor for vascular complications in individuals with diabetes mellitus. The aim of this study was to evaluate the predictive capacity of physical activity level for peripheral arterial disease (PAD) in patients with diabetes. Methods: A multicentre cross-sectional study was conducted in adults with diabetes undergoing vascular screening. Physical activity was assessed using the Spanish short version of the Minnesota Leisure-Time Physical Activity Questionnaire (VREM), with energy expenditure expressed as metabolic equivalents (MET-min/14 days). PAD was defined according to standard vascular criteria. Analyses included bivariate tests, Spearman correlation, multivariable logistic regression, and receiver operating characteristic (ROC) curve analysis. Results: Fifty-four participants were included, with a mean energy expenditure of 4031.8 &amp;amp;plusmn; 3986.9 MET-min/14 days. Physical activity was inversely correlated with PAD (&amp;amp;rho; = &amp;amp;minus;0.380; p = 0.005). Participants without PAD had significantly higher activity levels than those with PAD (p = 0.006). After adjustment for age, body mass index, glycated haemoglobin, and diabetes duration, higher physical activity remained independently associated with lower odds of PAD (OR = 0.621; 95% CI: 0.392&amp;amp;ndash;0.983; p = 0.042). The model showed good discrimination (AUC = 0.840). Conclusions: Higher leisure-time physical activity is associated with a reduced likelihood of PAD in individuals with diabetes, although the findings should be interpreted cautiously due to the study design and sample size.</p>
	]]></content:encoded>

	<dc:title>Association Between Physical Activity and Peripheral Arterial Disease in Patients with Diabetes: A Multicentre Cross-Sectional Study</dc:title>
			<dc:creator>Laura Palacios-Abril</dc:creator>
			<dc:creator>Aroa Tardáguila-García</dc:creator>
			<dc:creator>Francisco Javier Álvaro-Afonso</dc:creator>
			<dc:creator>Sol Tejeda-Ramírez</dc:creator>
			<dc:creator>Mateo López-Moral</dc:creator>
			<dc:creator>José Luis Lázaro-Martínez</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070137</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-15</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-15</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>137</prism:startingPage>
		<prism:doi>10.3390/diabetology7070137</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/137</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/136">

	<title>Diabetology, Vol. 7, Pages 136: When Pancreas Transplant Recipients Gain Weight: Challenges in Endogenous Insulin Delivery</title>
	<link>https://www.mdpi.com/2673-4540/7/7/136</link>
	<description>Background/Objectives: To determine the association between post-pancreas transplantation weight gain and graft dysfunction. Methods: Retrospective analysis of pancreas transplantation from 1 August 2008 to 1 November 2022. All patients &amp;amp;gt; 18 years old who underwent simultaneous kidney pancreas transplant (SPK), pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA) with at least one year of follow up were included. The association between post-transplant weight gain and graft dysfunction was assessed. Graft dysfunction was defined as HbA1c &amp;amp;gt; 6.5% or use of antihyperglycemic medication. Results: Twenty-five percent of recipients had substantial weight gain (SWG), defined as &amp;amp;gt;7% weight increase, by 1 year post-transplant. Recipients with T2D and SPK recipients were more likely to gain weight. SWG within the first year was significantly associated with the development of graft dysfunction at most recent follow up (Cox HR = 3.3, p = 0.005), but not at 1 year. Recipients with SWG in the first year had significantly higher HbA1C at most recent follow up (5.3 &amp;amp;plusmn; 0.7% vs. 5.9 &amp;amp;plusmn; 0.9%, p = 0.009), but not at 1 year. Among recipients with SWG occurring after 1 year, there were no differences in graft dysfunction or HbA1C at 1 year and no difference in graft dysfunction or HbA1C at most recent follow up. Conclusions: In this single-center study, SWG at 1 year post-transplant was associated with the development of graft dysfunction and elevated HbA1C in the long term.</description>
	<pubDate>2026-07-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 136: When Pancreas Transplant Recipients Gain Weight: Challenges in Endogenous Insulin Delivery</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/136">doi: 10.3390/diabetology7070136</a></p>
	<p>Authors:
		Nina L. Owen-Simon
		Geoffrey K. Dube
		Lloyd E. Ratner
		Kasi McCune
		</p>
	<p>Background/Objectives: To determine the association between post-pancreas transplantation weight gain and graft dysfunction. Methods: Retrospective analysis of pancreas transplantation from 1 August 2008 to 1 November 2022. All patients &amp;amp;gt; 18 years old who underwent simultaneous kidney pancreas transplant (SPK), pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA) with at least one year of follow up were included. The association between post-transplant weight gain and graft dysfunction was assessed. Graft dysfunction was defined as HbA1c &amp;amp;gt; 6.5% or use of antihyperglycemic medication. Results: Twenty-five percent of recipients had substantial weight gain (SWG), defined as &amp;amp;gt;7% weight increase, by 1 year post-transplant. Recipients with T2D and SPK recipients were more likely to gain weight. SWG within the first year was significantly associated with the development of graft dysfunction at most recent follow up (Cox HR = 3.3, p = 0.005), but not at 1 year. Recipients with SWG in the first year had significantly higher HbA1C at most recent follow up (5.3 &amp;amp;plusmn; 0.7% vs. 5.9 &amp;amp;plusmn; 0.9%, p = 0.009), but not at 1 year. Among recipients with SWG occurring after 1 year, there were no differences in graft dysfunction or HbA1C at 1 year and no difference in graft dysfunction or HbA1C at most recent follow up. Conclusions: In this single-center study, SWG at 1 year post-transplant was associated with the development of graft dysfunction and elevated HbA1C in the long term.</p>
	]]></content:encoded>

	<dc:title>When Pancreas Transplant Recipients Gain Weight: Challenges in Endogenous Insulin Delivery</dc:title>
			<dc:creator>Nina L. Owen-Simon</dc:creator>
			<dc:creator>Geoffrey K. Dube</dc:creator>
			<dc:creator>Lloyd E. Ratner</dc:creator>
			<dc:creator>Kasi McCune</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070136</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-15</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-15</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>136</prism:startingPage>
		<prism:doi>10.3390/diabetology7070136</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/136</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/135">

	<title>Diabetology, Vol. 7, Pages 135: The C Allele of rs2073618 and rs3134069 of the Osteoprotegerin Gene Is Associated with Diabetic Retinopathy in Slovenian Patients with Type 2 Diabetes</title>
	<link>https://www.mdpi.com/2673-4540/7/7/135</link>
	<description>Background: Osteoprotegerin (OPG) is best known for regulating bone remodeling, vascular calcification, apoptosis, and immune responses. Recent studies also suggest that OPG may play an important role in diabetic microvascular complications such as diabetic retinopathy (DR). Objectives: The aim of our cross-sectional case&amp;amp;ndash;control study was to assess the relationship between the OPG variants (rs2073618 and rs3134069) and DR in a large cohort of subjects with type 2 diabetes (T2DM). Methods: A total of 1554 subjects with T2DM were enrolled in this cross-sectional case&amp;amp;ndash;control study: 577 with DR and 977 without DR. Genotyping was performed using StepOne Real-Time PCR with TaqMan genotyping assays. Results: Our data indicated that the prevalence of the C minor allele was significantly higher among patients with DR and type 2 diabetes in both polymorphisms. Furthermore, individuals carrying the CC genotype of the rs2073618 had a 1.42-fold increased likelihood of DR, while carriers of the CC or CA genotypes of the rs3134069 exhibited a 1.55-fold higher likelihood of DR. Conclusions: Taken together with existing evidence, these results suggest that OPG polymorphisms may be involved in the development of DR.</description>
	<pubDate>2026-07-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 135: The C Allele of rs2073618 and rs3134069 of the Osteoprotegerin Gene Is Associated with Diabetic Retinopathy in Slovenian Patients with Type 2 Diabetes</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/135">doi: 10.3390/diabetology7070135</a></p>
	<p>Authors:
		Stella Stare
		Ema Šuligoj
		Melina Bešić
		Jernej Letonja
		Mojca Globočnik Petrovič
		Ines Cilenšek
		Daniel Petrovič
		</p>
	<p>Background: Osteoprotegerin (OPG) is best known for regulating bone remodeling, vascular calcification, apoptosis, and immune responses. Recent studies also suggest that OPG may play an important role in diabetic microvascular complications such as diabetic retinopathy (DR). Objectives: The aim of our cross-sectional case&amp;amp;ndash;control study was to assess the relationship between the OPG variants (rs2073618 and rs3134069) and DR in a large cohort of subjects with type 2 diabetes (T2DM). Methods: A total of 1554 subjects with T2DM were enrolled in this cross-sectional case&amp;amp;ndash;control study: 577 with DR and 977 without DR. Genotyping was performed using StepOne Real-Time PCR with TaqMan genotyping assays. Results: Our data indicated that the prevalence of the C minor allele was significantly higher among patients with DR and type 2 diabetes in both polymorphisms. Furthermore, individuals carrying the CC genotype of the rs2073618 had a 1.42-fold increased likelihood of DR, while carriers of the CC or CA genotypes of the rs3134069 exhibited a 1.55-fold higher likelihood of DR. Conclusions: Taken together with existing evidence, these results suggest that OPG polymorphisms may be involved in the development of DR.</p>
	]]></content:encoded>

	<dc:title>The C Allele of rs2073618 and rs3134069 of the Osteoprotegerin Gene Is Associated with Diabetic Retinopathy in Slovenian Patients with Type 2 Diabetes</dc:title>
			<dc:creator>Stella Stare</dc:creator>
			<dc:creator>Ema Šuligoj</dc:creator>
			<dc:creator>Melina Bešić</dc:creator>
			<dc:creator>Jernej Letonja</dc:creator>
			<dc:creator>Mojca Globočnik Petrovič</dc:creator>
			<dc:creator>Ines Cilenšek</dc:creator>
			<dc:creator>Daniel Petrovič</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070135</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-10</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-10</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>135</prism:startingPage>
		<prism:doi>10.3390/diabetology7070135</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/135</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/134">

	<title>Diabetology, Vol. 7, Pages 134: Relationship Between Diabetes Stigma and Outpatient Medical Costs in Patients with Type 2 Diabetes: A Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2673-4540/7/7/134</link>
	<description>Background/Objectives: Diabetes-related stigma decreases treatment motivation. While subjective financial burden is a known barrier, the impact of actual medical costs on stigma remains unclear. We investigated the relationship between annual outpatient medical costs (total and out-of-pocket) and stigma in type 2 diabetes to explore whether this association might be more closely related to direct financial hardship or underlying treatment complexity. Methods: In a cross-sectional study, we evaluated stigma in 232 outpatients using the Kanden Institute Stigma Scale (KISS). Patients scoring &amp;amp;ge;20 formed the high stigma group (n = 59). Annual medical costs were extracted from electronic hospital claims. We examined associations between medical costs and high stigma using multivariable logistic regression and restricted cubic spline (RCS) models. Results: Adjusted for sex and age, higher total medical cost (per 10,000 JPY/year) was significantly associated with high stigma (odds ratio [OR] = 1.03, 95% confidence interval [CI]: 1.01&amp;amp;ndash;1.05, p &amp;amp;lt; 0.01). However, this significance was attenuated after additionally adjusting for HbA1c and antidiabetic agent count (OR = 1.02, 95% CI: 1.00&amp;amp;ndash;1.04, p = 0.05). RCS analysis confirmed this dose&amp;amp;ndash;response association disappeared upon adjusting for treatment intensity. Notably, out-of-pocket costs showed no significant association with high stigma in any fully adjusted models (OR = 1.03, 95% CI: 0.95&amp;amp;ndash;1.11, p = 0.45). Conclusions: While total medical costs are associated with high stigma, the attenuation of this relationship after adjusting for clinical factors suggests that this association may be closely intertwined with the psychosocial burden of treatment complexity, such as polypharmacy and insulin injections, rather than acting solely through direct economic pain from out-of-pocket expenses. Clinicians should prioritize shared decision-making to mitigate psychological distress when intensifying treatment.</description>
	<pubDate>2026-07-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 134: Relationship Between Diabetes Stigma and Outpatient Medical Costs in Patients with Type 2 Diabetes: A Cross-Sectional Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/134">doi: 10.3390/diabetology7070134</a></p>
	<p>Authors:
		Mari Tanaka
		Hiroyuki Ito
		Erika Watanabe
		</p>
	<p>Background/Objectives: Diabetes-related stigma decreases treatment motivation. While subjective financial burden is a known barrier, the impact of actual medical costs on stigma remains unclear. We investigated the relationship between annual outpatient medical costs (total and out-of-pocket) and stigma in type 2 diabetes to explore whether this association might be more closely related to direct financial hardship or underlying treatment complexity. Methods: In a cross-sectional study, we evaluated stigma in 232 outpatients using the Kanden Institute Stigma Scale (KISS). Patients scoring &amp;amp;ge;20 formed the high stigma group (n = 59). Annual medical costs were extracted from electronic hospital claims. We examined associations between medical costs and high stigma using multivariable logistic regression and restricted cubic spline (RCS) models. Results: Adjusted for sex and age, higher total medical cost (per 10,000 JPY/year) was significantly associated with high stigma (odds ratio [OR] = 1.03, 95% confidence interval [CI]: 1.01&amp;amp;ndash;1.05, p &amp;amp;lt; 0.01). However, this significance was attenuated after additionally adjusting for HbA1c and antidiabetic agent count (OR = 1.02, 95% CI: 1.00&amp;amp;ndash;1.04, p = 0.05). RCS analysis confirmed this dose&amp;amp;ndash;response association disappeared upon adjusting for treatment intensity. Notably, out-of-pocket costs showed no significant association with high stigma in any fully adjusted models (OR = 1.03, 95% CI: 0.95&amp;amp;ndash;1.11, p = 0.45). Conclusions: While total medical costs are associated with high stigma, the attenuation of this relationship after adjusting for clinical factors suggests that this association may be closely intertwined with the psychosocial burden of treatment complexity, such as polypharmacy and insulin injections, rather than acting solely through direct economic pain from out-of-pocket expenses. Clinicians should prioritize shared decision-making to mitigate psychological distress when intensifying treatment.</p>
	]]></content:encoded>

	<dc:title>Relationship Between Diabetes Stigma and Outpatient Medical Costs in Patients with Type 2 Diabetes: A Cross-Sectional Study</dc:title>
			<dc:creator>Mari Tanaka</dc:creator>
			<dc:creator>Hiroyuki Ito</dc:creator>
			<dc:creator>Erika Watanabe</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070134</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-09</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-09</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>134</prism:startingPage>
		<prism:doi>10.3390/diabetology7070134</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/134</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/133">

	<title>Diabetology, Vol. 7, Pages 133: Multidisciplinary Management of Diabetic Foot Ulcers Impacted by Social Determinants of Health: A Review and Case Report</title>
	<link>https://www.mdpi.com/2673-4540/7/7/133</link>
	<description>Introduction: Diabetic foot ulcers (DFUs) are a debilitating complication of diabetes, and management by multidisciplinary foot teams has been shown to reduce serious sequelae, such as amputations. There are stark racial and ethnic disparities in morbidity and mortality from DFUs, and multidisciplinary care has been shown to reduce lower extremity amputations, length of hospital stays and readmissions. This is a review of the impact of multidisciplinary care on DFUs, particularly regarding social determinants of health, with an illustrative case. Case Presentation: This is a case of a 32-year-old African American male with Type 1 Diabetes, a history of poor glycemic control, attention deficit hyperactivity disorder, tobacco and marijuana use disorder, and multiple social and structural barriers to care. He presented with bilateral Wagner grade 3 DFUs with osteomyelitis to the emergency department, requiring hospitalization. Upon discharge, he was referred to a multidisciplinary diabetes clinic and received coordinated support from endocrinology, podiatry, vascular surgery, infectious disease, pedorthics, and behavioral health. Comprehensive evaluation, intensive wound care with adjuvant hyperbaric oxygen therapy, offloading, blood glucose management and medical source control of infection were established for his treatment plan. At the three-month follow-up, the patient&amp;amp;rsquo;s wound beds had significantly improved, and his Hemoglobin A1c declined from 12.6% to 9.3%. The right plantar wound completely epithelialized, and the left foot wound showed 90% contracture. Review and Discussion: This case highlights the importance of integrated, multidisciplinary care for DFUs, particularly in addressing both the clinical and social drivers of complications from diabetes.</description>
	<pubDate>2026-07-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 133: Multidisciplinary Management of Diabetic Foot Ulcers Impacted by Social Determinants of Health: A Review and Case Report</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/133">doi: 10.3390/diabetology7070133</a></p>
	<p>Authors:
		Kara Turner
		Denise Levy
		Jairo L. Arce-Morales
		Manasa Kanneganti
		Johanna P. Daily
		Alyson K. Myers
		</p>
	<p>Introduction: Diabetic foot ulcers (DFUs) are a debilitating complication of diabetes, and management by multidisciplinary foot teams has been shown to reduce serious sequelae, such as amputations. There are stark racial and ethnic disparities in morbidity and mortality from DFUs, and multidisciplinary care has been shown to reduce lower extremity amputations, length of hospital stays and readmissions. This is a review of the impact of multidisciplinary care on DFUs, particularly regarding social determinants of health, with an illustrative case. Case Presentation: This is a case of a 32-year-old African American male with Type 1 Diabetes, a history of poor glycemic control, attention deficit hyperactivity disorder, tobacco and marijuana use disorder, and multiple social and structural barriers to care. He presented with bilateral Wagner grade 3 DFUs with osteomyelitis to the emergency department, requiring hospitalization. Upon discharge, he was referred to a multidisciplinary diabetes clinic and received coordinated support from endocrinology, podiatry, vascular surgery, infectious disease, pedorthics, and behavioral health. Comprehensive evaluation, intensive wound care with adjuvant hyperbaric oxygen therapy, offloading, blood glucose management and medical source control of infection were established for his treatment plan. At the three-month follow-up, the patient&amp;amp;rsquo;s wound beds had significantly improved, and his Hemoglobin A1c declined from 12.6% to 9.3%. The right plantar wound completely epithelialized, and the left foot wound showed 90% contracture. Review and Discussion: This case highlights the importance of integrated, multidisciplinary care for DFUs, particularly in addressing both the clinical and social drivers of complications from diabetes.</p>
	]]></content:encoded>

	<dc:title>Multidisciplinary Management of Diabetic Foot Ulcers Impacted by Social Determinants of Health: A Review and Case Report</dc:title>
			<dc:creator>Kara Turner</dc:creator>
			<dc:creator>Denise Levy</dc:creator>
			<dc:creator>Jairo L. Arce-Morales</dc:creator>
			<dc:creator>Manasa Kanneganti</dc:creator>
			<dc:creator>Johanna P. Daily</dc:creator>
			<dc:creator>Alyson K. Myers</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070133</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-09</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-09</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>133</prism:startingPage>
		<prism:doi>10.3390/diabetology7070133</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/133</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/132">

	<title>Diabetology, Vol. 7, Pages 132: Therapeutic Education in Children and Adolescents with Type 1 Diabetes Mellitus: A Systematic Review</title>
	<link>https://www.mdpi.com/2673-4540/7/7/132</link>
	<description>Background/Objectives: Therapeutic education for children and adolescents with Type 1 Diabetes Mellitus (T1DM) is a continuous and essential process in the effective management of the disease. These programs consider the unique characteristics and developmental needs of each child or adolescent, aiming to empower them to take responsibility for their disease self-management, improve quality of life, and prevent complications. The purpose of this systematic review was to evaluate the impact of therapeutic education in children and adolescents with T1DM on self-management of their disease. Methods: International bibliography was reviewed using electronic databases such as PubMed, Cochrane Library, and Scopus. Key words such as &amp;amp;ldquo;Therapeutic Education&amp;amp;rdquo;, &amp;amp;ldquo;Type 1 diabetes&amp;amp;rdquo;, &amp;amp;ldquo;children&amp;amp;rdquo;, &amp;amp;ldquo;self-management&amp;amp;rdquo;, &amp;amp;ldquo;glycemic control&amp;amp;rdquo;, and &amp;amp;ldquo;educational programs&amp;amp;rdquo; in combination with Boolean operators (AND, OR) were used in English language to search for studies conducted during 2014&amp;amp;ndash;2024. Results: A total of 23 studies met the inclusion criteria. Most reported improvements in glycemic control, though not all showed statistically significant reductions in glycated hemoglobin (HbA1c). Enhanced treatment adherence and increased diabetes-related knowledge were common outcomes. Combined educational approaches incorporating psychoeducational interventions demonstrated greater effectiveness in promoting self-management. Digital tools, such as Continuous Glucose Monitoring (CGM), further supported adherence. Quality-of-life improvements were noted but were not always sustained long-term. Parental involvement appeared to improve children&amp;amp;rsquo;s confidence in disease management. The critical role of interdisciplinary diabetes care teams, particularly nurses&amp;amp;rsquo; role, was also highlighted. Conclusions: Therapeutic education appears to support self-management among children and adolescents with T1DM, particularly when programs are individualized, family-centered, multidisciplinary, and supported by psychosocial or technological components. However, effects on glycemic control were not consistent across studies, and further research is needed to confirm long-term outcomes.</description>
	<pubDate>2026-07-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 132: Therapeutic Education in Children and Adolescents with Type 1 Diabetes Mellitus: A Systematic Review</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/132">doi: 10.3390/diabetology7070132</a></p>
	<p>Authors:
		Despoina Rizikou
		Anastasia Ntikoudi
		Anastasia Papachristou
		Polyxeni Mangoulia
		Afroditi Tsalkitzi
		Eugenia Vlachou
		</p>
	<p>Background/Objectives: Therapeutic education for children and adolescents with Type 1 Diabetes Mellitus (T1DM) is a continuous and essential process in the effective management of the disease. These programs consider the unique characteristics and developmental needs of each child or adolescent, aiming to empower them to take responsibility for their disease self-management, improve quality of life, and prevent complications. The purpose of this systematic review was to evaluate the impact of therapeutic education in children and adolescents with T1DM on self-management of their disease. Methods: International bibliography was reviewed using electronic databases such as PubMed, Cochrane Library, and Scopus. Key words such as &amp;amp;ldquo;Therapeutic Education&amp;amp;rdquo;, &amp;amp;ldquo;Type 1 diabetes&amp;amp;rdquo;, &amp;amp;ldquo;children&amp;amp;rdquo;, &amp;amp;ldquo;self-management&amp;amp;rdquo;, &amp;amp;ldquo;glycemic control&amp;amp;rdquo;, and &amp;amp;ldquo;educational programs&amp;amp;rdquo; in combination with Boolean operators (AND, OR) were used in English language to search for studies conducted during 2014&amp;amp;ndash;2024. Results: A total of 23 studies met the inclusion criteria. Most reported improvements in glycemic control, though not all showed statistically significant reductions in glycated hemoglobin (HbA1c). Enhanced treatment adherence and increased diabetes-related knowledge were common outcomes. Combined educational approaches incorporating psychoeducational interventions demonstrated greater effectiveness in promoting self-management. Digital tools, such as Continuous Glucose Monitoring (CGM), further supported adherence. Quality-of-life improvements were noted but were not always sustained long-term. Parental involvement appeared to improve children&amp;amp;rsquo;s confidence in disease management. The critical role of interdisciplinary diabetes care teams, particularly nurses&amp;amp;rsquo; role, was also highlighted. Conclusions: Therapeutic education appears to support self-management among children and adolescents with T1DM, particularly when programs are individualized, family-centered, multidisciplinary, and supported by psychosocial or technological components. However, effects on glycemic control were not consistent across studies, and further research is needed to confirm long-term outcomes.</p>
	]]></content:encoded>

	<dc:title>Therapeutic Education in Children and Adolescents with Type 1 Diabetes Mellitus: A Systematic Review</dc:title>
			<dc:creator>Despoina Rizikou</dc:creator>
			<dc:creator>Anastasia Ntikoudi</dc:creator>
			<dc:creator>Anastasia Papachristou</dc:creator>
			<dc:creator>Polyxeni Mangoulia</dc:creator>
			<dc:creator>Afroditi Tsalkitzi</dc:creator>
			<dc:creator>Eugenia Vlachou</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070132</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-08</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-08</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>132</prism:startingPage>
		<prism:doi>10.3390/diabetology7070132</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/132</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/131">

	<title>Diabetology, Vol. 7, Pages 131: Comparative Certainty of Evidence for Diabetic Foot Ulcer Therapies: A Narrative Synthesis</title>
	<link>https://www.mdpi.com/2673-4540/7/7/131</link>
	<description>Background: Diabetic foot ulcers (DFUs) are a major cause of morbidity and lower extremity amputation. Numerous advanced wound therapies with various mechanisms of action have been developed to improve healing outcomes; however, the comparative certainty of evidence supporting these interventions remains unclear. This study evaluates randomized controlled trials (RCTs) of DFU therapies using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Methods: A narrative synthesis of RCTs published between January 2016-January 2026 evaluating therapies for DFUs was performed. For studies that reported 12&amp;amp;ndash;week healing outcomes, risk of bias was assessed using the Cochrane Risk of Bias 2 tool and certainty of evidence for each therapy subgroup was evaluated using the GRADE framework. Results: A total of 143 RCTs were included with 45 RCTs undergoing GRADE assessment. The proportion of studies demonstrating statistically significant improvements in 12-week healing rates relative to controls varied and was not reflected in the GRADE assessment. Moderate-certainty evidence was assigned to the hyperbaric oxygen therapy subgroup. Low-certainty evidence was assigned to silver dressings, biosynthetic scaffolds, stem cell therapy, and negative pressure wound therapy. Very low-certainty evidence was assigned to topical oxygen, synthetic structural scaffolds, moisture-retaining dressings, local antimicrobial delivery, placental-derived skin substitutes, platelet-rich plasma, acellular dermal matrices, allografts/xenografts, and off-loading devices. No therapy subgroup was assigned high-certainty evidence. Conclusions: The certainty of evidence supporting DFU therapies varies substantially across intervention categories. These findings highlight the need for larger, methodologically rigorous comparative trials to clarify the effectiveness of DFU therapies and guide evidence-based wound care.</description>
	<pubDate>2026-07-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 131: Comparative Certainty of Evidence for Diabetic Foot Ulcer Therapies: A Narrative Synthesis</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/131">doi: 10.3390/diabetology7070131</a></p>
	<p>Authors:
		Stephanie M. Mueller
		Hannah D. Shi
		Aditi Kaveti
		Amy Du
		Devin J. Clegg
		Romi Wagner
		Dennis P. Orgill
		</p>
	<p>Background: Diabetic foot ulcers (DFUs) are a major cause of morbidity and lower extremity amputation. Numerous advanced wound therapies with various mechanisms of action have been developed to improve healing outcomes; however, the comparative certainty of evidence supporting these interventions remains unclear. This study evaluates randomized controlled trials (RCTs) of DFU therapies using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Methods: A narrative synthesis of RCTs published between January 2016-January 2026 evaluating therapies for DFUs was performed. For studies that reported 12&amp;amp;ndash;week healing outcomes, risk of bias was assessed using the Cochrane Risk of Bias 2 tool and certainty of evidence for each therapy subgroup was evaluated using the GRADE framework. Results: A total of 143 RCTs were included with 45 RCTs undergoing GRADE assessment. The proportion of studies demonstrating statistically significant improvements in 12-week healing rates relative to controls varied and was not reflected in the GRADE assessment. Moderate-certainty evidence was assigned to the hyperbaric oxygen therapy subgroup. Low-certainty evidence was assigned to silver dressings, biosynthetic scaffolds, stem cell therapy, and negative pressure wound therapy. Very low-certainty evidence was assigned to topical oxygen, synthetic structural scaffolds, moisture-retaining dressings, local antimicrobial delivery, placental-derived skin substitutes, platelet-rich plasma, acellular dermal matrices, allografts/xenografts, and off-loading devices. No therapy subgroup was assigned high-certainty evidence. Conclusions: The certainty of evidence supporting DFU therapies varies substantially across intervention categories. These findings highlight the need for larger, methodologically rigorous comparative trials to clarify the effectiveness of DFU therapies and guide evidence-based wound care.</p>
	]]></content:encoded>

	<dc:title>Comparative Certainty of Evidence for Diabetic Foot Ulcer Therapies: A Narrative Synthesis</dc:title>
			<dc:creator>Stephanie M. Mueller</dc:creator>
			<dc:creator>Hannah D. Shi</dc:creator>
			<dc:creator>Aditi Kaveti</dc:creator>
			<dc:creator>Amy Du</dc:creator>
			<dc:creator>Devin J. Clegg</dc:creator>
			<dc:creator>Romi Wagner</dc:creator>
			<dc:creator>Dennis P. Orgill</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070131</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-07</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-07</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>131</prism:startingPage>
		<prism:doi>10.3390/diabetology7070131</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/131</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/130">

	<title>Diabetology, Vol. 7, Pages 130: Making Psychosocial Vulnerability Visible in Diabetes Care: Identification, Documentation, and Follow-Up</title>
	<link>https://www.mdpi.com/2673-4540/7/7/130</link>
	<description>Introduction: As diabetes care becomes increasingly digitalized, stratified, and differentiated, psychosocial vulnerability risks becoming less visible within routine care and documentation. To ensure that differentiated care pathways meaningfully incorporate psychosocial stratification, vulnerability must be identifiable, documented, and revisited as part of routine clinical practice. Aim: The aim of this study is to explore how healthcare professionals identify psychosocial vulnerability in routine diabetes care and how such vulnerability is documented and followed up in the electronic medical record (EMR). Methods: This quality improvement audit with a descriptive analysis component was conducted at Steno Diabetes Center Copenhagen as part of the development of a new differentiated outpatient pathway. Healthcare professionals across disciplines submitted cases of persons with diabetes whom they considered psychosocially vulnerable. Documentation from the preceding six months was reviewed descriptively in order to find patterns of identification, documentation, care planning, and follow-up. Results: A total of 334 referrals representing 275 unique persons with diabetes were submitted. Psychosocial vulnerability extended beyond predefined high-risk categories, as 37% of identified cases did not align with any of the six vulnerability groups described in the Danish VIVE framework. Vulnerability often reflected cumulative everyday-life strain rather than formal diagnoses. While healthcare professionals demonstrated substantial relational attentiveness to psychosocial concerns, this knowledge was not consistently evident in formal documentation. Explicit care plans and longitudinal follow-up were uncommon, and psychosocial concerns were frequently documented as isolated observations rather than as part of structured ongoing care. Conclusions: Psychosocial vulnerability was frequently identified through clinical dialogue and professional judgement and often extended beyond predefined vulnerability categories. The findings highlight the importance of developing shared approaches and a shared understanding of psychosocial vulnerability across professional groups. If psychosocial stratification is to become an operational component of differentiated diabetes care, information about what burdens matter to the person must be identifiable, documented, and carried forward across encounters alongside biomedical information.</description>
	<pubDate>2026-07-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 130: Making Psychosocial Vulnerability Visible in Diabetes Care: Identification, Documentation, and Follow-Up</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/130">doi: 10.3390/diabetology7070130</a></p>
	<p>Authors:
		Kristoffer Marsaa
		Julie E. Stenvang
		Jonatan I. Bagger
		</p>
	<p>Introduction: As diabetes care becomes increasingly digitalized, stratified, and differentiated, psychosocial vulnerability risks becoming less visible within routine care and documentation. To ensure that differentiated care pathways meaningfully incorporate psychosocial stratification, vulnerability must be identifiable, documented, and revisited as part of routine clinical practice. Aim: The aim of this study is to explore how healthcare professionals identify psychosocial vulnerability in routine diabetes care and how such vulnerability is documented and followed up in the electronic medical record (EMR). Methods: This quality improvement audit with a descriptive analysis component was conducted at Steno Diabetes Center Copenhagen as part of the development of a new differentiated outpatient pathway. Healthcare professionals across disciplines submitted cases of persons with diabetes whom they considered psychosocially vulnerable. Documentation from the preceding six months was reviewed descriptively in order to find patterns of identification, documentation, care planning, and follow-up. Results: A total of 334 referrals representing 275 unique persons with diabetes were submitted. Psychosocial vulnerability extended beyond predefined high-risk categories, as 37% of identified cases did not align with any of the six vulnerability groups described in the Danish VIVE framework. Vulnerability often reflected cumulative everyday-life strain rather than formal diagnoses. While healthcare professionals demonstrated substantial relational attentiveness to psychosocial concerns, this knowledge was not consistently evident in formal documentation. Explicit care plans and longitudinal follow-up were uncommon, and psychosocial concerns were frequently documented as isolated observations rather than as part of structured ongoing care. Conclusions: Psychosocial vulnerability was frequently identified through clinical dialogue and professional judgement and often extended beyond predefined vulnerability categories. The findings highlight the importance of developing shared approaches and a shared understanding of psychosocial vulnerability across professional groups. If psychosocial stratification is to become an operational component of differentiated diabetes care, information about what burdens matter to the person must be identifiable, documented, and carried forward across encounters alongside biomedical information.</p>
	]]></content:encoded>

	<dc:title>Making Psychosocial Vulnerability Visible in Diabetes Care: Identification, Documentation, and Follow-Up</dc:title>
			<dc:creator>Kristoffer Marsaa</dc:creator>
			<dc:creator>Julie E. Stenvang</dc:creator>
			<dc:creator>Jonatan I. Bagger</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070130</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-07</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-07</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>130</prism:startingPage>
		<prism:doi>10.3390/diabetology7070130</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/130</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2673-4540/7/7/129">

	<title>Diabetology, Vol. 7, Pages 129: Long-Term Cholecalciferol Supplementation and Metabolic Parameters in Postmenopausal Women with Type 2 Diabetes Mellitus: A Longitudinal Prospective Study</title>
	<link>https://www.mdpi.com/2673-4540/7/7/129</link>
	<description>Background/Objectives: Type 2 diabetes mellitus (T2DM) and menopause are associated with low levels of vitamin D (25[OH]D). Primary trials reported the effects of cholecalciferol supplementation on glycemia and T2DM incidence with conflicting results. This uncontrolled longitudinal prospective study aimed to evaluate changes in metabolic and cardiovascular parameters in postmenopausal women with T2DM during sequential cholecalciferol supplementation. Methods: Thirty-four postmenopausal women (mean of 63.8 &amp;amp;plusmn; 7.5 years) with T2DM received 1000 IU/day of cholecalciferol for 12 months, followed by 2000 IU/day for another 12 months. Fasting blood tests, anthropometric assessments, and physical examinations were performed at baseline, 12 months, and 24 months after the intervention. The levels of 25(OH)D, fasting glycemia, glycated hemoglobin, fasting insulin, homeostasis model assessment (HOMA) of insulin resistance, HOMA of &amp;amp;beta;-cell function (HOMA-&amp;amp;beta;), total cholesterol, high-density lipoprotein cholesterol (HDL-c), triglycerides, and C-reactive protein were evaluated. Systolic blood pressure (SBP), diastolic blood pressure, waist circumference (WC), waist-to-hip ratio, and body mass index were also assessed. Results: Serum 25(OH)D and HDL-c levels increased over time during the follow-up period. Lower WC and SBP values were observed across follow-up assessments. Although fasting blood glucose values showed a median of 120 mg/dL at baseline and 110 mg/dL after cholecalciferol supplementation, and HOMA-&amp;amp;beta; values were approximately 35% higher at the end of follow-up, these differences were not statistically significant (p = 0.059 and p = 0.158, respectively). Conclusions: The long-term 25(OH)D dosing regimen had modest beneficial effects on glucose homeostasis, lipid profiles, and blood pressure in postmenopausal women with T2DM. This study contributes to the search for an optimal daily 25(OH)D dose in postmenopausal women with diabetes.</description>
	<pubDate>2026-07-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Diabetology, Vol. 7, Pages 129: Long-Term Cholecalciferol Supplementation and Metabolic Parameters in Postmenopausal Women with Type 2 Diabetes Mellitus: A Longitudinal Prospective Study</b></p>
	<p>Diabetology <a href="https://www.mdpi.com/2673-4540/7/7/129">doi: 10.3390/diabetology7070129</a></p>
	<p>Authors:
		Monique Resende Costa Machado
		Claudio Melibeu Bentes
		Claudia Cardoso Netto
		Letícia Baptista de Paula Barros
		Rafael Bizarelo
		Karina Ribeiro Silva
		Humberto Miranda
		Pablo B. Costa
		Lizanka Paola Figueiredo Marinheiro
		</p>
	<p>Background/Objectives: Type 2 diabetes mellitus (T2DM) and menopause are associated with low levels of vitamin D (25[OH]D). Primary trials reported the effects of cholecalciferol supplementation on glycemia and T2DM incidence with conflicting results. This uncontrolled longitudinal prospective study aimed to evaluate changes in metabolic and cardiovascular parameters in postmenopausal women with T2DM during sequential cholecalciferol supplementation. Methods: Thirty-four postmenopausal women (mean of 63.8 &amp;amp;plusmn; 7.5 years) with T2DM received 1000 IU/day of cholecalciferol for 12 months, followed by 2000 IU/day for another 12 months. Fasting blood tests, anthropometric assessments, and physical examinations were performed at baseline, 12 months, and 24 months after the intervention. The levels of 25(OH)D, fasting glycemia, glycated hemoglobin, fasting insulin, homeostasis model assessment (HOMA) of insulin resistance, HOMA of &amp;amp;beta;-cell function (HOMA-&amp;amp;beta;), total cholesterol, high-density lipoprotein cholesterol (HDL-c), triglycerides, and C-reactive protein were evaluated. Systolic blood pressure (SBP), diastolic blood pressure, waist circumference (WC), waist-to-hip ratio, and body mass index were also assessed. Results: Serum 25(OH)D and HDL-c levels increased over time during the follow-up period. Lower WC and SBP values were observed across follow-up assessments. Although fasting blood glucose values showed a median of 120 mg/dL at baseline and 110 mg/dL after cholecalciferol supplementation, and HOMA-&amp;amp;beta; values were approximately 35% higher at the end of follow-up, these differences were not statistically significant (p = 0.059 and p = 0.158, respectively). Conclusions: The long-term 25(OH)D dosing regimen had modest beneficial effects on glucose homeostasis, lipid profiles, and blood pressure in postmenopausal women with T2DM. This study contributes to the search for an optimal daily 25(OH)D dose in postmenopausal women with diabetes.</p>
	]]></content:encoded>

	<dc:title>Long-Term Cholecalciferol Supplementation and Metabolic Parameters in Postmenopausal Women with Type 2 Diabetes Mellitus: A Longitudinal Prospective Study</dc:title>
			<dc:creator>Monique Resende Costa Machado</dc:creator>
			<dc:creator>Claudio Melibeu Bentes</dc:creator>
			<dc:creator>Claudia Cardoso Netto</dc:creator>
			<dc:creator>Letícia Baptista de Paula Barros</dc:creator>
			<dc:creator>Rafael Bizarelo</dc:creator>
			<dc:creator>Karina Ribeiro Silva</dc:creator>
			<dc:creator>Humberto Miranda</dc:creator>
			<dc:creator>Pablo B. Costa</dc:creator>
			<dc:creator>Lizanka Paola Figueiredo Marinheiro</dc:creator>
		<dc:identifier>doi: 10.3390/diabetology7070129</dc:identifier>
	<dc:source>Diabetology</dc:source>
	<dc:date>2026-07-06</dc:date>

	<prism:publicationName>Diabetology</prism:publicationName>
	<prism:publicationDate>2026-07-06</prism:publicationDate>
	<prism:volume>7</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>129</prism:startingPage>
		<prism:doi>10.3390/diabetology7070129</prism:doi>
	<prism:url>https://www.mdpi.com/2673-4540/7/7/129</prism:url>

	<cc:license rdf:resource="CC BY 4.0"/>
</item>
    
<cc:License rdf:about="https://creativecommons.org/licenses/by/4.0/">
	<cc:permits rdf:resource="https://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
